NZ718073B2 - Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease - Google Patents
Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease Download PDFInfo
- Publication number
- NZ718073B2 NZ718073B2 NZ718073A NZ71807314A NZ718073B2 NZ 718073 B2 NZ718073 B2 NZ 718073B2 NZ 718073 A NZ718073 A NZ 718073A NZ 71807314 A NZ71807314 A NZ 71807314A NZ 718073 B2 NZ718073 B2 NZ 718073B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- phenoxyphenyl
- nicotinamide
- mmol
- esi
- title compound
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 40
- 201000011510 cancer Diseases 0.000 title claims abstract description 28
- 208000023275 Autoimmune disease Diseases 0.000 title claims abstract description 20
- 206010061218 Inflammation Diseases 0.000 title abstract description 10
- 230000004054 inflammatory process Effects 0.000 title abstract description 10
- 239000003112 inhibitor Substances 0.000 title abstract description 9
- 238000011282 treatment Methods 0.000 title description 28
- 238000002360 preparation method Methods 0.000 title description 10
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 claims abstract description 70
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 claims abstract description 70
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 59
- 201000010099 disease Diseases 0.000 claims abstract description 48
- 150000001875 compounds Chemical class 0.000 claims description 431
- -1 4-phenoxyphenyl Chemical group 0.000 claims description 188
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 66
- 150000003839 salts Chemical class 0.000 claims description 54
- 229910052757 nitrogen Inorganic materials 0.000 claims description 47
- 229910052739 hydrogen Inorganic materials 0.000 claims description 38
- 235000005152 nicotinamide Nutrition 0.000 claims description 33
- 239000011570 nicotinamide Substances 0.000 claims description 33
- 229960003966 nicotinamide Drugs 0.000 claims description 33
- UMXNLAJMQHTHDJ-UHFFFAOYSA-N NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)N1CCNCC1 Chemical compound NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)N1CCNCC1 UMXNLAJMQHTHDJ-UHFFFAOYSA-N 0.000 claims description 30
- 230000001404 mediated effect Effects 0.000 claims description 21
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims description 9
- 229910052805 deuterium Inorganic materials 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- ODBSNFUBMFYMET-UHFFFAOYSA-N C=CC(N(CCCC1)C1C(C=C1)=NC(C(C=C2)=CC=C2OC2=CC=CC=C2)=C1C(N)=O)=O Chemical compound C=CC(N(CCCC1)C1C(C=C1)=NC(C(C=C2)=CC=C2OC2=CC=CC=C2)=C1C(N)=O)=O ODBSNFUBMFYMET-UHFFFAOYSA-N 0.000 claims description 6
- SEQQEDYOGJHQOG-UHFFFAOYSA-N C=CC(N(CCCC1)C1C1(C(N)=O)SC=C(C(C=C2)=CC=C2OC2=CC=CC=C2)N1)=O Chemical compound C=CC(N(CCCC1)C1C1(C(N)=O)SC=C(C(C=C2)=CC=C2OC2=CC=CC=C2)N1)=O SEQQEDYOGJHQOG-UHFFFAOYSA-N 0.000 claims description 6
- QWEWLLNSJDTOKH-UHFFFAOYSA-N 1,3-thiazole-2-carboxamide Chemical compound NC(=O)C1=NC=CS1 QWEWLLNSJDTOKH-UHFFFAOYSA-N 0.000 claims description 5
- FBWQTXQLPOCJOT-UHFFFAOYSA-N C=CC(N(CCC1)C1C(C=C1)=NC(C(C=C2)=CC=C2OC2=CC=CC=C2)=C1C(N)=O)=O Chemical compound C=CC(N(CCC1)C1C(C=C1)=NC(C(C=C2)=CC=C2OC2=CC=CC=C2)=C1C(N)=O)=O FBWQTXQLPOCJOT-UHFFFAOYSA-N 0.000 claims description 4
- KKGUMDCEXDSASL-UHFFFAOYSA-N C=CC(N(CCC1)C1C1(C(N)=O)OC=C(C(C=C2)=CC=C2OC2=CC=CC=C2)N1)=O Chemical compound C=CC(N(CCC1)C1C1(C(N)=O)OC=C(C(C=C2)=CC=C2OC2=CC=CC=C2)N1)=O KKGUMDCEXDSASL-UHFFFAOYSA-N 0.000 claims description 4
- AIALDORXXYKOOK-UHFFFAOYSA-N C=CC(N(CCCC1)C1C1(C(N)=O)OC=C(C(C=C2)=CC=C2OC2=CC=CC=C2)N1)=O Chemical compound C=CC(N(CCCC1)C1C1(C(N)=O)OC=C(C(C=C2)=CC=C2OC2=CC=CC=C2)N1)=O AIALDORXXYKOOK-UHFFFAOYSA-N 0.000 claims description 4
- XOKLXUJBWXSXOA-UHFFFAOYSA-N NC(C(C=C1)=C(C(C=C2)=CC=C2OC2=CC=CC=C2)N=C1N1CCCCC1)=O Chemical compound NC(C(C=C1)=C(C(C=C2)=CC=C2OC2=CC=CC=C2)N=C1N1CCCCC1)=O XOKLXUJBWXSXOA-UHFFFAOYSA-N 0.000 claims description 4
- 208000037976 chronic inflammation Diseases 0.000 claims description 4
- 230000006020 chronic inflammation Effects 0.000 claims description 4
- UJFGAOSRHYZWPQ-UHFFFAOYSA-N C=CC(N(CC1)CCN1C(C=C1)=NC(C(C=CC=C2)=C2OC(C=CC=C2)=C2F)=C1C(N)=O)=O Chemical compound C=CC(N(CC1)CCN1C(C=C1)=NC(C(C=CC=C2)=C2OC(C=CC=C2)=C2F)=C1C(N)=O)=O UJFGAOSRHYZWPQ-UHFFFAOYSA-N 0.000 claims description 3
- PJUZGPYSGRZNSY-UHFFFAOYSA-N C=CC(N(CCC1)C1C1(C(N)=O)SC=C(C(C=C2)=CC=C2OC2=CC=CC=C2)N1)=O Chemical compound C=CC(N(CCC1)C1C1(C(N)=O)SC=C(C(C=C2)=CC=C2OC2=CC=CC=C2)N1)=O PJUZGPYSGRZNSY-UHFFFAOYSA-N 0.000 claims description 3
- WEQUGRYKDCQCPE-UHFFFAOYSA-N C=CC(N(CCCC1)C1C(C=C1)=NC(C(C=C2)=CC=C2C(NC2=CC=CC=C2)=O)=C1C(N)=O)=O Chemical compound C=CC(N(CCCC1)C1C(C=C1)=NC(C(C=C2)=CC=C2C(NC2=CC=CC=C2)=O)=C1C(N)=O)=O WEQUGRYKDCQCPE-UHFFFAOYSA-N 0.000 claims description 3
- YHXDCBRGCMHMQE-UHFFFAOYSA-N C=CC(N(CCCC1)C1C(C=C1)=NC(C2=CC=C(C(C3=CC=CC=C3)O)C=C2)=C1C(N)=O)=O Chemical compound C=CC(N(CCCC1)C1C(C=C1)=NC(C2=CC=C(C(C3=CC=CC=C3)O)C=C2)=C1C(N)=O)=O YHXDCBRGCMHMQE-UHFFFAOYSA-N 0.000 claims description 3
- MDYGZDHLLMKWTI-UHFFFAOYSA-N C=CS(N(CCCC1)C1C(C=C1)=NC(C(C=C2)=CC=C2OC2=CC=CC=C2)=C1C(N)=O)(=O)=O Chemical compound C=CS(N(CCCC1)C1C(C=C1)=NC(C(C=C2)=CC=C2OC2=CC=CC=C2)=C1C(N)=O)(=O)=O MDYGZDHLLMKWTI-UHFFFAOYSA-N 0.000 claims description 3
- JDCYBWUGLULKBY-UHFFFAOYSA-N COCC1=CC=CC(C(N=C(C=C2)N(CC3)CCN3C(C=C)=O)=C2C(N)=O)=C1 Chemical compound COCC1=CC=CC(C(N=C(C=C2)N(CC3)CCN3C(C=C)=O)=C2C(N)=O)=C1 JDCYBWUGLULKBY-UHFFFAOYSA-N 0.000 claims description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 3
- OOGXZBYERRPDPA-UHFFFAOYSA-N NC(=O)c1ccc(nc1-c1ccc(OC2CCC(F)(F)CC2)cc1)N1CCN(CC1)C(=O)C=C Chemical compound NC(=O)c1ccc(nc1-c1ccc(OC2CCC(F)(F)CC2)cc1)N1CCN(CC1)C(=O)C=C OOGXZBYERRPDPA-UHFFFAOYSA-N 0.000 claims description 3
- WQMSGGCOUASYEO-UHFFFAOYSA-N NC(=O)c1ccc(nc1-c1ccc(OC2CCCCC2)cc1)N1CCN(CC1)C(=O)C=C Chemical compound NC(=O)c1ccc(nc1-c1ccc(OC2CCCCC2)cc1)N1CCN(CC1)C(=O)C=C WQMSGGCOUASYEO-UHFFFAOYSA-N 0.000 claims description 3
- YSLHZFWPYAMITN-UHFFFAOYSA-N NC(=O)c1ccc(nc1-c1ccc(Oc2cccc(F)c2)cc1)N1CCN(CC1)C(=O)C=C Chemical compound NC(=O)c1ccc(nc1-c1ccc(Oc2cccc(F)c2)cc1)N1CCN(CC1)C(=O)C=C YSLHZFWPYAMITN-UHFFFAOYSA-N 0.000 claims description 3
- BIEOPMSATBVWAY-UHFFFAOYSA-N NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)-c1ccc(NC(=O)C=C)cc1 Chemical compound NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)-c1ccc(NC(=O)C=C)cc1 BIEOPMSATBVWAY-UHFFFAOYSA-N 0.000 claims description 3
- MCLGYFUOGPHAAX-UHFFFAOYSA-N NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)-c1cccc(NC(=O)C=C)c1 Chemical compound NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)-c1cccc(NC(=O)C=C)c1 MCLGYFUOGPHAAX-UHFFFAOYSA-N 0.000 claims description 3
- QTBYHUSOXPOMAU-UHFFFAOYSA-N NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)N1CCN(CC1)C(=O)C=C Chemical compound NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)N1CCN(CC1)C(=O)C=C QTBYHUSOXPOMAU-UHFFFAOYSA-N 0.000 claims description 3
- TVVGIVUDWNGTBO-UHFFFAOYSA-N NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)N1CCN(CC1)S(=O)(=O)C=C Chemical compound NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)N1CCN(CC1)S(=O)(=O)C=C TVVGIVUDWNGTBO-UHFFFAOYSA-N 0.000 claims description 3
- GWYAVTPSLXPPJW-UHFFFAOYSA-N NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)nc1)N1CCN(CC1)C(=O)C=C Chemical compound NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)nc1)N1CCN(CC1)C(=O)C=C GWYAVTPSLXPPJW-UHFFFAOYSA-N 0.000 claims description 3
- LQTWOAKAPZKRHG-UHFFFAOYSA-N NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2F)cc1)N1CCN(CC1)C(=O)C=C Chemical compound NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2F)cc1)N1CCN(CC1)C(=O)C=C LQTWOAKAPZKRHG-UHFFFAOYSA-N 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- HKODXZQCALAKRP-UHFFFAOYSA-N 6-[4-[4-(dimethylamino)but-2-enoyl]piperazin-1-yl]-2-(4-phenoxyphenyl)pyridine-3-carboxamide Chemical compound CN(C)CC=CC(=O)N1CCN(CC1)c1ccc(C(N)=O)c(n1)-c1ccc(Oc2ccccc2)cc1 HKODXZQCALAKRP-UHFFFAOYSA-N 0.000 claims description 2
- DWKACRWTXQBWHU-UHFFFAOYSA-N C=CC(N(CC1)C1N1N=C(C(N)=O)C(C(C=C2)=CC=C2OC2=CC=CC=C2)=C1)=O Chemical compound C=CC(N(CC1)C1N1N=C(C(N)=O)C(C(C=C2)=CC=C2OC2=CC=CC=C2)=C1)=O DWKACRWTXQBWHU-UHFFFAOYSA-N 0.000 claims description 2
- WALHVRDFKRIKLA-UHFFFAOYSA-N C=CC(N(CC1)CCN1C(C=C1)=NC(C(C=CC=C2)=C2OC2=CC(F)=CC=C2)=C1C(N)=O)=O Chemical compound C=CC(N(CC1)CCN1C(C=C1)=NC(C(C=CC=C2)=C2OC2=CC(F)=CC=C2)=C1C(N)=O)=O WALHVRDFKRIKLA-UHFFFAOYSA-N 0.000 claims description 2
- PXQNIUUDTKEGHK-UHFFFAOYSA-N C=CC(N(CC1)CCN1C1=CC=C(C(C=C2)=CC=C2OC2=CC=CC=C2)C(C(O)=O)=N1)=O Chemical compound C=CC(N(CC1)CCN1C1=CC=C(C(C=C2)=CC=C2OC2=CC=CC=C2)C(C(O)=O)=N1)=O PXQNIUUDTKEGHK-UHFFFAOYSA-N 0.000 claims description 2
- IRGQYRXWSLESRZ-UHFFFAOYSA-N C=CC(N(CCC1)C1C(C(N)=O)(NC=C1)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1)=O Chemical compound C=CC(N(CCC1)C1C(C(N)=O)(NC=C1)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1)=O IRGQYRXWSLESRZ-UHFFFAOYSA-N 0.000 claims description 2
- NRWOIVOIIVHBLO-UHFFFAOYSA-N C=CC(N(CCC1)C1N1N=C(C(N)=O)C(C(C=C2)=CC=C2OC2=CC=CC=C2)=C1)=O Chemical compound C=CC(N(CCC1)C1N1N=C(C(N)=O)C(C(C=C2)=CC=C2OC2=CC=CC=C2)=C1)=O NRWOIVOIIVHBLO-UHFFFAOYSA-N 0.000 claims description 2
- VGNUKPGCDHRYRE-FQEVSTJZSA-N C=CC(N(CCC1)[C@@H]1C1=CN(C(C=C2)=CC=C2OC2=CC=CC=C2)N=C1C(N)=O)=O Chemical compound C=CC(N(CCC1)[C@@H]1C1=CN(C(C=C2)=CC=C2OC2=CC=CC=C2)N=C1C(N)=O)=O VGNUKPGCDHRYRE-FQEVSTJZSA-N 0.000 claims description 2
- CDOKUSVWLRQCCZ-UHFFFAOYSA-N C=CC(N(CCCC1)C1C1=CC=C(C(C=C2)=CC=C2OC2=CC=CC=C2)C(C#N)=N1)=O Chemical compound C=CC(N(CCCC1)C1C1=CC=C(C(C=C2)=CC=C2OC2=CC=CC=C2)C(C#N)=N1)=O CDOKUSVWLRQCCZ-UHFFFAOYSA-N 0.000 claims description 2
- VGLCHRJDIQQSQV-UHFFFAOYSA-N C=CC(NC1=CC=CC(N2N=C(C(N)=O)C(C(C=C3)=CC=C3OC3=CC=CC=C3)=C2)=C1)=O Chemical compound C=CC(NC1=CC=CC(N2N=C(C(N)=O)C(C(C=C3)=CC=C3OC3=CC=CC=C3)=C2)=C1)=O VGLCHRJDIQQSQV-UHFFFAOYSA-N 0.000 claims description 2
- BDRCQFYPHYADIP-UHFFFAOYSA-N CN(C)CC=CC(N(CCC1)C1N(C=C1C(N)=O)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1)=O Chemical compound CN(C)CC=CC(N(CCC1)C1N(C=C1C(N)=O)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1)=O BDRCQFYPHYADIP-UHFFFAOYSA-N 0.000 claims description 2
- KLHVOLRXKNVQKG-UHFFFAOYSA-N CNC(C1(N(CC2)CCN2C(C=C)=O)SC=C(C(C=C2)=CC=C2OC2=CC=CC=C2)N1)=O Chemical compound CNC(C1(N(CC2)CCN2C(C=C)=O)SC=C(C(C=C2)=CC=C2OC2=CC=CC=C2)N1)=O KLHVOLRXKNVQKG-UHFFFAOYSA-N 0.000 claims description 2
- MPKDWKUHJVCUNA-UHFFFAOYSA-N NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)N1CCC(C1)NC(=O)C=C Chemical compound NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)N1CCC(C1)NC(=O)C=C MPKDWKUHJVCUNA-UHFFFAOYSA-N 0.000 claims description 2
- YDEQRYUASBLUQQ-UHFFFAOYSA-N NC(=O)c1ccc(nc1-c1ccc(Oc2ccccn2)cc1)N1CCN(CC1)C(=O)C=C Chemical compound NC(=O)c1ccc(nc1-c1ccc(Oc2ccccn2)cc1)N1CCN(CC1)C(=O)C=C YDEQRYUASBLUQQ-UHFFFAOYSA-N 0.000 claims description 2
- WFUOTFUVJVNLRE-UHFFFAOYSA-N NC(C(C(C(C=C1)=CC=C1OC1=CC=CC=C1)=C1)=NN1C1=CC(N)=CC=C1)=O Chemical compound NC(C(C(C(C=C1)=CC=C1OC1=CC=CC=C1)=C1)=NN1C1=CC(N)=CC=C1)=O WFUOTFUVJVNLRE-UHFFFAOYSA-N 0.000 claims description 2
- RXLBSUXDQSYOQK-UHFFFAOYSA-N NC(=O)c1ccc(cc1-c1ccc(Oc2ccccc2)cc1)N1CCN(CC1)C(=O)C=C Chemical compound NC(=O)c1ccc(cc1-c1ccc(Oc2ccccc2)cc1)N1CCN(CC1)C(=O)C=C RXLBSUXDQSYOQK-UHFFFAOYSA-N 0.000 claims 2
- ALCPIQJGNIFEEW-UHFFFAOYSA-N NC(=O)c1ccc(nc1-c1ccc(Oc2ccc(F)cc2)cc1)N1CCN(CC1)C(=O)C=C Chemical compound NC(=O)c1ccc(nc1-c1ccc(Oc2ccc(F)cc2)cc1)N1CCN(CC1)C(=O)C=C ALCPIQJGNIFEEW-UHFFFAOYSA-N 0.000 claims 2
- RMUZYDLROYPACN-UHFFFAOYSA-N NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)N1CCC(CC1)NC(=O)C=C Chemical compound NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)N1CCC(CC1)NC(=O)C=C RMUZYDLROYPACN-UHFFFAOYSA-N 0.000 claims 2
- BXFGDOFCEWYOFA-APQPDGGLSA-N C/C=C(/C(N(CC1)C1C1=CN(C(C=C2)=CC=C2OC2=CC=CC=C2)N=C1C(N)=O)=O)\C#N Chemical compound C/C=C(/C(N(CC1)C1C1=CN(C(C=C2)=CC=C2OC2=CC=CC=C2)N=C1C(N)=O)=O)\C#N BXFGDOFCEWYOFA-APQPDGGLSA-N 0.000 claims 1
- FYCLXXCBRKRDKE-UHFFFAOYSA-N C=CC(N(CCCC1)C1C1=CC=C(C(N)=O)C(C(C=C2)=CC=C2OC2=CC=CC=C2)=C1)=O Chemical compound C=CC(N(CCCC1)C1C1=CC=C(C(N)=O)C(C(C=C2)=CC=C2OC2=CC=CC=C2)=C1)=O FYCLXXCBRKRDKE-UHFFFAOYSA-N 0.000 claims 1
- HKODXZQCALAKRP-RMKNXTFCSA-N CN(C/C=C/C(=O)N1CCN(CC1)C1=NC(=C(C(=O)N)C=C1)C1=CC=C(C=C1)OC1=CC=CC=C1)C Chemical compound CN(C/C=C/C(=O)N1CCN(CC1)C1=NC(=C(C(=O)N)C=C1)C1=CC=C(C=C1)OC1=CC=CC=C1)C HKODXZQCALAKRP-RMKNXTFCSA-N 0.000 claims 1
- NZVLPJWUBMOBOK-UHFFFAOYSA-N NC(C(C(C(C=C1)=CC=C1OC1=CC=CC=C1)=C1)=NN1N1CCC1)=O Chemical compound NC(C(C(C(C=C1)=CC=C1OC1=CC=CC=C1)=C1)=NN1N1CCC1)=O NZVLPJWUBMOBOK-UHFFFAOYSA-N 0.000 claims 1
- 150000005480 nicotinamides Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 description 379
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 321
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 304
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 251
- 239000000203 mixture Substances 0.000 description 217
- 239000000243 solution Substances 0.000 description 207
- 239000007787 solid Substances 0.000 description 203
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 135
- 229910001868 water Inorganic materials 0.000 description 128
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 102
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 100
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 98
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 85
- 239000003921 oil Substances 0.000 description 76
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 76
- 235000019198 oils Nutrition 0.000 description 75
- 238000005160 1H NMR spectroscopy Methods 0.000 description 74
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 70
- 238000004128 high performance liquid chromatography Methods 0.000 description 69
- 235000019439 ethyl acetate Nutrition 0.000 description 67
- 239000002904 solvent Substances 0.000 description 61
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 60
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 57
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 52
- 238000010898 silica gel chromatography Methods 0.000 description 44
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 43
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 43
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 43
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 42
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 42
- 239000012044 organic layer Substances 0.000 description 42
- 239000012267 brine Substances 0.000 description 41
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 41
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 37
- 238000001816 cooling Methods 0.000 description 37
- 239000012299 nitrogen atmosphere Substances 0.000 description 37
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 34
- 125000001424 substituent group Chemical group 0.000 description 33
- 239000007821 HATU Substances 0.000 description 32
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 32
- 239000004698 Polyethylene Substances 0.000 description 31
- 239000012043 crude product Substances 0.000 description 31
- 239000001257 hydrogen Substances 0.000 description 30
- 206010025323 Lymphomas Diseases 0.000 description 29
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 29
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 29
- 229910020008 S(O) Inorganic materials 0.000 description 28
- 239000012298 atmosphere Substances 0.000 description 27
- 238000004809 thin layer chromatography Methods 0.000 description 26
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 25
- 229910000027 potassium carbonate Inorganic materials 0.000 description 25
- 238000010992 reflux Methods 0.000 description 25
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 210000003719 b-lymphocyte Anatomy 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 22
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 22
- 241000124008 Mammalia Species 0.000 description 22
- 239000012230 colorless oil Substances 0.000 description 22
- 239000002253 acid Substances 0.000 description 21
- 229920006395 saturated elastomer Polymers 0.000 description 20
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 19
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 18
- 125000001072 heteroaryl group Chemical group 0.000 description 18
- 125000004076 pyridyl group Chemical group 0.000 description 18
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 17
- 125000004122 cyclic group Chemical group 0.000 description 17
- 239000000706 filtrate Substances 0.000 description 17
- 238000003818 flash chromatography Methods 0.000 description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 17
- 125000005843 halogen group Chemical group 0.000 description 16
- 125000003386 piperidinyl group Chemical group 0.000 description 16
- 230000001225 therapeutic effect Effects 0.000 description 16
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 15
- 208000011691 Burkitt lymphomas Diseases 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- 125000004429 atom Chemical group 0.000 description 14
- 239000011734 sodium Substances 0.000 description 14
- 125000003118 aryl group Chemical group 0.000 description 13
- 208000032839 leukemia Diseases 0.000 description 13
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 13
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 13
- 239000000741 silica gel Substances 0.000 description 13
- 229910002027 silica gel Inorganic materials 0.000 description 13
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- 125000000623 heterocyclic group Chemical group 0.000 description 12
- 229910052760 oxygen Inorganic materials 0.000 description 12
- 239000012071 phase Substances 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 11
- 229940124291 BTK inhibitor Drugs 0.000 description 11
- 101150041968 CDC13 gene Proteins 0.000 description 11
- 125000000753 cycloalkyl group Chemical group 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 11
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 210000001165 lymph node Anatomy 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 239000012074 organic phase Substances 0.000 description 11
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 11
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 11
- KFXUHRXGLWUOJT-UHFFFAOYSA-N (4-phenoxyphenyl)boronic acid Chemical compound C1=CC(B(O)O)=CC=C1OC1=CC=CC=C1 KFXUHRXGLWUOJT-UHFFFAOYSA-N 0.000 description 10
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 10
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 10
- 108010057466 NF-kappa B Proteins 0.000 description 10
- 102000003945 NF-kappa B Human genes 0.000 description 10
- 108091000080 Phosphotransferase Proteins 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000000543 intermediate Substances 0.000 description 10
- 150000002500 ions Chemical class 0.000 description 10
- 239000003208 petroleum Substances 0.000 description 10
- 102000020233 phosphotransferase Human genes 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 229910052938 sodium sulfate Inorganic materials 0.000 description 10
- 235000011152 sodium sulphate Nutrition 0.000 description 10
- 208000003950 B-cell lymphoma Diseases 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 9
- 210000001185 bone marrow Anatomy 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 125000005842 heteroatom Chemical group 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 125000004193 piperazinyl group Chemical group 0.000 description 9
- 125000000714 pyrimidinyl group Chemical group 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 9
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 8
- 201000003791 MALT lymphoma Diseases 0.000 description 8
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 230000001684 chronic effect Effects 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 238000002953 preparative HPLC Methods 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 125000000335 thiazolyl group Chemical group 0.000 description 8
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 7
- 241000400611 Eucalyptus deanei Species 0.000 description 7
- 206010066476 Haematological malignancy Diseases 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 description 7
- 235000011114 ammonium hydroxide Nutrition 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000001363 autoimmune Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000003325 follicular Effects 0.000 description 7
- 150000002431 hydrogen Chemical class 0.000 description 7
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 7
- 208000003747 lymphoid leukemia Diseases 0.000 description 7
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 7
- 208000021937 marginal zone lymphoma Diseases 0.000 description 7
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 239000012453 solvate Substances 0.000 description 7
- LFCADBSUDWERJT-UHFFFAOYSA-N 2,6-dichloropyridine-3-carbonitrile Chemical compound ClC1=CC=C(C#N)C(Cl)=N1 LFCADBSUDWERJT-UHFFFAOYSA-N 0.000 description 6
- TZQZNPXAAMVOKE-UHFFFAOYSA-N 2,6-dichloropyridine-3-carboxamide Chemical compound NC(=O)C1=CC=C(Cl)N=C1Cl TZQZNPXAAMVOKE-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- MUXGLQGODYPTNQ-UHFFFAOYSA-N NC(=O)c1ccc(Cl)nc1-c1ccc(Oc2ccccc2)cc1 Chemical compound NC(=O)c1ccc(Cl)nc1-c1ccc(Oc2ccccc2)cc1 MUXGLQGODYPTNQ-UHFFFAOYSA-N 0.000 description 6
- KYWVOWOLVWGDRW-UHFFFAOYSA-N NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)-c1cccc(c1)[N+]([O-])=O Chemical compound NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)-c1cccc(c1)[N+]([O-])=O KYWVOWOLVWGDRW-UHFFFAOYSA-N 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 125000002837 carbocyclic group Chemical group 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 6
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 230000002062 proliferating effect Effects 0.000 description 6
- 125000003373 pyrazinyl group Chemical group 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 238000010791 quenching Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 6
- IJVLVRYLIMQVDD-UHFFFAOYSA-N 1,3-thiazole-2-carboxylic acid Chemical compound OC(=O)C1=NC=CS1 IJVLVRYLIMQVDD-UHFFFAOYSA-N 0.000 description 5
- 108091008875 B cell receptors Proteins 0.000 description 5
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 description 5
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 5
- 102000001253 Protein Kinase Human genes 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000007815 allergy Effects 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 229910000024 caesium carbonate Inorganic materials 0.000 description 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 5
- 230000009977 dual effect Effects 0.000 description 5
- 208000027866 inflammatory disease Diseases 0.000 description 5
- 210000003563 lymphoid tissue Anatomy 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 108060006633 protein kinase Proteins 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000010189 synthetic method Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 4
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 4
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 4
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 4
- VHTCMKUZNKINHQ-AKRCKQFNSA-N C=CC(N(CCC1)C1N(C=C1)N[C@]1(C(N)=O)C(C=C1)=CC=C1OC1=CC=CC=C1)=O Chemical compound C=CC(N(CCC1)C1N(C=C1)N[C@]1(C(N)=O)C(C=C1)=CC=C1OC1=CC=CC=C1)=O VHTCMKUZNKINHQ-AKRCKQFNSA-N 0.000 description 4
- DRFCNGBPXYFDCL-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCC(C1)n1cc(C(N)=O)c(n1)-c1ccc(Oc2ccccc2)cc1 Chemical compound CC(C)(C)OC(=O)N1CCC(C1)n1cc(C(N)=O)c(n1)-c1ccc(Oc2ccccc2)cc1 DRFCNGBPXYFDCL-UHFFFAOYSA-N 0.000 description 4
- YGALICUDRIZUJA-UHFFFAOYSA-N CCOC(C(C=O)(C(C=C1)=CC=C1OC1=CC=CC=C1)Br)=O Chemical compound CCOC(C(C=O)(C(C=C1)=CC=C1OC1=CC=CC=C1)Br)=O YGALICUDRIZUJA-UHFFFAOYSA-N 0.000 description 4
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000034578 Multiple myelomas Diseases 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- 239000012131 assay buffer Substances 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 150000001602 bicycloalkyls Chemical group 0.000 description 4
- 210000000601 blood cell Anatomy 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 4
- 201000003444 follicular lymphoma Diseases 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- 125000001041 indolyl group Chemical group 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 208000025113 myeloid leukemia Diseases 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 125000005592 polycycloalkyl group Polymers 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 125000003226 pyrazolyl group Chemical group 0.000 description 4
- 125000002098 pyridazinyl group Chemical group 0.000 description 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 4
- 201000006845 reticulosarcoma Diseases 0.000 description 4
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- YHFUWPUJUMZXBD-UHFFFAOYSA-N tert-butyl 4-carbamoylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C(N)=O)CC1 YHFUWPUJUMZXBD-UHFFFAOYSA-N 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 3
- RXRIGCPVWWYVQV-UHFFFAOYSA-N 4-(4-bromophenoxy)benzonitrile Chemical compound C1=CC(Br)=CC=C1OC1=CC=C(C#N)C=C1 RXRIGCPVWWYVQV-UHFFFAOYSA-N 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 3
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- MNLATSKWISGBSP-HXUWFJFHSA-N C=CC(N(CCC1)[C@H]1C(C(C(N)=O)=C1)=NN1C(C=C1)=CC=C1OC1=CC=CC=C1)=O Chemical compound C=CC(N(CCC1)[C@H]1C(C(C(N)=O)=C1)=NN1C(C=C1)=CC=C1OC1=CC=CC=C1)=O MNLATSKWISGBSP-HXUWFJFHSA-N 0.000 description 3
- QOCOVGSICUKINB-UHFFFAOYSA-N CCOC(C1(C(C=C2)=CC=C2OC2=CC=CC=C2)NNC=C1)=O Chemical compound CCOC(C1(C(C=C2)=CC=C2OC2=CC=CC=C2)NNC=C1)=O QOCOVGSICUKINB-UHFFFAOYSA-N 0.000 description 3
- 206010064190 Cholestatic pruritus Diseases 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 208000017604 Hodgkin disease Diseases 0.000 description 3
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
- GVHKEKLRPZSPRB-UHFFFAOYSA-N NC(C(C=C1)(C(C=C2)=CC=C2OC2=CC=CC=C2)NN1N1CCC1)=O Chemical compound NC(C(C=C1)(C(C=C2)=CC=C2OC2=CC=CC=C2)NN1N1CCC1)=O GVHKEKLRPZSPRB-UHFFFAOYSA-N 0.000 description 3
- OZDILNMOOSUWQF-UHFFFAOYSA-N NC(C(C=C1)=C(C2=CC=C(C(C3=CC=CC=C3)O)C=C2)N=C1N1CCCCC1)=O Chemical compound NC(C(C=C1)=C(C2=CC=C(C(C3=CC=CC=C3)O)C=C2)N=C1N1CCCCC1)=O OZDILNMOOSUWQF-UHFFFAOYSA-N 0.000 description 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 238000006069 Suzuki reaction reaction Methods 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 238000009739 binding Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 3
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- WJWCBZIJPAIHLU-UHFFFAOYSA-N cyclopentanecarbothioamide Chemical compound NC(=S)C1CCCC1 WJWCBZIJPAIHLU-UHFFFAOYSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000003176 fibrotic effect Effects 0.000 description 3
- 210000001280 germinal center Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 201000009277 hairy cell leukemia Diseases 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000000415 inactivating effect Effects 0.000 description 3
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 3
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 description 3
- 230000002427 irreversible effect Effects 0.000 description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 3
- 125000001786 isothiazolyl group Chemical group 0.000 description 3
- 125000000842 isoxazolyl group Chemical group 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 210000004324 lymphatic system Anatomy 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 125000001715 oxadiazolyl group Chemical group 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- 210000004180 plasmocyte Anatomy 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
- VVDCRJGWILREQH-UHFFFAOYSA-N tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC(B2OC(C)(C)C(C)(C)O2)=C1 VVDCRJGWILREQH-UHFFFAOYSA-N 0.000 description 3
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 230000009424 thromboembolic effect Effects 0.000 description 3
- 125000004306 triazinyl group Chemical group 0.000 description 3
- 125000001425 triazolyl group Chemical group 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- LTKOMZPKLZGZBO-UHFFFAOYSA-N (4-phenoxyphenyl) propanoate Chemical compound C1=CC(OC(=O)CC)=CC=C1OC1=CC=CC=C1 LTKOMZPKLZGZBO-UHFFFAOYSA-N 0.000 description 2
- LGRURSNANBXOMS-UHFFFAOYSA-N (4-phenoxyphenyl)hydrazine Chemical compound C1=CC(NN)=CC=C1OC1=CC=CC=C1 LGRURSNANBXOMS-UHFFFAOYSA-N 0.000 description 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 2
- FZENGILVLUJGJX-NSCUHMNNSA-N (E)-acetaldehyde oxime Chemical compound C\C=N\O FZENGILVLUJGJX-NSCUHMNNSA-N 0.000 description 2
- DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- PQQRHWFRZHFGFM-UHFFFAOYSA-N 1,3-thiazole-4-carboxamide Chemical compound NC(=O)C1=CSC=N1 PQQRHWFRZHFGFM-UHFFFAOYSA-N 0.000 description 2
- PWKNBLFSJAVFAB-UHFFFAOYSA-N 1-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1F PWKNBLFSJAVFAB-UHFFFAOYSA-N 0.000 description 2
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 2
- VHCSBTPOPKFYIU-UHFFFAOYSA-N 2-chloroethanesulfonyl chloride Chemical compound ClCCS(Cl)(=O)=O VHCSBTPOPKFYIU-UHFFFAOYSA-N 0.000 description 2
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 2
- OACDNPXSDNRKSS-UHFFFAOYSA-N 4-(4-bromophenoxy)cyclohexan-1-one Chemical compound C1=CC(Br)=CC=C1OC1CCC(=O)CC1 OACDNPXSDNRKSS-UHFFFAOYSA-N 0.000 description 2
- RVVROWDMHKBZPX-UHFFFAOYSA-N 4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]benzonitrile Chemical compound O1C(C)(C)C(C)(C)OB1C(C=C1)=CC=C1OC1=CC=C(C#N)C=C1 RVVROWDMHKBZPX-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- 241000238876 Acari Species 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 201000010717 Bruton-type agammaglobulinemia Diseases 0.000 description 2
- XIZWBBAJHPOIER-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)C1N(C=C1C(O)=O)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1)=O Chemical compound CC(C)(C)OC(N(CC1)C1N(C=C1C(O)=O)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1)=O XIZWBBAJHPOIER-UHFFFAOYSA-N 0.000 description 2
- YSHWAJMMMCMXJK-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1C(C(C(C=C1)=CC=C1OC1=CC=CC=C1)=C1)=NC=C1C(N)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1C(C(C(C=C1)=CC=C1OC1=CC=CC=C1)=C1)=NC=C1C(N)=O)=O YSHWAJMMMCMXJK-UHFFFAOYSA-N 0.000 description 2
- HIZUSVYFJWYFJV-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1C1=C(C(C=C2)=CC=C2OC2=CC=CC=C2)C(C(N)=O)=CC=C1)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1C1=C(C(C=C2)=CC=C2OC2=CC=CC=C2)C(C(N)=O)=CC=C1)=O HIZUSVYFJWYFJV-UHFFFAOYSA-N 0.000 description 2
- GYXYGRHKJWXMEY-UHFFFAOYSA-N CCOC(C(C=O)C(C=C1)=CC=C1OC1=CC=CC=C1)=O Chemical compound CCOC(C(C=O)C(C=C1)=CC=C1OC1=CC=CC=C1)=O GYXYGRHKJWXMEY-UHFFFAOYSA-N 0.000 description 2
- XNGDXAYKHYHXTB-UHFFFAOYSA-N CCOC(C1=CN(C(CCCC2)(C(C)(C)C)N2C(O)=O)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1)=O Chemical compound CCOC(C1=CN(C(CCCC2)(C(C)(C)C)N2C(O)=O)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1)=O XNGDXAYKHYHXTB-UHFFFAOYSA-N 0.000 description 2
- 201000004085 CLL/SLL Diseases 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- 101100083253 Caenorhabditis elegans pho-1 gene Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- YDQJFSQUBWCPFU-UHFFFAOYSA-N Cl.OC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)N1CCNCC1 Chemical compound Cl.OC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)N1CCNCC1 YDQJFSQUBWCPFU-UHFFFAOYSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 208000034951 Genetic Translocation Diseases 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 2
- IXZKHCJOJAZJIV-UHFFFAOYSA-N NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)C1CCNCC1 Chemical compound NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)C1CCNCC1 IXZKHCJOJAZJIV-UHFFFAOYSA-N 0.000 description 2
- MBAMJJDJBUALFB-UHFFFAOYSA-N NC(C1=CN(N2CCCC2)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1)=O Chemical compound NC(C1=CN(N2CCCC2)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1)=O MBAMJJDJBUALFB-UHFFFAOYSA-N 0.000 description 2
- SVHDGHXOFVGKEF-UHFFFAOYSA-N NC1CCN(CC1)c1ccc(C(N)=O)c(Cl)n1 Chemical compound NC1CCN(CC1)c1ccc(C(N)=O)c(Cl)n1 SVHDGHXOFVGKEF-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 2
- 102000001712 STAT5 Transcription Factor Human genes 0.000 description 2
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 206010041660 Splenomegaly Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
- 241000009298 Trigla lyra Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 206010045240 Type I hypersensitivity Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000016349 X-linked agammaglobulinemia Diseases 0.000 description 2
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 201000009961 allergic asthma Diseases 0.000 description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 229960003116 amyl nitrite Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 description 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 208000024207 chronic leukemia Diseases 0.000 description 2
- 208000023738 chronic lymphocytic leukemia/small lymphocytic lymphoma Diseases 0.000 description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- OSAOIDIGMBDXED-UHFFFAOYSA-N cyclohexyloxybenzene Chemical compound C1CCCCC1OC1=CC=CC=C1 OSAOIDIGMBDXED-UHFFFAOYSA-N 0.000 description 2
- XRLDSWLMHUQECH-UHFFFAOYSA-N cyclopentanecarboxamide Chemical compound NC(=O)C1CCCC1 XRLDSWLMHUQECH-UHFFFAOYSA-N 0.000 description 2
- JBDSSBMEKXHSJF-UHFFFAOYSA-N cyclopentanecarboxylic acid Chemical compound OC(=O)C1CCCC1 JBDSSBMEKXHSJF-UHFFFAOYSA-N 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 2
- YZVONBRPYOAJNO-UHFFFAOYSA-N ethyl 3-(dimethylamino)-2-(4-phenoxybenzoyl)prop-2-enoate Chemical compound CCOC(=O)C(=CN(C)C)C(=O)c1ccc(Oc2ccccc2)cc1 YZVONBRPYOAJNO-UHFFFAOYSA-N 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- ATADHKWKHYVBTJ-UHFFFAOYSA-N hydron;4-[1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol;chloride Chemical compound Cl.CNCC(O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-UHFFFAOYSA-N 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000000066 myeloid cell Anatomy 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- REPVNSJSTLRQEQ-UHFFFAOYSA-N n,n-dimethylacetamide;n,n-dimethylformamide Chemical compound CN(C)C=O.CN(C)C(C)=O REPVNSJSTLRQEQ-UHFFFAOYSA-N 0.000 description 2
- CSDTZUBPSYWZDX-UHFFFAOYSA-N n-pentyl nitrite Chemical compound CCCCCON=O CSDTZUBPSYWZDX-UHFFFAOYSA-N 0.000 description 2
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 125000003551 oxepanyl group Chemical group 0.000 description 2
- 125000003566 oxetanyl group Chemical group 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 description 2
- KOPFEFZSAMLEHK-UHFFFAOYSA-N pyrazolecarboxylic acid Natural products OC(=O)C=1C=CNN=1 KOPFEFZSAMLEHK-UHFFFAOYSA-N 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 201000004595 synovitis Diseases 0.000 description 2
- OLZRMIGDZLTJLM-UHFFFAOYSA-N tert-butyl 2-carbamothioylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1C(N)=S OLZRMIGDZLTJLM-UHFFFAOYSA-N 0.000 description 2
- OIZXJJIHVIYNKZ-UHFFFAOYSA-N tert-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,5-dihydropyrrole-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC=C1B1OC(C)(C)C(C)(C)O1 OIZXJJIHVIYNKZ-UHFFFAOYSA-N 0.000 description 2
- FKLPAGOTHFVRLL-UHFFFAOYSA-N tert-butyl 3-carbamothioylpyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C(N)=S)C1 FKLPAGOTHFVRLL-UHFFFAOYSA-N 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- 125000001583 thiepanyl group Chemical group 0.000 description 2
- 206010043778 thyroiditis Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- LENLQGBLVGGAMF-UHFFFAOYSA-N tributyl([1,2,4]triazolo[1,5-a]pyridin-6-yl)stannane Chemical compound C1=C([Sn](CCCC)(CCCC)CCCC)C=CC2=NC=NN21 LENLQGBLVGGAMF-UHFFFAOYSA-N 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 2
- 235000019798 tripotassium phosphate Nutrition 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000009959 type I hypersensitivity Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- KLZOTDOJMRMLDX-YBBVPDDNSA-N (1r,3s,5z)-5-[(2e)-2-[(1s,3as,7as)-1-[(1r)-1-(4-ethyl-4-hydroxyhexoxy)ethyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](C)OCCCC(O)(CC)CC)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C KLZOTDOJMRMLDX-YBBVPDDNSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- KNXQDJCZSVHEIW-UHFFFAOYSA-N (3-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(F)=C1 KNXQDJCZSVHEIW-UHFFFAOYSA-N 0.000 description 1
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 description 1
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 description 1
- 125000006654 (C3-C12) heteroaryl group Chemical group 0.000 description 1
- LCFFREMLXLZNHE-GBOLQPHISA-N (e)-2-[(3r)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile Chemical compound C12=C(N)N=CN=C2N([C@@H]2CCCN(C2)C(=O)C(/C#N)=C/C(C)(C)N2CCN(CC2)C2COC2)N=C1C(C(=C1)F)=CC=C1OC1=CC=CC=C1 LCFFREMLXLZNHE-GBOLQPHISA-N 0.000 description 1
- UUHNQHFOIVLAQX-BJILWQEISA-N (e)-4-(dimethylamino)but-2-enoic acid;hydrochloride Chemical compound Cl.CN(C)C\C=C\C(O)=O UUHNQHFOIVLAQX-BJILWQEISA-N 0.000 description 1
- WIKBZUXHNPONPP-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoro-2-iodo-2-(trifluoromethyl)propane Chemical compound FC(F)(F)C(I)(C(F)(F)F)C(F)(F)F WIKBZUXHNPONPP-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
- CZSRXHJVZUBEGW-UHFFFAOYSA-N 1,2-thiazolidine Chemical compound C1CNSC1 CZSRXHJVZUBEGW-UHFFFAOYSA-N 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- JBCFJMYPJJWIRG-UHFFFAOYSA-N 1,3-oxazole-4-carboxylic acid Chemical compound OC(=O)C1=COC=N1 JBCFJMYPJJWIRG-UHFFFAOYSA-N 0.000 description 1
- YZVFSQQHQPPKNX-UHFFFAOYSA-N 1,3-thiazole-5-carboxylic acid Chemical compound OC(=O)C1=CN=CS1 YZVFSQQHQPPKNX-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- KZPUZEPLLNUDDZ-UHFFFAOYSA-N 1,3-thiazolidine 1-oxide Chemical compound O=S1CCNC1 KZPUZEPLLNUDDZ-UHFFFAOYSA-N 0.000 description 1
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
- 125000005960 1,4-diazepanyl group Chemical group 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- YHIIJNLSGULWAA-UHFFFAOYSA-N 1,4-thiazinane 1-oxide Chemical compound O=S1CCNCC1 YHIIJNLSGULWAA-UHFFFAOYSA-N 0.000 description 1
- DJNIFZYQFLFGDT-UHFFFAOYSA-N 1-(4-phenoxyphenyl)ethanone Chemical compound C1=CC(C(=O)C)=CC=C1OC1=CC=CC=C1 DJNIFZYQFLFGDT-UHFFFAOYSA-N 0.000 description 1
- HAVMFTOWTMBQPY-UHFFFAOYSA-N 1-(trifluoromethylsulfonyloxy)pyrazole-3-carboxylic acid Chemical compound OC(=O)C=1C=CN(OS(=O)(=O)C(F)(F)F)N=1 HAVMFTOWTMBQPY-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- UCCUXODGPMAHRL-UHFFFAOYSA-N 1-bromo-4-iodobenzene Chemical compound BrC1=CC=C(I)C=C1 UCCUXODGPMAHRL-UHFFFAOYSA-N 0.000 description 1
- AIORJRDUJIKUEY-UHFFFAOYSA-N 1-cyclopentyl-3-(4-phenoxyphenyl)pyrazole-4-carboxylic acid Chemical compound OC(=O)C1=CN(C2CCCC2)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 AIORJRDUJIKUEY-UHFFFAOYSA-N 0.000 description 1
- ZLVANJFVMCRFOS-UHFFFAOYSA-N 1-fluoro-2-(4-nitrophenoxy)benzene Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC1=CC=CC=C1F ZLVANJFVMCRFOS-UHFFFAOYSA-N 0.000 description 1
- UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 description 1
- QDWAYVZXKAWFPX-UHFFFAOYSA-N 1-piperidin-1-ylpyrazole-3-carboxamide Chemical compound N1=C(C(=O)N)C=CN1N1CCCCC1 QDWAYVZXKAWFPX-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 1
- OACCNUGECQQVLB-UHFFFAOYSA-N 2,4-dichloropyrimidine-5-carboxamide Chemical compound NC(=O)C1=CN=C(Cl)N=C1Cl OACCNUGECQQVLB-UHFFFAOYSA-N 0.000 description 1
- SGLTYXRTDQXURA-UHFFFAOYSA-N 2,9-diazaspiro[4.5]decane Chemical compound C1NCCC21CNCCC2 SGLTYXRTDQXURA-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- TXIPVVLKTCCGPA-UHFFFAOYSA-N 2-[3-[2-[[1-(cyclopropanecarbonyl)piperidin-3-yl]amino]pyrimidin-4-yl]-2-quinolin-2-ylimidazol-4-yl]acetonitrile Chemical compound C1(CC1)C(=O)N1CC(CCC1)NC1=NC=CC(=N1)N1C(=NC=C1CC#N)C1=NC2=CC=CC=C2C=C1 TXIPVVLKTCCGPA-UHFFFAOYSA-N 0.000 description 1
- KTFQNBOQEGSXOV-UHFFFAOYSA-N 2-[4-(3-fluorophenoxy)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C(C=C1)=CC=C1OC1=CC=CC(F)=C1 KTFQNBOQEGSXOV-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical compound C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- CPQYFOSHDOBGQJ-UHFFFAOYSA-N 2-chloro-6-(3-nitrophenyl)pyridine-3-carbonitrile Chemical compound [O-][N+](=O)C1=CC=CC(C=2N=C(Cl)C(C#N)=CC=2)=C1 CPQYFOSHDOBGQJ-UHFFFAOYSA-N 0.000 description 1
- FFNVQNRYTPFDDP-UHFFFAOYSA-N 2-cyanopyridine Chemical compound N#CC1=CC=CC=N1 FFNVQNRYTPFDDP-UHFFFAOYSA-N 0.000 description 1
- HQRAQTQJCULKSE-UHFFFAOYSA-N 2-cyclopentyl-4-(4-phenoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound NC(=O)C=1SC(C2CCCC2)=NC=1C(C=C1)=CC=C1OC1=CC=CC=C1 HQRAQTQJCULKSE-UHFFFAOYSA-N 0.000 description 1
- HFHFGHLXUCOHLN-UHFFFAOYSA-N 2-fluorophenol Chemical compound OC1=CC=CC=C1F HFHFGHLXUCOHLN-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- YBBLSBDJIKMXNQ-UHFFFAOYSA-N 3,4-dihydro-2h-1,4-benzothiazine Chemical compound C1=CC=C2NCCSC2=C1 YBBLSBDJIKMXNQ-UHFFFAOYSA-N 0.000 description 1
- YRLORWPBJZEGBX-UHFFFAOYSA-N 3,4-dihydro-2h-1,4-benzoxazine Chemical compound C1=CC=C2NCCOC2=C1 YRLORWPBJZEGBX-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- CONVAEXWACQJSA-UHFFFAOYSA-N 3-oxabicyclo[2.2.2]octane Chemical compound C1CC2CCC1OC2 CONVAEXWACQJSA-UHFFFAOYSA-N 0.000 description 1
- GZPHSAQLYPIAIN-UHFFFAOYSA-N 3-pyridinecarbonitrile Chemical compound N#CC1=CC=CN=C1 GZPHSAQLYPIAIN-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- XOTBQGILYQQOKD-UHFFFAOYSA-N 4-(2-fluorophenoxy)aniline Chemical compound C1=CC(N)=CC=C1OC1=CC=CC=C1F XOTBQGILYQQOKD-UHFFFAOYSA-N 0.000 description 1
- AIPUNCFCQBDNDJ-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CCNCC1 AIPUNCFCQBDNDJ-UHFFFAOYSA-N 0.000 description 1
- BICZJRAGTCRORZ-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(O)C=C1 BICZJRAGTCRORZ-UHFFFAOYSA-N 0.000 description 1
- SLEMRDFEPSOWJS-UHFFFAOYSA-N 4-(4-phenoxyphenyl)-2-piperidin-1-yl-1,3-thiazole-5-carboxamide Chemical compound NC(=O)c1sc(nc1-c1ccc(Oc2ccccc2)cc1)N1CCCCC1 SLEMRDFEPSOWJS-UHFFFAOYSA-N 0.000 description 1
- ITGIYLMMAABTHC-UHFFFAOYSA-N 4-(dimethylazaniumyl)but-2-enoate Chemical compound CN(C)CC=CC(O)=O ITGIYLMMAABTHC-UHFFFAOYSA-N 0.000 description 1
- NYVWYZMUMRFMRR-UHFFFAOYSA-N 4-(iminomethylideneamino)-n,n-dimethylpentan-1-amine Chemical compound N=C=NC(C)CCCN(C)C NYVWYZMUMRFMRR-UHFFFAOYSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- JAVZWSOFJKYSDY-UHFFFAOYSA-N 4-bromo-2-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Br)C=C1Cl JAVZWSOFJKYSDY-UHFFFAOYSA-N 0.000 description 1
- GZFGOTFRPZRKDS-UHFFFAOYSA-N 4-bromophenol Chemical compound OC1=CC=C(Br)C=C1 GZFGOTFRPZRKDS-UHFFFAOYSA-N 0.000 description 1
- AEKVBBNGWBBYLL-UHFFFAOYSA-N 4-fluorobenzonitrile Chemical compound FC1=CC=C(C#N)C=C1 AEKVBBNGWBBYLL-UHFFFAOYSA-N 0.000 description 1
- WOYZXEVUWXQVNV-UHFFFAOYSA-N 4-phenoxyaniline Chemical compound C1=CC(N)=CC=C1OC1=CC=CC=C1 WOYZXEVUWXQVNV-UHFFFAOYSA-N 0.000 description 1
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
- ZAJBYTSUTBCMRM-UHFFFAOYSA-N 5-(2-methylpyrazol-3-yl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carboxylic acid Chemical compound CN1N=CC=C1C1CC(C(C(O)=O)=NN2)=C2C1 ZAJBYTSUTBCMRM-UHFFFAOYSA-N 0.000 description 1
- GXWNSJYVSIJRLS-UHFFFAOYSA-N 6-bromo-8-methylimidazo[1,2-a]pyrazine Chemical compound CC1=NC(Br)=CN2C=CN=C12 GXWNSJYVSIJRLS-UHFFFAOYSA-N 0.000 description 1
- TZJCHPJAIAODQY-UHFFFAOYSA-N 7-oxa-2-thiaspiro[3.4]octane Chemical compound C1SCC11COCC1 TZJCHPJAIAODQY-UHFFFAOYSA-N 0.000 description 1
- VRIQDFAVVXWZQU-UHFFFAOYSA-N 8-(4-bromophenoxy)-1,4-dioxaspiro[4.5]decane Chemical compound C1=CC(Br)=CC=C1OC1CCC2(OCCO2)CC1 VRIQDFAVVXWZQU-UHFFFAOYSA-N 0.000 description 1
- 238000003727 ADP Glo Kinase Assay Methods 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 239000004229 Alkannin Substances 0.000 description 1
- 206010001767 Alopecia universalis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 206010002412 Angiocentric lymphomas Diseases 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
- 230000024704 B cell apoptotic process Effects 0.000 description 1
- 108700024832 B-Cell CLL-Lymphoma 10 Proteins 0.000 description 1
- 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 description 1
- 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 description 1
- 208000037914 B-cell disorder Diseases 0.000 description 1
- 102100021631 B-cell lymphoma 6 protein Human genes 0.000 description 1
- 102100037598 B-cell lymphoma/leukemia 10 Human genes 0.000 description 1
- 208000012526 B-cell neoplasm Diseases 0.000 description 1
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 description 1
- 101150074953 BCL10 gene Proteins 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 241001674044 Blattodea Species 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 241000713704 Bovine immunodeficiency virus Species 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- IXWOZGNWUGNVPW-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CC(C1)N1NC(C=C1)(C(=O)OCC)C1=CC=C(C=C1)OC1=CC=CC=C1 Chemical compound C(C)(C)(C)OC(=O)N1CC(C1)N1NC(C=C1)(C(=O)OCC)C1=CC=C(C=C1)OC1=CC=CC=C1 IXWOZGNWUGNVPW-UHFFFAOYSA-N 0.000 description 1
- SGKMEMLKZHSVJW-UHFFFAOYSA-N C(N)(=O)C=1C(=NC(=NC1)C1CN(CC1)C(=O)OC(C)(C)C)C1=CC=C(C=C1)OC1=CC=CC=C1 Chemical compound C(N)(=O)C=1C(=NC(=NC1)C1CN(CC1)C(=O)OC(C)(C)C)C1=CC=C(C=C1)OC1=CC=CC=C1 SGKMEMLKZHSVJW-UHFFFAOYSA-N 0.000 description 1
- CKBHNOKSXIATMM-UHFFFAOYSA-N C(N)(=O)C=1C(=NC(=NC=1)C1=CCN(CC1)C(=O)OC(C)(C)C)C1=CC=C(C=C1)OC1=CC=CC=C1 Chemical compound C(N)(=O)C=1C(=NC(=NC=1)C1=CCN(CC1)C(=O)OC(C)(C)C)C1=CC=C(C=C1)OC1=CC=CC=C1 CKBHNOKSXIATMM-UHFFFAOYSA-N 0.000 description 1
- ULFPXDVAJMLGAU-UHFFFAOYSA-N C1=CNC(NC1=O)(C(=O)O)O Chemical compound C1=CNC(NC1=O)(C(=O)O)O ULFPXDVAJMLGAU-UHFFFAOYSA-N 0.000 description 1
- VGNUKPGCDHRYRE-UHFFFAOYSA-N C=CC(N(CCC1)C1C1=CN(C(C=C2)=CC=C2OC2=CC=CC=C2)N=C1C(N)=O)=O Chemical compound C=CC(N(CCC1)C1C1=CN(C(C=C2)=CC=C2OC2=CC=CC=C2)N=C1C(N)=O)=O VGNUKPGCDHRYRE-UHFFFAOYSA-N 0.000 description 1
- DFOYLZAGQBQQIX-UHFFFAOYSA-N C=CC(N(CCC1)C1C1=NC(C(N)=O)=C(C(C=C2)=CC=C2OC2=CC=CC=C2)S1)=O Chemical compound C=CC(N(CCC1)C1C1=NC(C(N)=O)=C(C(C=C2)=CC=C2OC2=CC=CC=C2)S1)=O DFOYLZAGQBQQIX-UHFFFAOYSA-N 0.000 description 1
- RYTGIBFYYWGIAT-UHFFFAOYSA-N C=CC(N(CCCC1)C1C1(C(N)=O)SC(C(C=C2)=CC=C2OC2=CC=CC=C2)=CN1)=O Chemical compound C=CC(N(CCCC1)C1C1(C(N)=O)SC(C(C=C2)=CC=C2OC2=CC=CC=C2)=CN1)=O RYTGIBFYYWGIAT-UHFFFAOYSA-N 0.000 description 1
- WWNMYRYCKUWXAM-UHFFFAOYSA-N C=CC(N(CCCC1)C1C1=NC(C(N)=O)=C(C(C=C2)=CC=C2OC2=CC=CC=C2)S1)=O Chemical compound C=CC(N(CCCC1)C1C1=NC(C(N)=O)=C(C(C=C2)=CC=C2OC2=CC=CC=C2)S1)=O WWNMYRYCKUWXAM-UHFFFAOYSA-N 0.000 description 1
- GGHJKQBPUQFTGK-UHFFFAOYSA-N C=CC(N(CCCC1)C1N(C=C1C(N)=O)N=C1C1=CC=C(C(C2=CC=CC=C2)O)C=C1)=O Chemical compound C=CC(N(CCCC1)C1N(C=C1C(N)=O)N=C1C1=CC=C(C(C2=CC=CC=C2)O)C=C1)=O GGHJKQBPUQFTGK-UHFFFAOYSA-N 0.000 description 1
- XIRKHIRRPOZTQB-UHFFFAOYSA-N C=CC(NC(C=C1)=CC=C1N1N=C(C(N)=O)C(C(C=C2)=CC=C2OC2=CC=CC=C2)=C1)=O Chemical compound C=CC(NC(C=C1)=CC=C1N1N=C(C(N)=O)C(C(C=C2)=CC=C2OC2=CC=CC=C2)=C1)=O XIRKHIRRPOZTQB-UHFFFAOYSA-N 0.000 description 1
- YXJXIHDTZWPEBP-UHFFFAOYSA-N CC(C)(C)C(C=CC1)(C2=NC=C(C(N)=O)C(C(C=C3)=CC=C3OC3=CC=CC=C3)=N2)N1C(O)=O Chemical compound CC(C)(C)C(C=CC1)(C2=NC=C(C(N)=O)C(C(C=C3)=CC=C3OC3=CC=CC=C3)=N2)N1C(O)=O YXJXIHDTZWPEBP-UHFFFAOYSA-N 0.000 description 1
- XJNCEUNCBGIFBC-UHFFFAOYSA-N CC(C)(C)C(CC1)(N1C(O)=O)N(C=C1C(N)=O)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 Chemical compound CC(C)(C)C(CC1)(N1C(O)=O)N(C=C1C(N)=O)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XJNCEUNCBGIFBC-UHFFFAOYSA-N 0.000 description 1
- VNQIFCNBARWBHF-UHFFFAOYSA-N CC(C)(C)C(CCC1)(C2=NC=C(C(N)=O)C(C(C=C3)=CC=C3OC3=CC=CC=C3)=N2)N1C(O)=O Chemical compound CC(C)(C)C(CCC1)(C2=NC=C(C(N)=O)C(C(C=C3)=CC=C3OC3=CC=CC=C3)=N2)N1C(O)=O VNQIFCNBARWBHF-UHFFFAOYSA-N 0.000 description 1
- PDMCJMGGKVXFLV-UHFFFAOYSA-N CC(C)(C)C(CCC1)(N1C(O)=O)N(C=C1C(N)=O)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 Chemical compound CC(C)(C)C(CCC1)(N1C(O)=O)N(C=C1C(N)=O)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 PDMCJMGGKVXFLV-UHFFFAOYSA-N 0.000 description 1
- ZBYCWQAWPFUHGU-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCC(C1)c1nc(c(s1)C(N)=O)-c1ccc(Oc2ccccc2)cc1 Chemical compound CC(C)(C)OC(=O)N1CCC(C1)c1nc(c(s1)C(N)=O)-c1ccc(Oc2ccccc2)cc1 ZBYCWQAWPFUHGU-UHFFFAOYSA-N 0.000 description 1
- GPTVRHBYESLQAM-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCC(CC1)c1cc(nn1-c1ccc(Oc2ccccc2)cc1)C(N)=O Chemical compound CC(C)(C)OC(=O)N1CCC(CC1)c1cc(nn1-c1ccc(Oc2ccccc2)cc1)C(N)=O GPTVRHBYESLQAM-UHFFFAOYSA-N 0.000 description 1
- MAEUHLKTSHMSHY-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCC(CC1)c1ccc(C(N)=O)c(n1)-c1ccc(Oc2ccccc2)cc1 Chemical compound CC(C)(C)OC(=O)N1CCC(CC1)c1ccc(C(N)=O)c(n1)-c1ccc(Oc2ccccc2)cc1 MAEUHLKTSHMSHY-UHFFFAOYSA-N 0.000 description 1
- RDDIFBJASRTCTP-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCC(CC1)c1nc(c(s1)C(N)=O)-c1ccc(Oc2ccccc2)cc1 Chemical compound CC(C)(C)OC(=O)N1CCC(CC1)c1nc(c(s1)C(N)=O)-c1ccc(Oc2ccccc2)cc1 RDDIFBJASRTCTP-UHFFFAOYSA-N 0.000 description 1
- ZERFASUTZMZHBO-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCCC(C1)c1nc(C(N)=O)c(s1)-c1ccc(Oc2ccccc2)cc1 Chemical compound CC(C)(C)OC(=O)N1CCCC(C1)c1nc(C(N)=O)c(s1)-c1ccc(Oc2ccccc2)cc1 ZERFASUTZMZHBO-UHFFFAOYSA-N 0.000 description 1
- MTYSNQQYXYWJQE-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCCC(C1)c1nc(c(s1)C(N)=O)-c1ccc(Oc2ccccc2)cc1 Chemical compound CC(C)(C)OC(=O)N1CCCC(C1)c1nc(c(s1)C(N)=O)-c1ccc(Oc2ccccc2)cc1 MTYSNQQYXYWJQE-UHFFFAOYSA-N 0.000 description 1
- KUNQTVJZWIWTBR-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1C(C(C(C=C1)=CC=C1C(NC1=CC=CC=C1)=O)=C1)=NC=C1C(N)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1C(C(C(C=C1)=CC=C1C(NC1=CC=CC=C1)=O)=C1)=NC=C1C(N)=O)=O KUNQTVJZWIWTBR-UHFFFAOYSA-N 0.000 description 1
- OBHSADKAPGLHQO-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1C(C(C1=CC=C(C(C2=CC=CC=C2)O)C=C1)=C1)=NC=C1C(N)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1C(C(C1=CC=C(C(C2=CC=CC=C2)O)C=C1)=C1)=NC=C1C(N)=O)=O OBHSADKAPGLHQO-UHFFFAOYSA-N 0.000 description 1
- KALHWBORARWOMQ-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1C1(C(O)=O)SC=C(C(C=C2)=CC=C2OC2=CC=CC=C2)N1)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1C1(C(O)=O)SC=C(C(C=C2)=CC=C2OC2=CC=CC=C2)N1)=O KALHWBORARWOMQ-UHFFFAOYSA-N 0.000 description 1
- IFXFGFWCPJERBO-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1C1=CC(C(NBr)=O)=CC=C1)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1C1=CC(C(NBr)=O)=CC=C1)=O IFXFGFWCPJERBO-UHFFFAOYSA-N 0.000 description 1
- BVODEMIVYIHHQB-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1C1=NC(Cl)=CC=C1C#N)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1C1=NC(Cl)=CC=C1C#N)=O BVODEMIVYIHHQB-UHFFFAOYSA-N 0.000 description 1
- LMUWAKJEDPDYQP-UHFFFAOYSA-N CC(C)(C)OC(N(CCC1)C1C1(C(O)=O)SC=C(C(C=C2)=CC=C2OC2=CC=CC=C2)N1)=O Chemical compound CC(C)(C)OC(N(CCC1)C1C1(C(O)=O)SC=C(C(C=C2)=CC=C2OC2=CC=CC=C2)N1)=O LMUWAKJEDPDYQP-UHFFFAOYSA-N 0.000 description 1
- OXNDNFATFUUDJM-UHFFFAOYSA-N CC(C)(C)OC(N(CCC1)C1N(C=C1)NC1(C(O)=O)C(C=C1)=CC=C1OC1=CC=CC=C1)=O Chemical compound CC(C)(C)OC(N(CCC1)C1N(C=C1)NC1(C(O)=O)C(C=C1)=CC=C1OC1=CC=CC=C1)=O OXNDNFATFUUDJM-UHFFFAOYSA-N 0.000 description 1
- OFHOKQLHFOSODN-UHFFFAOYSA-N CC(C)(C)OC(N(CCC1)C=C1C(C(C(C=C1)=CC=C1OC1=CC=CC=C1)=C1)=NC=C1C(N)=O)=O Chemical compound CC(C)(C)OC(N(CCC1)C=C1C(C(C(C=C1)=CC=C1OC1=CC=CC=C1)=C1)=NC=C1C(N)=O)=O OFHOKQLHFOSODN-UHFFFAOYSA-N 0.000 description 1
- GHJRFNPAJKFMIS-UHFFFAOYSA-N CC(C)(C)OC(N(CCC1)CC1C(C(C(C=C1)=CC=C1OC1=CC=CC=C1)=C1)=NC=C1C(N)=O)=O Chemical compound CC(C)(C)OC(N(CCC1)CC1C(C(C(C=C1)=CC=C1OC1=CC=CC=C1)=C1)=NC=C1C(N)=O)=O GHJRFNPAJKFMIS-UHFFFAOYSA-N 0.000 description 1
- UZPKERFIHQIGPZ-UHFFFAOYSA-N CC(C)(C)OC(N(CCCC1)C1C1(C(O)=O)SC=C(C(C=C2)=CC=C2OC2=CC=CC=C2)N1)=O Chemical compound CC(C)(C)OC(N(CCCC1)C1C1(C(O)=O)SC=C(C(C=C2)=CC=C2OC2=CC=CC=C2)N1)=O UZPKERFIHQIGPZ-UHFFFAOYSA-N 0.000 description 1
- FKJAMHGOTGMLSC-UHFFFAOYSA-N CC(C)(C)OC(N(CCCC1)C1C1=CC(C(O)=O)=NN1C(C=C1)=CC=C1OC1=CC=CC=C1)=O Chemical compound CC(C)(C)OC(N(CCCC1)C1C1=CC(C(O)=O)=NN1C(C=C1)=CC=C1OC1=CC=CC=C1)=O FKJAMHGOTGMLSC-UHFFFAOYSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- LJLPYRYZUJCRPZ-UHFFFAOYSA-N CCOC(=O)c1cc(O)n(n1)-c1ccc(Oc2ccccc2)cc1 Chemical compound CCOC(=O)c1cc(O)n(n1)-c1ccc(Oc2ccccc2)cc1 LJLPYRYZUJCRPZ-UHFFFAOYSA-N 0.000 description 1
- ZWCYIXQSQAJGLW-UHFFFAOYSA-N CCOC(=O)c1cn(nc1-c1ccc(Oc2ccccc2)cc1)-c1ccc(cc1)[N+]([O-])=O Chemical compound CCOC(=O)c1cn(nc1-c1ccc(Oc2ccccc2)cc1)-c1ccc(cc1)[N+]([O-])=O ZWCYIXQSQAJGLW-UHFFFAOYSA-N 0.000 description 1
- RMUDBHYEIBHIAS-UHFFFAOYSA-N CCOC(C(C(C(C=C1)=CC=C1OC1=CC=CC=C1)=O)OC(C(CCC1)CN1C(O)=O)=O)=O Chemical compound CCOC(C(C(C(C=C1)=CC=C1OC1=CC=CC=C1)=O)OC(C(CCC1)CN1C(O)=O)=O)=O RMUDBHYEIBHIAS-UHFFFAOYSA-N 0.000 description 1
- LGXBVIRKDFFSHQ-UHFFFAOYSA-N CCOC(C1(C(CC2)CN2C(OC(C)(C)C)=O)SC=C(C(C=C2)=CC=C2OC2=CC=CC=C2)N1)=O Chemical compound CCOC(C1(C(CC2)CN2C(OC(C)(C)C)=O)SC=C(C(C=C2)=CC=C2OC2=CC=CC=C2)N1)=O LGXBVIRKDFFSHQ-UHFFFAOYSA-N 0.000 description 1
- GKBHYNDUAYLCTA-UHFFFAOYSA-N CCOC(C1(C(CCC2)CN2C(OC(C)(C)C)=O)SC(C(C=C2)=CC=C2OC2=CC=CC=C2)=CN1)=O Chemical compound CCOC(C1(C(CCC2)CN2C(OC(C)(C)C)=O)SC(C(C=C2)=CC=C2OC2=CC=CC=C2)=CN1)=O GKBHYNDUAYLCTA-UHFFFAOYSA-N 0.000 description 1
- BDHDDAWUAMPXSP-UHFFFAOYSA-N CCOC(C1(C(CCC2)N2C(OC(C)(C)C)=O)OC=C(C(C=C2)=CC=C2OC2=CC=CC=C2)N1)=O Chemical compound CCOC(C1(C(CCC2)N2C(OC(C)(C)C)=O)OC=C(C(C=C2)=CC=C2OC2=CC=CC=C2)N1)=O BDHDDAWUAMPXSP-UHFFFAOYSA-N 0.000 description 1
- UEAYQRCYFLHDCC-UHFFFAOYSA-N CCOC(C1(C2CCCC2)SC=C(C(C=C2)=CC=C2OC2=CC=CC=C2)N1)=O Chemical compound CCOC(C1(C2CCCC2)SC=C(C(C=C2)=CC=C2OC2=CC=CC=C2)N1)=O UEAYQRCYFLHDCC-UHFFFAOYSA-N 0.000 description 1
- DRNMIIQWLQLNMH-UHFFFAOYSA-N CCOC(C1(N2CCCCC2)SC=C(C(C=C2)=CC=C2OC2=CC=CC=C2)N1)=O Chemical compound CCOC(C1(N2CCCCC2)SC=C(C(C=C2)=CC=C2OC2=CC=CC=C2)N1)=O DRNMIIQWLQLNMH-UHFFFAOYSA-N 0.000 description 1
- XZWJNMDIIZFIHJ-UHFFFAOYSA-N CCOC(C1(N2CCNCC2)SC=C(C(C=C2)=CC=C2OC2=CC=CC=C2)N1)=O Chemical compound CCOC(C1(N2CCNCC2)SC=C(C(C=C2)=CC=C2OC2=CC=CC=C2)N1)=O XZWJNMDIIZFIHJ-UHFFFAOYSA-N 0.000 description 1
- XAZJQJQCRUNXIP-UHFFFAOYSA-N CCOC(C1=C(C(C=C2)=CC=C2OC2=CC=CC=C2)SC(C(CCCC2)N2C(OC(C)(C)C)=O)=N1)=O Chemical compound CCOC(C1=C(C(C=C2)=CC=C2OC2=CC=CC=C2)SC(C(CCCC2)N2C(OC(C)(C)C)=O)=N1)=O XAZJQJQCRUNXIP-UHFFFAOYSA-N 0.000 description 1
- NOGBXVWQXAAJRX-UHFFFAOYSA-N CCOC(C1=CC=CC(C(CC2)=CCN2C(O)=O)=C1C(C=C1)=CC=C1OC1=CC=CC=C1)=O Chemical compound CCOC(C1=CC=CC(C(CC2)=CCN2C(O)=O)=C1C(C=C1)=CC=C1OC1=CC=CC=C1)=O NOGBXVWQXAAJRX-UHFFFAOYSA-N 0.000 description 1
- GWZOSDRURYGLKY-UHFFFAOYSA-N CCOC(C1=CN(C(CC2)N2C(OC(C)(C)C)=O)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1)=O Chemical compound CCOC(C1=CN(C(CC2)N2C(OC(C)(C)C)=O)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1)=O GWZOSDRURYGLKY-UHFFFAOYSA-N 0.000 description 1
- RFLNJGOWRNXBFR-UHFFFAOYSA-N CCOC(C1=NC(C(C=C2)=CC=C2OC2=CC=CC=C2)=C(N2CCCCC2)O1)=O Chemical compound CCOC(C1=NC(C(C=C2)=CC=C2OC2=CC=CC=C2)=C(N2CCCCC2)O1)=O RFLNJGOWRNXBFR-UHFFFAOYSA-N 0.000 description 1
- AAIXXOWZMRVOER-UHFFFAOYSA-N CCOC(C1=NC(C(C=C2)=CC=C2OC2=CC=CC=C2)=C(N2CCNCC2)S1)=O Chemical compound CCOC(C1=NC(C(C=C2)=CC=C2OC2=CC=CC=C2)=C(N2CCNCC2)S1)=O AAIXXOWZMRVOER-UHFFFAOYSA-N 0.000 description 1
- HXTWBBOCGOISJA-UHFFFAOYSA-N CCOC([S+]1C(C(CCC2)N2C(OC(C)(C)C)=O)=NC(C(C=C2)=CC=C2OC2=CC=CC=C2)=C1)=O Chemical compound CCOC([S+]1C(C(CCC2)N2C(OC(C)(C)C)=O)=NC(C(C=C2)=CC=C2OC2=CC=CC=C2)=C1)=O HXTWBBOCGOISJA-UHFFFAOYSA-N 0.000 description 1
- TYZALJFVPCCOON-UHFFFAOYSA-N CN(C1=CC=CC=C1)C(C=C1)=CC=C1C1=NN(C(CCCC2)N2C(C=C)=O)C=C1C(N)=O Chemical compound CN(C1=CC=CC=C1)C(C=C1)=CC=C1C1=NN(C(CCCC2)N2C(C=C)=O)C=C1C(N)=O TYZALJFVPCCOON-UHFFFAOYSA-N 0.000 description 1
- RCNOOPKSPWGZLR-UHFFFAOYSA-N CNC(=O)c1sc(nc1-c1ccc(Oc2ccccc2)cc1)N1CCN(CC1)C(=O)OC(C)(C)C Chemical compound CNC(=O)c1sc(nc1-c1ccc(Oc2ccccc2)cc1)N1CCN(CC1)C(=O)OC(C)(C)C RCNOOPKSPWGZLR-UHFFFAOYSA-N 0.000 description 1
- IPDKXGRMFIDNLE-UHFFFAOYSA-N CNC(=O)c1sc(nc1-c1ccc(Oc2ccccc2)cc1)N1CCNCC1 Chemical compound CNC(=O)c1sc(nc1-c1ccc(Oc2ccccc2)cc1)N1CCNCC1 IPDKXGRMFIDNLE-UHFFFAOYSA-N 0.000 description 1
- XXZUINPHUUAJAQ-UHFFFAOYSA-N COC(C(C=C1)=CC=C1C1=NC=CC(Cl)=C1C(N)=O)=O Chemical compound COC(C(C=C1)=CC=C1C1=NC=CC(Cl)=C1C(N)=O)=O XXZUINPHUUAJAQ-UHFFFAOYSA-N 0.000 description 1
- BXTSJNPPOKEKNE-UHFFFAOYSA-N COc1cc(ccc1C)-c1nc(ccc1C(N)=O)N1CCNCC1 Chemical compound COc1cc(ccc1C)-c1nc(ccc1C(N)=O)N1CCNCC1 BXTSJNPPOKEKNE-UHFFFAOYSA-N 0.000 description 1
- 101100451306 Caenorhabditis elegans hnd-1 gene Proteins 0.000 description 1
- 101100366937 Caenorhabditis elegans sto-4 gene Proteins 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 244000045232 Canavalia ensiformis Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- XHWVCWIZRXMBTC-UHFFFAOYSA-N Cl.NC(=O)c1ccc(cc1-c1ccc(Oc2ccccc2)cc1)N1CCNCC1 Chemical compound Cl.NC(=O)c1ccc(cc1-c1ccc(Oc2ccccc2)cc1)N1CCNCC1 XHWVCWIZRXMBTC-UHFFFAOYSA-N 0.000 description 1
- YXBHTSRFQLREAQ-UHFFFAOYSA-N ClC=1C=C(C=CC=1C(=O)OCC)C1=CCN(CC1)C(=O)OC(C)(C)C Chemical compound ClC=1C=C(C=CC=1C(=O)OCC)C1=CCN(CC1)C(=O)OC(C)(C)C YXBHTSRFQLREAQ-UHFFFAOYSA-N 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 108010088874 Cullin 1 Proteins 0.000 description 1
- 102000006311 Cyclin D1 Human genes 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 206010011841 Dacryoadenitis acquired Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 101100130497 Drosophila melanogaster Mical gene Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 201000011275 Epicondylitis Diseases 0.000 description 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
- 240000006890 Erythroxylum coca Species 0.000 description 1
- WXQUBTOSDAWZRY-UHFFFAOYSA-N FC(CC1)(CCC1OC(C=CC=C1)=C1Br)F Chemical compound FC(CC1)(CCC1OC(C=CC=C1)=C1Br)F WXQUBTOSDAWZRY-UHFFFAOYSA-N 0.000 description 1
- 206010016228 Fasciitis Diseases 0.000 description 1
- 241000713800 Feline immunodeficiency virus Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000007465 Giant cell arteritis Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 101000914489 Homo sapiens B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 description 1
- 101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 description 1
- 101000971234 Homo sapiens B-cell lymphoma 6 protein Proteins 0.000 description 1
- 101000864342 Homo sapiens Tyrosine-protein kinase BTK Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 201000003803 Inflammatory myofibroblastic tumor Diseases 0.000 description 1
- 206010067917 Inflammatory myofibroblastic tumour Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 208000000209 Isaacs syndrome Diseases 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000021605 Large-Cell Immunoblastic Lymphoma Diseases 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 244000062939 Leptospermum ericoides Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 description 1
- 206010025280 Lymphocytosis Diseases 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 101150053046 MYD88 gene Proteins 0.000 description 1
- 102100025169 Max-binding protein MNT Human genes 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 101100345589 Mus musculus Mical1 gene Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 102100024134 Myeloid differentiation primary response protein MyD88 Human genes 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 208000005927 Myosarcoma Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- MIRXMGGJPMTRKM-UHFFFAOYSA-N N#CC1(C(C=C2)=CC=C2OC2=CC=CC=C2)NC=CC=C1N1CCCCC1 Chemical compound N#CC1(C(C=C2)=CC=C2OC2=CC=CC=C2)NC=CC=C1N1CCCCC1 MIRXMGGJPMTRKM-UHFFFAOYSA-N 0.000 description 1
- XPWBKFAGBJKDMI-UHFFFAOYSA-N N-(2-chloro-4-phenoxyphenyl)pyridine-3-carboxamide Chemical compound C=1C=C(NC(=O)C=2C=NC=CC=2)C(Cl)=CC=1OC1=CC=CC=C1 XPWBKFAGBJKDMI-UHFFFAOYSA-N 0.000 description 1
- COHKDVHEXVSOSR-UHFFFAOYSA-N NC(=O)c1ccc(Cl)nc1-c1ccc(cc1)C(=O)c1ccccc1 Chemical compound NC(=O)c1ccc(Cl)nc1-c1ccc(cc1)C(=O)c1ccccc1 COHKDVHEXVSOSR-UHFFFAOYSA-N 0.000 description 1
- BGGRGYAMQIPDEX-UHFFFAOYSA-N NC(=O)c1ccc(nc1-c1ccc(OC2CCCCC2)cc1)N1CCNCC1 Chemical compound NC(=O)c1ccc(nc1-c1ccc(OC2CCCCC2)cc1)N1CCNCC1 BGGRGYAMQIPDEX-UHFFFAOYSA-N 0.000 description 1
- FOVPGEGKCVVOCG-UHFFFAOYSA-N NC(=O)c1ccc(nc1-c1ccc(Oc2ccc(cc2)C#N)cc1)N1CCN(CC1)C(=O)C=C Chemical compound NC(=O)c1ccc(nc1-c1ccc(Oc2ccc(cc2)C#N)cc1)N1CCN(CC1)C(=O)C=C FOVPGEGKCVVOCG-UHFFFAOYSA-N 0.000 description 1
- LRKDBEWAKQURBV-UHFFFAOYSA-N NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)-c1ccc(N)cc1 Chemical compound NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)-c1ccc(N)cc1 LRKDBEWAKQURBV-UHFFFAOYSA-N 0.000 description 1
- KHVQMSOUAPDTFR-UHFFFAOYSA-N NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)-c1cccc(N)c1 Chemical compound NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)-c1cccc(N)c1 KHVQMSOUAPDTFR-UHFFFAOYSA-N 0.000 description 1
- WUNLKXZIMJQNRX-UHFFFAOYSA-N NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)C1CCCNC1 Chemical compound NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)C1CCCNC1 WUNLKXZIMJQNRX-UHFFFAOYSA-N 0.000 description 1
- SACLVQCBKGYIST-UHFFFAOYSA-N NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1F)N1CCNCC1 Chemical compound NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1F)N1CCNCC1 SACLVQCBKGYIST-UHFFFAOYSA-N 0.000 description 1
- BCJVYFOBVNMFIG-UHFFFAOYSA-N NC(=O)c1ccc(nc1-c1ccc(cc1)C(O)c1ccccc1)C1CCNCC1 Chemical compound NC(=O)c1ccc(nc1-c1ccc(cc1)C(O)c1ccccc1)C1CCNCC1 BCJVYFOBVNMFIG-UHFFFAOYSA-N 0.000 description 1
- ODOMVNAJAYLSTE-UHFFFAOYSA-N NC(=O)c1ccc(nc1Cl)-c1cccc(c1)[N+]([O-])=O Chemical compound NC(=O)c1ccc(nc1Cl)-c1cccc(c1)[N+]([O-])=O ODOMVNAJAYLSTE-UHFFFAOYSA-N 0.000 description 1
- HJNYVZKHEFKJAT-UHFFFAOYSA-N NC(=O)c1cn(nc1-c1ccc(Oc2ccccc2)cc1)C1CN(C1)C(O)=O Chemical compound NC(=O)c1cn(nc1-c1ccc(Oc2ccccc2)cc1)C1CN(C1)C(O)=O HJNYVZKHEFKJAT-UHFFFAOYSA-N 0.000 description 1
- FOCCRPPRTCTKCJ-UHFFFAOYSA-N NC(=O)c1cnc(Cl)nc1-c1ccc(Oc2ccccc2)cc1 Chemical compound NC(=O)c1cnc(Cl)nc1-c1ccc(Oc2ccccc2)cc1 FOCCRPPRTCTKCJ-UHFFFAOYSA-N 0.000 description 1
- SVQPEPLHZUCQNZ-UHFFFAOYSA-N NC(C(C(C(C=C1)=CC=C1OC1=CC=CC=C1)=NC=C1)=C1N1CCCC1)=O Chemical compound NC(C(C(C(C=C1)=CC=C1OC1=CC=CC=C1)=NC=C1)=C1N1CCCC1)=O SVQPEPLHZUCQNZ-UHFFFAOYSA-N 0.000 description 1
- SREGUVOYSZPIME-UHFFFAOYSA-N NC(C(C=C1)(C(C=C2)=CC=C2OC2=CC=CC=C2)NN1C(C=C1)=CC=C1[N+]([O-])=O)=O Chemical compound NC(C(C=C1)(C(C=C2)=CC=C2OC2=CC=CC=C2)NN1C(C=C1)=CC=C1[N+]([O-])=O)=O SREGUVOYSZPIME-UHFFFAOYSA-N 0.000 description 1
- MTMZZEKTUVNEPU-UHFFFAOYSA-N NC(C(C=C1)(C(C=C2)=CC=C2OC2=CC=CC=C2)NN1N1CCCC1)=O Chemical compound NC(C(C=C1)(C(C=C2)=CC=C2OC2=CC=CC=C2)NN1N1CCCC1)=O MTMZZEKTUVNEPU-UHFFFAOYSA-N 0.000 description 1
- ROPPEYSBVRZXGZ-UHFFFAOYSA-N NC(C(C=C1)=C(C(C=C2)=CC=C2C(NC2=CC=CC=C2)=O)N=C1N1CCCCC1)=O Chemical compound NC(C(C=C1)=C(C(C=C2)=CC=C2C(NC2=CC=CC=C2)=O)N=C1N1CCCCC1)=O ROPPEYSBVRZXGZ-UHFFFAOYSA-N 0.000 description 1
- XEBCDNVIEUSIFG-UHFFFAOYSA-N NC(C(N=C1C(C=C2)=CC=C2OC2=CC=CC=C2)=NC=C1N1CCCC1)=O Chemical compound NC(C(N=C1C(C=C2)=CC=C2OC2=CC=CC=C2)=NC=C1N1CCCC1)=O XEBCDNVIEUSIFG-UHFFFAOYSA-N 0.000 description 1
- YBVDXGIHMUMTDA-UHFFFAOYSA-N NC(C1(C(C=C2)=CC=C2OC2=CC=CC=C2)NN(C(CC2)N2C(CC#N)=O)C=C1)=O Chemical compound NC(C1(C(C=C2)=CC=C2OC2=CC=CC=C2)NN(C(CC2)N2C(CC#N)=O)C=C1)=O YBVDXGIHMUMTDA-UHFFFAOYSA-N 0.000 description 1
- BSIXIWYXKGNJQZ-UHFFFAOYSA-N NC(C1(N2CCNCC2)SC=C(C(C=C2)=CC=C2OC2=CC=CC=C2)N1)=O Chemical compound NC(C1(N2CCNCC2)SC=C(C(C=C2)=CC=C2OC2=CC=CC=C2)N1)=O BSIXIWYXKGNJQZ-UHFFFAOYSA-N 0.000 description 1
- NAPCCLWVVVIFND-UHFFFAOYSA-N NC(C1=CN=C(C(CC2)=CCN2C(O)=O)C(C(C=C2)=CC=C2OC2=CC=CC=C2)=C1)=O Chemical compound NC(C1=CN=C(C(CC2)=CCN2C(O)=O)C(C(C=C2)=CC=C2OC2=CC=CC=C2)=C1)=O NAPCCLWVVVIFND-UHFFFAOYSA-N 0.000 description 1
- KXYRYSJLSCSZKZ-UHFFFAOYSA-N NC(C1=NC=C(C2CCNCC2)C(C(C=C2)=CC=C2OC2=CC=CC=C2)=N1)=O Chemical compound NC(C1=NC=C(C2CCNCC2)C(C(C=C2)=CC=C2OC2=CC=CC=C2)=N1)=O KXYRYSJLSCSZKZ-UHFFFAOYSA-N 0.000 description 1
- CQODFRDRLLAKOW-UHFFFAOYSA-N NC1CCN(C1)c1ccc(C(N)=O)c(n1)-c1ccc(Oc2ccccc2)cc1 Chemical compound NC1CCN(C1)c1ccc(C(N)=O)c(n1)-c1ccc(Oc2ccccc2)cc1 CQODFRDRLLAKOW-UHFFFAOYSA-N 0.000 description 1
- BHHPEQORXCRRJZ-UHFFFAOYSA-N NC1CCN(CC1)c1ccc(C(N)=O)c(n1)-c1ccc(Oc2ccccc2)cc1 Chemical compound NC1CCN(CC1)c1ccc(C(N)=O)c(n1)-c1ccc(Oc2ccccc2)cc1 BHHPEQORXCRRJZ-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010072359 Neuromyotonia Diseases 0.000 description 1
- 101100083259 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pho-4 gene Proteins 0.000 description 1
- KEDRJDHPUYWEGH-UHFFFAOYSA-N O=C(C1=NC=CC(C(C=C2)=CC=C2OC2=CC=CC=C2)=N1)NCl Chemical compound O=C(C1=NC=CC(C(C=C2)=CC=C2OC2=CC=CC=C2)=N1)NCl KEDRJDHPUYWEGH-UHFFFAOYSA-N 0.000 description 1
- VHMDCZDDLBLRIK-UHFFFAOYSA-N ON=C(C(=O)OCC)/C(C1=CC=C(C=C1)OC1=CC=CC=C1)=O Chemical compound ON=C(C(=O)OCC)/C(C1=CC=C(C=C1)OC1=CC=CC=C1)=O VHMDCZDDLBLRIK-UHFFFAOYSA-N 0.000 description 1
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 description 1
- 206010053854 Opsoclonus myoclonus Diseases 0.000 description 1
- 208000005225 Opsoclonus-Myoclonus Syndrome Diseases 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 206010031149 Osteitis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 235000010617 Phaseolus lunatus Nutrition 0.000 description 1
- 206010035742 Pneumonitis Diseases 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036524 Precursor B-lymphoblastic lymphomas Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010038563 Reocclusion Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 208000034712 Rickettsia Infections Diseases 0.000 description 1
- 206010061495 Rickettsiosis Diseases 0.000 description 1
- 208000007893 Salpingitis Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040550 Shigella infections Diseases 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
- 206010043781 Thyroiditis chronic Diseases 0.000 description 1
- 206010048873 Traumatic arthritis Diseases 0.000 description 1
- 208000037280 Trisomy Diseases 0.000 description 1
- 206010063092 Trisomy 12 Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000010094 Visna Diseases 0.000 description 1
- 208000003728 Vulvodynia Diseases 0.000 description 1
- 206010069055 Vulvovaginal pain Diseases 0.000 description 1
- 102000007624 ZAP-70 Protein-Tyrosine Kinase Human genes 0.000 description 1
- 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- NPXOILYTGBDCHZ-UHFFFAOYSA-N [O-]C([S+]1C(C2CCCC2)=NC(C(C=C2)=CC=C2OC2=CC=CC=C2)=C1)=O Chemical compound [O-]C([S+]1C(C2CCCC2)=NC(C(C=C2)=CC=C2OC2=CC=CC=C2)=C1)=O NPXOILYTGBDCHZ-UHFFFAOYSA-N 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 208000012761 aggressive behavior Diseases 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 208000032775 alopecia universalis congenita Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000003367 anti-collagen effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- QXNDZONIWRINJR-UHFFFAOYSA-N azocane Chemical compound C1CCCNCCC1 QXNDZONIWRINJR-UHFFFAOYSA-N 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 description 1
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- FUHMZYWBSHTEDZ-UHFFFAOYSA-M bispyribac-sodium Chemical compound [Na+].COC1=CC(OC)=NC(OC=2C(=C(OC=3N=C(OC)C=C(OC)N=3)C=CC=2)C([O-])=O)=N1 FUHMZYWBSHTEDZ-UHFFFAOYSA-M 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 208000018339 bone inflammation disease Diseases 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- BRTFVKHPEHKBQF-UHFFFAOYSA-N bromocyclopentane Chemical compound BrC1CCCC1 BRTFVKHPEHKBQF-UHFFFAOYSA-N 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 235000008957 cocaer Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000037011 constitutive activity Effects 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
- 230000005574 cross-species transmission Effects 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- JMYVMOUINOAAPA-UHFFFAOYSA-N cyclopropanecarbaldehyde Chemical compound O=CC1CC1 JMYVMOUINOAAPA-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 201000004400 dacryoadenitis Diseases 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- RAFNCPHFRHZCPS-UHFFFAOYSA-N di(imidazol-1-yl)methanethione Chemical compound C1=CN=CN1C(=S)N1C=CN=C1 RAFNCPHFRHZCPS-UHFFFAOYSA-N 0.000 description 1
- PBGGNZZGJIKBMJ-UHFFFAOYSA-N di(propan-2-yl)azanide Chemical compound CC(C)[N-]C(C)C PBGGNZZGJIKBMJ-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007435 diagnostic evaluation Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- ZOCHARZZJNPSEU-UHFFFAOYSA-N diboron Chemical compound B#B ZOCHARZZJNPSEU-UHFFFAOYSA-N 0.000 description 1
- UFMVNSFONAZFOT-UHFFFAOYSA-N dichloromethane;n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound ClCCl.CCN(C(C)C)C(C)C UFMVNSFONAZFOT-UHFFFAOYSA-N 0.000 description 1
- SYZWSSNHPZXGML-UHFFFAOYSA-N dichloromethane;oxolane Chemical compound ClCCl.C1CCOC1 SYZWSSNHPZXGML-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- IEPRKVQEAMIZSS-AATRIKPKSA-N diethyl fumarate Chemical compound CCOC(=O)\C=C\C(=O)OCC IEPRKVQEAMIZSS-AATRIKPKSA-N 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- ZHXTWWCDMUWMDI-UHFFFAOYSA-N dihydroxyboron Chemical compound O[B]O ZHXTWWCDMUWMDI-UHFFFAOYSA-N 0.000 description 1
- JMRYOSQOYJBDOI-UHFFFAOYSA-N dilithium;di(propan-2-yl)azanide Chemical compound [Li+].CC(C)[N-]C(C)C.CC(C)N([Li])C(C)C JMRYOSQOYJBDOI-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- UZZWBUYVTBPQIV-UHFFFAOYSA-N dme dimethoxyethane Chemical compound COCCOC.COCCOC UZZWBUYVTBPQIV-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 208000019479 dysautonomia Diseases 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 208000010227 enterocolitis Diseases 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- AFZNLSCFUNHBQH-UHFFFAOYSA-N ethyl 2-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]-4-(4-phenoxyphenyl)-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C=1SC(N2CCN(CC2)C(=O)OC(C)(C)C)=NC=1C(C=C1)=CC=C1OC1=CC=CC=C1 AFZNLSCFUNHBQH-UHFFFAOYSA-N 0.000 description 1
- LKCXWGGSDRJUBE-UHFFFAOYSA-N ethyl 2-bromo-3-oxo-3-(4-phenoxyphenyl)propanoate Chemical compound CCOC(=O)C(Br)C(=O)c1ccc(Oc2ccccc2)cc1 LKCXWGGSDRJUBE-UHFFFAOYSA-N 0.000 description 1
- KTOVHAREPNFBCH-UHFFFAOYSA-N ethyl 3-(4-phenoxyphenyl)-1h-pyrazole-5-carboxylate Chemical compound N1C(C(=O)OCC)=CC(C=2C=CC(OC=3C=CC=CC=3)=CC=2)=N1 KTOVHAREPNFBCH-UHFFFAOYSA-N 0.000 description 1
- CAXNCSRMNJVMKD-UHFFFAOYSA-N ethyl 3-oxo-3-(4-phenoxyphenyl)propanoate Chemical compound C1=CC(C(=O)CC(=O)OCC)=CC=C1OC1=CC=CC=C1 CAXNCSRMNJVMKD-UHFFFAOYSA-N 0.000 description 1
- XQVYFOKOFIFZEA-UHFFFAOYSA-N ethyl 5-(4-phenoxyphenyl)-1h-pyrazole-4-carboxylate Chemical compound C1=NNC(C=2C=CC(OC=3C=CC=CC=3)=CC=2)=C1C(=O)OCC XQVYFOKOFIFZEA-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000017215 gastric mucosa-associated lymphoid tissue lymphoma Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 210000001102 germinal center b cell Anatomy 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000009033 hematopoietic malignancy Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000002557 hidradenitis Diseases 0.000 description 1
- 201000007162 hidradenitis suppurativa Diseases 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 102000053446 human BTK Human genes 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 1
- UVNXNSUKKOLFBM-UHFFFAOYSA-N imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=CSC2=NC=CN21 UVNXNSUKKOLFBM-UHFFFAOYSA-N 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000012760 immunocytochemical staining Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical class [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 201000011649 lymphoblastic lymphoma Diseases 0.000 description 1
- 208000006116 lymphomatoid granulomatosis Diseases 0.000 description 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000003826 marginal zone b cell Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- YOFNWWZZELAVRX-UHFFFAOYSA-N methanethione Chemical compound S=[CH+] YOFNWWZZELAVRX-UHFFFAOYSA-N 0.000 description 1
- GRWIABMEEKERFV-UHFFFAOYSA-N methanol;oxolane Chemical compound OC.C1CCOC1 GRWIABMEEKERFV-UHFFFAOYSA-N 0.000 description 1
- UDCCTNIBELHUQN-UHFFFAOYSA-N methyl 2-bromo-3-fluorobenzoate Chemical compound COC(=O)C1=CC=CC(F)=C1Br UDCCTNIBELHUQN-UHFFFAOYSA-N 0.000 description 1
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000002077 muscle cancer Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- VOVZXURTCKPRDQ-CQSZACIVSA-N n-[4-[chloro(difluoro)methoxy]phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-5-yl)pyridine-3-carboxamide Chemical compound C1[C@H](O)CCN1C1=NC=C(C(=O)NC=2C=CC(OC(F)(F)Cl)=CC=2)C=C1C1=CC=NN1 VOVZXURTCKPRDQ-CQSZACIVSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000010309 neoplastic transformation Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 208000005963 oophoritis Diseases 0.000 description 1
- 201000005737 orchitis Diseases 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- XHWNEBDUPVMPKI-UHFFFAOYSA-N oxazetidine Chemical compound C1CON1 XHWNEBDUPVMPKI-UHFFFAOYSA-N 0.000 description 1
- UHHKSVZZTYJVEG-UHFFFAOYSA-N oxepane Chemical compound C1CCCOCC1 UHHKSVZZTYJVEG-UHFFFAOYSA-N 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 125000003544 oxime group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- HZIVRQOIUMAXID-UHFFFAOYSA-N oxocane Chemical compound C1CCCOCCC1 HZIVRQOIUMAXID-UHFFFAOYSA-N 0.000 description 1
- 125000005475 oxolanyl group Chemical group 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- IIKFXOLJMNWWCH-UHFFFAOYSA-N piperidine-1,4-dicarboxylic acid Chemical compound OC(=O)C1CCN(C(O)=O)CC1 IIKFXOLJMNWWCH-UHFFFAOYSA-N 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 206010035653 pneumoconiosis Diseases 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 235000014483 powder concentrate Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000018290 primary dysautonomia Diseases 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- ODNFVADIRXKBCY-UHFFFAOYSA-N pyrrolidin-1-yl carbamate Chemical compound NC(=O)ON1CCCC1 ODNFVADIRXKBCY-UHFFFAOYSA-N 0.000 description 1
- ADPQWEGXWVSSKZ-UHFFFAOYSA-N pyrrolidine-1,3-dicarboxylic acid Chemical compound OC(=O)C1CCN(C(O)=O)C1 ADPQWEGXWVSSKZ-UHFFFAOYSA-N 0.000 description 1
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 201000001223 septic arthritis Diseases 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- LBJQKYPPYSCCBH-UHFFFAOYSA-N spiro[3.3]heptane Chemical compound C1CCC21CCC2 LBJQKYPPYSCCBH-UHFFFAOYSA-N 0.000 description 1
- 238000010911 splenectomy Methods 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- YJKYWSNCNLSYIP-UHFFFAOYSA-N tert-butyl 2-(trifluoromethylsulfonyloxy)-2,5-dihydropyrrole-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1CC=CC1OS(=O)(=O)C(F)(F)F YJKYWSNCNLSYIP-UHFFFAOYSA-N 0.000 description 1
- KIFYKONQFFJILQ-UHFFFAOYSA-N tert-butyl 2-carbamoylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1C(N)=O KIFYKONQFFJILQ-UHFFFAOYSA-N 0.000 description 1
- RIOKPEBUTRGTEA-UHFFFAOYSA-N tert-butyl 3-(4-methylphenyl)sulfonyloxyazetidine-1-carboxylate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC1CN(C(=O)OC(C)(C)C)C1 RIOKPEBUTRGTEA-UHFFFAOYSA-N 0.000 description 1
- MWACHFODPQVXHF-UHFFFAOYSA-N tert-butyl 3-(4-methylphenyl)sulfonyloxypyrrolidine-1-carboxylate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC1CN(C(=O)OC(C)(C)C)CC1 MWACHFODPQVXHF-UHFFFAOYSA-N 0.000 description 1
- NHDGOVOBEZPXMY-UHFFFAOYSA-N tert-butyl 3-carbamoylpyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C(N)=O)C1 NHDGOVOBEZPXMY-UHFFFAOYSA-N 0.000 description 1
- XRRXRQJQQKMFBC-UHFFFAOYSA-N tert-butyl 3-hydroxyazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(O)C1 XRRXRQJQQKMFBC-UHFFFAOYSA-N 0.000 description 1
- RIFXIGDBUBXKEI-UHFFFAOYSA-N tert-butyl 3-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(=O)C1 RIFXIGDBUBXKEI-UHFFFAOYSA-N 0.000 description 1
- JSOMVCDXPUXKIC-UHFFFAOYSA-N tert-butyl 3-oxopyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)C1 JSOMVCDXPUXKIC-UHFFFAOYSA-N 0.000 description 1
- RHAKDMVNJLPYCZ-UHFFFAOYSA-N tert-butyl 4-(6-cyanopyridin-2-yl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=CC(C#N)=N1 RHAKDMVNJLPYCZ-UHFFFAOYSA-N 0.000 description 1
- VXOCSENAGKVASP-UHFFFAOYSA-N tert-butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2h-pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(B2OC(C)(C)C(C)(C)O2)=C1 VXOCSENAGKVASP-UHFFFAOYSA-N 0.000 description 1
- ZRKPIWQNLHUKOY-UHFFFAOYSA-N tert-butyl 5-(trifluoromethylsulfonyloxy)-3,4-dihydro-2h-pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(OS(=O)(=O)C(F)(F)F)=C1 ZRKPIWQNLHUKOY-UHFFFAOYSA-N 0.000 description 1
- FRHOQDDDDFBHGW-UHFFFAOYSA-N tert-butyl n-piperidin-1-ylcarbamate Chemical compound CC(C)(C)OC(=O)NN1CCCCC1 FRHOQDDDDFBHGW-UHFFFAOYSA-N 0.000 description 1
- CKXZPVPIDOJLLM-UHFFFAOYSA-N tert-butyl n-piperidin-4-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCNCC1 CKXZPVPIDOJLLM-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- ISXOBTBCNRIIQO-UHFFFAOYSA-N tetrahydrothiophene 1-oxide Chemical compound O=S1CCCC1 ISXOBTBCNRIIQO-UHFFFAOYSA-N 0.000 description 1
- NNLBRYQGMOYARS-UHFFFAOYSA-N thiane 1-oxide Chemical compound O=S1CCCCC1 NNLBRYQGMOYARS-UHFFFAOYSA-N 0.000 description 1
- 125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 description 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 1
- GGNIKGLUPSHSBV-UHFFFAOYSA-N thiazole-5-carboxamide Chemical compound NC(=O)C1=CN=CS1 GGNIKGLUPSHSBV-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- JWCVYQRPINPYQJ-UHFFFAOYSA-N thiepane Chemical compound C1CCCSCC1 JWCVYQRPINPYQJ-UHFFFAOYSA-N 0.000 description 1
- XSROQCDVUIHRSI-UHFFFAOYSA-N thietane Chemical compound C1CSC1 XSROQCDVUIHRSI-UHFFFAOYSA-N 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 125000003441 thioacyl group Chemical group 0.000 description 1
- AMIGYDGSJCJWSD-UHFFFAOYSA-N thiocane Chemical compound C1CCCSCCC1 AMIGYDGSJCJWSD-UHFFFAOYSA-N 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 1
- 125000004953 trihalomethyl group Chemical group 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 206010047470 viral myocarditis Diseases 0.000 description 1
- 208000002003 vulvitis Diseases 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000012447 xenograft mouse model Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Abstract
Disclosed are substituted nicotinamide derivatives as inhibitors of Bruton's Tyrosine Kinase (BTK) and are useful in treating associated diseases including cancer, inflammation, and autoimmune diseases.
Description
TUTED NICOTINIMIDE TORS OF BTK AND THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE CROSS-REFERENCE TO RELATED APPLICATIONS This ation claims priority under 35 U.S.C. 119(e) to US. Provisional Patent ation No. 61/884,958, filed on September 30, 2013 and entitled "Kinase ting Compounds," and under 35 U.S.C. 1 19(a) to Chinese Patent Application No. 4850481, filed on October 16, 2013 and entitled tic Amide Derivative, Method of its Preparation, and its Application on Medicine." The entire contents of each of the above-referenced applications are incorporated herein by reference.
FIELD AND BACKGROUND The present invention relates to chemical compounds, pharmaceutical compositions including these compounds, and their use in treatment of disease. In particular, the present invention relates to the use of substituted nicotinimides as irreversible inhibitors of tyrosine kinases useful in the treatment of diseases mediated by Bruton’s Tyrosine Kinase (BTK) including cancer, inflammation and autoimmune disease.
BTK is a Tec family ceptor protein kinase which plays a role in multiple signal- transduction ys regulating survival, activation, proliferation, and differentiation of B- lineage lymphoid cells. BTK is overexpressed and active in several B-lineage lymphoid malignancies. BTK is expressed in ant cells in humans with B-Cell Precursor (BCP)— Acute Lymphoblastic Leukemia (ALL), c Lymphocytic Leukemia (CLL), and Non- Hodgkin’s Lymphoma (NHL). BTK is an upstream activator of anti-apoptotic ing molecules and networks, including: Signal Transducer and Activator of Transcription 5 (STAT5) protein, Phosphatidylinositol (PI), 3-kinase/AKT/Mammalian Target of Rapamycin (mTOR) pathway, and Nuclear Factor kappa B (NF-KB). D’Cruz, Osmond J., OncoTargets and Therapy 2013:6,161-176. to De Man et al. describes that BTK is expressed in B cells and myeloid cells, and is a terminal enzyme in the B-Cell antigen Receptor (BCR) signaling pathway. ons in human BTK leads to X-Linked Agammaglobulinemia (XLA), an immunodeficiency disease d to a failure to generate mature B cells leading to reduced immunoglobulin in serum. BTK is therefore implicated in regulation of the tion of auto-antibodies in autoimmune diseases. Furthermore, BTK may play a role in treatment of autoimmune diseases terized by production of flammatory cytokines and chemokines by B cells due to BTK's position in the BCR pathway. BTK inhibitors may be used for treatment of B cell lymphomas due to BTK' s involvement in the regulation of proliferation and apoptosis of B cells. tion of BTK is relevant in ular for B cell lymphomas due to chronic active BCR ing. Davis et al., Nature, 463 (2010), 88-94.
Adaptive immune responses may involve B lymphocyte tion and absence of B lymphocyte tion is an indication of autoimmune disease. Treatment of autoimmune e, such as Rheumatoid Arthritis (RA), with Rituximab, an anti-CD20 therapy, trates that B cell therapies are effective. Additionally, treatment with Rituximab has been shown to improve disease symptoms in Relapsing Remitting Multiple Sclerosis (RRMS) and Systemic Lupus Erythematosus (SLE) patients. Accordingly, targeting B cell immunity is effective for treatment of autoimmune diseases.
SUMMARY The present invention includes certain substituted compounds described herein, their pharmaceutically acceptable salts, solvates and hydrates, preparation of the compounds, intermediates, pharmaceutical compositions and ations thereof, and methods of treating disease including cancers, inflammation, and autoimmune diseases therewith.
It is an object of the present invention to overcome or ameliorate at least one of the disadvantages of the prior art, or to provide a useful alternative.
The present invention includes compounds of Formula I and pharmaceutically acceptable salts thereof as provided below and further defined herein: In some aspects, compounds of the invention are irreversible inhibitors of kinases, including Bruton’s Tyrosine Kinase (BTK). In some aspects, compounds ofthe invention are selective tors of BTK.
In some s, the invention includes methods of treating proliferative disease, particularly cancers, conditions g inflammation, and autoimmune diseases mediated at least in part by BTK, alone or in combination regimens with other therapies.
Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as inhibitors of protein kinases. In some embodiments, the compounds are effective as tors of Bruton’s ne Kinase (BTK). In some aspects, the invention includes pharmaceutically acceptable salts of the compounds of a I: wherein: A is ed from C3_12cycloalkyl, C3_12heterocycloalkyl, C3_12aryl, or C3_12heteroaryl, any of which is optionally substituted with G1 substituents; B1 is selected from C3_12cycloalkyl—C0_1zalky1—, C34gheterocycloalkyl—C0_12alkyl—, aryl— C0_12alkyl—, aryl—C3_12cycloalkyl—, aryl—C3_lzheterocycloalkyl—, heteroaryl—C0_12alkyl—, heteroaryl—C3_12cycloalkyl—, or heteroaryl—C3_1zheterocycloalky1—, any h is ally substituted with G2 substituents; B2 is selected from C0_12alkyl, C3-12cycloalkyl—Co_12alkyl—, C3-12heterocycloalkyl—Co_ 12alkyl—, aryl—C0_12alkyl—, aryl—C3_12cycloalkyl—, aryl—C3_12heterocycloalkyl—, heteroaryl—C0_ 12alkyl—, heteroaryl—C3_12cycloalkyl—, or heteroaryl—C3_lzheterocycloalkyl—, any of which is optionally substituted with G3 substituents; L1 is selected from —C0_2alkyl—, —CR5R6—, —C0_3alkyl(R5)(OH)—, —C(O)—, —CH20—, — OCH2—, —CF2—, —SCR5R6—, —CR5R6S—, —N(R5)—, —N(R5)C(O)—, —C(O)N(R5)—, — N(R5)C(0)N(R")—, —0—, —S—, —S(0)mi—, —N(R5)S(O)mi—, or —S(0)miN(R5)—; L2 is selected from —C0_4alkyl—, , —N(R7)—, —N(R7)C(O)—, or —N(R7)S(O)m2—; X is selected from C342cycloalkyl—C0_12alkyl—, C34gheterocycloalkyl—Cdlzalkyl—, aryl— C0_12alkyl—, aryl—C3_12cycloalkyl—, aryl—C3_lgheterocycloalkyl—, heteroaryl—C0_12alkyl—, heteroaryl—C3_12cycloalkyl—, or heteroaryl—C3_1gheterocycloalkyl—, any ofwhich is optionally substituted with G4 tuents; Y is selected from —C(O)—, —N(R8)—, —N(R8)C(O)—, g—, or S(O)m3—; R1 is selected from —C(O)R9,—C(O)NR9R1°,—C(O)OR9, C14alkynyl, 0R9, S(O)m4R9R10, or —CN; R2, R3, and R4 are each independently selected from C0_12alkyl, —CN, halo, C3- 12cycloalkyl—C0_1zalkyl—, C3-1gheterocycloalkyl—C0_12alkyl—, aryl—C0_12alkyl—, aryl—C3_ oalkyl—, aryl—C3_1gheterocycloalkyl—, heteroaryl—C0_12alkyl—, heteroaryl—C3_lzcycloalkyl—, or heteroaryl—C3_lzheterocycloalkyl—, any ofwhich is optionally substituted with G5 substituents; R5, R6, R7, R8, R9, and R10 are each independently selected from Co_12alkyl, C3- 12cycloalkyl—C0_1zalkyl—, eterocycloalkyl—C0_12alkyl—, aryl—C0_12alkyl—, 3_ 12cycloalkyl—, aryl—C3_1zheterocycloalkyl—, heteroaryl—C0_12alkyl—, heteroaryl—C3_1chcloalkyl—, or heteroaryl—C3_lzheterocycloalkyl—, any of which is optionally substituted with G6 substituents; G1, G2, G3, G4, G5, and G6 are each independently selected from one or more of C0. lzalkyl, —C2_12alkenyl, —C2_12alkynyl, D, —CD3, —OCD3, halo, CN, OX0 , CF3, OCFg, OCHFz, —N02, —B(OH)2, —1>(0)c0_3 alkyl, —PO(OR")2, —PO(OR")R12, ycloalkyl—C0_ lgalkyl—, C34gheterocycloalkyl—C0_1zalkyl—, aryl—Co_12alkyl—, aryl—C3_12cycloalkyl—, aryl—C3_ lzheterocycloalkyl—, aryl—C0_12alkyl—, heteroaryl—C3_12cycloalkyl—, heteroaryl—C3_ lzheterocycloalkyl—, —C0_6alkleR11,—OC(O)NR"R12, —C(O)OR",—C(O)NR"R12,—C(O)R", — NRUR", —NR"C(O)R12, —NR13C(0)NR"R", —S(O)m5R", and O)m5R12, any ofwhich is optionally substituted with Q1 substituents; Q1 is selected from one or more of C0_1zalkyl—, —C2_12alkenyl, —C2_12alkynyl, D, halo, — CN, —CD3, —OCD3, —oxo—, —CF3, —OCF3, —OCHF2, —N02, —B(OH)2, —PO(OR14)2, — PO(OR14)R15,NR14R15, —C(O)NR14OH, —C0_6alkleR14, aryl—C0_12alkyl—, heteroaryl—C0_12alkyl— , C34gcycloalkyl—C0_12alkyl—, C3-12heterocycloalkyl—Co_12alkyl—, aryl—C0_1gcycloalkyl—, heteroaryl—C3_12cycloalkyl—, terocycloalkyl—C3_12cycloalkyl—, C3_12cycloalkyl—C3_ 12cycloalkyl—, C3.12heterocycloalkyl—C3_12heterocycloalkyl—, aryl—C3_1gheterocycloalkyl—, heteroaryl—C3_12heterocycloalkyl—, —C(O)-C(O)NR14R15, —C(O)-C(O)OR14, —OC(O)R14, — NR14C(O)R15, —NR14S(O)m6R15, —(CR15R16)n1C(O)R14, —(CR15R16)n1C(O)OR14, — 16)H1C(O)NR14R17, —(CR15R16)H1S(O)m6NR14R17, —(CR15R16)H1NR14R17, —(CR15R16)H10R14, —(CR15R16)H18(O)m6R14, —NR16C(O)NR14R15, and —NR16S(O)m6NR14R15, any of which is optionally substituted with independently ed E1 substituents; E1 is selected from one or more of C0_12alkyl—, —C2_12alkenyl, —C2_12alkynyl, D, halo, — CN, —oxo—, —CD3, —OCD3, —CF3, —OCF3, —OCHF2, —N02, —B(OH)2, —PO(OR18)2, — PO(OR18)R19, R180H, —C(O)NR18R19, —C0_12alkleR18, aryl—C0_12alkyl—, heteroaryl—C0_ lzalkyl—, C34gcycloalkyl—C0_12alkyl—, C3-1gheterocycloalkyl—Cmgalkyl—, aryl—C0_12cycloalkyl—, heteroaryl—C3_12cycloalkyl—, C34gheterocycloalkyl—C3_12cycloalkyl—, C3_12cycloalkyl—C3_ lzcycloalkyl—, C34zheterocycloalkyl—C3_1zheterocycloalkyl—, aryl—C3_1gheterocycloalkyl—, heteroaryl—C3_12heterocycloalkyl—, —C(O)-C(O)NR18R19, —C0_12alkle(O)OR18, —C(O)- C(O)OR18, —OC(O)R18, —NR18C(O)R19, —NR18C(O)OR19, —NR188(O)m7R19, — (CR19R2°)n2C(O)R18, —(CR19R20)n2C(O)OR18,—(CR19R2°)n2C(O)NR18R21, — )HZS(O)m7NR18R21, —(CR19R20)n2NR18R21, —(CR19R20)HZOR18, —(CR19R20)HZS(O)m7R18’ _ NR2°C(O)NR18R19, and —NR2°S(O)m7NR18R19 substituents; R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, and R21 are each independently ed from H, C1_5alkyl—, C3_gcycloalkyl—C0_6alkyl—, C3_gheterocycloalkyl—C0_6alkyl—, aryl—Co_5alkyl—, aryl—C3_gcycloalkyl—, 3_gheterocycloalkyl—, heteroaryl—C1_6alkyl—, heteroaryl—C3_ 8cycloalkyl—, or heteroaryl—C3-8heterocycloalkyl—g R3 and R4 are taken together with the carbon atoms to which they are attached to form a 3-12 membered partially ted or unsaturated ring, wherein said ring optionally includes one or more onal heteroatoms selected from O, N, or S(O)m8; ml, m2, m3, m4, m5, m6, m7, m8, nl, and n2 are each independently selected from 0, l, or 2; or a pharmaceutically able salt, solvate or a prodrug thereof.
In some aspects of Formula 1, compounds of the present invention are a subgenus of Formula I, having the Formula Ia: wherein: B1 is selected from C3-12cycloalkyl—C0_1zalky1—, C3_12heterocycloalkyl—C0_12alkyl—, aryl— C0_12alkyl—, aryl—C3_12cycloalkyl—, aryl—C3_lgheterocycloalkyl—, heteroaryl—C0_12alkyl—, heteroaryl—C3_12cycloalkyl—, or heteroaryl—C3_1zheterocycloalkyl—, any ofwhich is ally substituted with G2 substituents; B2 is selected from C0_12alkyl, ycloalkyl—C0_12alkyl—, eterocycloalkyl—C0_ 12alkyl—, aryl—C0_12alkyl—, aryl—C3_12cycloalkyl—, aryl—C3_lzheterocycloalkyl—, heteroaryl—C0_ 12alkyl—, aryl—C3_12cycloalkyl—, or heteroaryl—C3.12heterocycloalkyl—, any of which is ally substituted with G3 substituents; L1 is selected from —C0_2alkyl—, —CR5R6—, —C0_3alkyl(R5)(OH)—, —C(O)—, —CH20—, — OCH2—, —CF2—, 6—, —CR5R6S—, —N(R5)—, —N(R5)C(O)—, —C(O)N(R5)—, — N(R5)C(O)N(R6)—i -O—i —S-i _S(O)m1_a _N(R5)S(O)m1_a 0r —S(O)m1N(R5)-; L2 is selected from —C0_4alkyl—, —C(O)—, —N(R7)—, —N(R7)C(O)—, or —N(R7)S(O)m2—; X is selected from C3_12cycloalkyl—C0_12alkyl—, C34gheterocycloalkyl—Cdlzalkyl—, aryl— C0_12alkyl—, aryl—C3_12cycloalkyl—, aryl—C3_lgheterocycloalkyl—, heteroaryl—C0_12alkyl—, heteroaryl—C3_12cycloalkyl—, or heteroal'yl—C3_1gheterocycloalkyl—, any ofwhich is optionally substituted with G4 substituents; Y is selected from , —N(R8)—, —N(R8)C(O)—, —S(O)m3—, or —N(R8)S(O)m3—; Z1 is (CRa)o-1; Z2 is selected from CRb, NRb, O, or S; Z3 is selected from C or N; Z4 is selected from CRC, NR°, O, or S; R1 is selected from —C(O)R9,—C(O)NR9R10,—C(O)OR9, C1_4alkynyl, 0R9, S(O)m4R9R1°, or —CN; R2, R3, R4, Ra, Rb, and R0 are each independently selected from C0_12alkyl, —CN, halo, C3- 12cycloalkyl—C0_1zalkyl—, C3_1gheterocycloalkyl—C0_12alkyl—, aryl—C0_12alkyl—, aryl—C3_ 12cycloalkyl—, aryl—C3_1gheterocycloalkyl—, heteroaryl—Co_12all(0)c0_3 alkyl, —PO(OR")2, —PO(OR")R12, C3_12cycloalkyl—C0_ lzalkyl—, C3_1gheterocycloalkyl—C0_lzalky1—, aryl—C0_12alkyl—, 3_12cycloalky1—, aryl—C3_ 12heterocycloalkyl—, heteroaryl—C0_12alkyl—, aryl—C3_1zcycloalkyl—, heteroaryl—C3_ lzheterocycloalkyl—, —C0_6a1kyIOR11,—OC(O)NR"R12, —C(O)OR", —C(O)NR"R12, —C(O)R", — NRUR", —NR"C(O)R12, —NR"C(0)NR"R", —S(O)m5R", and —NR"S(O)m5R12, any ofwhich is optionally substituted with independently selected Q1 substituents; Q1 is selected from one or more of C0_12alky1—, —C2_12alkenyl, —C2_12alkyny1, D, halo, — CN, —CD3, —OCD3, —oxo—, —CF3, —OCF3, —OCHF2, —N02, —B(OH)2, 14)2, — PO(OR14)R15,NR14R15, —C(O)NR14OH, —C0_6alky10R14, aryl—Co_12alkyl—, heteroaryl—C0_12alkyl— , ycloalkyl—C0_12alkyl—, C3-12heterocycloalkyl—C0_12alkyl—, aryl—C0_1zcycloalkyl—, heteroaryl—C3_12cycloalky1—, C34zheterocycloalkyl—C3_12cycloalkyl—, C3_12cycloalkyl—C3_ 12cycloalkyl—, C34gheterocycloalkyl—C3_12heterocycloalkyl—, aryl—C3_1gheterocycloalkyl—, heteroaryl—C3_lzheterocycloalkyl: —C(O)-C(O)NR14R15, —C(O)-C(O)OR14, R14, — NR14C(O)R15, —NR14S(O)m6R15, —(CR15R16)H1C(O)R14, —(CR15R16)H1C(O)OR14, — (CR15R16)H1C(O)NR14R17, —(CR15R16)H1S(O)m6NR14R17, —(CR15R16)n1NR14R17, —(CR15R16)H10R14, R16)HIS(O)m6R14, —NR16C(O)NR14R15, and —NR16S(O)m6NR14R15, any of which is optionally substituted with independently selected El substituents; E1 is ed from one or more of C0_12alky1—, —C2_12alkenyl, —C2_12alkynyl, D, halo, — CN, —oxo—, —CD3, —OCD3, —CF3, —OCF3, , —N02, —B(OH)2, —PO(OR18)2, — PO(OR18)R19, —C(O)NR180H, R18R19, —C0_12alkleR18, aryl—C0_12alkyl—, heteroaryl—C0_ lzalkyl—, C342cycloalkyl—C0_12alkyl—, C34zheterocycloalkyl—C0_1zalkyl—, aryl—C0_1zcycloalkyl—, heteroaryl—C3_ucycloalkyl—, C3.12heterocycloalkyl—C3_12cycloalkyl—, C3_12cycloalkyl—C3_ 12cycloalkyl—, C34gheterocycloalkyl—C3_12heterocycloalkyl—, aryl—C3_1gheterocycloalkyl—, heteroaryl—C3_lzheterocycloalkyl—, —C(O)—C(O)NR18R19, alkle(O)OR18, —C(O)- C(O)OR18, —OC(O)R18, —NR18C(O)R19, —NR18C(O)OR19, —NRISS(O)m7R19, — (CR19R2°)n2C(O)R18, —(CR19R20)n2C(O)OR18,—(CR19R2°)n2C(O)NR18R21, — (CR19R20)H28(O)m7NR18R21, —(CR19R20)n2NR18R21, —(CR19R20)HZOR18, —(CR19R20)HZS(O)m7R18, _ O)NR18R19, and —NRZOS(O)m7NR18R19 substituents; R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, and R21 are each independently selected from H, C1_6alkyl—, C3_gcycloalkyl—C0_6alkyl—, C3_gheterocycloalkyl—C0_6alkyl—, aryl—C0_6alkyl—, aryl—C3_gcycloalkyl—, aryl—C3_gheterocycloalkyl—, heteroaryl—C1_5alkyl—, heteroaryl—C3_ gcycloalkyl—, or heteroaryl—C3_gheterocycloalkyl—; R3 and R4 are taken together with the carbon atoms to which they are attached to form a 3-12 ed partially saturated or unsaturated ring, wherein said ring ally includes one or more additional heteroatoms selected from O, N, or S(O)mg; ml, m2, m3, m4, m5, m6, m7, m8, n1, and n2 are each independently selected from 0, l, or 2; or a pharmaceutically acceptable salt, e or a prodrug thereof.
In some aspects of Formula 1, compounds of the present invention are a subgenus of a I selected from one of Formulas Ib-Ii: R4 o \ leB2 R3\H\ / L2 A\ / Y/ \X N R2 and R4 N \ L1\B2 1 / R3 L2 / Y/ \x 0 wherein: B1 is selected from C3-12cycloalkyl—C0_1zalky1—, C3_12heterocycloalkyl—C0_12alkyl—, aryl— C0_lzalkyl—, aryl—C3_12cycloalkyl—, aryl—C3_lzheterocycloalkyl—, heteroaryl—C0_12alkyl—, heteroaryl—C3_12cycloalkyl—, or heteroaryl—C3_1gheterocycloalkyl—, any ofwhich is ally substituted with G2 substituents; B2 is selected from C0_12alkyl, ycloalkyl—C0_12alkyl—, C3-12heterocycloalkyl—C0_ 12alkyl—, aryl—C0_12alkyl—, 3_12cycloalkyl—, aryl—C3_lzheterocycloalkyl—, heteroaryl—C0_ 12alkyl—, heteroaryl—C3_12cycloalkyl—, or heteroaryl—C3_12heterocycloalkyl—, any of which is optionally substituted with G3 substituents; L1 is selected from lkyl—, —CR5R6—, —C0_3alkyl(R5)(OH)—, —C(O)—, —CHzO—, — OCH2—, —CF2—, —SCR5R6—, —CR5R6S—, —N(R5)—, —N(R5)C(O)—, —C(O)N(R5)—, — N(R5)C(0)N(R6)-a , -S-» -S(0)m1-, -N(R5)S(O)m1-, 0r -S(0)m1N(R5)-; L2 is selected from —C0_4alkyl—, , —N(R7)—, —N(R7)C(O)—, or —N(R7)S(O)m2—; X is selected from C3_1zcycloalkyl—C0_12alkyl—, C34gheterocycloalkyl—C0_lzalkyl—, aryl— C0_12alkyl—, aryl—C3_12cycloalkyl—, aryl—C3_lgheterocycloalkyl—, heteroaryl—C0_12alkyl—, heteroaryl—C3_12cycloalkyl—, or heteroaryl—C3_1zheterocycloalkyl—, any ofwhich is optionally tuted with G4 substituents; Y is selected from —C(O)—, —N(R8)—, —N(R8)C(O)—, —S(O)m3—, or —N(R8)S(O)m3—; R1 is selected from —C(O)R9,—C(O)NR9R10,—C(O)OR9, nyl, 0R9, S(O)m4R9R1°, or —CN; R2, R3, and R4 are each independently selected from C0_12alkyl, —CN, halo, C3- 12cycloalkyl—C0_1zalkyl—, C34gheterocycloalkyl—C0_12alkyl—, aryl—C0_12alkyl—, aryl—C3_ 12cycloalkyl—, aryl—C3_1gheterocycloalkyl—, heteroaryl—C0_12alkyl—, aryl—C3_lgcycloalkyl—, or heteroaryl—C3_12heterocycloalkyl—, any of which is optionally substituted with G5 substituents; R5, R6, R7, R8, R9, and R10 are each ndently selected from C0_12alkyl, C3- 12cycloalkyl—C0_1galkyl—, C3.1gheterocycloalkyl—Co_1zalky1—, aryl—C0_12alkyl—, aryl—C3_ 12cycloalkyl—, aryl—C3_1gheterocycloalkyl—, heteroaryl—C0_12alkyl—, aryl—C3_lzcycloalkyl—, or heteroaryl—C3_1zheterocycloalkyl—, any of which is optionally substituted with G6 substituents; G1, G2, G3, G4, G5, and G6 are each independently selected from one or more of C0- 12alkyl, —C2_12alkenyl, —C2_12alkynyl, D, —CD3, —OCD3, halo, CN, OX0 , CF3, OCFg, OCHFZ, —N02, —B(OH)2, —1>(0)c0_3 alkyl, —PO(OR")2, ")R12, C3_12cycloalkyl—C0_ lzalkyl—, C34gheterocycloalkyl—C0_1Zalkyl—, aryl—C0_12alkyl—, aryl—C3_12cycloalkyl—, aryl—C3_ 12heterocycloalkyl—, heteroaryl—C0_12alkyl—, heteroaryl—C3_12cycloalkyl—, heteroaryl—C3_ 12heterocycloalkyl—, —C0_6alkleR11,—OC(O)NR"R12, —C(O)OR", —C(O)NR"R12, —C(O)R", — NRllRlz, —NR"C(O)R12, 0)NR"R", —S(O)m5R", and —NR"S(O)m5R12, any h is optionally tuted with independently selected Q1 substituents; Q1 is selected from one or more of Co_1zalkyl—, —C2_12alkenyl, —C2_12alkynyl, D, halo, — CN, —CD3, —OCD3, —oxo—, —CF3, —OCF3, —OCHF2, —N02, —B(OH)2, —PO(OR14)2, — PO(OR14)R15,NR14R15, —C(O)NR14OH, —C0_6alkleR14, aryl—C0_12alkyl—, heteroaryl—C0_12alkyl— , ycloalkyl—C0_12alkyl—, C3-12heterocycloalkyl—C0_lzalkyl—, aryl—C0_12cycloalkyl—, heteroaryl—C3_12cycloalkyl—, C34gheterocycloalkyl—C3_12cycloalkyl—, C3_1zcycloalkyl—C3_ 12cycloalkyl—, C34gheterocycloalkyl—C3_12heterocycloalkyl—, aryl—C3_1gheterocycloalkyl—, heteroaryl—C3_12heterocycloalkyl—, —C(O)-C(O)NR14R15, —C(O)-C(O)OR14, —OC(O)R14, — NR14C(O)R15, —NR14S(O)m6R15, —(CR15R16)H1C(O)R14, —(CR15R16)n1C(O)OR14, — (CR15R16)H1C(O)NR14R17, —(CR15R16)H1S(O)m6NR14R17, —(CR15R16)H1NR14R17, R16)n10R14, —(CR15R16)nlS(O)m6R14, —NR16C(O)NR14R15, (O)m6NR14R15, any ofwhich is optionally substituted with independently selected E1 substituents; E1 is selected from one or more of C0_12alkyl—, —C2_12alkenyl, —C2_12alkynyl, D, halo, — CN, —oxo—, —CD3, —OCD3, —CF3, —OCF3, —OCHF2, —N02, —B(OH)2, —PO(OR18)2, — PO(OR18)R19, —C(O)NR180H, —C(O)NR18R19, —C0_12alkleR18, aryl—C0_12alkyl—, heteroaryl—C0_ 12alkyl—, C3_1gcycloalkyl—C0_1zalkyl—, C34gheterocycloalkyl—Cmzalkyl—, aryl—C0_12cycloalkyl—, heteroaryl—C3_12cycloalkyl—, C34gheterocycloalkyl—C3_12cycloalkyl—, C3_1zcycloalkyl—C3_ 12cycloalkyl—, C34gheterocycloalkyl—C3_12heterocycloalkyl—, aryl—C3_1gheterocycloalkyl—, heteroaryl—C3_12heterocycloalkyl—, —C(O)-C(O)NR18R19, —C0_12alkle(O)OR18, —C(O)- C(O)OR18, —OC(O)R18, —NR18C(O)R19, —NR18C(O)OR19, —NR18S(0)m7R19, — (CR19R2°)n2C(O)R18, —(CR19R20)HZC(O)OR18, R20)n2C(O)NR18R21, — (CR19R20)HZS(O)m7NR18R21, —(CR19R20)n2NR18R21, —(CR19R20)HZOR18, —(CR19R20)HZS(O)m7R18, _ NR20C(O)NR18R19, and —NRZOS(O)m7NR18R19 substituents; R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, and R21 are each independently selected from H, C1_6alkyl—, C3_gcycloalkyl—C0_6alkyl—, C3_gheterocycloalkyl—C0_6alkyl—, aryl—C0_6alkyl—, aryl—C3_gcycloalkyl—, aryl—C3_8heterocycloalkyl—, heteroaryl—C1_6alkyl—, heteroaryl—C3_ gcycloalkyl—, or heteroaryl—C3_gheterocycloalkyl—; R3 and R4 are taken together with the carbon atoms to which they are attached to form a 3-12 membered lly saturated or unsaturated ring, wherein said ring optionally es one or more additional atoms selected from O, N, or S(O)mg; ml, m2, m3, m4, m5, m6, m7, m8, n1, and n2 are each independently selected from 0, 1, or 2; or a ceutically acceptable salt, solvate or a prodrug thereof.
In some ments of Formulas I, and Ia-Ii, B1 is selected from C4_gcycloalkyl—C0_ l—, C4_gheterocycloalkyl—C0_12alkyl—, C4_garyl—C0_12alkyl—, or C4_gheteroaryl—C0_12alkyl—, any of which is optionally substituted with G2 substituents.
In some embodiments of Formulas I, and Ia-Ii, B2 is selected from C4_gcycloalkyl—Co_ 12alkyl—, C4_gheterocycloalkyl—C0_12alkyl—, C4_garyl—C0_12alkyl—, or C4_gheteroaryl—C0_12alkyl—, any of which is optionally substituted with G3 substituents.
In some embodiments of Formulas I, and Ia-Ii, L1 is selected from —C0_2alkyl—, —CR5R6—, —C0_3alkyl(R5)(OH) , C(O) , CHZO , OCH2 , CF2 , N(R5) , N(R5)C(O)—, —C(O)N(R5)—, —O—, or —S(O)m1—.
In some ments of Formulas I, and Ia-Ii, L1 is selected from —C0_2alkyl—, —CR5R6—, —C1_2alkyl(R5)(OH)—, —C(O)—, —CF2—, —N(R5)—, —N(R5)C(O)—, —C(O)N(R5)—, —o—, or 1—.
In some embodiments of Formulas I, and Ia-Ii, L2 is selected from —C0_2alkyl—, , or —N(R7)—.
In some embodiments of Formulas I, and Ia-Ii, X is selected from C4_8cycloalkyl—C0_ 12alkyl—, C4_gheterocycloalkyl—C0_12alkyl—, C4_garyl—C0_12alkyl—, or C4_gheteroaryl—C0_12alkyl—.
In some embodiments of as I, and Ia-Ii, Y is selected from —C(O)—, —N(R8)—, — N(R8)C(O)—, or —S(O)m3—.
In some embodiments of Formulas I, and Ia—Ii, R1 is selected from —C(O)R9, — C(O)NR9R10, —C(O)OR9, C1_4alkynyl, or —CN.
In some embodiments of as I, and Ia-Ii, R2, R3, and R4 are each independently selected from C0_12alkyl, —CN, halo, C3_6cycloalkyl—C0_12alkyl—, C3_6heterocycloalkyl—C0_1galkyl— of which is optionally substituted with G5 tuents. , any In some embodiments of Formulas I, and Ia-Ii, G1, G2, G3, G4, G5, and G6 are each independently selected from one to three of C0_12alkyl, —C2_12alkenyl, —C2_12alkynyl, D, —CD3, — OCD3, halo, CN, oxo , CF3, OCF3, OCHFZ, —N02, —B(OH)2, —P(O)C0_3 alkyl, — PO(OR")2, —PO(OR")R12, C34zcycloalkyl—C0_12alkyl—, C3-12heterocycloalkyl—C0_12alkyl—,aryl— C0_12alkyl—, aryl—C3_1zcycloalkyl—, aryl—C3_12heterocycloalkyl—, heteroaryl—C0_12alkyl—, heteroaryl—C3_12cycloalkyl—, heteroaryl—C3-12heterocycloalkyl—, —C0_6all In some ments of Formulas I, and Ia-Ii, G1, G2, G3, G4, G5, and G6 are each independently selected from one to two of C0_12alkyl, —C2_12alkenyl, —C2_12alkynyl, D, —CD3, — OCD3, halo, CN, oxo , CF3, OCF3, OCHFZ, —N02, —B(OH)2, —P(O)C0_3 alkyl, — PO(OR")2, —PO(OR")R12, C34zcycloalkyl—C0_12alkyl—, C3_12heterocycloalkyl—C0_12alkyl—,aryl— C0_12alkyl—, aryl—C3_1zcycloalkyl—, 3_12heterocycloalkyl—, heteroaryl—C0_12alkyl—, heteroaryl—C3_12cycloalkyl—, aryl—C3_12heterocycloalkyl—, —C0_6all In some aspects, the t invention includes a nd selected from the group consisting of: 6-(3-acrylamidophenyl)(4-phenoxyphenyl)nicotinamide; 6-(1-acryloylpiperidinyl)(4-phenoxyphenyl)nicotinamide; 6-(4-acryloylpiperazinyl)(4-phenoxyphenyl)nicotinamide; N N 6-(1-acryloylpyrrolidinyl)(4-phenoxyphenyl)nicotinamide; N N 6-(4-acrylamidophenyl)(4-phenoxyphenyl)nicotinamide; O N N O 6-(1-acryloylpiperidinyl)(4-phenoxyphenyl)nicotinamide; O NH2 N N crylamidopiperidinyl)(4-phenoxyphenyl)nicotinamide; O N N N O 6-(3-acrylamidopyrrolidinyl)(4-phenoxyphenyl)nicotinamide; HN N N 1-(1-acryloylpyrrolidinyl)(4-phenoxyphenyl)-1H-pyrazolecarboxamide; O N N O 1-(1-acryloylazetidinyl)(4-phenoxyphenyl)-1H-pyrazolecarboxamide; N O 1-(4-acrylamidophenyl)(4-phenoxyphenyl)-1H-pyrazolecarboxamide; N O 1-(3-acrylamidophenyl)(4-phenoxyphenyl)-1H-pyrazolecarboxamide; N N N O (S)(1-acryloylpyrrolidinyl)(4-phenoxyphenyl)-1H-pyrazolecarboxamide; O N O N N (1-acryloylpyrrolidinyl)(4-phenoxyphenyl)-1H-pyrazolecarboxamide; O N N O 2-(1-acryloylpyrrolidinyl)(4-phenoxyphenyl)pyrimidinecarboxamide; N NH2 N N (4-(4-(dimethylamino)butenoyl)piperazinyl)(4- phenoxyphenyl)nicotinamide; N N N O 6-(4-acryloylpiperazinyl)(4-(cyclohexyloxy)phenyl)nicotinamide; N N 6-(4-acryloylpiperazinyl)(3-methoxymethylphenyl)nicotinamide; N N 6-(4-acryloylpiperazinyl)-6'-phenoxy-2,3'-bipyridinecarboxamide; N N N O 6-(4-acryloylpiperazinyl)(4-(pyridinyloxy)phenyl)nicotinamide; N N O N 1-(1-(4-(dimethylamino)butenoyl)pyrrolidinyl)(4-phenoxyphenyl)-1H-pyrazole- 4-carboxamide; O N N O 6-(4-acryloylpiperazinyl)(4-(3-fluorophenoxy)phenyl)nicotinamide; N N O F 6-(4-acryloylpiperazinyl)(3-fluorophenoxyphenyl)nicotinamide; N N cryloylpiperazinyl)(4-(4-fluorophenoxy)phenyl)nicotinamide; N N 6-(4-acryloylpiperazinyl)(4-(2-fluorophenoxy)phenyl)nicotinamide; N N 6-(4-acryloylpiperazinyl)(2-fluorophenoxyphenyl)nicotinamide; N N F O 2-(1-acryloylpiperidinyl)(4-phenoxyphenyl)thiazolecarboxamide; O S N N cryloylpyrrolidinyl)(4-phenoxyphenyl)thiazolecarboxamide; N N O 2-(1-acryloylpiperidinyl)(4-phenoxyphenyl)oxazolecarboxamide; O O N N O 2-(1-acryloylpyrrolidinyl)(4-phenoxyphenyl)oxazolecarboxamide; N N 2-(1-acryloylpyrrolidinyl)(4-phenoxyphenyl)thiazolecarboxamide; N S 2-(1-acryloylpiperidinyl)(4-phenoxyphenyl)thiazolecarboxamide; O N N S O cryloylpiperidinyl)(4-phenoxyphenyl)oxazolecarboxamide; N O 2-(1-acryloylpyrrolidinyl)(4-phenoxyphenyl)oxazolecarboxamide; O O 2-(1-acryloylpiperidinyl)(4-phenoxyphenyl)thiazolecarboxamide; S O 2-(1-acryloylpiperidinyl)(4-phenoxyphenyl)thiazolecarboxamide; N O 2-(1-acryloylpiperidinyl)(4-phenoxyphenyl)oxazolecarboxamide; O N N O O -(1-acryloylpiperidinyl)-4'-phenoxybiphenylcarboxamide; -(4-acryloylpiperazinyl)-4'-phenoxybiphenylcarboxamide; 6-(1-acryloylpiperidinyl)(4-(hydroxy(phenyl)methyl)phenyl)nicotinamide; O OH (1-(2-cyanobutenoyl)azetidinyl)(4-phenoxyphenyl)-1H-pyrazole carboxamide; N O 6-(4-acryloylpiperazinyl)(4-((4,4-difluorocyclohexyl)oxy)phenyl)nicotinamide; N N F cryloylpiperidinyl)(4-(phenylcarbamoyl)phenyl)nicotinamide; N N O O 2-(4-phenoxyphenyl)(4-(vinylsulfonyl)piperazinyl)nicotinamide; N N S O 2-(4-phenoxyphenyl)(1-(vinylsulfonyl)piperidinyl)nicotinamide; S O or a pharmaceutically acceptable salt thereof.
In some aspects, the present invention includes a compound selected from the group consisting of: 2-(4-phenoxyphenyl)(piperidinyl)nicotinamide; 2-(4-phenoxyphenyl)(piperazinyl)nicotinamide; N N tidinyl)(4-phenoxyphenyl)-1H-pyrazolecarboxamide; N O 1-(3-aminophenyl)(4-phenoxyphenyl)-1H-pyrazolecarboxamide; H2N N O 6-(1-acryloylpiperidinyl)(4-phenoxyphenyl)pyridinecarbonitrile; 6-(4-acryloylpiperazinyl)(4-phenoxyphenyl)pyridinecarboxylic acid; N N 2-(4-acryloylpiperazinyl)-N-methyl(4-phenoxyphenyl)thiazolecarboxamide; N O O .
In some aspects, the present ion includes a compound having a Formula IId, or a pharmaceutically acceptable salt or solvate thereof: R3 X Z R2 O O Formula IId N N N N wherein X is , , , or ; Z is C or N; G1, G2, and G3 are selected from the group ting of one or more H, D (deuterium), C1-12 alkyl, halogen, and CF3; R2 and R3 are each independently selected from the group consisting of H, D, C1-12 alkyl, halogen, CN, and CF3, wherein C1-12 alkyl is ally substituted with NR11R12; R4 is selected from the group consisting of H, D, C1-12 alkyl, halogen, CN, and CF3; and R11 and R12 are independently H or C1-6 alkyl.
In some aspects, the t invention includes a pharmaceutical ition for treating a disease mediated by Bruton’s tyrosine Kinase (BTK), comprising a compound of Formula I or a nd of Formula IId described herein, and a pharmaceutically acceptable salt thereof.
In some aspects, the present invention includes a use of a compound described herein in the manufacture of a medicament for treating of at least one of cancer, chronic inflammation, and autoimmune e mediated at least in part by BTK.
In some aspects, the present invention includes a ceutical composition including the compound or salt of any one of the compounds of Formula I, formulated with or without one or more pharmaceutical carriers.
In some aspects, the present invention includes a method for the treatment of at least one of cancer, chronic inflammation, and autoimmune disease mediated at least in part by BTK including administering to a subject in need thereof a therapeutically effective amount of a compound or salt of the compound of Formula I.
In some aspects, the present invention includes a method of treating cancer, chronic inflammation, or autoimmune disease in a mammal including administering a therapeutically effective amount of a compound of Formula I, or a pharmaceutically able salt thereof, to the mammal in need thereof.
In some aspects, the present invention includes a method of irreversibly ting tyrosine s, the method including administering to a patient a therapeutically effective amount of a tyrosine kinase inhibitor including a compound of Formula I.
In some aspects, the present invention includes a method of irreversibly inhibiting BTK, the method including administering to a patient a therapeutically effective amount of a BTK inhibitor ing a compound according to Formula I.
The methods described herein include administering to a subject in need a composition containing a therapeutically effective amount of one or more BTK tor compounds described herein. t being bound by theory, the diverse roles played by BTK signaling in s hematopoietic cell functions, e.g., B-cell receptor activation, suggests that small molecule BTK inhibitors are useful for ng the risk of or treating a variety of es affected by or affecting many cell types of the hematopoetic lineage including, e.g., autoimmune diseases, heteroimmune ions or diseases, inflammatory diseases, cancer ( e.g., B-cell proliferative disorders), and thromboembolic disorders. Further, the BTK inhibitor nds described herein can be used to inhibit a small subset of other tyrosine kinases that share homology with BTK by having a cysteine e (including a Cys 481 residue) that can form a [Followed by page 15]. covalent bond with the tor. Thus, a subset of tyrosine s other than BTK may be usefiil as therapeutic targets in a number of health conditions.
The methods described herein can be used to treat an autoimmune disease, which includes, but is not d to, rheumatoid arthritis, psoriatic tis, osteoarthritis, Still's disease, juvenile arthritis, lupus, diabetes (type I and type II), myasthenia gravis, oto's thyroiditis, Ord's thyroiditis, Graves' disease Sjogren's syndrome, multiple sclerosis, Guillain- Barre syndrome, acute disseminated encephalomyelitis, Addison's disease, opsoclonus- myoclonus me, ankylosing spondylitisis, antiphospholipid antibody syndrome, aplastic anemia, autoimmune hepatitis, c disease, sture's syndrome, idiopathic ocytopenic purpura, optic neuritis, scleroderma, primary biliary cirrhosis, Takayasu's arteritis, temporal arteritis, warm autoimmune hemolytic anemia, Wegener‘s granulomatosis, psoriasis, alopecia universalis, Behcet's disease, chronic fatigue, dysautonomia, endometriosis, interstitial cystitis, neuromyotonia, scleroderma, and vulvodynia.
The methods described herein can be used to treat heteroimmune conditions or diseases, which include, but are not limited to graft versus host e, transplantation, usion, anaphylaxis, allergies (e. g., allergies to plant pollens, latex, drugs, foods, insect poisons, animal hair, animal dander, dust mites, or cockroach calyx), type I hypersensitivity, allergic conjunctivitis, allergic rhinitis, allergic asthma, and atopic dermatitis.
The methods described herein can be used to treat an inflammatory disease, which includes, but is not limited to asthma, inflammatory bowel disease, icitis, blepharitis, bronchiolitis, bronchitis, bursitis, cervicitis, cholangitis, ystitis, colitis, conjunctivitis, cystitis, dacryoadenitis, dermatitis, omyositis, alitis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibrositis, gastritis, gastroenteritis, hepatitis, hidradenitis suppurativa, laryngitis, mastitis, meningitis, is myocarditis, myositis, tis, oophoritis, orchitis, osteitis, otitis, pancreatitis, parotitis, rditis, peritonitis, pharyngitis, pleuritis, phlebitis, pneumonitis, pneumonia, proctitis, prostatitis, pyelonephritis, rhinitis, salpingitis, sinusitis, itis, synovitis, tendonitis, tonsillitis, uveitis, vaginitis, vasculitis, and vulVitis.
The methods described herein can be used to treat a cancer, e. g., B-cell proliferative disorders, which include, but are not limited to diffuse large B cell lymphoma, ular lymphoma, chronic lymphocytic lymphoma, chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia, splenic marginal zone lymphoma, plasma cell myeloma, cytoma, extranodal marginal zone B cell lymphoma, nodal marginal zone B cell lymphoma, mantle cell lymphoma, mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary on lymphoma, t lymphoma/leukemia, and lymphomatoid granulomatosis.
The methods described herein can be used to treat thromboembolic disorders, which include, but are not limited to myocardial infarct, angina pectoris (including unstable angina), reocclusions or restenoses after angioplasty or oronary bypass, stroke, transitory ischemia, peripheral arterial occlusive ers, pulmonary embolisms, and deep venous thromboses.
Disclosed herein is a method for ng a hematological malignancy in an dual in need thereof, comprising: administering to the individual a composition containing a eutic amount of at least one compound having the structure of as I, Ia-Ii or IIa-IId.
The hematological malignancy is a chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), high risk CLL, or a non-CLL/SLL lymphoma. In some embodiments, the hematological malignancy is follicular lymphoma, diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, Waldenstrom's lobulinemia, multiple a, marginal zone lymphoma, Burkitt's lymphoma, rkitt high grade B cell ma, or extranodal marginal zone B cell lymphoma. In some embodiments, the logical malignancy is acute or chronic myelogenous (or myeloid) leukemia, myelodysplastic syndrome, or acute lymphoblastic leukemia. In some embodiments, the hematological malignancy is relapsed or refractory diffuse large B-cell lymphoma (DLBCL), relapsed or refractory mantle cell lymphoma, relapsed or refractory follicular lymphoma, relapsed or refractory CLL; relapsed or refractory SLL; relapsed or refractory multiple myeloma.
In some embodiments, the hematological malignancy is a hematological malignancy that is classified as high-risk. In some embodiments, the hematological malignancy is high risk CLL or high risk SLL.
B-cell proliferative disorders (BCLDs) are neoplasms of the blood and encompass, inter alia, non-Hodgkin lymphoma, multiple myeloma, and leukemia. BCLDs can originate either in the lymphatic tissues (as in the case of lymphoma) or in the bone marrow (as in the case of leukemia and myeloma), and they all are involved with the uncontrolled growth of lymphocytes or white blood cells. There are many subtypes of BCLD, e.g., chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). The disease course and treatment of BCLD is dependent on the BCLD e; however, even within each subtype the clinical presentation, morphologic appearance, and response to y is heterogeneous.
Malignant lymphomas are neoplastic transformations of cells that reside predominantly within lymphoid tissues. Two groups of malignant lymphomas are Hodgkin's lymphoma and non-Hodgkin's lymphoma (NHL). Both types of lymphomas infiltrate reticuloendothelial s.
However, they differ in the neoplastic cell of origin, site of disease, presence of systemic symptoms, and response to treatment (Freedman et al., "Non—Hodgkin's Lymphomas" Chapter 134, Cancer ne, (an approved publication of the American Cancer Society, B.C. Decker Inc., Hamilton, Ontario, 2003).
Disclosed herein is a method for treating a non-Hodgkin's lymphoma in an individual in need f, comprising: administering to the individual a composition containing a therapeutic amount of at least one compound having the ure of Formulas I, Ia-Ii or Ila-11d.
Further disclosed herein, is a method for treating relapsed or refractory non-Hodgkin's lymphoma in an individual in need thereof, comprising: administering to the individual a composition containing a therapeutic amount of at least one compound having the structure of Formulas I, Ia—Ii or Ila-11d. In some ments, the non-Hodgkin's lymphoma is relapsed or refractory diffuse large B-cell lymphoma (DLBCL), relapsed or refractory mantle cell lymphoma, or relapsed or refractory follicular ma.
Non-Hodgkin lymphomas (NHL) are a diverse group of malignancies that are predominately of B-cell origin. NHL may p in any organs associated with lymphatic system such as spleen, lymph nodes or tonsils and can occur at any age. NHL is often marked by enlarged lymph nodes, fever, and weight loss. NHL is classified as either B-cell or T-cell NHL.
Lymphomas related to lymphoproliferative disorders following bone marrow or stem cell transplantation are usually B-cell NHL. In the Working Formulation classification scheme, NHL has been divided into low-, ediate-, and high-grade categories by virtue of their natural histories (see "The Non-Hodgkin's Lymphoma Pathologic Classification Project," Cancer 49 (1982):2112—2135). The low-grade lymphomas are indolent, with a median survival of 5 to 10 years (Homing and Rosenberg (1984) N. Engl. J. Med. 311:1471-1475). Although herapy can induce ions in the majority of indolent lymphomas, cures are rare and most patients eventually e, ing r y. The intermediate- and high-grade lymphomas are more sive tumors, but they have a greater chance for cure with chemotherapy. However, a significant proportion of these ts will relapse and require further treatment.
A miting list of the B-cell NHL includes Burkitt's lymphoma (e.g., Endemic Burkitt's Lymphoma and Sporadic Burkitt's Lymphoma), Cutaneous B-Cell ma, ous al Zone Lymphoma (MZL), Diffiise Large Cell Lymphoma (DLBCL), Diffuse Mixed Small and Large Cell Lympoma, Diffuse Small Cleaved Cell, e Small Lymphocytic Lymphoma, odal Marginal Zone B-cell lymphoma, follicular lymphoma, Follicular Small Cleaved Cell (Grade 1), Follicular Mixed Small Cleaved and Large Cell (Grade 2), Follicular Large Cell (Grade 3), Intravascular Large B—Cell Lymphoma, Intravascular Lymphomatosis, Large Cell Immunoblastic Lymphoma, Large Cell Lymphoma (LCL), Lymphoblastic Lymphoma, MALT Lymphoma, Mantle Cell Lymphoma (MCL), immunoblastic large cell lymphoma, precursor B—lymphoblastic lymphoma, mantle cell lymphoma, chronic cytic leukemia (CLL)/small lymphocytic lymphoma (SLL), extranodal marginal zone B-cell lymphoma-mucosa-associated lymphoid tissue (MALT) lymphoma, Mediastinal Large B-Cell Lymphoma, nodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma, primary mediastinal B-cell ma, lymphoplasmocytic lymphoma, hairy cell leukemia, Waldenstrom's Macroglobulinemia, and primary l nervous system (CNS) lymphoma.
Additional non-Hodgkin's lymphomas are contemplated within the scope of the present invention and apparent to those of ordinary skill in the art.
Disclosed herein is a method for treating a DLCBL in an individual in need thereof, comprising: administering to the individual a composition containing a therapeutic amount of at least one compound having the structure of Formulas I, Ia-Ii or Ila-11d.
As used herein, the term "Diffuse large B-cell lymphoma (DLBCL)" refers to a neoplasm of the germinal center B lymphocytes with a diffuse growth n and a high-intermediate proliferation index. DLBCLs represent approximately 30% of all lymphomas and may present with several morphological variants including the blastic, immunoblastic, T-cell/histiocyte rich, stic and plasmoblastic subtypes. Genetic tests have shown that there are different subtypes of DLBCL. These subtypes seem to have ent outlooks (prognoses) and responses to treatment. DLBCL can affect any age group but occurs mostly in older people (the average age is mid-60$).
Disclosed herein is a method for treating diffuse large B-cell lymphoma, activated B cell- like subtype (ABC-DLBCL), in an individual in need thereof, comprising: administering to the individual an irreversible BTK inhibitor in an amount from 300 mg/day up to, and including, 1000 . The ABC subtype of diffuse large B-cell lymphoma (ABC-DLBCL) is t to arise from post germinal center B cells that are ed during plasmatic differentiation. The ABC subtype of DLBCL (ABC-DLBCL) accounts for approximately 30% total DLBCL diagnoses. It is considered the least curable of the DLBCL molecular subtypes and, as such, patients sed with the ABC-DLBCL typically display significantly d survival rates compared with individuals with other types of DLCBL. ABC-DLBCL is most ly associated with chromosomal translocations deregulating the germinal center master regulator BCL6 and with mutations inactivating the PRDMl gene, which encodes a transcriptional repressor required for plasma cell differentiation.
A particularly relevant signaling pathway in the pathogenesis ofABC-DLBCL is the one mediated by the nuclear factor (NF)-1 The dependence ofABC DLBCLs on NF-KB s on a signaling pathway upstream of IkB kinase comprised of CARDl l, BCLlO and MALTl (the CBM complex). Interference with the CBM pathway extinguishes NF-KB ing in ABC DLBCL cells and induces apoptosis. The molecular basis for constitutive ty of the NF-KB y is a subject of current investigation but some somatic alterations to the genome ofABC DLBCLs clearly invoke this pathway. For example, somatic ons of the coiled—coil domain of CARDll in DLBCL render this signaling scaffold protein able to spontaneously nucleate protein-protein interaction with MALTl and BCL10, causing IKK activity and NF-KB activation. Constitutive activity of the B cell receptor signaling y has been implicated in the activation ofNF-KB in ABC DLBCLs with wild type CARDl l, and this is associated with mutations within the cytoplasmic tails of the B cell receptor subunits CD79A and CD79B. Oncogenic activating mutations in the ing adapter MYD88 activate NF-KB and synergize with B cell receptor signaling in ning the survival ofABC DLBCL cells. In addition, inactivating mutations in a negative regulator of the NF-KB pathway, A20, occur almost ively in ABC DLBCL.
Indeed, genetic alterations ing multiple components of the NF-KB signaling pathway have been recently identified in more than 50% DLBCL patients, where these lesions promote constitutive NF-1 An even larger fraction of cases (30%) carry biallelic genetic lesions inactivating the negative NF-KB regulator A20. Further, high levels of expression ofNF-KB target genes have been observed in ABC-DLBCL tumor samples. See, e.g., U. Klein et al., (2008), Nature Reviews Immunology 8:22-23; R. E. Davis et al., (2001), Journal of Experimental Medicine 61- 1874; G. Lentz et al., (2008), Science 319:1676-1679; M. Compagno et al., (2009), Nature 459:712-721; and L. Srinivasan et al., (2009), Cell 139:573—586).
Disclosed herein is a method for treating a follicular lymphoma in an individual in need thereof, comprising: administering to the individual a composition containing a therapeutic amount of at least one compound having the structure of Formulas I, Ia-Ii or IIa-IId.
As used herein, the term "follicular ma" refers to any of several types of non- Hodgkin's lymphoma in which the lymphomatous cells are clustered into nodules or follicles.
The term follicular is used because the cells tend to grow in a circular, or nodular, pattern in lymph nodes. The average age for people with this lymphoma is about 60.
Disclosed herein is a method for treating a CLL or SLL in an individual in need thereof, comprising: administering to the individual a composition containing a therapeutic amount of at least one compound having the structure of Formulas I, Ia-Ii or d. c lymphocytic leukemia and small cytic lymphoma (CLL/SLL) are commonly thought as the same disease with slightly ent manifestations. Where the cancerous cells gather determines whether it is called CLL or SLL. When the cancer cells are primarily found in the lymph nodes, lima bean shaped structures of the lymphatic system (a system primarily of tiny vessels found in the body), it is called SLL. SLL accounts for about 5% to 10% of all lymphomas. When most of the cancer cells are in the tream and the bone marrow, it is called CLL.
Both CLL and SLL are slow-growing diseases, although CLL, which is much more common, tends to grow slower. CLL and SLL are treated the same way. They are usually not considered curable with standard treatments, but depending on the stage and growth rate of the disease, most patients live longer than 10 years. Occasionally over time, these slow—growing mas may transform into a more aggressive type of lymphoma.
Chronic lymphoid leukemia (CLL) is the most common type of leukemia. It is ted that 100,760 people in the United States are living with or are in remission from CLL. Most (>75%) people newly diagnosed with CLL are over the age of 50. Currently CLL treatment focuses on lling the disease and its symptoms rather than on an outright cure. CLL is treated by chemotherapy, radiation therapy, biological therapy, or bone marrow transplantation.
Symptoms are sometimes treated surgically (splenectomy removal of enlarged spleen) or by radiation therapy ("de-bulking" n lymph nodes). Though CLL progresses slowly in most cases, it is considered generally incurable. Certain CLLs are classified as high-risk. As used herein, "high risk CLL" means CLL characterized by at least one of the following 1) ; 2) 11q22—; 3) unmutated IgVH together with ZAP-70+ and/or CD3 8+; or 4) trisomy 12.
CLL treatment is typically stered when the t's clinical symptoms or blood counts indicate that the disease has progressed to a point where it may affect the patient's y of life.
Small lymphocytic leukemia (SLL) is very similar to CLL described supra, and is also a cancer of B-cells. In SLL the abnormal lymphocytes mainly affect the lymph nodes. However, in CLL the abnormal cells mainly affect the blood and the bone marrow. The spleen may be affected in both conditions. SLL accounts for about 1 in 25 of all cases of non-Hodgkin lymphoma. It can occur at any time from young adulthood to old age, but is rare under the age of 50. SLL is considered an indolent lymphoma. This means that the disease sses very , and patients tend to live many years after diagnosis. However, most patients are diagnosed with advanced disease, and although SLL responds well to a variety of chemotherapy drugs, it is generally considered to be incurable. Although some cancers tend to occur more often in one gender or the other, cases and deaths due to SLL are evenly split n men and women. The average age at the time of diagnosis is 60 years.
Although SLL is indolent, it is persistently progressive. The usual pattern of this disease is one of high response rates to radiation y and/or chemotherapy, with a period of disease remission. This is followed months or years later by an inevitable relapse. Re-treatment leads to a response again, but again the e will relapse. This means that although the short-term prognosis of SLL is quite good, over time, many patients develop fatal complications of recurrent disease. Considering the age of the individuals typically diagnosed with CLL and SLL, there is a need in the art for a simple and effective treatment of the disease with minimum side- effects that do not impede on the patient's quality of life. The t invention fulfills this long standing need in the art.
Disclosed herein is a method for treating a Mantle cell lymphoma in an individual in need thereof, comprising: administering to the dual a composition containing a therapeutic amount of at least one compound having the structure of as I, Ia-Ii or IIa-IId.
As used herein, the term, "Mantle cell lymphoma" refers to a subtype of B-cell lymphoma, due to CD5 positive antigen-naive minal center B-cell within the mantle zone that surrounds normal germinal center follicles. MCL cells generally over-express cyclin D1 due to a t(l l;l4) chromosomal translocation in the DNA. More specifically, the translocation is at t(l l;l4)(ql3;q32). Only about 5% of lymphomas are of this type. The cells are small to medium in size. Men are affected most often. The average age of patients is in the early 605. The lymphoma is usually read when it is diagnosed, involving lymph nodes, bone marrow, and, very often, the spleen. Mantle cell ma is not a very fast growing lymphoma, but is difficult to treat.
Disclosed herein, in n embodiments, is a method for treating a al zone B-cell lymphoma in an individual in need thereof, comprising: administering to the individual a composition containing a therapeutic amount of at least one compound having the structure of Formulas I, Ia—Ii or Ila-11d.
As used herein, the term "marginal zone B-cell ma" refers to a group of related B- cell neoplasms that involve the lymphoid tissues in the marginal zone, the patchy area outside the follicular mantle zone. Marginal zone lymphomas account for about 5% to 10% of lymphomas.
The cells in these lymphomas look small under the microscope. There are 3 main types of marginal zone lymphomas including extranodal marginal zone B-cell lymphomas, nodal marginal zone B-cell lymphoma, and c marginal zone lymphoma.
Disclosed herein, in n embodiments, is a method for ng a MALT in an individual in need thereof, comprising: administering to the individual a composition containing a therapeutic amount of at least one compound having the structure of Formulas I, Ia—Ii or IIa—IId.
The term "mucosa-associated lymphoid tissue (MALT) lymphoma", as used , refers to extranodal manifestations of marginal-zone lymphomas. Most MALT lymphoma are a low grade, although a ty either manifest initially as ediate-grade non-Hodgkin lymphoma (NHL) or evolve from the low-grade form. Most of the MALT lymphoma occur in the h, and roughly 70% of gastric MALT lymphoma are associated with Helicobacter pylori infection. Several cytogenetic abnormalities have been identified, the most common being trisomy 3 or t(l l;18). Many of these other MALT lymphoma have also been linked to infections with bacteria or viruses. The average age of patients with MALT ma is about 60.
Disclosed herein, in certain embodiments, is a method for ng a nodal marginal zone B-cell lymphoma in an individual in need thereof, comprising: administering to the dual a ition containing a therapeutic amount of at least one compound having the structure of Formulas I, Ia—Ii or Ila-11d.
The term "nodal marginal zone B-cell lymphoma" refers to an indolent B-cell lymphoma that is found mostly in the lymph nodes. The disease is rare and only accounts for 1% of all Non- Hodgkin's mas (NHL). It is most commonly diagnosed in older patients, with women more susceptible than men. The disease is classified as a marginal zone lymphoma because the mutation occurs in the marginal zone of the B-cells. Due to its confinement in the lymph nodes, this disease is also classified as nodal.
Disclosed herein, in certain embodiments, is a method for treating a splenic marginal zone B-cell lymphoma in an individual in need thereof, comprising: administering to the individual a composition containing a therapeutic amount of at least one compound having the structure of Formulas I, Ia-Ii or Ila-11d.
The term "splenic al zone B-cell lymphoma" refers to specific low-grade small B- cell lymphoma that is incorporated in the World Health Organization classification.
Characteristic features are splenomegaly, moderate lymphocytosis with villous morphology, intrasinusoidal pattern of involvement of various organs, especially bone marrow, and ve indolent course. Tumor progression with increase of blastic forms and aggressive behavior are observed in a minority of patients. Molecular and netic s have shown heterogeneous s probably because of the lack of standardized diagnostic ia.
Disclosed herein, in certain embodiments, is a method for ng a Burkitt lymphoma in an individual in need thereof, comprising: administering to the individual a composition containing a therapeutic amount of at least one compound having the structure of Formulas I, Ia- Ii or IIa-Hd.
The term "Burkitt lymphoma" refers to a type ofNon-Hodgkin Lymphoma (NHL) that commonly affects children. It is a highly aggressive type of B-cell lymphoma that often starts and involves body parts other than lymph nodes. In spite of its fast—growing , Burkitt's lymphoma is often curable with modern intensive therapies. There are two broad types of Burkitt's lymphoma—the sporadic and the endemic varieties: Endemic Burkitt's lymphoma and Sporadic Burkitt's lymphoma.
Endemic Burkitt's lymphoma involves children much more than adults, and is related to Epstein Barr Virus (EBV) infection in 95% cases. It occurs primarily in equatorial Africa, where about half of all childhood cancers are Burkitt's lymphoma. It characteristically has a high chance of involving the jawbone, a rather distinctive feature that is rare in ic Burkitt's. It also commonly involves the abdomen.
Sporadic Burkitt's lymphoma is a type of Burkitt's lymphoma that affects the rest of the world, including Europe and the as. Here too, it's mainly a disease in children. The link between Epstein Barr Virus (EBV) is not as strong as with the endemic variety, though direct evidence of EBV infection is present in one out of five patients. More than the involvement of lymph nodes, it is the abdomen that is notably affected in more than 90% of the children. Bone marrow involvement is more common than in the sporadic variety.
Disclosed herein, in n embodiments, is a method for treating a Waldenstrom macroglobulinemia in an dual in need thereof, comprising: administering to the individual a composition containing a therapeutic amount of at least one compound having the ure of Formulas I, Ia—Ii or Ila-11d.
The term "Waldenstrom macroglobulinemia", also known as lymphoplasmacytic ma, is cancer involving a subtype of white blood cells called cytes. It is characterized by an uncontrolled clonal proliferation of terminally entiated B lymphocytes.
It is also characterized by the lymphoma cells making an antibody called immunoglobulin M (IgM). The IgM antibodies circulate in the blood in large amounts, and cause the liquid part of the blood to thicken, like syrup. This can lead to decreased blood flow to many organs, which can cause problems with Vision (because of poor circulation in blood vessels in the back of the eyes) and neurological problems (such as headache, dizziness, and confiJsion) caused by poor blood flow within the brain. Other symptoms can include feeling tired and weak, and a tendency to bleed easily. The underlying etiology is not fully understood but a number of risk factors have been identified, including the locus 6p21.3 on some 6. There is a 2- to 3-fold risk increase of ping WM in people with a personal history of autoimmune diseases with autoantibodies and particularly elevated risks associated with hepatitis, human immunodeficiency Virus, and rickettsiosis.
Disclosed herein, in n embodiments, is a method for treating a myeloma in an dual in need f, comprising: stering to the individual a composition containing a therapeutic amount of at least one nd having the ure of as I, Ia-Ii or IIa-IId.
Multiple a, also known as MM, a, plasma cell myeloma, or as Kahler's disease (after Otto Kahler) is a cancer of the white blood cells known as plasma cells. A type of B cell, plasma cells are a crucial part of the immune system responsible for the production of antibodies in humans and other vertebrates. They are produced in the bone marrow and are transported through the lymphatic system.
Disclosed herein, in certain embodiments, is a method for treating a leukemia in an individual in need thereof, comprising: administering to the individual a composition containing a therapeutic amount of at least one compound having the structure of Formulas I, Ia—Ii or d.
Leukemia is a cancer of the blood or bone marrow characterized by an abnormal increase of blood cells, usually leukocytes (white blood cells). Leukemia is a broad term covering a spectrum of diseases. The first division is n its acute and chronic forms: (i) acute leukemia is characterized by the rapid increase of immature blood cells. This crowding makes the bone marrow unable to produce healthy blood cells. Immediate treatment is required in acute leukemia due to the rapid progression and accumulation of the malignant cells, which then spill over into the bloodstream and spread to other organs of the body. Acute forms of leukemia are the most common forms of leukemia in children; (ii) chronic leukemia is distinguished by the excessive build up of relatively mature, but still abnormal, white blood cells. Typically taking months or years to progress, the cells are produced at a much higher rate than normal cells, resulting in many abnormal white blood cells in the blood. Chronic leukemia mostly occurs in older people, but can theoretically occur in any age group. Additionally, the diseases are ided according to which kind of blood cell is ed. This split divides leukemias into lymphoblastic or lymphocytic leukemias and myeloid or myelogenous leukemias: (i) in lymphoblastic or lymphocytic leukemias, the cancerous change takes place in a type of marrow cell that normally goes on to form lymphocytes, which are infection-fighting immune system cells; (ii) in myeloid or myelogenous leukemias, the cancerous change takes place in a type of marrow cell that normally goes on to form red blood cells, some other types of white cells, and platelets.
Within these main categories, there are several subcategories including, but not limited to, Acute blastic leukemia (ALL), Acute myelogenous leukemia (AML), Chronic myelogenous leukemia (CML), and Hairy cell leukemia (HCL).
Symptoms, diagnostic tests, and prognostic tests for each of the above—mentioned conditions are known in the art. See, e. g., Harrison's Principles of al ne®," 16th ed., 2004, The McGraw-Hill Companies, Inc. Dey et a1. (2006), Cytojournal 3(24), and the "Revised European American Lymphoma" (REAL) classification system (see, e.g., the website maintained by the al Cancer Institute).
A number of animal models are useful for establishing a range of therapeutically effective doses of BTK inhibitor compounds for treating any of the ing diseases.
For example, dosing of BTK tor compounds for treating an autoimmune disease can be assessed in a mouse model ofrheumatoid arthitis. In this model, arthritis is induced in Balb/c mice by administering anti-collagen antibodies and lipopolysaccharide. See Nandakumar et al. (2003), Am. J. Pathol 163:1827-1837.
In another example, dosing of BTK inhibitors for the treatment of B-cell proliferative disorders can be examined in, e.g., a to-mouse xenograft model in which human B-cell lymphoma cells (e. g. Ramos cells) are implanted into defficient mice (e.g., "nude" mice) as described in, e.g., Pagel et al. (2005), Clin Cancer Res ll(l3):4857-4866.
Animal models for treatment of thromboembolic disorders are also known.
The eutic efficacy of the compound for one of the foregoing diseases can be zed during a course of treatment. For example, a subject being treated can undergo a diagnostic evaluation to correlate the relief of disease ms or pathologies to inhibition of in vivo BTK activity achieved by administering a given dose of a BTK inhibitor. Cellular assays known in the art can be used to determine in vivo activity ofBTK in the ce or absence of an BTK inhibitor. For example, since activated BTK is orylated at tyrosine 223 (Y223) and tyrosine 551 (Y551), phospho-specific immunocytochemical staining of P—Y223 or P-Y551- positive cells can be used to detect or quantify activation of BTK in a population of cells (e.g., by FACS analysis of stained vs unstained cells). See, e.g., Nisitani et al. (1999), Proc. Natl. Acad.
Sci, USA 1-2226. Thus, the amount of the BTK inhibitor compound that is administered to a subject can be increased or decreased as needed so as to maintain a level of BTK inhibition optimal for treating the subject's disease state.
Compounds disclosed herein irreversibly inhibit BTK and may be used to treat mammals suffering from Bruton's tyrosine kinase-dependent or ‘s tyrosine kinase ed conditions or diseases, including, but not limited to, cancer, autoimmune and other inflammatory diseases. Compounds sed herein have shown efficacy in a wide variety of diseases and conditions that are described herein.
A further aspect resides in the use of compounds of Formulas I, Ia-Ii or IIa-IId or a ceutically acceptable salt thereof for the manufacture of a medicament to be used for the treatment of chronic B cell disorders in which T cells play a prominent role.
In yet r aspect, the compounds of Formulas I, Ia-Ii or IIa-IId are used for the manufacture of a medicament to be used for the treatment of BTK-mediated diseases or conditions. These include, but are not limited to, the treatment of B cell mas resulting from chronic active B cell receptor signaling.
BTK mediated disorders or BTK mediated conditions as used herein, mean any disease state or other deleterious condition in which B cells, mast cells, myeloid cells or lasts play a central role. These diseases include but are not limited to, , autoimmune and inflammatory diseases, allergies, infectious diseases, bone resorption disorders and proliferative diseases.
Immune, autoimmune and inflammatory diseases that can be treated or prevented with the compounds of Formulas I, Ia-Ii or d further include rheumatic diseases (e.g. infectious arthritis, progressive chronic arthritis, ing arthritis, traumatic arthritis, gouty tis, osteoporosis, Reiter's syndrome, polychondritis, acute synovitis and spondylitis), glomerulonephritis (with or without nephrotic syndrome), autoimmune hematologic disorders (e.g. hemolytic , aplasic anemia, idiopathic ocytopenia, and neutropenia), and autoimmune inflammatory bowel diseases (e.g. ulcerative colitis and Crohn's disease), host versus graft disease, allograft ion, chronic thyroiditis, schleroderma, primary billiary cirrhosis, systemic lupus erythematosis, contact dermatitis, eczema, skin sunbums, chronic renal insufficiency, Stevens-Johnson syndrome, inflammatory pain, idiopathic sprue, cachexia, sarcoidosis, kerato conjunctivitis, otitis media, periodontal disease, pulmonary interstitial fibrosis, pneumoconiosis, pulmonary ciency me, pulmonary emphysema, pulmonary fibrosis, silicosis, chronic inflammatory pulmonary disease (e.g. chronic obstructive pulmonary disease) and other inflammatory or obstructive disease on airways.
Allergies that can be treated or prevented include, among others, ies to foods, food additives, insect s, dust mites, pollen, animal materials and contact allergans, type I hypersensitivity allergic asthma, allergic conjunctivitis.
Infectious diseases that can be treated or prevented e, among others, , septic shock, endotoxic shock, sepsis by Gram-negative bacteria, shigellosis, meningitis, al malaria, pneumonia, tuberculosis, viral myocarditis, viral hepatitis (hepatitis A, hepatitis B and hepatitis C), HIV infection, retinitis caused by cytomegalovirus, influenza, herpes, treatment of infections associated with severe burns, myalgias caused by infections, cachexia secondary to infections, and nary viral infections such as lentivirus, caprine arthritic virus, visna-maedi virus, feline immunodeficiency virus, bovine immunodeficiency virus or canine immunodeficiency virus.
In some embodiments of Formula I, compounds are present as a material in substantially pure form.
In some embodiments of a 1, compounds are selected from any one of the Examples herein or a pharmaceutically acceptable salt f.
Each variable definition above includes any subset thereof and the compounds of Formula I include any combination of such les or variable s.
The present ion es the compounds and salts thereof, their physical forms, preparation of the compounds, useful intermediates, and pharmaceutical compositions and ations thereof.
The compounds of the present invention and the term und" in the claims include any pharmaceutically acceptable salts or solvates, and any amorphous or crystal forms, or tautomers, Whether or not specifically recited in context.
The present invention includes all isomers of the compounds. Compounds may have one or more asymmetric carbon atoms and can exist as two or more isomers. Where a compound of the invention contains an alkenyl or alkenylene group, geometric cis/trans (or Z/E) isomers are possible. Where the compound contains, for example, a keto or oxime group or an ic moiety, tautomeric isomerism ('tautomerism') can occur. A single compound may t more than one type of isomerism.
The present invention includes any isomers, even if not specifically shown, individually as well as mixtures, geometric isomers, and pharmaceutically acceptable salts thereof, including compounds exhibiting more than one type of isomerism,. Where a compound or stereocenter is described or shown without definitive stereochemistry, it is to be taken to embrace all possible individual isomers, configurations, and mixtures thereof. Thus, a material sample containing a mixture of stereoisomers would be embraced by a recitation of either of the stereoisomers or a recitation without definitive stereochemistry. Also contemplated are any cis/trans isomers or ers of the compounds described. When a tautomer of the compound of a I exists, the compound of Formula I of the present ion includes any possible tautomers and pharmaceutically acceptable salts thereof, and mixtures thereof, except where specifically stated otherwise.
DETAILED DESCRIPTION OF THE INVENTION Described herein are compounds of Formula I, which include compounds of Formulas Ia- Ii and IIa-IId, and compositions and formulations containing such compounds, and methods of using and making such compounds. These compounds are useful in treating es or ions modulated at least in part by BTK.
In an embodiment, a compound according to Formula I and above embodiments is provided, wherein the nd of Formula I is ented by the nd of Formula 11a: /21 R1 | 62 x/ \24 R3 L2 wherein, Rl-R4, G2, G3, L1, L2, X, Y, and 21-24, are as previously described for a compound of a I and B1 and B2 are independently selected from oalkyl, C6heterocycloalkyl, C6aryl, or C6heteroaryl.
In an embodiment, a compound according to Formula I and above embodiments is provided, wherein the nd of Formula I is represented by the compound of Formula 11b: 2/21 R1 23 L1 R2 n 26/ \24 31/ \82 R3 Y\L2/Z wherein, Rl-R4, B1, B2, L1, L2, Y, and 21-24, are as previously described for a compound of Formula I, Z5 and Z6 are each independently selected from C(Ra) or N, where Ra is alkyl or H, and n and m are each independently selected from 0, l, or 2.
In an embodiment, a compound according to Formula I and above embodiments is provided, wherein the compound of Formula I is represented by the compound of Formula IIc: /z1 R1 22 I (P9326 z3 L1 / \Z4 / Bl \BZ n, Rl-R4, B1, B2, L1, L2, and 21-24, are as previously bed for a compound of Formula I, Z5 and Z6 are each independently selected from C or N, and n and m are each independently selected from 0, l, or 2.
In an embodiment, a compound according to Formula I and above embodiments is provided, wherein the compound of Formula I is represented by the compound of Formula 11d: | 62 G3 R2 0 (W326 \Z4 \ Z5 R3 L2 L1 wherein, Rl-R4, L1, L2, G2, G3, and Zl—Z4, are as previously described for a compound of Formula I, Z5 and Z6 are each independently selected from C or N, B1 and B2 are independently selected from C6cycloalkyl, C6heterocycloalkyl, C6aryl, or C6heteroaryl, and n and m are each independently selected from 0, l, or 2.
The t invention includes the compounds, intermediates, es and synthetic methods described herein. Compounds of Formula I are prepared according to reaction schemes described herein. Unless otherwise indicated, the substituents in the schemes are defined as above.
Synthetic Methods: Compounds of the present invention include the intermediates, examples, and synthetic methods described herein. Synthetic methods provided herein are generally preceded by their respective tic schemes. Where a procedure for an intermediate or example refers to an analogous procedure for an analogous intermediate or example, such reference includes the procedure for that analogous ediate or example, the associated synthetic scheme as well as the procedures and s utilized for the synthesis of the analogous intermediate or example.
The compounds of Formulas I, Ia-Ii and IIa-d may be prepared by the methods described below, together with synthetic methods known in the art of organic chemistry, or modifications and derivatizations that are ar to those of ordinary skill in the art. The starting materials used herein are commercially ble or may be prepared by e methods known in the art [such as those methods sed in standard reference books such as the Compendium of Organic tic Methods, Vol. I-VI (Wiley-Interscience); or the hensive Organic Transformations, by RC. Larock (Wiley-Interscience)]. Preferred methods include, but are not limited to, those described below.
During any of the following synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This can be achieved by means of conventional protecting groups, such as those described in T. W. , Protective Groups in Organic Chemistry, John Wiley & Sons, 1981; T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Chemistry, John Wiley & Sons, 1991, and T. W. Greene and P. G.
M. Wuts, Protective Groups in Organic Chemistry, John Wiley & Sons, 1999, which are hereby orated by reference.
Compounds of Formulas I, Ia—Ii and Ila-d, or their pharmaceutically acceptable salts, can be prepared according to the on schemes discussed hereinbelow and utilizing ordinary skill in the art. Unless otherwise indicated, the substituents in the schemes are defined as above.
Isolation and ation of the products is accomplished by standard procedures, which are known to a chemist of ordinary skill.
When a general or exemplary synthetic procedure is referred to, one skilled in the art can readily determine the appropriate ts, if not indicated, extrapolating from the general or exemplary procedures. Some of the general procedures are given as examples for general preparation of compounds. One skilled in the art can readily adapt such procedures to the synthesis of other specific compounds. Representation of an unsubstituted on in ures shown or referred to in the general procedures is for convenience and does not preclude substitution as bed elsewhere herein. For specific groups that can be present, either as groups in the general procedures or as optional tuents not shown, refer to the descriptions in the remainder of this nt, including the claims and detailed description.
A general procedure for the synthesis of compounds of Formulas I, Ia-Ii and Ila-d is shown in the General Scheme, below. l Scheme: CN 02NXB/ —B\L’I_B2 NH2 o N /L CouplingSuzuki OZNX/ 2 \X/ SuzukiCoupling B1 \Bz 2)acetaldoxime CuCI2 MKKUN'G (c) R2 O o o )LNHZ R3 \ 2LNH2 Pd/C, H2 R4 R4 —> 1 —>RWMXH 1 B1’L\B2 3 /L H2N\X/ Base '31 \32 LG = Leaving Group R2 0 (d) (e) Where A, B1, B2, L1, X, R2, R3, and R4 are as defined previously for a compound of Formulas I, Ia-Ii and IIa-d and LG is equal to a suitable leaving group such as triflate, mesylate, tosylate, HATU, Cl, Br or I.
In a typical preparation of a compound of Formulas I, Ia-Ii and Ila-d, a compound of Formula (a) was reacted under Suzuki coupling conditions with a suitable boronic acid. Suitable conditions include, but are not limited to, treating nds of Formula (a) with a suitable base, such as CszC03 or K2C03, and a suitable palladium catalyst, such as Pd(dppf)C12'DCM. le solvents for use in the above sis include 1,4-dioxane, water, DME and mixtures thereof. The mixture was ed with nitrogen six times and refluxed for about 16 h under nitrogen here to afford the compound of Formula (b). The above process was carried out at temperatures between about 50° C and about 150° C. ably, the reaction was carried out at about 100° C. The above process was ably carried out at or about atmospheric pressure although higher or lower pressures may be used if desired. Substantially equimolar amounts of reactants were preferably used although higher or lower amounts may be used if desired.
The compound of Formula (b) was d with a suitable boronic acid under Suzuki coupling conditions. Suitable conditions include, but are not limited to, treating compounds of Formula (b) with a suitable base, such as Cs2C03 or K2C03, and a le palladium catalyst, such as Pd(dppt)C12‘DCM or Pd(PPh3)4. Suitable solvents for use in the above synthesis include 1,4-dioxane, water, DME and mixtures thereof. The mixture was degassed with nitrogen six times and refluxed for about 5 h under nitrogen atmosphere to afford the compound of a (c). The above process was carried out at temperatures between about 40° C and about 120° C. ably, the reaction was carried out at about 900 C. The above process was preferably carried out at or about atmospheric pressure although higher or lower pressures may be used if d.
Substantially equimolar amounts of reactants were preferably used although higher or lower amounts may be used if d.
The compound of a (c) was d under hydrogen atmosphere with palladium on carbon, preferably ing the mixture with hydrogen about 6 times. Suitable solvents for use in the above synthesis include ethyl e and methanol. The above process was carried out at temperatures between about 10° C and about 60° C, or ably at ambient temperature, to afford the compound of Formula (d).The above process was preferably carried out at or about atmospheric pressure although higher or lower pressures may be used if desired. Substantially equimolar amounts ofreactants were preferably used although higher or lower amounts may be used if desired.
The compound of Formula (d) was reacted with a suitable acryloyl chloride with a suitable base. Suitable bases include organic bases such as TEA or DIPEA. The above s was carried out at temperatures between about -10° C and about ambient temperature, or preferably at 0° C, to afford the compound of Formula (d). The above process was preferably carried out at or about atmospheric pressure although higher or lower pressures may be used if desired. ntially equimolar amounts of reactants were preferably used although higher or lower amounts may be used if desired.
Examples: Preparations and Intermediates Scheme 1 08,0H 0 (m \ \ 2 l l/ NH2 CNPdd / \ (PP)fCl2 C$2CO i 3 N Cl acetaldoxime, CuCl2 N CI —> —'> CI N CI 14-gioxane/H20 THF/H20,11O°C 110 0.161121% No2 16h, 84% N02 1 3 4 Pd2(dba)3 5C32003 £20—>©Pd/C H2 | : NH2 14-dioxane/HZO EA, r..t, 16h O N 0 110°C 16h 60% TEA, DCM 61):) 0°C 10min Example1 2-chlor0(3-nitr0phenyl)nicotinonitrile (3). To a solution of ophenylboronic acid 2 (5.19 g, 30 mmol), CSQCOg (19.56 g, 60 mmol) and 2,6-dichloronicotinonitrile 1 (5.51 g, 33 mmol) in dry 1,4-dioxane (100 mL) was added Pd(dppf)Clg’DCM (2.4 g, 3.0 mmol) under nitrogen atmosphere, and the mixture was degassed with nitrogen 6 times, then refluxed for 16 h under nitrogen atmosphere. After cooling to room temperature, the solvent was evaporated and the e was purified by flash chromatography, eluting with 20:1 to 3:1 PE/EA to afford the title compound as a yellow solid (1.6 g, 21%). 2-chlor0(3-nitr0phenyl)nic0tinamide (4). To a solution of 2-chloro(3- nitrophenyl)nicotinonitrile 3 (259 mg, 1.0 mmol) and doxirne (88 mg, 1.5 mmol) in ydrofuran (5 mL) and water (5 mL) was added CuClz (15 mg, 0.1 mmol) under nitrogen atmosphere, and the mixture was degassed with nitrogen 6 times, then heated to 90°C and stirred for 16 h under en atmosphere. After cooling to room temperature, the solvent was evaporated and the crude product was purified by flash chromatography, eluting with 20:1 DCM/MeOH to afford the title compound as a yellow solid (240 mg, 84%). MS (ESI): m/Z =277.9 [M+H]+. 6-(3-nitrophenyl)(4-phenoxyphenyl)nic0tinamide (6). To a solution of 2-chloro—6-(3- nitrophenyl)nicotinamide 4 (240 mg, 0.87 mmol), Cs2C03 (567 mg, 1.74 mmol) and biphenyl ylboronic acid 5 (203 mg, 0.95 mmol) in 1,4—dioxane (10 mL) and water (2.5 mL) was added Pd2(dba)3 (80 mg, 0.09 mmol) under nitrogen here, and the mixture was degassed with nitrogen 6 times, then refluxed for 16 h under nitrogen atmosphere. After cooling to room temperature, the solvent was ated and the crude product was purified by flash chromatography eluting with 150:1 DCM/MeOH to afford the title compound as a yellow solid (110 mg, crude). 6-(3-aminophenyl)—2—(4-phen0xyphenyl)nicotinamide (7). To a solution of 6-(3-nitrophenyl)- 2-(4-phenoxyphenyl)nicotinamide 6 (110 mg, 0.27 mmol) in ethyl acetate (5 mL) was added Pd/C (10 mg) under hydrogen here, and the e was degassed with hydrogen 6 times, then stirred for 16 h at ambient temperature under hydrogen atmosphere. The solution was filtered and the filtrate was evaporated to the crude product as red oil (61 mg, 60%). MS (ESI): m/z = 382.1 [M+H]+.
Example 1 6-(3-acrylamidophenyl)(4-phen0xyphenyl)nicotinamide (0&0NH2| : HN\n/\ To a solution of 6-(3—aminophenyl)—2-(4-phenoxyphenyl)nicotinamide 7 (38 mg, 0.1 mmol) in DCM (5 mL) was added TEA (0.05 mL, 0.4 mmol) and acryloyl chloride 8 (9 mg, 0.1 mmol) at 0 oC. The mixture was stirred at 0 0C for 10 s. The solvent was removed and the residue was purified by Prep-TLC g with 25 :1 DCM/MeOH to afford the title compound (30 mg, 71%) as white solid. 1H NMR (400 MHz, DMSO) 8 10.36 (s, 1H), 8.43 (s, 1H), 7.72—7.97 (m, 7H), 7.49 (s, 1H), 7.33—7.52(m, 3H), 7.24(t, J: 6.9 Hz, 1H), 13(m, 4H), 6.45 (dd, J: 16.9, 10.0 Hz, 1H), 6.30 (d, J: 16.9 Hz, 1H), 5.79 (d, J: 10.5 Hz, 1H), MS (ESI, method A): m/Z = 436.0 [M + H]+, tR=1.553 min., HPLC: 97.5% (214nm), 98.0% (254nm).
Scheme 2 (1 or"O O N(H2304concszo \ \ N...2 Pd(dppf)Clz 052003 I ""2 —> | —> / 90°C 1h 73% N/ 1,4-dioxane/HZO Cl N CI Cl 110°C, 16h, 53% o0 1 2 4 Dc ,0 I PM: H2 Pd(PPh3)4, ch03 N/ DME/HZO EA rt 16h BOC/ 90°C, 5h 84% O O VLCI \ \ NH2 I TFA, DCM, | 9 N r1, 1h, 71% TEA DCM HN NHZOQ O 0°C,10min 44% Example3 2,6-dichloronicotinamide (2). To 2,6-dichloronicotinonitrile 1 (l .73 g, 10 mmol) was added conc H2804 (10 mL) and water (2 mL). The e was heated to 90°C and stirred for l h.
After cooling to room temperature, the solution was poured into ice—cold water, then adjusted to PH = 8 with ammonia water. The precipitate was filtered, washed with water (20 mL) and dried under vacuum to afford the title compound as an brown solid (1.4 g, 73%). MS (ESI): m/z = 191.1 [M+H]+. 6-chlor0(4-phenoxyphenyl)nicotinamide (4). To a solution of 2,6-dichloronicotinamide 2 (668 mg, 3.5 mmol), C82C03 (1.14 g, 7 mmol) and 4—phenoxyphenylboronic acid 3 (749 mg, 3.5 mmol) in 1,4-dioxane (30 mL) was added Pd(dppf)C12‘DCM (285 mg, 0.35 mmol) under nitrogen atmosphere, and the mixture was degassed with nitrogen 6 times, then refluxed for 16 h under nitrogen atmosphere. After cooling to room temperature, the solvent was evaporated and the e was purified by flash chromatography, eluting with 20:] to 3:1 petroleum ethyl acetate (PE/EA) to afford the title nd as a yellow solid (611 mg, 53%). MS (ESI): m/Z = 325.0 [M+H]*. utyl(5-carbamoyl(4-phenoxyphenyl)pyridinyl)—5,6—dihydropyridine—1(2H)— carboxylate (6). To a solution of 4-(4,4,5,5—tetramethyl-1,3,2-dioxaborolanyl)-1 ,2,3,6- tetrahydropyridine 5 (232 mg, 0.75 mmol), K2C03 (207 mg, 1.50 mmol) and 6-chloro—2-(4— phenoxyphenyl)nicotinamide 4 (162 mg, 0.50 mmol) in 1,2-dimethoxyethane (5 mL) and water (1 mL) was added 3)4 (115 mg, 0.10 mmol) under en atmosphere, and the mixture was ed with nitrogen 6 times, then heated to 90°C and stirred for 5 h under nitrogen atmosphere. After cooling to room temperature, the solvent was evaporated and the crude product was purified by flash chromatography, eluting with 70:1 DCM/MeOH to afford the title compound as a white solid (232 mg, crude). tert-butyl 4-(5-carbamoyl—6—(4-phenoxyphenyl)pyridinyl)piperidine—l-carboxylate (7).
To a solution of 4-(5 -carbamoyl(4-phenoxyphenyl)pyridinyl)—5,6-dihydropyridine-1(2H)- carboxylate 6 (232 mg, 0.75 mmol) in ethyl acetate (5 mL) was added Pd/C (10 mg) under hydrogen atmosphere, and the mixture was degassed with hydrogen 6 times, then stirred for 16 h at ambient temperature under hydrogen atmosphere. The solution was filtered and the filtrate was evaporated to the crude t as brown solid (215 mg, 60% for two steps). MS (ESI): m/z = 474.1 [M+H]+. 2-(4-phenoxyphenyl)(piperidinyl)nicotinamide le 2) (8). To a solution of tert- butyl 4-(5 -carbamoyl(4-phenoxyphenyl)pyridinyl)piperidine— 1 -carboxylate 7 (215 mg, 0.45 mmol) in dry dichloromethane (6 mL) was added TFA (2 mL), and the resulting mixture was stirred for 1 h at ambient temperature. The solvent was removed and the residue was partitioned between saturated aqueous sodium onate (30 mL) and ethyl acetate (20 mL).
The organic phase was separated, dried over anhydrous sodium sulfate, filtered and concentrated.
The crude residue was purified by flash chromatography, eluting with 5 :1 DCM/MeOH to afford the title compound as a white solid (120 mg, 71%). MS (ESI): m/z = 374.2 [M+H]+.
Example 3 6-(1-acryloylpiperidinyl)—2-(4-phenoxyphenyl)nic0tinamide To a on of 2-(4-phenoxyphenyl)—6-(piperidin-4—yl)nicotinamide 8 (26 mg, 0.07 mmol) in DCM (5 mL) was added TEA (0.05 mL, 0.4 mmol) and acryloyl chloride 9 (7 mg, 0.07 mmol) at 0 °C. The mixture was stirred at 0 °C for 10 minutes. The solvent was removed and the residue was purified by Prep-TLC eluting with 25 :1 OH to afford the title compound (13 mg, 44%) as white solid. 1H NMR (400 MHz, CDC13) 8 7.90 (d, J= 8.0 Hz, 1H), 7.71—7.62 (m, 2H), 7.42—7.31 (m, 2H), 7.21—7.11 (m, 2H), 7.10— 7.01 (m, 4H), 6.60 (dd, J: 16.8, 10.5 Hz, 1H), 6.26 (dd, J: 16.8, 2.0 Hz, 1H), 5.84 (s, 1H), 5.68 (dd, J: 10.5, 2.0 Hz, 1H), 5.54 (s, 1H), 4.79 (d, J: 13.3 Hz, 1H), 4.13 (d,J= 12.8 Hz, 1H), 3.17 (t, J: 12.3 Hz, 1H), 3.39 (t, J: 11.7 Hz, 1H), 2.76 (t, J: 11.7 Hz, 1H), 2.03 (br, 2H), 1.80 (ddd, J: 25.5, 12.5, 4.2 Hz, 2H). MS (ESI, method A): m/z = 428.0 [M + H]+, 80 min. HPLC: 96.7% (214nm), 99.3% (254nm).
Scheme 3 [f] 0 \ \ I NQI H2804((conc)/H20 | NHz Cl N/ CI K2CO3, ethanol 9,o°c 1h, 94% (\N N Cl reflux 4h, 62% BOG/N HNd 1 3 4 (1 03""O O \ NH2 Pd(dppf)C| 2! Cs co2 3 IN/ | . HQN N/ TEA DCM, (\N 1,4-dloxane/H20 110°C, 16h, 58% N\2 6 0°C,10min N O Example 4 tert-butyl 4-(6-ch10rocyan0pyridiny])piperazine-l-carboxylate (3). To a solution of 2,6- dichloronicotinonitrile 1 (519 mg, 3.0 mmol) and tert—butyl zine-l-carboxylate 2 (558 mg, 3.0 mmol) in ethanol (15 mL) was added K2C03 (636 mg, 6.0 mmol), and the resulting solution was refluxed for 4 h. After cooling to room temperature, the solvent was evaporated and the crude product was purified by flash chromatography, eluting with 5:1 to 2:1 PE/EA to afford the title compound as a white solid (600 mg, 62%). MS (ESI): m/z = 345.1 [M + Na]+. 6-chlor0(4—phen0xyphenyl)nicotinamide (4). To tert-butyl-(6-chloro-5—cyanopyridin y1)piper azine—l-carboxylate 3(600 mg, 10 mmol) was added H2S04 (60716., 5 mL) and water (1 mL). The mixture was heated to 90°C and d for 1 h. After cooling to room temperature, the solution was poured into ice—cold water, then adjusted to PH = 8 with ammonia water. The precipitate was filtered, washed with water (20 mL) and dried under vacuum to afford the title compound as an off-white solid , 94%). MS (ESI): m/z = 241.0 [M + H]+. 2-(4-phenoxyphenyl)(piperazinyl)nicotinamide (Example 4) (6). To a solution of 6— chloro(4-phenoxyphenyl)nicotinamide 4 (420 mg, 1.75 mmol), K2C03 (483 mg, 3.5 mmol) and 4-phenoxyphenylboronic acid 5 (374 mg, 1.75 mmol) in 1,4-dioxane (15 mL) and water (3 mL) was added Pd(PPh3)4 (231 mg, 0.20 mmol) under nitrogen atmosphere, and the mixture was degassed with nitrogen 6 times, then heated to 90°C and stirred for 5 h under nitrogen atmosphere. After cooling to room temperature, the solvent was evaporated and the crude product was purified by flash chromatography eluting with 70:1 DCM/MeOH to afford the title compound as a white solid (260 mg, 58%). MS (ESI): m/z = 375.0 [M + H]+.
Example 5 6-(4-acryloylpiperazin-l-y])—2-(4-phenoxyphenyl)nicotinamide Nominee|\/ NH2 To a on of 2-(4-phenoxyphenyl)—6-(piperazin-1—yl)nicotinamide 6 (59 mg, 0.16 mmol) in DCM (5 mL) was added TEA (0.05 mL, 0.4 mmol) and yl chloride 7 (14 mg, 0.16 mmol) at 0°C. The e was stirred at 0°C for 10 minutes. The solvent was removed and the residue was purified by Prep-TLC eluting with 25 :1 DCM/MeOH to afford the title compound (27 mg, 40%) as light yellow solid. 1H NMR (400 MHz, CDClg) 8 8.04 (d, J: 8.7 Hz, 1H), 7.64 (d, J= 8.2 Hz, 2H), 7.40 (t, J: 7.6 Hz, 2H), 7.18 (t, J: 7.3 Hz, 1H), 7.08 (dd, J: 12.0, 8.4 Hz, 4H), 6.66 (d, J= 8.5 Hz, 1H), .56 (m, 1H), 6.37 (d, J= 16.7 Hz, 1H), 5.77 (d, J= 10.6 Hz, 1H), .57 (s, 1H), 5.33 (s, 1H), 3.81 (s, 4H), 3.73 (s, 4H).MS (ESI, method A): m/z = 429.2 [M + H]+, tR=1.454 min., HPLC: 97.5% (214nm), 98.0% (254nm).
Scheme 4 Z\/ NH2 HCIIEtOH CIJK/ Example 6 6-chlor0(4-phenoxyphenyl)nic0tinamide (1). 6-chloro(4-phenoxyphenyl)nicotinamide 1 was synthesized by using the same procedure above providing a yellow solid (611 mg, 53%).
MS (ESI): m/z = 325.0 [M+H]+. tert-butyl(5-carbamoyl(4-phenoxyphenyl)pyridinyl)—2,S-dihydro-lH-pyrrole-l- carboxylate (3). The title compound was synthesized using a procedure analogous to the procedure described in tert-butyl 4-(5-carbamoyl-6—(4-phenoxypheny1)pyridin-2—y1)-5,6— dihydropyridine-1(2H)- carboxylate ed as white solid (300 mg, crude). MS (ESI): m/z = 458.2 [M+H]+. tert-butyl(5-carbam0yl—6-(4-phenoxyphenyl)pyridin-2—yl)pyrrolidine-l-carboxylate (4).
The title compound was synthesized using a procedure analogous to the procedure described in tert-butyl 4-(5—carbamoyl(4—phenoxyphenyl)pyridinyl)piperidinecarboxylate provided as white solid (240 mg, 45% for two steps). MS (ESI): m/z = 460.1 [M+H]+. 2-(4-phenoxyphenyl)(pyrrolidinyl)nic0tinamide(5). The title compound was synthesized using a procedure analogous to the procedure described in 2-(4-phenoxyphenyl)—6-(piperidin otinamide as white solid (190 mg, . MS (ESI): m/z = 360.1 .
Example 6 6-(1-acryloylpyrrolidinyl)(4-phenoxyphenyl)nic0tinamide N K) The title compound was synthesized using a procedure analogous to the procedure described in Example 3 as a white solid (18 mg, 29%). 1H NMR (300 MHZ, CD30D) 8 7.85 (d, J: 7.9 Hz, 1H), 7.72 (d, J: 8.8 Hz, 2H), 7.37 (m, 3H), 7.15 (t, J: 7.4 Hz, 1H), 7.02 (m, 4H), 6.65 (dd, J: 16.7, 10.6 Hz, 1H), 6.28 (m, 1H), 5.74 (dd, J: 9.5, 7.4 Hz, 1H), 3.98 (m, 2H), 3.69 (m, 3H), 2.34 (dtd, J: 30.9, 12.6, 8.0 Hz, 2H). MS (ESI, method A): m/z = 414.2 [M + H]+, tR=1.421 min.
HPLC: 100% (214nm), 100% (254nm).
Scheme 5 03‘OH |\ NHZ / / N WOO—*0 O N O O Pd(dppf)C]2, 032003 OZN o 1, 4--dioxane/HZO 110°C, 16h 58% O O VLCI Pd/C H2 5 EA, r..,t 90%H16h,ZINON\4020 TEA, DCM, 02 0):) °OC, 10min Example? tert-butyl 4-(6-chlorocyanopyridin-Z-priperazine-l-carboxylate (3). To a solution of 6- chloro(4-phenoxyphenyl)nicotinamide 1 (130 mg, 0.4 mmol) and 4-nitrophenylboronic acid 2 (67 mg, 0.4 mmol) in DME (10 mL) /water (3 mL), was added K2C03 (110 mg, 0.8 mmol) and Pd(dppf)Clz (33 mg, 0.04 mmol) under en atmosphere, and the mixture was degassed with nitrogen 6 times, then heated to 90°C and d for 5 h under nitrogen atmosphere. After cooling to room temperature, the t was evaporated and the crude product was purified by flash chromatography eluting with 70:1 DCM/MeOH to afford the title compound as a white solid (60 mg, crude). MS (ESI): m/z = 412.1 [M+H]+. 6-(4-aminophenyl)(4-phenoxyphenyl)nic0tinamide (4). To a solution of tert-butyl 4-(6— cyanopyridinyl)piperazinecarboxylate 3 (60 mg, 0.15 mmol) in ethyl acetate (5 mL) was added Pd/C (6 mg) under en atmosphere, and the mixture was degassed with hydrogen 6 times, then stirred for 16 h at ambient temperature under hydrogen atmosphere. The solution was filtered and the filtrate was evaporated to the crude product as brown solid (42 mg, 90%). MS (ESI): m/Z = 382.0 [M+H]+.
Example 7 6-(4-acrylamidophenyl)(4-phen0xyphenyl)nicotinamide | \/ NH2 0 O N O Q leu 0 To a solution of 6-(4-aminophenyl)—2-(4-phenoxyphenyl)nicotinamide 4 (42 mg, 0.11 mmol) in DCM (5 mL) was added TEA (0.05 mL, 0.4 mmol) and acryloyl chloride 5 (10 mg, 0.11 mmol) at 0 oC. The mixture was stirred at 0 0C for 10 minutes. The t was removed and the residue was purified by Prep-TLC eluting with 25 :1 DCM/MeOH to afford the title compound (2.5 mg, %) as white solid. 1H NMR (300 MHz, CD3OD) 8 8.17—8.11 (m, 1H), 7.98—7.92 (m, 1H), 7.90—7.84 (m, 1H), 7.81 (s, 3H), 7.69— 7.60 (m, 2H), 7.58—7.52 (m, 1H), 7.42—7.34 (m, 2H), 7.18—7.12 (m, 1H), .00 (m, 3H), 6.47— 6.38 (m, 2H), 5.82—5.76 (m, 1H). MS (ESI, method A): m/z = 435.9 [M + H]+, tR=1.540 min., HPLC: 97.5% (214nm), 98.7% (254nm).
Scheme 6 fo ,Tf <3 i?"3:3? ‘9? (To LDA B\o THF -78°C-rt (JCT Pd(dppf)C[2 KOAC1 4-dioxane Boc 6h, 85% B06 85°C 16h, 54% Bee 1 5 \ \ | NHZ Boc I I CI N/ N Nit—>00Pd/C H2 N Pd(dPPf)012 052003 O EA r.t. 16h 14--dioxaneIH20 Bee Bee 7 6 90°C, 16h, 71% 8 \ NH2 I TFA | / 1—> N TEA DCM DCM 0°C 1h , , N 0 0 0 10mino 41% H 9 34% utyl 5-(trifluoromethylsulfonyloxy)—3,4-dihydr0pyridine-1(2H)—carb0xylate (3). To a solution of tert-butyl 3-oxopiperidine-l-carboxylate l (495 mg, 5.0 mmol) in tetrahydrofuran (10 mL) in a three-necked flask was added m diisopropylamide (2.0M, 2.5 mL, 5.0 mmol) at - 78 °C. After stirring for 2 h at -78 °C, a solution of trifluoro—N-phenyl-N— (trifluoromethylsulfonyl)methanesulfonamide 2 (1.8 g, 5.0 mmol) in tetrahydrofuran (5 mL) was added, and the solution was stirred for another 30 min at this temperature, then warmed to room temperature and stirred for 3 h. Water (30 mL) was added to quench the reaction, and the on was extracted with ethyl acetate (3 X 30 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography eluting with eum ether to afford the title compound as brown oil (1.4 g, 85%). tert-butyl-S-(4,4,5,5-tetramethyl—1,3,2-dioxab0rolanyl)-3,4-dihydr0pyridine-1(2H)- carboxylate (5). To a solution of 4,4,4',4',5,5,5',5'—octamethyl-2,2'—bi(1,3,2—dioxaborolane) 4 (559 mg, 2.2 mmol), KOAc (588 mg, 6.0 mmol) and tert-butyl 5-(trifluoromethylsulfonyloxy)— 3,4-dihydropyridine-1(2H)-carboxylate 3 (662 mg, 2.0 mmol) in dry l,4-dioxane (10 mL) was added Pd(dppf)Clz'DCM (326 mg, 0.4 mmol) under en atmosphere, and the mixture was ed with nitrogen 6 times, then heated to 85°C and stirred overnight under nitrogen atmosphere. After cooling to room temperature, the solvent was evaporated and the crude product was purified by silica gel column chromatography, g with 100:1 to 20:1 PE/EA to afford the title compound as brown oil (336 mg, 54%). tert-butyl(5-carbamoyl-6—(4-phenoxyphenyl)pyridin-2—yl)—3,4—dihydr0pyridine-1(2H)— ylate (7). To a solution of tert-butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl) -3,4- dihydropyridine-1(2H)- carboxylate 5 (260 mg, 0.84 mmol), C82CO3 (456 mg, 1.4 mmol) and 6- chloro(4-phenoxyphenyl)nicotinamide 6 (227 mg, 0.7 mmol) in 1,4-dioxane (10 mL) was added Pd(dppf)Clz'DCM (57 mg, 0.07 mmol) under nitrogen atmosphere, and the mixture was degassed with nitrogen 6 times, then heated to 90°C and stirred overnight under nitrogen atmosphere. After cooling to room ature, the solvent was evaporated and the crude product was d by silica gel column chromatography eluting with 100:1 to 20:1 DCM/MeOH to afford the title compound as white solid (240 mg, 71%). MS (ESI): m/Z = 472.2 [M + Hr. tert-butyl 3-(5-carbam0yl—6—(4-phenoxyphenyl)pyridinyl)piperidine-l-carboxylate (8).
To a solution of tert-butyl 5-(5 -carbamoyl(4-phenoxyphenyl)pyridinyl)-3,4- dihydropyridine-1(2H)- carboxylate 7 (240 mg, 0.5 mmol) in ethyl acetate (5 mL) was added Pd/C (24 mg) under hydrogen atmosphere, and the mixture was degassed with hydrogen 6 times, then stirred for 16 h at ambient temperature under hydrogen atmosphere. The solution was filtered and the filtrate was evaporated to the crude product as brown solid (230 mg, crude). MS (ESI): m/Z = 474.2 [M + Hr. 2-(4-phenoxyphenyl)(piperidinyl)nicotinamide (9). To a solution of tert—butyl 3-(5- carbamoyl(4-phenoxyphenyl)pyridinyl)piperidinecarboxylate 8 (150 mg, 0.32 mmol) in dry dichloromethane (6 mL) was added TFA (2 mL), and the resulting mixture was stirred for 1 h at ambient ature. The solvent was removed and the residue was partitioned between ted aqueous sodium bicarbonate (30 mL) and ethyl acetate (20 mL). The organic phase was separated, dried over anhydrous sodium sulfate, filtered and concentrated. The crude residue was purified by silica gel column tography eluting with 5:1 DCM/MeOH to afford the title compound as a white solid (77 mg, 71%). MS (ESI): m/z =374.2 [M + H]+.
Example 8 6-(1-acryloylpiperidinyl)—2-(4-phenoxyphenyl)nicotinamide To a solution of 2-(4-phenoxyphenyl)—6-(piperidin-3—yl)nicotinamide 9 (19 mg, 0.05 mmol) in DCM (5 mL) was added TEA (0.05 mL, 0.4 mmol) and acryloyl chloride 10 (5 mg, 0.05 mmol) at 0°C. The mixture was stirred at 0°C for 10 minutes. The solvent was removed and the residue was purified by Prep-TLC eluting with 25 :1 DCM/MeOH to afford the title nd (7 mg, 34%) as white solid. 1H NMR (300 MHZ, CDClg) 8 7.97 (d, J: 8.9 Hz, 1H), 7.69 (d, J: 8.1 Hz, 2H), 7.38 (t, J: 7.8 Hz, 2H), 7.24—7.15 (m, 2H), 7.12—7.01 (m, 4H), 6.62 (dd, J: 16.6, 10.6 Hz, 1H), 6.28 (d, J= 16.4 Hz, 1H), 5.75—5.60 (m, 2H), 5.46 (s, 1H), 4.89—4.55 (m, 1H), 4.30—3.90 (m, 1H), 3.50 (t, J: 12.2 Hz, 0.5H), 3.24—3.06 (m, 1H), 2.99 (d, J: 10.7 Hz, 1H), 2.80 (t, J: 12.2 Hz, 0.5H), 2.13 (s, 1H), 1.87 (d, J: 13.4 Hz, 2H), 1.64 (s, 1H). MS (ESI, method A): m/z = 428.0 [M + H]+, tR=1.526 min., HPLC: 93.3% (214nm), 99.8% (254nm).
Scheme 7 HN§>—NH3°C 0 elm?" K200: ethanol \ NH2 N N/ H2804(conc)/H20 CI l —’ / 90°C, 1h. 96% DN N Cl reflux 6h 70% HN Boc HZN 3 4 E103:" O f)C|2, 052003 1 ,4—dioxane/HZO GIN: Who—,0 \jLNO": H2N TEA, DCM, NHZOQ 110°C, 1611, 31% 0°C,10min Example9 utyl 1-(6-chlorocyanopyridiny])piperidin-4—ylcarbamate (3). To a on of 2,6- dichloronicotinonitrile 1 (346 mg, 2.0 mmol) in ethanol (10 mL) was added tert-butyl piperidin- 4-ylcarbamate 2 (400 mg, 2.0 mmol) and K2C03 (552 mg, 4.0 mmol). The mixture was heated to reflux stirred for 4 h. After g to room temperature, the solvent was evaporated and the crude product was purified by silica gel column chromatography eluting with 20:1 to 5 :1 PE/EA to afford the title compound as a white solid (470 mg, 70%). MS (ESI, method A): m/Z = 337.2 [M + H].+ 6-(4-aminopiperidinyl)chloronicotinamide (4). To tert—butyl 1-(6-chlorocyanopyridin- 2-yl) piperidinylcarbamate 3 (470 mg, 1.4 mmol) was added H2804 (conc., 5 mL) and water (1 mL). The mixture was heated to 90°C and stirred for 1 h. After cooling to room temperature, the solution was poured into ice-cold water, then adjusted to PH = 8 with ammonia water. The precipitate was filtered, washed with water (10 mL) and dried under vacuum to afford the title compound as a white solid (340 mg, 96%). MS (ESI): m/z = 255.0 [M + H]+. 6-(4-amin0piperidinyl)—2—(4-phenoxyphenyl)nicotinamide (6). To a solution of 6-(4- aminopiperidinyl)—2-chloronicotinamide 4 (51 mg, 0.2 mmol), K2C03 (55 mg, 0.4 mmol) and 4-phenoxyphenylboronic acid 5 (43 mg, 0.2 mmol) in 1,4-dioxane (15 mL) and water (3 mL) was added Pd(dppf)Clz (18 mg, 0.02 mmol) under nitrogen atmosphere, and the mixture was degassed with nitrogen 6 times, then heated to 90°C and stirred for 5 h under nitrogen atmosphere. After cooling to room ature, the solvent was evaporated and the crude t was purified by silica gel column chromatography eluting with 70:1 DCM/MeOH to afford the title compound as a white solid (24 mg, 31%). MS (ESI): m/Z = 389.2 [M + H]+.
Example 9 crylamid0piperidinyl)(4-phenoxyphenyl)nic0tinamide VLN ONO/ D To a solution of 6-(4—aminopiperidin—1-yl)(4-phenoxyphenyl)nicotinamide 6 (62 mg, 0.16 mmol) in DCM (5 mL) was added TEA (0.05 mL, 0.4 mmol) and acryloyl chloride 7 (15 mg, 0.16 mmol) at 0°C. The mixture was d at 0°C for 10 minutes. The solvent was removed and the residue was purified by Prep-TLC eluting with 25 :1 OH to afford the title compound (14 mg, 20%) as white solid. 1H NMR (300 MHz, CDC13) 8 7.98 (d, J = 8.8 Hz, 1H), 7.62 (d, J: 8.5 Hz, 2H), 7.38 (t, J: 7.8 Hz, 2H), 7.16 (t, J: 7.4 Hz, 1H), 7.12—7.00 (m, 4H), 6.65 (d, J: 8.9 Hz, 1H), 6.31 (d, J: 16.9 Hz, 1H), 6.07 (dd, J=16.9, 10.2 Hz, 1H), 5.66 (d, J: .2 Hz, 1H), 5.52—5.48 (m, 1H), 5.28 (s, 1H), 4.44 (d, J= 13.4 Hz, 2H), 4.24—4.08 (m, 1H), 3.08 (t, J: 11.9 Hz, 2H), 2.08 (d, J: 10.7 Hz, 2H), 1.62 (s, 1H), 1.47 (dt, .1: 11.3, 6.1 Hz, 2H).
MS (ESI, method A): m/z = 443.2 [M + H]+, tR=1.434 min., HPLC: 99.1% (214nm), 99.3% (254nm).
Scheme8 HNQ/ ‘Boc 0 2 \ \ NH2 \ | 1 K2003, ethanol / H2804(C0nC)/H20 / | N N Clo—o> N N CI CI N CI 9091111964 reflux, 6h, 70% Boc—‘NH H2N 1 4 CL 0°" 0 |\ NH2 Pd(dPPf)C|2.Cszcos N N —> NHo/Q 1,4—dioxane/H20 H N H%:lN\TEA, DCM 110°C, 16h, 31% 5 0°C 10min % \0 Example 10 tert-butyl 1-(6-chlor0cyanopyridin-Z-yl)pyrrolidinylcarbamate (3). To a solution of 2, 6-dichloronicotinonitrile 1 (346 mg, 2.0 mmol) in ethanol (10 mL) was added tert-butyl piperidinylcarbamate 2 (372 mg, 2.0 mmol) and K2C03 (552 mg, 4.0 mmol). The mixture was heated to reflux and stirred for 4 h. After cooling to room temperature, the solvent was evaporated and the crude product was purified by silica gel column chromatography eluting with :1 to 5:1 PE/EA to afford the title compound as a white solid (365 mg, 57%). MS (ESI, method A): m/Z = 345.1 [M + Nar. min0piperidinyl)—2—chloronicotinamide (4). To tert-butyl l-(6-chlorocyanopyridin- 2-yl) pyrrolidiny1carbamate 3 (357 mg, 1.1 mmol) was added H2804 (00:10., 5 mL) and water (1 mL). The mixture was heated to 90°C and stirred for 1 h. After cooling to room temperature, the solution was poured into ld water, then adjusted to PH = 8 with ammonia water. The precipitate was filtered, washed with water (10 mL) and dried under vacuum to afford the title compound as brown solid (192 mg, 72%). MS (ESI, method A): m/z = 241.0 [M + H]+. minopyrrolidinyl)(4-phenoxyphenyl)nic0tinamide (6). To a solution of 6-(4- iperidin-l-yl)—2-chloronicotinamide 4 (192 mg, 0.79 mmol), K2C03 (220 mg, 1.6 mmol) and 4-phenoxyphenylboronic acid 5 (171 mg, 0.8 mmol) in 1,4-dioxane (15 mL) and water (3 mL) was added Pd(dppf)Clz (69 mg, 0.08 mmol) under nitrogen atmosphere, and the mixture was degassed with nitrogen 6 times, then heated to 90°C and stirred for 5 h under en atmosphere. After cooling to room temperature, the solvent was evaporated and the crude product was purified by flash chromatography eluting with 70:1 DCM/MeOH to afford the title compound as a white solid (92 mg, 31%). MS (ESI): m/z = 375.2 [M + H]+.
Example 10 6-(3-acrylamid0pyrrolidinyl)(4-phen0xyphenyl)nicotinamide l NH2 Q N Oo To a on of 6-(3—aminopyrrolidin-l-yl)(4-phenoxyphenyl)nicotinamide 6 (92 mg, 0.25 mmol) in DCM (5 mL) was added TEA (0.14 mL, 1.0 mmol) and acryloyl chloride 7 (23 mg, 0.25 mmol) at 0 oC. The mixture was stirred at 0 0C for 10 s. The solvent was removed and the residue was purified by Prep—TLC g with 25 :1 DCM/MeOH to afford the title compound (58 mg, 54%) as white solid. 1H NMR (300 MHz, CDCl3) 8 7.95 (d, J = 8.7 Hz, 1H), 7.62 (d, J= 8.5 Hz, 2H), 7.38 (t, J= 7.8 Hz, 2H), 7.16 (t, J= 7.4 Hz, 1H), 7.05 (dd, J= 12.6, 8.3 Hz, 4H), 6.40—625 (m, 1H), 6.10 (dd, J: 16.8, 10.2 Hz, 2H), 5.67 (d, J: 10.2 Hz, 1H), 5.48 (s, 1H), 5.31 (s, 1H), 4.71 (d, J: 4.4 Hz, 1H), 3.85 (dd, J: 11.2, 6.0 Hz, 1H), 3.75—340 (m, 4H), 2.40—2.25 (m, 1H), 2.10—1.90 (m, 1H). MS (ESI, method A): m/z = 429.0 [M + H]+, tR=l.443 min., HPLC: 100% (214nm), 100% (254nm).
Example 1 1 1-(1-acryloylpiperidinyl)(4-phenoxyphenyl)—1H-pyrazole-4—carb0xamide PhO0"):o ""2 Refer to Example 34 schemes and associated experimental procedures and data bed below.
Example 12 1-(1-acryloylpiperidinyl)—3-(4-phen0xyphenyl)-1H-pyrazole-4—carboxamide PhDM0 "HZ Refer to Example 34 schemes and associated experimental procedures and data described below.
Example 13 cryloylpyrrolidinyl)—3-(4-phenoxyphenyl)—1H-pyrazolecarb0xamide PhD 0 ""2 Refer to Example 34 schemes and associated experimental ures and data described below.
Example 14 1-(azetidinyl)—3-(4—phenoxyphenyl)—1H-pyrazolecarb0xamide PhOMo NH2 Refer to Example 34 scheme and associated experimental procedures and data described below.
Scheme 9 N'NH HO TsC|,Pyridine Tso d C 3"0 b— 3 OE. G LiOH/EtOH , ‘NQN’BOC N D —.N . overni9 ht .
BOG BOG 052003 DMF o 100°C; 3h NH4CLHATU O HC|,DCM,rt ‘N’CN’BOC —— DIEA,DMF 7 Example 15 tert-butyl 3-(tosyloxy)azetidine—l-carboxylate (2). To a solution of tert-butyl 3- hydroxyazetidinecarboxylate 1 (2.0 g, 11.5 mmol) in pyridine (25 mL) was added TsCl (2.64 g, 13.8 mmol), and the resulting solution was stirred for 16 h at rt. The solvent was evaporated and the crude residue was purified by silica gel column, eluting with 5 :1 petroleum ether/ethyl acetate to afford the title compound (3.2 g, 85%) as colorless oil. MS (ESI): m/z = 350.0 [M+Na]+.
Ethyl(1-(tert-butoxycarbonyl)azetidin-3—yl)—3-(4-phenoxyphenyl)—1H—pyrazole carboxylate (4). To a solution of utyl yloxy)azetidine-l-carboxylate 2 (1.3 g, 3.88 mmol) and CsC03 (2.12 g, 6.48 mmol) in DMF (25 mL) was added ethyl 3-(4-phenoxyphenyl)- 1H-pyrazolecarboxylate 3 (1.0 g, 3.24 mmol), and the resulting solution was d for 16 h at 100°C. The solvent was evaporated and the crude residue was purified by silica gel column g with 3:1 petroleum ether/ethyl acetate to afford the title compound (1.39 g, 93%) as white solid. MS (ESI): m/Z = 464.0 . 1-(1-(tert—butoxycarbonyl)azetidinyl)—3-(4-phenoxyphenyl)—1H-pyrazole—4-carboxylic acid (5). To a solution of ethyl 1-(1-(tert-butoxycarbonyl)azetidinyl)—3-(4-phenoxyphenyl)- lH—pyrazole-4—carboxylate 4 (1.39 g, 3.0 mmol) in EtOH (20 mL) and water (2 mL) was added LiOH (630 mg, 15.0 mmol), and the resulting solution was stirred for 16 h at rt. The solvent was evaporated, and the e was dissolved in water (5 mL) and the resulting solution was acidified with 2 N hydrochloric acid to pH = 6. The precipitate was filtered, washed with water (15 mL) and dried under vacuum to afford the title compound (1.2 g, 92%) as a white solid. MS (ESI): m/Z = 436.0 [M+H]+. tert-butyl(4-carbamoyl(4-phenoxyphenyl)—1H-pyrazol—1-yl)azetidine—l-carboxylate (6). To a solution of 1-(1-(tert-butoxycarbonyl)azetidinyl)(4-phenoxyphenyl)-1H-pyrazole- 4-carboxylic acid 5 (800 mg, 1.84 mmol), NH4C1 (120 mg, 2.21 mmol) and HATU (1.04 mg, 2.76 mmol) in dry DMF (10 mL) was added DIPEA (957 mg, 7.36 mmol), and the resulting solution was stirred overnight at rt. After the reaction was completed, the solution was concentrated, d with ethyl acetate (30 mL) and washed with water (2 X 20 mL) and brine (2 X 20 mL). The organic layer was dried over anhydrous sodium e, filtered and trated.
The residue was purified by silica gel column eluting with 40:1 OH to afford the title compound (700 mg, 82%) as white solid. MS (ESI): m/z = 435.0 [M+H]+. 1-(azetidinyl)(4-phen0xyphenyl)-1H-pyrazolecarb0xamide (7). To a solution of 3-(4- carbamoyl(4-phenoxyphenyl)-1H-pyrazol—1-yl)azetidinecarboxylate 6 (700 mg, 1.61 mmol) in DCM (20 mL) was added conc. HCl (5 mL) and the reaction mixture was stirred at rt for 1 h. After the reaction was completed, the solution was concentrated to afford the title compound (600 mg, 100%) as white solid. MS (ESI): m/z = 335.0 [M + H]+.
Example 15 1-(1-acryloylazetidinyl)—3-(4-phen0xyphenyl)—1H-pyrazole—4-carb0xamide /N\N’CN/<; To a solution of tidinyl)—3-(4-phenoxyphenyl)—1H—pyrazolecarboxamide 7 (300 mg, 0.81 mmol) in dry DCM (15 mL) were added DIEA (316 mg, 2.43 mmol) and acryloyl chloride (88 mg, 0.97 mmol) at 0°C, and the resulting solution was stirred at 0°C for 10 min. Water (10 mL) was added to quench the reaction. The mixture was diluted with DCM (20 mL), and washed with water (2 X 20 mL) and brine (2 X 20 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by Prep—HPLC zO = -70, 0.1%FA) to afford the title compound (160 mg, 51%) as a white solid. 1H NMR (400 MHz, DMSO) 5 8.38 (s, 1H), 7.81 (d, J: 8.7 Hz, 2H), .38 (m, 3H), 7.20—7.14 (m, 1H), 7.11—6.99 (m, 5H), 6.43—6.34 (m, 1H), 6.20—6.12(m, 1H), 5.76—5.70 (m, 1H), 5.38—5.29 (m, 1H), 4.78—4.68 (m, 1H), 4.59—4.49 (m, 1H), 4.48—4.40 (m, 1H), 4.32—4.22 (m, 1H). MS (ESI, Method A): m/Z = 389.1 [M + H]+, tR = 1.374 min. HPLC: 99.7% ), 99.7% (254nm).
Example 16 1-(4-acrylamid0phenyl)—3-(4-phenoxyphenyl)—1H—pyrazolecarb0xamide HN’<§ PhOMo NH2 Refer to Example 34 schemes and associated experimental procedures and data bed below.
Example 17 1-(3-aminophenyl)—3-(4-phen0xyphenyl)—1H-pyrazolecarboxamide PhDMo ""2 Refer to Example 34 schemes and associated experimental procedures and data described below.
Example 18 1-(3-acrylamid0phenyl)(4-phen0xyphenyl)-1H-pyrazolecarb0xamide Refer to Example 34 schemes and associated experimental procedures and data described below.
Example 19 (S)(1-acryloylpyrrolidinyl)—3-(4-phenoxyphenyl)—1H-pyrazolecarboxamide Refer to Example 34 schemes and associated experimental procedures and data described below.
Example 20 (R)(1-acryloylpyrrolidinyl)(4-phen0xyphenyl)—1H-pyrazole—4-carboxamide N’ [\I PhDMo ""2 Refer to Example 34 schemes and associated experimental ures and data described below.
Scheme 10 0 OH O C] gOH "Hz 3H PCI5, POC13 g NH3 in dioxane gm CL 0‘OH 0 N?" N/N —’ 115 °C, overnight Y 0 °c to ,1 NYN Pd(dppf)C[2, K2003, OH Cl C] dioxane—HZO (8/1 V) 60 O 1 2 c, 3 h it Pd(PPh3)4,K2003 N \ 0 c1 N —» I DME-HZO (8/1 V) N I 85 °C, ght Boc Boc’N OO NI \ 0 Pd/C, H2 CF3COOH —> 000 EtOAc, rt, overnight N Boc’ O)\N/ DCM, It 2 h \JLCI DCM 0 °C 1 h q©fi$oQ e 21 2,4-dichloropyrimidine—S-carbonyl chloride (2). To a on of 2,4-dihydroxypyrimidine carboxylic acid (5.0 g, 32.0 mmol) in POC13 (50 mL) was added PC15 (23.9 g, 115.2 mmol), and the resulting solution was heated to 115 °C and stirred for 12 h. The solvent was evaporated and the crude residue was d with ethyl acetate (100 mL). The solid was filtered and the filtrate was concentrated to give the title compound as brown oil (6.2 g, 92%). 2,4-dichloropyrimidine-S-carboxamide (3). To a solution of 2,4-dichloropyrimidine carbonyl de (6.2 g, 29.3 mmol) in 1,4-dioxane (50 mL) was added ammonia (1.0 g, 58.3 mmol) in 1,4-dioxane (50 mL) dropwise at 0 0C, and the resulting solution was stirred for 12 h at ambient temperature. The mixture was diluted with ethyl acetate (50 mL), and washed with water (2 X 80 mL) and brine (2 X 80 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated to afford the title compound as a white solid (4.5 g, 80%). MS (ESI): m/Z = 191.8 [M + Hr. 2-chloro(4—phenoxyphenyl)pyrimidine—S-carboxamide (4). To a solution of 4- phenoxyphenylboronic acid (1.0 g, 4.7 mmol), K2C03 (1.4 g, 10.4 mmol) and 2,4- dichloropyrimidine-5—carboxamide (1.0 g, 5.2 mmol) in 1,4—dioxane (24 mL) and water (3 mL) was added Pd(dppf)C12 (380 mg, 0.52 mmol) under en atmosphere, and the mixture was degassed with nitrogen 6 times, then heated to 60 °C and stirred for 3 h under nitrogen atmosphere. After cooling to room temperature, the solution was poured into water (50 mL), and then extracted with ethyl acetate (3 X 40 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by column tography, eluting with 100 : l dichloromethane/methanol to afford the title compound as a brown solid (410 mg, 24%). MS (ESI): m/Z = 325.9 [M + H]+. tert-butyl 4-(5-carbamoyl-4—(4-phenoxyphenyl)pyrimidinyl)—5,6-dihydr0pyridine—1(2H)- carboxylate (6). To a solution of 2-chloro-4—(4-phenoxyphenyl)pyrimidine—5-carboxamide 4 (410 mg, 1.26 mmol), K2C03 (521.6 mg, 3.78 mmol) and tert-butyl 4-(4,4,5,5-tetramethyl —1,3,2- dioxaborolan—2—yl)-5,6—dihydropyridine-1(2H)—carboxylate 5 (583 mg, 1.89 mmol) in DME (30 mL) and water (5 mL) was added Pd(PPh3)4 (146 mg, 0.126 mmol) under nitrogen atmosphere, and the mixture was degassed with en 6 times, and then heated to 85 °C and stirred for 12 h under nitrogen atmosphere. After cooling to room temperature, the solvent was evaporated and the crude product was purified by flash chromatography g with 80 : 1 DCM/MeOH to afford the title compound as a brown solid (420 mg, 71%). MS (ESI): m/Z = 472.8 [M + H]+. tert-butyl 4-(5-carbam0yl—4—(4-phenoxyphenyl)pyrimidinyl)piperidine—l-carboxylate (7).
To a solution of tert—butyl 4-(5-carbamoyl-4—(4-phenoxyphenyl)pyrimidin-2—yl)—5,6— dihydropyridine-1(2H)- carboxylate 6 (100 mg, 0.212 mmol) in ethyl acetate (5 mL) was added Pd/C (20 mg) under hydrogen atmosphere, and the mixture was ed with hydrogen 6 times, then stirred for 16 h at ambient temperature under hydrogen atmosphere. The on was filtered and the filtrate was evaporated to the crude product as brown solid (96 mg). MS (ESI): m/Z = 474.8 [M+H]+. 4-(4-phen0xyphenyl)(piperidinyl)pyrimidinecarb0xamide (8). To a solution of tert- butyl 4-(5-carbamoyl—4-(4-phenoxyphenyl)pyrimidinyl) piperidine-l-carboxylate 7 (96 mg, crude) in dry dichloromethane (2 mL) was added TFA (2 mL), and the resulting mixture was stirred for 1 h at ambient temperature. The solvent was removed and the residue was partitioned between saturated aqueous sodium bicarbonate (30 mL) and ethyl e (20 mL). The c phase was separated, dried over anhydrous sodium sulfate, d and concentrated. The crude residue was purified by flash chromatography, eluting with 5 : l DCM/MeOH to afford the title compound as a white solid (70 mg, 88% for two . MS (ESI): m/z = 374.9 [M+H]+.
Example 21 2-(1-acryloylpiperidinyl)—4-(4-phenoxyphenyl)pyrimidinecarb0xamide N \ O O"I / W" O To a solution of 4-(4-phenoxyphenyl)(piperidin-4—yl)pyrimidinecarboxamide 8 (70 mg, 0.187 mmol) in DCM (3 mL) was added TEA (56.7 mg, 0.56 mmol) and yl chloride (25.3 mg, 0.28 mmol) at 0°C. The mixture was stirred at 0°C for 10 min. The t was removed and the residue was purified by Prep-TLC eluting with 25 : 1 DCM/MeOH to afford the title compound (50 mg, 63%) as light yellow solid. 1H NMR (400 MHz, CDCl3) 5 8.95 (s, 1H), 7.82 (d, J= 8.8 Hz, 2H), 7.49—7.36 (m, 2H), 7.27—7.17 (m, 1H), 7.16—7.04 (m, 4H), 6.64 (dd, J: 16.8, 10.6 Hz, 1H), 6.29 (dd,.]= 16.8, 1.9 Hz, 1H), 5.94 (s, 1H), 5.77 (s, 1H), 5.71 (dd,.]= 10.6, 1.9 Hz, 1H), 4.76 (d, J: 12.5 Hz, 1H), 4.14 (d, J: 14.1 Hz, 1H), 3.37—3.19 (m, 2H), 2.89 (t, J: 11.5 Hz, 1H), 2.16 (d, J= 11.0 Hz, 2H), 1.97 (d, J= 9.9 Hz, 2H). MS (ESI, method F): m/z = 428.8 [M + H]+, tR=1.407 min., HPLC: 99.8% (214nm), 99.6% (254nm).
Scheme 11 OTf 0335:? 3% NH2 fig PhN(CF3802)2 / >§(N:I)NI\N,O N| \ NH2 CF3COOH CI OXN/ N 0 DCMrch ODCMO°C1h\O [’3/ o 7 Example 22 1-(tert-but0xycarbonyl)—2,5-dihydro-1H-pyrrol—3-yl trifluoromethanesulfonate (2). To a solution of tert—butyl 3-oxopyrrolidinecarboxylate 1 (5.0 g, 27.0 mmol) in tetrahydrofuran (130 mL) in a three-necked flask was added lithium diisopropylamide (2.0M, 16.2 mL, 32.4 mmol) at -78 °C. After stirring for 2 h at -78 °C, a solution of trifluoro-N-phenyl-N— (trifluoromethylsulfonyl) methanesulfonamide (10.1 g, 28.4 mmol) in tetrahydrofiiran (20 mL) was added, and the solution was stirred for r 30 min at this temperature, then warmed to room temperature and stirred for 3 h. Water (30 mL) was added to quench the reaction, and the solution was extracted with ethyl acetate (3 X 200 mL). The c layers were combined, dried over anhydrous sodium e, filtered and trated. The residue was purified by silica gel column chromatography, eluting with petroleum ether to afford the title compound as a brown oil (4.2 g, 49%).MS (ESI): m/z = 318.1 [M + H]+. tert-butyl-(4,4,5,5-tetramethyl—1,3,2-dioxabor01anyl)-2H-pyrrole-1(5H)-carb0xylate (3).
To a solution of bis(pinacolato)diborone (4.0 g, 15.9 mmol), KOAc (2.59 g, 26.4 mmol) and 1- (tert—butoxycarbonyl)—2,5-dihydro-1H—pyrrolyl trifluoromethanesulfonate 2 (4.2 g, 13.2 mmol) in dry 1,4-dioxane (10 mL) was added Pd(dppf)C12 (965 mg, 1.32 mmol) under nitrogen atmosphere, and the mixture was degassed with nitrogen 6 times, then heated to 85 OC and stirred overnight under nitrogen atmosphere. After cooling to room temperature, the solvent was evaporated and the crude t was ed by silica gel column chromatography, eluting from 100 : 1 to 20 : 1 eum ether/ethyl e to afford the title compound as brown oil (1.2 g, 31%). MS (ESI): m/Z = 296.1 [M + H. tert-butyl(5-carbamoyl-4—(4-phenoxyphenyl)pyrimidinyl)-2H-pyrrole—1(5H)— carboxylate (5). To a solution of tert—butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)—2H— pyrrole-1(5H)- carboxylate 3 (136 mg, 0.46 mmol), K2C03 (127 mg, 0.92 mmol) and 2-chloro (4-phenoxyphenyl)pyrimidinecarboxamide 4 (100 mg, 0.31 mmol) in 1,4-dioxane (15 mL) and water (3 mL) was added Pd(PPh3)4 (35.5 mg, 0.031 mmol) under nitrogen here. The mixture was degassed with nitrogen 6 times, then heated to 90 CC and stirred for 12 h under nitrogen atmosphere. After cooling to room temperature, the solvent was evaporated and the crude product was purified by flash chromatography eluting with 70 : 1 DCM/MeOH to afford the title compound as a white solid (90 mg, 64%). MS (ESI): m/Z = 458.8 [M + H]+. tert-butyl(5-carbamoyl-4—(4-phenoxyphenyl)pyrimidinyl)pyrrolidine—l-carboxylate (6). To a solution of tert-butyl 3-(5-carbamoyl(4-phenoxyphenyl)pyrimidinyl)-2H-pyrrole- 1(5H) -carboxy1ate 5 (90 mg, 0.20 mmol) in ethyl acetate (3 mL) and MeOH (3 mL) was added Pd/C (20 mg) under hydrogen atmosphere, and the mixture was degassed with en 6 times, then stirred for 16 h at ambient temperature under hydrogen atmosphere. The solution was filtered and the filtrate was evaporated to the crude product as brown solid (80 mg, 88%). MS (ESI): m/Z = 461.1 [M+H]+. 4-(4-phenoxyphenyl)—2-(pyrrolidinyl)pyrimidine—S-carboxamide (7). To a solution of tert- butyl 3-(5 -carbamoyl(4-phenoxyphenyl)pyrimidinyl)pyrrolidine-l- carboxylate 6 (80 mg, 0.174 mmol) in dry dichloromethane (2 mL) was added TFA (2 mL), and the resulting mixture was stirred for 1 h at ambient temperature. The solvent was removed and the residue was partitioned n saturated aqueous sodium onate (30 mL) and ethyl acetate (20 mL).
The c phase was separated, dried over anhydrous sodium sulfate, filtered and concentrated to afford the title compound as a white solid (70 mg, . MS (ESI): m/z = 360.8 [M+H]+.
Example 22 2-(1-acryloylpyrrolidinyl)(4-phenoxyphenyl)pyrimidine—5-carb0xamide To a solution of 4-(4-phenoxyphenyl)(pyrrolidinyl)pyrimidinecarboxamide 7 (70 mg, crude) in DCM (5 mL) was added TBA (59 mg, 0.58 mmol) and acryloyl chloride (26 mg, 0.29 mmol) at 0°C. The mixture was stirred at 0°C for 10 min. The solvent was removed and the residue was purified by Prep-TLC eluting with 25 : 1 DCM/MeOH to afford the title compound (20 mg, 25%) as a white solid. 1H NMR (400 MHZ, CDClg) 5 8.95 (d, J: 6.2 Hz, 1H), 7.82 (d, J = 6.6 Hz, 2H), 7.42 (t, J: 7.8 Hz, 2H), 7.22 (t, J: 7.4 Hz, 1H), 7.10 (t, J: 7.9 Hz, 4H), 6.55— 6.47 (m, 1H), 6.39 (d,J= 16.8, Hz, 1H), 5.84 (s, 2H), 5.71 (d, J: 10.1 Hz, 1H), 4.14—3.96 (m, 2H), .78 (m, 2H), 3.76—3.62 (m, 1H), .36 (m, 2H). MS (ESI, method F): m/z = 414.8 [M + H]+, tR=1.382 min, HPLC: 99.0% (214nm), 98.4% ).
Scheme 12 3’0 3)4. \ 0 | K2003 / —> + / CI N N Q DME-HZO (8/1 V) \ 85 Oc, 16 h Boo o 1 2 \ NH \ ""2 2 Pd/C, H2 | CFscOOH I —> N —> N MeOH/EtOAc. rt, overnight DCM, rt, 2 h HN 0 N O , 0 4 5 d \ NH2 CI l —’ N DCM,O°C, 10 min N O / 0 Example 23 tert-butyl—3-(5-carbamoyl(4-phen0xyphenyl)pyridinyl)—2H—pyrrole-1(5H)-carb0xylate (3). To a solution of tert—butyl 3—(4,4,5,5-tetramethyl—1,3,2-dioxaborolanyl)—2H—pyrrole- 1(5H)—carboxylate 1 (136 mg, 0.0.46 mmol), K2C03 (127.5 mg, 0.92 mmol) and 6-chloro(4- phenoxyphenyl) nicotinamide 2 (100 mg, 0.31 mmol) in 1,2-dimethoxyethane (5 mL) and water (1 mL) was added Pd(PPh3)4 (35.6 mg, 0.031 mmol) under nitrogen atmosphere, and the mixture was degassed with nitrogen 6 times, then heated to 85 °C and stirred for 12 h under nitrogen atmosphere. After cooling to room temperature, the t was evaporated and the crude product was purified by flash chromatography, eluting with 50 : 1 DCM/MeOH to afford the title nd as a white solid (84 mg, 60%). MS (ESI): m/z = 458.1 [M+H]+. tert-butyl 3-(5-carbamoyl(4-phenoxyphenyl)pyridin-Z-yl)pyrrolidine-l-carboxylate (4).
To a solution of tert—butyl 3-(5-carbamoyl(4-phenoxyphenyl)pyridinyl)—2H—pyrrole-1(5H)- ylate 3 (84 mg, 0.18 mmol) in ethyl acetate (5 mL) and MeOH (5 mL) was added Pd/C (40 mg) under hydrogen atmosphere, and the mixture was degassed with hydrogen 6 times, then stirred for 12 h at ambient temperature under hydrogen atmosphere. The solution was filtered and the filtrate was evaporated to the crude t as brown solid (80 mg, 95%). MS (ESI): m/z = 459.8 [M+H]+. 2-(4-phenoxyphenyl)—6-(pyrrolidinyl)pyridinecarb0xamide (5). To a on of tert- butyl 3-(5 moyl(4-phenoxyphenyl)pyridinyl)pyrrolidinecarboxylate 4 (80 mg, 0.17 mmol) in dry dichloromethane (2 mL) was added TFA (2 mL), and the resulting mixture was stirred for 1 h at ambient temperature. The solvent was removed and the residue was partitioned between saturated aqueous sodium bicarbonate (30 mL) and ethyl acetate (20 mL). The organic phase was separated, dried over anhydrous sodium sulfate, d and concentrated to afford the title compound as a white solid (70 mg, crude). MS (ESI): m/z = 359.9 [M+H]+.
Example 23 6-(1-acryloylpyrrolidinyl)—2-(4-phenoxyphenyl)pyridine—3-carboxamide To a solution of 2-(4-phenoxyphenyl)(pyrrolidinyl)pyridine-3—carboxamide 5 (70 mg, crude) in DCM (5 mL) was added TBA (59 mg, 0.58 mmol) and acryloyl chloride (26.4 mg, 0.29 mmol) at 0 OC. The e was stirred at 0 °C for 10 min. The solvent was removed and the residue was purified by Prep-TLC eluting with 25 : l DCM/MeOH to afford the title compound (18 mg, 25% for two steps) as white solid. 1H NMR (400 MHz, CDC13) 8 8.06 (s, 1H), 7.72 (s, 2H), 7.41 (t, J: 7.8 Hz, 2H), 7.28—7.24 (m, 1H), 7.19 (t, J: 7.4 Hz, 1H), 7.11—7.09 (m, 4H), 6.55—6.47 (m, 1H), 6.41 (d,J= 16.8, Hz, 1H), 5.71 (d,J= 10.1 Hz, 1H), 5.65 (br, 1H), 5.45 (br, 1H), 4.14—3.96 (m, 1H), .78 (m, 2H), 3.76—3.62 (m, 2H), 2.55—2.36 (m, 2H). MS (ESI, method F): m/z = 413.8 [M + H]+, tR=1.393 min, HPLC: 97.3% ), 99.5% (254nm).
Scheme 13 0% O \ o CN ' Va" Boc’N 100 0C’ 3 h o HN o/O DCM, 0 DC, 10 min 1 2 Ar"%l/" 0Q Example 24 2-(4-phen0xyphenyl)—6-(piperidinyl)pyridinecarbonitrile (2). A solution of tert—butyl 4- (5 -carbamoyl(4-phenoxyphenyl)pyrimidinyl)piperidine- 1 xylate (100 mg, 0.21 mmol) in POCl3 (3 mL) was heated to 100 °C and stirred for 3 h. After cooling to room temperature, the reaction mixture was poured into water (3 mL), and basified by saturate aqueous NaHC03 to PH=10. Then the solution was extracted with ethyl acetate (3 X 60 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The crude residue was d by preparative TLC eluting with 8 : 1 DCM/MeOH to afford the title compound as brown oil (10 mg, 13%). MS (ESI): m/z = 356.1 [M + H]+.
Example 24 6-(1-acryloylpiperidinyl)—2-(4-phen0xyphenyl)pyridinecarb0nitrile Ar"0%l/N 0 To a solution of 2-(4-phenoxyphenyl)(piperidinyl)pyridinecarbonitrile 2 (10 mg, 0.028 mmol) in DCM (2 mL) was added TEA (8.5 mg, 0.084 mmol) and acryloyl chloride (3.8 mg, 0.042 mmol) at 0 oC. The mixture was stirred at 0 0C for 10 min. The t was removed and the residue was purified by Prep-TLC eluting with 25 : 1 DCM/MeOH to afford the title compound (13 mg, 44%) as white solid. 1H NMR (400 MHz, CDCl3) 5 8.01 (d, J = 8.1 Hz, 1H), 7.97 (dd, J: 92,23 Hz, 2H), 7.41 (t, J: 7.9 Hz, 2H), 7.24—7.17 (m, 2H), 7.16—7.09 (m, 4H), 6.64 (dd, .1: 16.8, 10.6 Hz, 1H), 6.32 (dd, .1: 16.8, 1.8 Hz, 1H), 5.73 (dd, J: 10.6, 1.9 Hz, 1H), 4.85—4.79 (m, lH),4.21—4.16(m, 25—4.18(m, 1H), 3.12 (tt,J= 12.0, 3.8 Hz, 1H), 2.84— 2.78 (m, 1H), 2.09—2.06 (m, 2H), 1.93—1.82 (m, 2H). MS (ESI, method F): m/Z = 409.8 [M + Hr, tR=1.669 min, HPLC: 98.7% (214nm), 98.8% (254nm).
Scheme 14 WE] \ H? K2003 | "Hz / sto4/H20 |\ —> N N CI / N N CI CI , p EtOH reflux 3h Boo/Nd 90°C,40mm HNQ 2 3 4 ' F’d2(dba)3, 05003 I +11 <1B\0H 1 OH HATU DIPEA 1,4-dioxaneIH20 "NJ o0+w —. o Hg 0 DMF,rt.12h 90°C, 16h | : NH2 " O Example 25 tert-butyl 4-(6-chloro—S-cyanopyridinyl)piperazine-l-carboxylate (3). To a solution of 2,6- dichloronicotinonitrile 1 (1.0 g, 5.78 mmol) and tert—butyl piperazine-l-carboxylate 2 (1.08 g, .78 mmol) in ethanol (20 mL) was added K2C03 (636 mg, 6.0 mmol). The ing solution was refluxed for 3 h. After cooling to room temperature, the solvent was evaporated and the crude product was purified by flash chromatography eluting from 5:1 to 2:1 PE/EA to afford the title compound as a white solid (800 mg, 43%). MS (ESI): m/z = 345.1 [M + Na]+. 6-chlor0(4—phenoxyphenyl)nicotinamide (4). To tert—butyl-(6-chlorocyanopyridin yl)piper azine-l-carboxylate 3(800 mg, 2.5 mmol) was added conc. H2S04 (5 mL) and water (1 mL). The mixture was heated to 90°C and stirred for 40 min. After cooling to room temperature, the solution was poured into ice-cold water, then adjusted to PH = 8 by ammonia water. The precipitate was d, washed with water (20 mL) and dried under vacuum to afford the title compound as an off-white solid (580 mg, 96%). MS (ESI): m/z = 241.1 [M + H]+. 2-(4-phen0xyphenyl)—6-(piperazinyl)nic0tinamide (6). To a on of 6-chloro(4- phenoxyphenyl)nicotinamide 4 (580 mg, 2.41 mmol), Cs2C03 (2.35 g, 7.23 mmol) and 4— phenoxyphenylboronic acid 5 (619 mg, 2.89 mmol) in l,4-dioxane (15 mL) and water (3 mL) was added Pd2(dba)3 (220 mg, 0.24 mmol) under nitrogen atmosphere, and the mixture was degassed with nitrogen 6 times, then heated to 90 °C and stirred for 12 h under nitrogen atmosphere. After cooling to room temperature, the solvent was evaporated and the crude product was purified by flash chromatography eluting with 10:1 DCM/MeOH to afford the title compound as a white solid (480 mg, 52%). MS (ESI): m/z = 375.1 [M + H]+.
Example 25 (E)—6-(4-(4-(dimethylamino)but—2-enoyl)piperazinyl)(4-phen0xyphenyl)nic0tinamide ©| : NH2 A mixture of 2-(4-phenoxyphenyl)(piperazinyl)nicotinamide 6 (100 mg, 0.27 mmol), (E)- 4-(dimethylamino)but—2-enoic acid hydrochloride 7 (53 mg, 0.32 mmol), HATU (152 mg, 0.4 mmol), and DIPEA (172.5 mg, 1.34 mmol) in DMF (10 mL) was stirred at rt for 12 h. The solution was poured into water (50 mL), and then extracted with ethyl acetate (3 X 50 mL). The ed organic layers were dried over anhydrous sodium sulfate, filtered and concentrated.
The residue was d by Prep-TLC eluting with 10:1 DCM/MeOH to afford the title compound (30 mg, 23%) as a white solid. 1H NMR (400 MHz, MeOD) 8 7.78 (d, J = 8.7 Hz, 1H), 7.69 (d, J: 8.6 Hz, 2H), 7.40 (t, J: 7.9 Hz, 2H), 7.17 (d, J: 7.4 Hz, 1H), 7.04 (dd, J: .3, 8.3 Hz, 4H), 6.93 (d, J: 15.3 Hz, 1H), 6.82 (d, J: 8.7 Hz, 1H), 6.77 (m, 1H), 3.89—3.68 (m, 10H), 2.76 (s, 6H). MS (ESI, method F): m/z = 485.9 [M + H]+, tR=1.249 min, HPLC: 93.3% (214nm), 93.0% (254nm).
Scheme 15 \ EHH Pd(dppf)C|2 K2003 (\N N Cl 1 4--dioxane/HZO Boc’N Boc’N 110°C 12h con.HC|, sealed tube IN/ EtN, CH Cl 115°c,5h HNQ OHOQ 3 2 2’ min HCI 4 e 26 2-(4-phen0xyphenyl)—6-(piperazinyl)nic0tinamide (3). To a solution of tert—butyl 4-(6— chlorocyanopyridinyl)piperazinecarboxylate 1 (300 mg, 0.93 mmol), K2C03 (385 mg, 2.79 mmol) and 4-phenoxyphenylboronic acid 2 (297 mg, 1.39 mmol) in 1,4-dioxane (12 mL) and water (2 mL) was added Pd(dppf)Clz (68 mg, 0.093 mmol) under en atmosphere. The mixture was degassed with nitrogen 6 times, then heated to 90 CC and d for 12 h under nitrogen atmosphere. After cooling to room temperature, the solvent was evaporated and the crude product was purified by flash chromatography eluting with 20:1 DCM/MeOH to afford the title compound as a white solid (260 mg, 58%). MS (ESI): m/z = 457.1 [M + H]+. 2-(4-phenoxyphenyl)—6-(piperazin-l-yl)nicotinic acid hydrochloride (4). In a 20 mL sealed tube, was placed a solution of 2-(4-phenoxyphenyl)(piperazinyl)nicotinamide 3 (140 mg, 0.31 mmol) in come. HCl (5 mL). The mixture was heated to 115 °C and stirred for 4 h. After cooling to room temperature, the solution was concentrated under vacuum to afford the title compound as an off—white solid (120 mg, 95%). MS (ESI): m/z = 376.1 [M + H]+.
Example 26 cryloylpiperazinyl)(4-phenoxyphenyl)pyridine—3-carb0xylic acid To a solution of 2-(4—phenoxyphenyl)(piperazinyl)nicotinic acid hydrochloride 4 (120 mg, 0.32 mmol) in DCM (5 mL) was added TEA (162 mg, 1.6 mmol) and acryloyl de (35 mg, 0.38 mmol) at 0°C. The mixture was stirred at 0 0C for 10 minutes. The solvent was removed and the residue was d by Prep-TLC eluting with 20:1 DCM/MeOH to afford the title compound (15 mg, 11%) as a white solid. 1H NMR (400 MHz, CDClg) 8 8.17 (d, J= 8.9 Hz, 1H), 7.55 (d, J: 8.3 Hz, 2H), 7.38 (t, J: 7.7 Hz, 2H), 7.16 (t, J: 7.4 Hz, 1H), 7.11 (d, J: 8.0 Hz, 2H), 7.03 (d, J: 8.3 Hz, 2H), 6.65—6.55(m, 2H), 6.38 (d, J: 16.7 Hz, 1H), 5.78 (d, J: 10.6 Hz, 1H), 3.86—375 (m, 8H). MS (ESI, method F): m/z = 429.8 [M + H]+, tR=1.477 min., HPLC: 93.5% (214nm), 93.0% (254nm).
Scheme 16 OH H o K2003 DMF Pd(dppf)C|2 KOAc + 1150c:N/O:OBDMFreflux ,o 1 2 4 O O \ NH2 \ | | NH2 Pd2(dba)3, CSZCO3 N N/ pN N/ dioxane/HZO, 120°C p Et3N CHZCIQO0°C HN O N 06% /\n,01 /j (\N N’ 01 HNd 5 Example 27 4-(4-bromophenoxy)benzonitrile (3). The e of 4-bromophenol 1 (0.50 g, 2.9 mmol), 4- fluorobenzonitrile 2 (0.28 g, 2.31 mmol), K2C03 (0.80 g, 5.8 mmol) and DMF (4 mL) was stirred at 115 °C for 16 h. After cooled to It, the mixture was concentrated in vacuo. The residue was purified by silica gel chromatography eluting with 100:] petroleum ether/EtOAc to afford the title compound (0.59 g, 74%) as white solid. 1H NMR (400 MHZ, DMSO-d6) 8 7.86 (d, J = 8.7 Hz, 2H), 7.64 (d, J: 6.0 Hz, 2H), 7.13 (dd, J: 5.1, 4.7 Hz, 4H). 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)phenoxy)benzonitrile (4). The mixture of 4-(4-bromophenoxy)benzonitrile 3 (0.59 g, 2.15 mmol), acolato diboron (1.09 g, 4.3 mmol), KOAc (0.63 g, 6.45 mmol), f)Clz (0.157 g, 0.215 mmol) and DMF (3.5 mL) was degassed with N2 6 times and then stirred under reflux for 16 h. After cooled to rt, the mixture was concentrated in vacuo. The residue was purified by silica gel chromatography eluting with 50:1 petroleum ether/EtOAc to afford the title compound (0.55 g, 79%) as white solid. 4-cyan0phenoxy)phenyl)—6-(piperazinyl)nic0tinamide (6). The title compound was obtained using a procedure analogous to the ure described in 2-(4- xy(phenyl)methyl)phenyl)(piperidin—4-yl)nicotinamide (see Scheme 48) as yellow solid (0.15 g, 37%). MS (ESI): m/z = 400.1 [M + H.
Example 27 6-(4-acryloylpiperazinyl)—2-(4-(4-cyanophenoxy)phenyl)nicotinamide The title compound was obtained using a procedure analogous to the procedure described in Example 1 as white solid (40 mg, 23%). 1H NMR (400 MHz, DMSO—d6) 8 7.88 (d, J = 8.7 Hz, 2H), 7.73 (d, J: 8.6 Hz, 2H), 7.68 (d, J: 8.7 Hz, 1H), 7.59 (s, 1H), 7.26 (s, 1H), 7.21—7.14 (m, 4H), 6.86 (dd, J= 17.8, 9.3 Hz, 2H), 6.16 (dd, J= 16.7, 2.2 Hz, 1H), 5.73 (dd, J= 10.4, 2.2 Hz, 1H), 3.66—3.67 (m, 8H). MS (ESI, method A): m/z = 454.1 [M + H]+, tR=1.685 (min). HPLC: 97.1% (214nm), 99.7% (254nm).
Scheme 17 I O OH Cul,1,10-phenanthroline Pd(dppf)C[2 KOAc ngco3 toluene 1200c 0/0of»DMF reflux + 8’0 1 2 4 O O \ \ Ed2(dba)3,ngcog I NH2 I NH2 E N CH Cl 000 / dloxane/H20,120 0C (\N N t3, 2 2. (\N N 0 HNd O O Nd rr" Arc} 0 0 / (‘N N’c 6 Example 28 1-br0mo(cyclohexyloxy)benzene (3). The mixture of 1-bromo-4—iodobenzene l (2.83 g, 10 mmol), cyclohexanol 2 (5.0 g, 50 mmol), CuI (0.381 g, 2.0 mmol), 1,10-phenanthroline (0.793 g, 4.0 mmol), CS2C03 (8.15 g, 25 mmol) and toluene (5 mL) was stirred at 120 °C in a sealed tube under N2 for 16 h. After cooled to rt, the mixture was filtered over celite. The filtrate was dried over NazSO4, concentrated in vacuo and purified by silica gel chromatography eluting with 20:1 eum ether/EtOAc to afford the title compound (1.17 g, 46%) as colorless oil. 1H NMR (400 MHz, CDC13) 5 7.40—7.33 (m, 2H), 6.83—6.77 (m, 2H), 4.26—4.16 (m, 1H), 2.04—1.92 (m, 2H), 1.87—1.75 (m, 2H), 1.65—1.47 (m, 3H), 1.45—1.25 (m, 3H). 2-(4-(cyclohexyloxy)phenyl)—4,4,5,5—tetramethyl-1,3,2-di0xab0rolane (4). The title nd was obtained using a procedure analogous to the procedure described in 4-(4-(4,4,5,5- tetramethyl-1,3,2-dioxaborolanyl)phenoxy)benzonitrile (see Scheme 16) as brown oil (1.04 g, 75%). 1H NMR (400 MHz, CDClg) 6 7.75 (d, J: 8.5 Hz, 2H), 6.91 (d, J: 8.5 Hz, 2H), 4.40— 4.25 (m, 1H), 2.09—1.94 (m, 2H), 1.89—1.76 (m, 2H), 1.66—1.49 (m, 4H), 1.48—1.23 (m, 14H). 2-(4-(cyclohexyloxy)phenyl)(piperazinyl)nicotinamide (6). The title compound was obtained using a procedure analogous to the ure described in 6-(3 -nitrophenyl)(4- yphenyl)nicotinamide (see Scheme 1) as brown gum (0.157 g, 41%). MS (ESI): m/z = 381.1 [M + H.
Example 28 6-(4-acryloylpiperazinyl)(4-(cyclohexyloxy)phenyl)nicotinamide The title compound was obtained using a procedure analogous to the procedure described in e 1 as white solid (61 mg, 34%). 1H NMR(400 MHZ, CD30D) 5 7.76 (d, J = 8.7 HZ, 1H), 7.63 (d, J= 8.7 Hz, 2H), 6.96 (d, J: 8.7 Hz, 2H), 6.87—6.76 (m, 2H), 6.27 (dd, J: 16.8, 1.8 Hz, 1H), 5.80 (dd, J: 10.6, 1.8 Hz, 1H), 4.43—4.35 (m, 1H), .75 (m, 8H), 2.07—1.96 (m, 2H), 1.89—1.78 (m, 2H), 1.63—1.34 (m, 6H). MS (ESI, method A): m/z = 435.2 [M + H]+, tR=1.800 (min). HPLC: 98.2% (214nm), 98.5% (254nm).
Scheme 18 NNHZ Pd2(()3dba,C52003 ()ZHO28\©/\O\ dioxane/HZO 120°C \ NH2 + I HO / p / O N N CI \ Et3N, , o 00 | / O\ MCI O O 0 Z Example 29 2-(3-methoxy—4-methylphenyl)—6-(piperazinyl)nicotinamide (3). The title nd was obtained using a procedure analogous to the procedure described in 2-(4- (hydroxy(phenyl)methyl)phenyl)(piperidinyl)nicotinamide (see Scheme 48) as brown solid (0.238 g, 58%). MS (ESI): m/z = 327.1 [M + H.
Example 29 6-(4-acryloylpiperazinyl)—2-(3-meth0xy—4-methylphenyl)nicotinamide The title compound was obtained using a procedure analogous to the procedure described in Example 1 as white solid (115 mg, 43%). 1H NMR (400 MHZ, CDC13) 5 7.77 (d, J: 8.7 HZ, 1H), 7.23 (s, 1H), 7.21—7.15 (m, 2H), 6.88—6.78 (m, 2H), 6.26 (dd, J: 16.8, 1.9 Hz, 1H), 5.80 (dd, J: 10.6, 1.9 Hz, 1H), 3.88 (s, 3H), 3.75—3.78 (m, 8H), 2.24 (s, 3H).MS (ESI, method A): m/z = 381.1 [M + H]+, tR=l.513 (min). HPLC: 95.9% (214nm), 98.7% (254nm).
Scheme 19 Pd2(()3dba,CSZC03 | NH2 ()2H023\©[:K dioxane/HZO 120°C \ | NH2 (\N / / O N Cl (\N N \ Example 30 2-(4-flu0r0methoxyphenyl)—6-(piperazinyl)nic0tinamide (3). The title compound was obtained using a procedure analogous to the procedure described in 6-(3 -nitrophenyl)(4- phenoxyphenyl)nicotinamide (see Scheme 1) as brown gum (0.264 g, 72%). MS (ESI): m/z = 331.1 [M + H. e 30 6-(4-acryloylpiperazinyl)—2-(4-flu0rometh0xyphenyl)nicotinamide The title compound was obtained using a procedure analogous to the procedure described in e 1 as White solid (45 mg, 15%). 1H NMR (400 MHz, CDgOD) 5 7.78 (d, J: 8.7 Hz, 1H), 7.41 (dd, J: 8.3, 2.0 Hz, 1H), 7.28—7.22 (m, 1H), 7.16—7.12(m,= 1H), 6.88—6.77 (m, 2H), 6.27 (dd, J: 16.8, 1.9 Hz, 1H), 5.80 (dd, J: 10.6, 1.9 Hz, 1H), 3.93 (s, 3H), 3.87—3.71 (m, 8H).
MS (ESI, method A): m/z = 385.1 [M + H]+, tR=1.527 (min). HPLC: 99.6% (214nm), 99.7% (254nm).
Scheme 20 0H ch03 DMF d(,dppf)C|2 KOAc \ DMF reflux + | 115°C B’0 1 2 3 4 o o \ NH \ NH Pd2(dba)3,C32003 | 2 | 2 / / dioxane/H20,120°C (\N N |\ EtsN,CHzC|2,0°C (\N N l\ o HNJ N/ 0 0 We] Nd N/ O (\N N/ 01 6 Example31 -br0m0phen0xypyridine (3). The title compound was ed using a procedure analogous to the procedure described in romophenoxy)benzonitrile (see Scheme 16) as yellow solid (3.85 g, 81%). 2-phenoxy—5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-Z-yl)pyridine (4). The title nd was obtained using a procedure ous to the procedure described in 4-(4-(4,4,5,5- tetramethyl-l,3,2-dioxaboroIanyl)phenoxy)benzonitrile (see Scheme 16) as yellow solid (0.536 g, 90%). 6'-phen0xy-6—(piperazinyl)-2,3'-bipyridine—3-carb0xamide (6). The title compound was obtained using a procedure analogous to the procedure described in 6-(3 -nitrophenyl)(4- phenoxyphenyl)nicotinamide (see Scheme 1) as brown gum (0.14 g, 55%). MS (ESI): m/z = 376.1 [M + H.
Example 3 1 6-(4-acryloylpiperazin-l-yl)-6'-phen0xy—2,3 '-bipyridine—3-carb0xamide (\N \ 0}" | N’ 0 / G The title compound was obtained using a procedure analogous to the procedure described in Example 1 as white solid (50 mg, 31%). 1H NMR (400 MHz, CDgOD) 5 8.43 (d, J: 2.4 Hz, 1H), 8.10 (dd, J: 8.6, 2.4 Hz, 1H), 7.80 (d, J: 8.7 Hz, 1H), 7.49—7.41 (m, 2H), 7.29—7.22 (m, 1H), 7.16 (d, J: 7.9 Hz, 2H), 6.97 (d, J: 8.6 Hz, 1H), 6.88—6.77 (m, 2H), 6.27 (dd, J: 16.8, 1.8 Hz, 1H), 5.80 (dd, J: 10.6, 1.8 Hz, 1H), 3.87—3.69 (m, 8H). MS (ESI, method A): m/Z = 430.1 [M + H]+, tR=1.620 (min). HPLC: 95.1% (214nm), 96.2% (254nm).
Scheme 21 F K2003 DMF f)C|2 KOAc Pd2(dba)s.052003 115 DMF reflux dioxane/HZO, 120 °C + \N DC Br {NJ/03m11'1 0% 11 4 HO N CI | NH2 (\N N/ Et3N CHZCIZ 0°C N/ 0 To \ \ 6 Example 32 2-(4-br0mophen0xy)pyridine (3). The title compound was obtained using a procedure analogous to the procedure described in 4-(4-bromophenoxy)benzonitrile (see Scheme 16) as yellow solid (2.83 g, 57%). MS (ESI): m/z = 250.1 [M + H]+. 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxab0r0]anyl)phenoxy)pyridine (4). The title compound was obtained using a procedure analogous to the procedure described in 4,4,5,5- tetramethyl-1,3,2-dioxaborolanyl)phenoxy)benzonitrile (see Scheme 16) as brown solid (0.882 g, 74%). MS (ESI): m/z = 298.1 [M + Hr. 6-(piperazinyl)(4-(pyridin-Z-yloxy)phenyl)nic0tinamide (6). The title compound was obtained using a procedure analogous to the ure described in 2-(4- (hydroxy(phenyl)methyl)phenyl)(piperidin—4-yl)nicotinamide (see Scheme 48) as brown gum (0.198 g, 53%). MS (ESI): m/z = 376.0 [M + Hr.
Example 32 6-(4-acryloylpiperazinyl)—2-(4-(pyridinyloxy)phenyl)nic0tinamide |\ NH2 N N The title compound was obtained using a procedure analogous to the procedure bed in Example 1 as white solid (41 mg, 18%). 1H NMR (400 MHz, CDgOD) 5 8.18 (dd, J: 5.0, 1.4 Hz, 1H), 7.86 (ddd, J: 8.4, 7.3, 2.0 Hz, 1H), 7.82—7.74 (m, 3H), 7.20—7.14(m, 3H), 7.01 (d, J: 8.3 Hz, 1H), 6.88—6.79 (m, 2H), 6.27 (dd, J: 16.8, 1.9 Hz, 1H), 5.80 (dd, J: 10.6, 1.9 Hz, 1H), 3.86—3.71 (m, 8H). MS (ESI, method A): m/z = 430.1 [M + H]+, tR=1.560 (min). HPLC: 100% (214nm), 100% (254nm).
Scheme 22 O O Pd2(dba)3, C52C03 \ NH, (HO)2B dioxaneiH20,120°C \ | NH2 ET3NVCH2C'2yOOC | + —> —> (\N / / N CI CI (\N N m" HNd HNd 0 1 2 3 |\ NH2 (\N N/ Oj/N\2 CI Example33 2-(4-chlor0phenyl)(piperazinyl)nic0tinamide (3). The title compound was obtained using a procedure analogous to the procedure described in 2—(4-(hydroxy(phenyl)methyl)phenyl)—6- (piperidinyl)nicotinamide (see Scheme 48) as brown gum (0.23 g, 72%).
Example 33 6-(4-acryloylpiperazinyl)(4-chlorophenyl)nic0tinamide Oj/Q / N N The title compound was obtained using a ure ous to the procedure described in e 1 as white solid (50 mg, 18%). 1H NMR (400 MHZ, CDgOD) 5 7.78 (d, J: 8.7 Hz, 1H), 7.72—7.64 (m, 2H), 7.45—7.39 (m, 2H), 6.88—6.76 (m, 2H), 6.27 (dd, J: 16.8, 1.9 Hz, 1H), .80 (dd, J: 10.6, 1.9 Hz, 1H), 3.87—3.69 (m, 8H). MS (ESI, method A): m/z = 371.0 [M + H]+, tR=1.645 (min). HPLC: 95.1% (214nm), 95.3% (254nm).
Scheme 23 o o o o o 00<0E02 DMF-DMA O/\ N2H4.Et0H —> —> | —> PhO NaH, e PhOWOA PhO N/ 1 2 3 ,R‘ ,R‘ N’N N’N TsO-RBoc orF-RNO2 ' / ‘ / LiOH, EtOH HATU, NHs. DMF a)052003 DMF 0 OH Pho O Pho or b) 052003 NMP \\ O 4 s 7 ,R ,R ,R N/N a)HC|/EtOH DOM N—N . N—N or b) Zn NH4C| EtOH I / acwlovlchlorlde I / TEA, DCM PhD 0 "Hz PhO 0 "Hz C: 9 1o . N'w w'w (7 Q r: O O Boc 30¢ Boc l|30c (1 0:1 b c e @ 3:9 M 1'4 E: (5W NH (1,, 0 (SR) HNO f0 JO f (£0 a b c d e\ f 9 h Ethyl 3-0x0(4-phen0xyphenyl)propanoate (2). To a on of diethyl carbonate (14 g, 120 mmol) in toluene (100 mL) was added NaH (60%, 4.7 g, 12 mmol) at 0 °C, and the resulting solution was heated to 90 CC, then a solution of l-(4—phenoxyphenyl)ethanone 1 (10 g, 47 mmol) in toluene (50 mL) was added drop-wise over 30 min, and the solution was refluxed for 20 min.
After cooling to room temperature, AcOH/HZO (55 mL/275 mL) was added. Toluene was removed under vacuum, and the crude e was diluted with water (500 mL). Then the mixture was extracted with dichloromethane (4 X 800 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was d by silica gel column chromatography eluting with 9:1 PE/EA to get the title compound as brown oil (11.5 g, 79%). MS (ESI): m/Z = 285.0 [M + H] i Ethyl 3-(dimethylamino)—2-(4-phenoxybenzoyl)acrylate (3). A solution of ethyl 3—oxo-3—(4- phenoxyphenyl)propanoate 2 (9.6 g, 34 mmol) in DMA-DMF (100 mL) was stirred at 100 0C for 1 h. The resulting solution was concentrated in high vacuum to get the title compound (12 g, 100%) as brown thick oil. MS (ESI): m/Z = 340.1 [M + Hr.
Ethyl 3-(4-phenoxyphenyl)—1H-pyrazole—4—carboxylate (4). To a solution of ethyl 3- (dimethylamino)(4-phenoxybenzoyl)acrylate 3 (6 g, 17 mmol) in ethanol (30 mL) was added hydrazine hydrate (875 mg, 17 mmol), and the resulting on was heated to 85 °C and stirred for 3 h. The solvent was evaporated and the crude residue was purified by silica gel column chromatography eluting with 4:1 PE/EA to get the title compound as brown oil (4.3 g, 78%). MS (ESI): m/Z = 309.0 [M + H.
Ethyl(1-(tert-but0xycarb0nyl)pyrrolidinyl)(4-phen0xyphenyl)—lH-pyrazole—4- carboxylate (6c). C52C03 (1.08 g, 3.3 mmol) was added to a solution of ethyl 3-(4- phenoxyphenyl)-1H-pyrazolecarboxylate 4 (500 mg, 1.6 mmol) and tert-butyl 3— (tosyloxy)pyrrolidinecarboxylate 5c (1.1 g, 3.2 mmol) in DMF (20 mL) and the resulting mixture was stirred at 100 CC for 16 h. The reaction mixture was concentrated in high vacuum and the crude e was purified by silica gel column chromatography eluting with 20:1 DCM/EA to get the title compound (780 mg, 100%) as colorless thick oil. MS (ESI): m/z = 478.1 [M + Hr.
Similar procedures were used to prepare the following compounds: 6a, 6b, 6d, 6g, 6h. tert-butyl(4-(ethoxycarbonyl)(4-phenoxyphenyl)—1H-pyrazolyl)piperidine—1- carboxylate (6a) = 492.1 [M + H]+. , thick ess oil, 340 mg, 36%. MS (ESI): m/z tert-butyl(4-(ethoxycarbonyl)—3-(4-phenoxyphenyl)—1H-pyrazolyl)piperidine—1- carboxylate (6b), thick oil 557 mg, 71%. MS (ESI): m/z = 492.1 [M + H]+.
Ethyl(1-(tert-butoxycarbonyl)azetidinyl)—3-(4-phen0xyphenyl)—1H—pyrazole—4- ylate (6d), white solid, 1.7 g, 61%. MS (ESI): m/z = 464.1 [M + H]+. hyl(1-(tert-but0xycarb0nyl)pyrrolidinyl)—3-(4-phenoxyphenyl)—1H-pyrazole—4- carboxylate (6g), colorless oil, 1.5 g, 99%. MS (ESI): m/z = 478.1 [M + H]+.
(R)—ethyl(1-(tert-but0xycarb0nyl)pyrrolidinyl)(4—phenoxyphenyl)—1H-pyrazole—4- ylate (6h), yellow oil, 2 g, 100%. MS (ESI): m/z = 478.1 [M + H]+.
Ethyl 1-(4-nitrophenyl)(4-phenoxyphenyl)—1H-pyrazole—4-carboxylate (6e). To a solution of ethyl 3-(4-phenoxyphenyl)—1H—pyrazolecarboxylate 4 (300 mg, 1.0 mmol) and 1-fluoro nitrobenzene 5e (140 mg, 1.0 mmol) in 1-methylpyrrolidone (8 mL) was added cesium carbonate (950 mg, 3.0 mmol), and the resulting solution was heated to 130 oC and stirred for 3 h. After cooling to ambient temperature, the solvent was evaporated and the crude residue was purified by silica gel column chromatography eluting with 4:1 PE/EA to get the title compound as a yellow solid (290 mg, 68%). MS (ESI): m/Z = 430.1 [M + H]+.
Similar procedures were used to prepare compound of 6f: ethyl 1-(3-nitr0phenyl)—3-(4-phenoxyphenyl)—1H-pyrazole—4-carboxylate (61), yellow solid , 290 mg, 40%. MS (ESI): m/Z = 430.1 [M + H]+. 1-(1-(tert-but0xycarb0nyl)pyrrolidinyl)(4-phenoxyphenyl)-1H-pyrazole—4—carb0xylic acid (7c). To a solution of ethyl 1-(1—(tert—butoxycarbonyl)pyrrolidin—3-yl)—3—(4- phenoxyphenyl)—1H- lecarboxylate 6c (390 mg, 0.8 mmol) in EtOH (8 mL) was added 1N LiOH/HZO (4 mL). the reaction mixture was stirred at 75 °C for 1 h. Then to the solution was added 1N HCl/HgO to pH = 4—5, trated to give title compound (690 mg, crude) as white solid contented LiCl salt. MS (ESI): m/z = 450.1 [M + H]+.
Similar procedures were used to prepare the following compounds: 7a, 7b, 7d, 7e, 7f, 7g, 7h. tert—butoxycarb0nyl)piperidinyl)—3-(4-phen0xyphenyl)—lH—pyrazolecarb0xylic acid (7a), white solid, 310 mg, 100%. MS (ESI): m/z = 464.1 [M + H]+. 1-(1-(tert—butoxycarb0nyl)piperidinyl)—3-(4-phen0xyphenyl)—1H-pyrazolecarb0xylic acid (7b), yellow solid, 525 mg, 99%. MS (ESI): m/z = 464.1 [M + H]+. 1-(1-(tert—butoxycarbonyl)azetidinyl)—3-(4-phenoxyphenyl)—1H-pyrazole—4-carb0xylic acid (7d), yellow solid, 300 mg, 80%. MS (ESI): m/Z = 436.1 [M + Hr. 1-(4-nitr0phenyl)—3-(4-phen0xyphenyl)—1H-pyrazole—4-carb0xylic acid (7e), white solid, 280 mg, 99%. MS (ESI): m/z = 402.1 [M + Hr. itr0phenyl)—3-(4-phe0nxyphenyl)—1H-pyrazole—4-carb0xylic acid (71), yellow oil, 260 mg, 100%. MS (ESI): m/Z = 402.1 [M + H]+.
(S)(1-(tert—butoxycarbonyl)pyrrolidinyl)(4-phen0xyphenyl)—lH-pyrazole carboxylic acid (7g) = 450.1 [M + H]+. , yellow foam, 1.2 g, 99%. MS (ESI): m/z (1-(tert—butoxycarbonyl)pyrrolidinyl)—3-(4-phen0xyphenyl)—1H-pyrazole carboxylic acid (7h), yellow oil, 1.2 g, 99%. MS (ESI): m/z = 450.1 [M + H]+.
Tert-butyl(4-carbamoyl(4-phenoxyphenyl)—lH-pyrazolyl)pyrrolidine-l-carboxylate (80). To a solution of 1-(1-(tert-butoxycarbonyl)pyrrolidinyl)—3-(4-phenoxyphenyl)-1H- pyrazole carboxylic acid 7c (630 mg, crude, 0.67 mmol) in DMF (20 mL) was added HATU (510 mg, 1.33 mmol) and stirred at rt for 30 minutes, the resulting on was bubbled with NH3 gas for 10 minutes. After ng at rt for 1 h, the on was concentrated in high vacuum and the crude residue was diluted with DCM (50 mL), washed with water (3 X 20 mL), dried over , concentrated to give a residue which was purified by silica gel column chromatography eluting with 100:1 DCM/MeOH to get the title compound (120 mg, 33%) as colorless foam. MS (ESI): m/z = 471.2 [M + Na]+.
Similar procedures were used to prepare the following compounds: 8a, 8b, 8d, 8e, 8f, 8g, 8h tert-butyl(4-carbamoyl(4-phen0xyphenyl)-1H-pyrazol-l-yl)piperidine-l-carboxylate (83), colorless oil, 310 mg, 100%. MS (ESI): m/z = 463.1 [M + H]+. tert-butyl(4-carbamoyl(4-phen0xyphenyl)-1H-pyrazol-l-yl)piperidine-l-carboxylate (8b), yellow solid, 320 mg, 63%. MS (ESI): m/Z = 463.1 [M + Hr. tert-butyl(4-carbam0yl(4-phenoxyphenyl)—1H-pyrazolyl)azetidine-l-carboxylate (8d), yellow solid, 300 mg, 99%. MS (ESI): m/Z = 435.1 [M + H]+. 1-(4-nitrophenyl)—3-(4-phenoxyphenyl)—1H-pyrazolecarb0xamide (8e), yellow solid, 230 mg, 99%. MS (ESI): m/Z = 401.1 [M + Hr. 1-(3-nitrophenyl)—3-(4-phenoxyphenyl)—1H-pyrazolecarb0xamide (81), yellow solid, 260 mg, 100%. MS (ESI): m/Z = 401.0 [M + H]+. rt—butyl(4-carbam0yl(4-phenoxyphenyl)—1H-pyrazolyl)pyrrolidine carboxylate (8g), white solid, 1.2 g, 100%. MS (ESI): m/z = 449.0 [M + H]+.
(R)-tert-butyl(4-carbamoyl(4-phen0xyphenyl)—lH-pyrazolyl)pyrrolidine-l- carboxylate (8h), white solid, 960 mg, 80%. MS (ESI): m/z = 449.0 [M + H]+. 3-(4-phenoxyphenyl)(pyrrolidinyl)-1H-pyrazolecarboxamide. To a solution of tert- butyl 3 -(4-carbamoyl(4-phenoxyphenyl)-1H-pyrazolyl)pyrrolidinecarboxylate 80 (120 mg, 0.27 mmol) in DCM (10 mL) was added 6 N HCl/EtOH (5 mL, 30 mmol), stirred at rt for 1h, the resulting solution was concentrated in high vacuum and the crude residue was purified by Prep-HPLC to give title compound (86 mg, 91%) as white solid. 1H NMR (400 MHZ, CDgOD): 5 8.20 (s, 1H), 7.75 (d, J: 8.6 Hz, 2H), 7.43—7.36 (m, 2H), 7.20—7.13 (m, 1H), .00 (m, 4H), .32—5.27 (m, 1H), 3.87—3.72 (m, 3H), 3.59—3.50 (m, 1H), 2.67—2.56 (m, 1H), 2.52—2.43 (m, 1H). MS (ESI, Method A): m/z = 349.1 [M + H]+, tR= 1.242 min. HPLC: 99.3% (214nm), 99.5% (254nm).
Similar procedures were used to prepare the following compounds: 9a, 9b, 9d, 9g, 9e, and 9f. 3-(4-phen0xyphenyl)—1-(piperidinyl)—1H—pyrazolecarboxamide (921), white solid, 240 mg, 99%. 1H NMR (400 MHz, CD30D): 8 8.23 (s, 1H), 7.73 (d, J: 8.6 Hz, 2H), 7.48—7.31 (m, 2H), 7.21—7.12 (m, 1H), .97 (m, 4H), 4.76—4.65 (m, 1H), 3.74—3.57 (m, 2H), 3.43—3.36 (m, 1H), 3.28—3.15 (m, 1H), 2.39—2.02 (m, 3H), 2.01—1.84 (m, 1H). MS (ESI, Method A): m/Z = 363.2 [M + H]+, tR= 1.255 min. HPLC: 100% (214nm), 100% (254nm). 3-(4-phen0xyphenyl)—1-(piperidin-4—yl)—1H—pyrazolecarboxamide (9b), light yellow solid, 3.1 mg, 40%. 1H NMR (300 MHz, CD30D)I 5 8.18 (s, 1H), 7.67 (d, J: 8.7 Hz, 2H), 7.43—7.31 (m, 2H), 7.19—7.09 (m, 1H), 7.07—6.95 (m, 4H), .55 (m, 1H), 3.64—3.54 (m, 2H), 3.29— 3.17(m, 2H), 2.42—2.23 (m, 4H). MS (ESI, Method A): m/z = 363.0 [M + H]+, tR= 1.288 min.
HPLC: 100% (214nm), 100% (254nm). 1-(azetidinyl)—3-(4—phenoxyphenyl)—1H-pyrazolecarboxamide (Example 14) (9d), yellow solid, 300 mg, 100%. 1H NMR (300 MHz, CD30D)I 8 8.20—8.14 (m, 1H), 7.82—7.66 (m, 2H), 7.44—7.30 (m, 2H), 7.18—7.11(m, 1H), 7.07—6.96 (m, 4H), 5.52—5.40 (m, 1H), 4.64—4.55 (m, 4H). MS (ESI, Method A): m/Z = 335.1 [M + H]+, tR= l.235-l.255 min. HPLC: 100% ), 100% (254nm).
(S)—3-(4-phenoxyphenyl)—1-(pyrrolidinyl)—1H-pyrazole—4-carboxamide (9g), white solid, 90 mg, 83%. 1H NMR (400 MHz, CD3OD)I 6 8.25 (s, 1H), .68 (m, 2H), 7.45—7.33 (m, 2H), 7.20—7.11 (m, 1H), 7.11—6.98 (m, 4H), 5.38—5.25 (m, 1H), 3.88—3.69 (m, 3H), 3.62—3.49 (m, 1H), 2.68—2.54 (m, 1H), 2.54—2.40 (m, 1H). MS (ESI, Method A): m/z = 349.1 [M + H]+, tR= 1.219 min. HPLC: 100% (214nm), 100% ). (4-phen0xyphenyl)—1-(pyrrolidinyl)-1H-pyrazole—4-carboxamide (9h), yellow oil, 100mg, 100%. MS (ESI, Method A): m/z = 349.1 [M + H]+. 1-(4-amin0phenyl)—3-(4-phen0xyphenyl)—1H-pyrazolecarboxamide (9e). To a solution of 1-(4—nitrophenyl)-3—(4-phenoxyphenyl)-1H-pyrazolecarboxamide 8e (200 mg, 0.50 mmol) in ethanol (8 mL) was added saturated aqueous NH4Cl (4 mL), followed by the addition of zinc powder (260 mg, 4.0 mmol) in n over 5 min, then the resulting solution was stirred for 10 h at ambient temperature. The mixture was filtered and the filtrate was diluted with ethyl acetate (30 mL), and washed with water (2 X 20 mL) and brine (2 X 20 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated to give the title compound as a yellow solid (150 mg, 81%). 1H NMR (400 MHz, cogoD): 8 8.47 (s, 1H), 7.78 (d, J: 8.7 Hz, 2H), 7.51 (d, J: 8.7 Hz, 2H), 7.44—7.36 (m, 2H), 7.16 (s, 1H), 7.19—7.13 (m, 4H), 6.83 (d, J: 8.7 Hz, 2H). MS (ESI, Method A): m/z = 371.1 [M + H]+, tR= 1.468 min. HPLC: 97.8% (214nm), 98.0% (254nm).
Similar ures were used to prepare compound 8f. minophenyl)—3-(4-phenoxyphenyl)—1H-pyrazole—4-carb0xamide (81), white solid, 105 mg, 47%. 1H NMR (400 MHz, CD30D)C 8 8.60 (s, 1H), 7.81 (d, J: 8.6 Hz, 2H), 7.44—7.36 (m, 2H), 7.28—7.03 (m, 8H), 6.75 (d, J: 7.9 Hz, 1H). MS (ESI, Method A): m/z = 371.1 [M + H]+, tR= 1.507 min. HPLC: 96.9% (214nm), 98.2% ). 1-(1-acryloylpyrrolidinyl)—3-(4-phen0xyphenyl)-1H-pyrazolecarboxamide (Example 13) (10c). To a solution of 3-(4-phenoxyphenyl)—1-(pyrrolidinyl)—1H-pyrazole-4—carboxamide 9c (43 mg, 0.12 mmol) and TEA (50 mg, 0.5 mmol) in DCM (10 mL) was added acryloyl chloride (22 mg, 0.24 mmol) and stirred at 75 °C for 1 h, the resulting was concentrated and purified by Prep-TLC eluting with 10:1 DCM/MeOH to get the title compound (17 mg, 35%) as white solid. 1H NMR (400 MHz, CD3OD)I 8 8.18 (d, J= 8.7 Hz, 1H), 7.70 (d, J= 8.6 Hz, 2H), 7.43—7.34 (m, 2H), 7.18—7.08 (m, 1H), 7.03 (dd, J: 15.5, 8.3 Hz, 4H), .58 (m, 1H), 6.32 (dd, J: 15.9, 4.0 Hz, 1H), 5.83—5.73 (m, 1H), 5.18—5.04 (m, 1H), 4.21—3.65 (m, 4H), 2.63—2.45 (m, 2H). MS (ESI, Method A): m/Z = 403.1 [M + H]+, tR= 1.414 min. HPLC: 95.3% (214nm), 95.3% (254nm).
Similar procedures were used to e the following compounds: 10a, 10b, 10d, 10e, 10f, 10g and 10h. 1-(1-acryloylpiperidiny])(4-phenoxyphenyl)—1H-pyrazole-4—carb0xamide (Example 11) (1021). White solid, 39 mg, 23%. 1H NMR (400 MHz, CDgOD) 8 8.20 (d, J: 5.4 Hz, 1H), 7.71 (d, J: 8.3 Hz, 2H), 7.44—7.35 (m,2H),7.19—7.12(m, 1H), 7.04 (dd, J: 12.3, 8.4 Hz, 4H), 6.89—6.73 (m, 1H), 63—612 (m, 1H), 5.76 (dd, J: 25.5, 10.7 Hz, 1H), 4.71 (d, J: 11.5 Hz, 0.5 H), 4.45—4.17 (m, 2H), 4.08 (d, J: 14.3 Hz, 0.5 H), .73 (m, 0.5 H), 3.45—3.34 (m, 1H), 3.27—3.14 (m, 0.5 H), 2.39—2.18 (m, 2H), 2.06—1.92 (m, 1H), 1.71—1.61 (m, 1H). MS (ESI, Method A): m/z = 417.2 [M + H]+, tR= 1.468 min. HPLC: 97.7% (214nm), 98.7% (254nm). 1-(1-acryloylpiperidinyl)—3-(4-phen0xyphenyl)—1H-pyrazole-4—carb0xamide (Example 12) (10b). White solid, 4.7 mg, 20.8%. 1H NMR (400 MHz, CD30D) 8 8.19 (s, 1H), 7.69 (d, J: 8.5 Hz, 2H), 7.45—7.33 (m, 2H), 7.25—7.12 (m, 1H), 7.04 (dd, J: 12.2, 8.5 Hz, 4H), 6.84 (dd, J: 16.8, 10.7 Hz, 1H), 6.24 (dd,J= 16.8, 1.5 Hz, 1H), 5.79 (dd, J: 10.7, 1.5 Hz, 1H), 4.77—4.64 (m, 1H), 4.61—4.46 (m, 1H), 4.35—4.23 (m, 1H), 3.38 (d, J: 13.0 Hz, 1H), 3.03—2.92 (m, 1H), 2.34—2.17(m, 2H), 2.12—1.96 (m, 2H). MS (ESI, Method A): m/z = 417.1 [M + H]+, tR=1.421 min. HPLC: 97.5% (214nm), 97.8% ). 1-(1-acryloylazetidinyl)—3-(4-phen0xyphenyl)—1H-pyrazole—4-carb0xamide (10d). White solid, 19 mg, 18%. 1H NMR (300 MHz, CD30D) 5 8.21 (s, 1H), 7.71 (d, J= 9.1 Hz, 2H), 7.42— 7.31 (m, 2H), 7.20—7.09 (m, 1H), 7.06—6.94 (m, 4H), 6.46—6.22 (m, 2H), 5.78 (dd, J: 9.9, 2.3 Hz, 1H), 5.33 (td, J: 8.0, 4.0 Hz, 1H), 4.83—4.65 (m, 2H), 4.62—4.41 (m, 2H). MS (ESI, Method A): m/Z = 389.1 [M + H]+, tR=1.388-1.401 min. HPLC: 95.1% ), 96.1% (254nm). 1-(4-acrylamid0phenyl)—3-(4-phenoxyphenyl)—1H-pyrazolecarboxamide (Example 16) (10e). White solid, 52 mg, 46%. 1H NMR (400 MHz, CD3OD) 8 8.67 (s, 1H), 7.89—7.78 (m, 6H), 7.44—7.36 (m, 2H), 7.20—7.12 (m, 1H), .02 (m, 4H), .37 (m, 2H), 5.82 (dd, J: 9.4, 2.4 Hz, 1H). MS (ESI, Method A): m/z = 425.2 [M + H]+, tR=1.521 min. HPLC: 97.3% (214nm), 97.0% (254nm). 1-(3-acrylamid0phenyl)—3-(4-phenoxyphenyl)—1H-pyrazolecarb0xamide (Example 18) (101). White solid, 24 mg, 24%. 1H NMR (400 MHz, CD30D) 8 8.70 (s, 1H), 8.35 (s, 1H), 7.84 (d, J: 8.7 Hz, 2H), 7.60 (d, J: 8.1 Hz, 2H), .48 (m, 1H), 7.44—7.36 (m, 2H), 7.11—7.03 (m, 1H), 7.20—7.13(m, 4H), 6.53—6.38(m, 2H), 5.83 (dd, J: 9.2, 2.6 Hz, 1H). MS (ESI, Method A): m/z = 425.1 [M + H]+, tR=1.547 (min). HPLC: 97.6% (214nm), 98.6% (254nm).
(S)(1-acryloylpyrrolidinyl)—3-(4-phenoxyphenyl)—1H-pyrazolecarboxamide (Example 20) (10g). Gray solid, 120 mg, 27%. 1H NMR (400 MHz, CD30D) : 8 8.21 (d, J = 6.6 Hz, 1H), 7.73—7.64 (m, 2H), 7.43—7.34 (m, 2H), 7.20—7.10 (m, 1H), 7.10—6.96 (m, 4H), 6.75— 6.55 (m, 1H), 6.32 (ddd, J: 16.8, 4.8, 1.9 Hz, 1H), 5.86—5.72 (m, 1H), 5.21—5.03 (m, 1H), 4.22— 4.07 (m, 1H), 4.05—3.67 (m, 3H), 2.64—2.43 (m, 2H). MS (ESI, Method A): m/z = 403.2 [M + H]+, tR= 1.421 min. HPLC: 99.0% (214nm), 99.0% (254nm).
(R)(1-acryloylpyrrolidinyl)(4-phenoxyphenyl)—1H-pyrazole—4-carboxamide (Example 19) (10h). White solid, 20 mg, 6%. 1H NMR (300 MHz, CDgOD) : 8 8.16 (d, J: 5.9 Hz, 1H), 7.67 (d, J: 8.7 Hz, 2H), 7.42—7.30 (m, 2H), 7.17—6.92 (m, 5H), 6.71—6.56 (m, 1H), 6.34—6.25 (m, 1H), .72 (m, 1H), 5.18—5.02 (m, 1H), 4.20—4.05 (m, 1H), 4.02—3.65 (m, 3H), 2.62—2.45 (m, 2H). MS (ESI, Method A): m/z = 403.1 [M + H]+, tR= 1409 min. HPLC: 95.0% (214nm), 97.0% (254nm).
Scheme 24 0 I HomN\ 1 1 N‘N N—N M HATU, TEA, DMF M PhD 0 ""2 PhD o ""2 Example 34 Example 34 1-(1-(4-(dimethylamin0)but—2-enoyl)pyrrolidinyl)(4—phenoxyphenyl)—1H-pyrazole—4- carboxamide 0 | PhDMo ""2 To a solution of 4-(dimethylamino)butenoic acid 11 (22 mg, 0.17 mmol) and HATU (98 mg, 0.26 mmol) in DMF (10 mL) was added 3-(4-phenoxyphenyl)—1-(pyrrolidinyl)-lH-pyrazole- 4-carboxamide 90 (Scheme 23) (60 mg, 0.17 mmol) and DIPEA (22 mg, 0.5 mmol). The reaction mixture was stirred at rt for 1 h. The solution was concentrated in high vacuum and the residue was diluted in DCM (10 mL), washed with water (3 X 10 mL), dried over NazSO4, concentrated to give a residue which was purified by LC eluting with 10:1 OH to get the title compound (26 mg, 37%) as brown solid. 1H NMR (300 MHz, CD3OD)I 8 8.20 (d, J: 9.0 Hz, 1H), 7.73—7.56 (m, 2H), 7.41—7.27 (m, 2H), 7.11 (t, J: 7.4 Hz, 1H), 7.05—6.91 (m, 4H), .66 (m, 2H), 5.22—5.02 (m, 1H), 4.24—4.06 (m, 1H), 4.05—3.76 (m, 4.5H), 3.76—3.61 (m, 0.5H), 2.86 (d, J: 6.1 Hz, 6H), 2.66—2.39 (m, 2H). MS (ESI, Method A): m/z = 459.8 [M + H]+, tR= 1.244 min. HPLC: 97.5% (214nm), 98.2% (254nm).
Scheme 25 OH )2, Et3N Pd(dppf)Cl2, KOAc 4A MS 0 DMF, reflux cH Cl rt —> —B(L:)12_> go i‘B-B\0% O 0 Br O )‘—/\ 1 2 4 \ \ Pd2(dba)3 052003 | NH2 / / dioxane/HZO 120°C IN HNQ Et3N CHZCIZ 0°C (\N N /\n/C' Example 35 4-(4,4,5,5-tetramethyl-1,3,2-di0xab0rolany1)phenol (2). The title compound was obtained using a procedure analogous to the procedure described in 4—(4-(4,4,5,5-tetramethyl-1,3,2- dioxaboro1any1)phenoxy)benzonitri1e (see Scheme 16) as white solid (10.2 g, 80%). 2-(4-(3-flu0r0phenoxy)phenyl)-4,4,5,5-tetramethyl—1,3,2-di0xab0rolane (4). The mixture of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)phenol 2 (1.0g, 4.5mmol), 3-fluorophenylboronic acid 3 (0.70 g, 5.0 mmol), Cu(OAc)2 (1.0 g, 5.0 mmol), Eth (2.75 g, 27.3 mmol), 4A lar sieves (1 g) and CHzClz (15 mL) was d at rt for 16 h. Then the mixture was concentrated in vacuo and the e was purified by silica gel chromatography eluting with 20:1 petroleum ether/EtOAc to afford the title compound (0.45 g, 32%) as white solid. 2-(4-(3-fluor0phen0xy)phenyl)—6-(piperazinyl)nicotinamide (6). The title compound was obtained using a procedure analogous to the procedure described in 6-(3 -nitropheny1)(4- phenoxyphenyl)nicotinamide (see Scheme 1) as white solid (0.15 g, 41%). MS (ESI): m/z = 393.1 [M + H.
Example 35 6-(4-acryloylpiperaziny])—2-(4-(3-flu0rophenoxy)phenyl)nicotinamide (\N N/ o Nd j 0 The title compound was obtained using a procedure analogous to the procedure described in Example 1 as white solid (50 mg, 27%). 1H NMR (400 MHz, CDgOD) 5 7.79 (d, J = 8.7 Hz, 1H), 7.77—7.70 (m, 2H), 7.42—7.33 (m, 1H), 7.13—7.06 (m, 2H), 6.93—6.75 (m, 5H), 6.27 (dd, J: 16.8, 1.9 Hz, 1H), 5.80 (dd, J: 10.6, 1.9 Hz, 1H), 3.84 —3.72 (m, 8H). MS (ESI, method A): m/z = 447.1 [M + H]+, tR=1.746 (min). HPLC: 95.9% (214nm), 96.4% (254nm).
Scheme 26 OH )2, Et3N B(OH)2 4A Ms Pd(dppf)C[2 KOAc Pd2(dba)3 052003 e/HZO 120°C + 1 o Br \ClIN 1 2 CH2C12,rt©/E|3r—>]©\DMF reflux 5 HNJ0N O O \ \ NH2 (\N N/ Et3N,CH2CI2,o°C (\N N/ HN\/‘ ON F6 2,Cl j FE) Example 36 4-brom0flu0ro-l-phenoxybenzene (3). The title compound was obtained using a procedure analogous to the procedure described in 2-(4-(3-fluorophenoxy)phenyl)—4,4,5,5-tetramethyl— 1,3,2-dioxaborolane (see Scheme 25) as yellow oil (1.5 g, 21%). MS (ESI): m/z = 267.1 [M + 2-(3-flu0r0phenoxyphenyl)—4,4,5,5-tetramethyl—1,3,2-di0xaborolane (5). The title compound was obtained using a procedure analogous to the procedure described in 4-(4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolanyl)phenoxy)benzonitrile (see Scheme 16) as yellow oil (1.04 g, 73%). 2-(3-fluor0phen0xyphenyl)—6-(piperazinyl)nic0tinamide (7). The title compound was obtained using a procedure analogous to the procedure described in 6-(3 -nitrophenyl)(4- phenoxyphenyl)nicotinamide (see Scheme 1) as brown gum (0.194 g, 49%). MS (ESI): m/z = 393.1 [M + H.
Example 36 6-(4-acryloylpiperaziny])—2-(3-flu0r0phenoxyphenyl)nic0tinamide The title compound was obtained using a procedure analogous to the procedure described in Example 1 as white solid (38 mg, 17%). 1H NMR (400 MHZ, 6) 8 (m, 2H), 7.59 (d, J = 11.4 Hz, 1H), 7.48 (d, J: 8.2 Hz, 1H), 7.42 (t, J: 7.7 Hz, 2H), 7.35—7.28 (m, 1H), 7.24—7.15 (m, 2H), 7.04 (d, J: 7.9 Hz, 2H), 6.95—6.81 (m, 2H), 6.16 (d, J: 16.6 Hz, 1H), 5.73 (d, J: 10.2 Hz, 1H), 3.79—3.50 (m, 8H). MS (ESI, method A): m/z = 447.1 [M + H]+, tR=1.753 (min).
HPLC: 98.6% (214nm), 98.4% (254nm).
Scheme 27 F Cuu(OAc)2, £th 4A MS Pd2(dba)s 082C03 N/ dioxane/HZO 120°C + CH2C|2,rt 474 B(0H)2 <10; Ad\IN 1 2 3 5 Eth, CHZCIZ, 0 00 e 37 2-(4-(4-flu0r0phen0xy)phenyl)-4,4,5,5-tetramethyl—1,3,2-di0xab0rolane (3). The title compound was obtained using a ure analogous to the procedure described in 2—(4-(3— fluorophenoxy)phenyl)-4,4,5,5-tetramethy1—1,3,2-dioxaborolane (see Scheme 25) as White solid (0.45 g, 32%). 2-(4-(4-fluorophenoxy)phenyl)—6-(piperazinyl)nic0tinamide (5). The title compound was obtained using a procedure analogous to the procedure described in 6-(3 phenyl)(4- phenoxypheny1)nicotinamide (see Scheme 1) as brown gum (0.18 g, 41%).
Example 37 6-(4-acryloylpiperazinyl)(4-(4-flu0rophenoxy)phenyl)nic0tinamide \ NH2 ‘/\N N/ The title compound was obtained using a procedure analogous to the procedure described in Example 1 as white solid (80 mg, 44%). 1H NMR (400 MHZ, CD30D) 5 7.77 (d, J = 8.7 Hz, 1H), 7.69 (d, J: 8.7 Hz, 2H), .05 (m, 4H), 7.00 (d, J: 8.7 Hz, 2H), 6.87—6.76 (m, 2H), 6.26 (dd, J: 16.8, 1.8 Hz, 1H), 5.80 (dd, J: 10.6, 1.8 Hz, 1H), 3.87—3.71 (m, 8H). MS (ESI, method A): m/z = 447.0 [M + H]+, 39 (min). HPLC: 99.8% (214nm), 100% (254nm).
Scheme 28 052003, DMF Fe NH4C| CHZIZ, amyl nitrite OM32 + CE: —’E:E: 120 °c ONOZ EtOH 70°C a:ONHZ CHgCN 75°C F OH 1 2 Pd2(dban 052co Pd(dppf)C|2 KOAc | 0 o / . 03 DMF reflux dioxane/HZO, 120 C ‘/\N N Wit-1m".OB‘o O HNd F I o HN\) Pg Et3N, CHZCIZ, 0 °C KN Example 38 l-flu0r0(4-nitr0phen0xy)benzene (3). The mixture of 1-fluoronitrobenzene 1 (10.0 g, 70.8 mmol), 2-fluorophenol 2 (9.54 g, 85.0 mmol), CS2C03 (34.6 g, 106 mrnol) and DMF (80 mL) was heated to 120 °C and stirred for 2 h. After being cooled to rt, the mixture was diluted with water (150 mL) and extracted with EtOAc (200 mL X 2). The ed organic phase was washed with brine (100 mL X 3), dried over Na2S04 and filtered. The filtrate was concentrated in vacuo. The residue was recrystallized from MeOH (20 mL X 2) to afford the title compound as light yellow solid (14.6 g, 88%). uorophenoxy)benzenamine (4). To the mixture of 1-fluoro-2—(4-nitrophenoxy)benzene 3 (16.2 g, 69.3 mmol), saturated aqueous NH4Cl solution (30 mL) and EtOH (150 mL) was added iron powder (19.4 g, 347 mmol) slowly and then the resulting mixture was heated to 70 CC for 3.5 h. After being cooled to rt, the mixture was d. The filtrate was concentrated in vacuo.
The residue was dissolved in EtOAc (160 mL) and washed successively with water (100 mL X 2) and brine (100 mL X 2). The organic phase was dried over Na2S04, d and concentrated in vacuo to afford the title compound (13.6 g, 96%) as yellow solid. 1H NMR (400 MHz, DMSO- d6) 8 7.35—7.28 (m, 1H), 7.14—7.00 (m, 2H), 6.93—6.85 (m, 1H), 6.80—6.73 (m, 2H), .56 (m, 2H), 4.99 (brs, 2H). 1-flu0r0(4-iodophenoxy)benzene (5). The mixture of 4-(2—fluorophenoxy)benzenamine 4 (7.94 g, 39.1 mmol), CHZIZ (29.0 g, 136.8 mmol) and CH3CN (120 mL) was heated to 55 °C and then amyl nitrite (11.6 g, 97.7 mmol) was added. The resulting mixture was heated to 75 °C for 3.5 h. After being cooled to rt, the mixture was diluted with EtOAc and then washed successively with 10% NazSgOg and brine. The organic phase was dried over Na2S04, filtered, concentrated in vacuo and purified by silica gel chromatography eluting with petroleum ether to afford the title compound (4.12 g, 51%) as light yellow oil. 1H NMR (400 MHZ, DMSO) 8 7.78— 7.63 (m, 2H), 7.44—7.37 (m, 1H), 7.34—7.14 (m, 3H), 6.87—6.74 (m, 2H). 2-(4-(2-flu0r0phenoxy)phenyl)-4,4,5,5-tetramethyl—1,3,2-di0xab0rolane (7). The title compound was obtained using a procedure analogous to the procedure described in 4-(4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolanyl)phenoxy)benzonitrile (see Scheme 16) as yellow oil (0.40 g, 13%). 2-(4-(2-fluorophenoxy)phenyl)—6-(piperazinyl)nic0tinamide (9). The title compound was ed using a ure analogous to the procedure described in 6-(3 -nitrophenyl)(4- phenoxyphenyl)nicotinamide (see Scheme 1) as white solid (0.16 g, 31%). MS (ESI): m/z = 393.1 [M + Hr.
Example 38 6-(4-acryloylpiperaziny])(4-(2-flu0rophenoxy)phenyl)nicotinamide O / N The title compound was ed using a procedure analogous to the procedure described in Example 1 as white solid (28 mg, 24%). 1H NMR (400 MHZ, CDgOD) 5 7.77 (d, J = 8.7 Hz, 1H), 7.71—7.68 (m, 2H), 7.34—7.13 (m, 4H), 6.99 (d, J: 8.7 Hz, 2H), 6.88—6.79 (m, 2H), 6.26 (dd, J: 16.8, 1.9 Hz, 1H), 5.80 (dd, J: 10.6, 1.9 Hz, 1H), 3.89—3.71 (m, 8H). MS (ESI, method A): m/z = 447.1 [M + H]+, tR=1.723 (min). HPLC: 98.6% (214nm), 98.8% (254nm).
Scheme 29 Cu(OAc)2, Et3N f)C|2 KOAc 4A MS Pd2(dba)3, 052003 DMF reflux ,1 dioxane/HZO, 120°C —>F CHZCIZ , , é <1 115 5 55 M 1:5 o . 511* |/\N N/ CI 1 2 4 I Et N CH3 2CI 1 21 0°C 6N N/ HN¢F 0qu O/NdFj o 11 <5 Example 39 3-fluor0(4,4,5,5-tetramethyl-1,3,2-di0xab0r01anyl)phenol (2). The title compound was obtained using a procedure analogous to the procedure described in 4-(4,4,5,5-tetramethy1—1,3,2- dioxaborolan-2—y1)phenol (see Scheme 25) as white solid (4.1 g, 66%). MS (ESI): m/z = 239.2 [M + Hr. 2-(2-fluoro-4—phenoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxab0rolane (4). The title nd was obtained using a procedure analogous to the procedure described in 2-(4-(3- fluorophenoxy)phenyl)-4,4,5,5-tetrarnethyl-1,3,2-dioxaborolane (see Scheme 25) as white solid ( g9 ) 2-(2-fluoro-4—phenoxyphenyl)—6-(piperazinyl)nicotinamide (6). The title compound was obtained using a procedure analogous to the procedure described in 6-(3 -nitropheny1)(4- phenoxyphenyl)nicotinamide (see Scheme 1) as brown solid (0.105 g, 21%). MS (ESI): m/z = 393.1 [M + Hr.
Example 39 6-(4-acryloylpiperazinyl)—2-(2-flu0r0phenoxyphenyl)nic0tinamide / ZIN Oj/O N F o / i) The title nd was obtained using a procedure analogous to the procedure bed in Example 1 as white solid (78 mg, 65%). 1H NMR(400 MHz, MeOD) 5 7.78 (d, J = 8.7 Hz, 1H), 7.59 (dd, J: 11.8, 2.0 Hz, 1H), 7.48 (d, J: 9.2 Hz, 1H), 7.44—7.33 (m, 2H), 7.17—7.06 (m, 2H), 7.05—6.99 (m, 2H), 6.90—6.79 (m, 2H), 6.27 (dd, J= 16.8, 1.8 Hz, 1H), 5.80 (dd, J: 10.6, 1.8 Hz, 1H), 3.86—3.70 (m, 8H). MS (ESI, method A): m/z = 447.0 [M + H]+, tR=1.770 (min).
HPLC: 96.5% (214nm), 96.9% (254nm).
Scheme 30 o O o s o CAOH )L CI 0«I/ O O NH2 Lawesson reagent 0%.
NH; "4 1NB°° —> NB°° THF/TEA/NH3‘HZO e "3°C EtOHl60°C COOH COOEt BocN BocN«3,8,3 LiOH 00—»THFH20 DMF/DIPEA CONH CONHZ 2 BOON0*? ofl’g W (DD—*09 \CONHz Example 40 tert-butyl 2-carbamoylpiperidine—l-carboxylate (2). To a solution of 1-(tert— butoxycarbonyl)piperidinecarboxylic acid 1 (5.0 g, 21.8 mmol) in dry THF (100 mL) was added TEA (3.30 g, 32.7 mmol), isobutyl carbonochloridate (3.27 g, 23.99 mmol) at 0°C and the resulting solution was d for 20 min. NH3-H20 was added and stirred at rt for 2 h. The mixture was diluted with ethyl acetate (30 mL), and washed with sat. aq. N32C03 (2 X 20 mL) and sat. aq. citric acid (2 X 20 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated to give crude product (3.6 g, 72%) as white solid. MS (ESI): m/z = 173.0 [M — 551+. tert-butyl 2-carbamothioylpiperidinecarb0xylate (3). To a solution of tert—butyl 2- oylpiperidine-l-carboxylate 2 (2.0 g, 8.77 mmol) in dry toluene (20 mL) was added Lawesson’s reagent (2.13 g, 5.26 mmol) at N2 atmosphere. The resulting solution was stirred at 80°C for 16 h. The mixture was diluted with ethyl e (30 mL), and washed with saturated aqueous (sat. aq.) N32C03 (2 X 20 mL) and brine (2 X 20 mL). The c layer was dried over anhydrous sodium sulfate, filtered and concentrated to give crude product which was purified by silica gel column chromatography eluting with 4 : 1 PE/EA to get the title compound (330 mg, %) as white solid. MS (ESI): m/Z = 245.2 [M + H. ethyl(1-(tert-butoxycarbonyl)piperidinyl)(4-phen0xyphenyl)thiazole-5—carboxylate (5). A solution of tert-butyl 2-carbamothioylpiperidinecarboxylate 3 (60 mg, 0.239 mmol) and ethyl 2-bromooxo(4-phenoxyphenyl)propanoate 4 (250 mg, 0.7 mmol) in EtOH (10 mL) was stirred for 2 h at 60°C. The mixture was d with ethyl acetate (30 mL), and washed with water (2 X 20 mL) and brine (2 X 20 mL). The organic layer was dried over anhydrous sodium e, filtered and concentrated. The residue was purified by silica gel column chromatography eluting with 40 : 1 PE/EA to get the title compound (120 mg, 34%) as colorless oil. MS (ESI): m/Z = 509.3[M + HT. 2-(1-(tert-butoxycarbonyl)piperidinyl)(4-phenoxyphenyl)thiazolecarboxylic acid (6). A solution of ethyl 2-(1-(tert-butoxycarbonyl)piperidin-3 -yl)(4-phenoxyphenyl)thiazole- oxylate 5 (120 mg, 0.263 mmol ) in THF-HZO (1/1, 20 mL) and added LiOH (30 mg, 0.71 mmol) was stirred at rt for 13 h. The mixture was evaporated and diluted with water (5 mL), and the solution was acidified with 2 N hydrochloric acid to pH = 4. The residue was extracted with Ethyl Acetate (EA) (3 X 30 mL). Dried and concentrated to get crude compound (110 mg, 100%) as light red liquid. MS (ESI): m/Z = 481.0 [M + H]+. tert-butyl arbamoyl(4-phenoxyphenyl)thiazolyl)piperidine—l-carboxylate (7).
The mixture of 2-(1-(tert-butoxycarbonyl)piperidinyl)(4-phenoxyphenyl)thiazole-S- ylic acid 6 (110 mg, 0.229 mmol), HATU (113 mg, 0.297 mmol), DIPEA (88 mg, 0.687 mmol) and dry DMF (10 mL) was bubbled with NH3 for 20 min, and the resulting solution was stirred for 3 h at ambient temperature. The mixture was diluted with ethyl acetate (30 mL), and washed with water (2 X 20 mL) and brine (2 X 20 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was d by Prep-TLC with 3 : 2 PE/EA to get the title compound (100 mg, 75%) as colorless oil. MS (ESI): m/z = 480.1 [M + H]+. 4-(4-phenoxyphenyl)(piperidinyl)thiazole—5-carb0xamide (8). To a solution of tert—butyl arbamoyl(4—phenoxyphenyl)thiazolyl)piperidine- l -carboxylate 7 (100 mg, 0.21 mmol) in DCM (5 mL) was added TFA (2.5 mL) at ambient temperature. The mixture was d for 3 h. The mixture was diluted with water (2 X 150 mL) and extracted with ethyl acetate (2 X 20 mL) and washed with brine (2 X 150 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated to give the title compound (60 mg, 76%) as brown oil.
MS (ESI): m/Z = 380.0 [M + H.
Example 40 2-(1-acryloylpiperidinyl)(4-phen0xyphenyl)thiazolecarb0xamide .1] CONH2 M1606.
To a solution of 4-(4-phenoxyphenyl)(piperidinyl)thiazole-5—carboxamide 8 (60 mg, 0.155 mmol) in dry dichloromethane (10 mL) were added TEA (19 mg, 0.21 mmol) and acryloyl chloride 9 (32 mg, 0.316 mmol), and the resulting solution was d at rt for l h. Water (10 mL) was added to quench the reaction. The mixture was diluted with ethyl acetate (30 mL), washed with brine (2 X 20 mL). The organic layer was dried over NazSO4, filtered and concentrated to get the residue which was purified by Prep-TLC with 17:1 DCM/MeOH to get the title compound (33 mg, 50%) as a white solid. 1H NMR (400 MHz, DMSO) 8 7.76 (d, J = 8.5 Hz, 2H), 7.76 (brs, 1H),7.70 (brs, 1H), 7.44 (t, J= 8.0 Hz, 2H), 7.19 (t, J: 7.4 Hz, 1H), 7.08 (t, J = 8.6 Hz, 4H), 6.92—6.82 (m, 1H), 6.14—6.04 (m, 1H), 5.73—5.64 (m, 1H), 4.65—4.62 (m, 0.5H), .04 (m, 0.5H), 4.02—4.00 (m, 1H), 3.59—3.56 (m, 0.5H), .14 (m, 15H), 3.09—2.98 (m, 1H), 2.22—2.16 (m, 1H), .74 (m, 2H), 1.58—1.48 (m, 1H). MS (ESI, method A): m/z = 433.8 [M + H]+, tR=l.488 min. HPLC: 99.1% (214 nm), 99.2% (254 nm).
Scheme 31 Omoo 0 S \/ 0A CIOO/Y Lawessons reagent 0 0 NHZ NH2 BOON BOCN THF/TEAINH3-H20 toluene BocN 1 EtOH/60°C COO" COOEt (>4: —> BocN(>4: BocN 00 THEH20 00—,DMFIDIPEA CONH2 CONH2 CONH2 O’Qil —>BOCNO’<:\THF (Vim? BocN OHCQI tert-butlyl 3-carbam0ylpyrrolidine—l-carboxylate (2). To a solution of 1-(tert-Example 41 butoxycarbonyl)pyrrolidinecarboxylic acid 1 (5 g, 23.23 mmol) in dry THF (100 mL) was added TEA (4.69 6 mmol), isobutyl carbonochloridate (3.8 g, 27.87 mmol) at 0°C and the resulting solution was stirred for 20 min. NH3-H20 added and stirred at rt for 2 h. The mixture was diluted with ethyl acetate (30 mL), and washed with saturated (sat) Na2C03 (2 X 20 mL) and sat. citric acid (2 X 20 mL). The organic layer was dried over anhydrous sodium e, d and concentrated to give crude product (2.39 g, 49%) as yellow solid. MS (ESI): m/z = 159.0 [M + H. tert-butyl 3-carbamothioylpyrrolidine—l-carboxylate (3). To a solution of tert-butyl 3- carbamoylpyrrolidine—1-carboxylate 2 (0.76 g, 3.55 mmol) in dry toluene (20 mL) was added Lawesson’s regent (0.71 g, 1.77 mmol) at N; atmosphere . The resulting solution was stirred at 80°C for 16 h.The mixture was diluted with ethyl acetate (30 mL), and washed with sat. Na2C03 (2 X 20 mL) and brine (2 X 20 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated to give crude product which was purified by silica gel column chromatography g with 6 : 1 PE/EA to get the title compound (230 mg, 28%) as brown oil.
MS (ESI): m/Z = 175.2 [M + Hr. ethyl 2-(1-(tert-butoxycarbonyl)pyrrolidinyl)-4—(4-phenoxyphenyl)thiazole—S-carboxylate (5). A solution of tert—butyl 3-carbamothioylpyrrolidinecarboxylate 3 (360 mg, 0.1 mmol) and ethyl 2—bromo—3-oxo—3-(4-phenoxyphenyl)propanoate 4 (230 mg, 0.1 mmol) in EtOH (10 mL) was d for 2 h at 60°C. The mixture was diluted with ethyl acetate (30 mL), and washed with water (2 X 20 mL) and brine (2 X 20 mL). The organic layer was dried over anhydrous sodium sulfate, d and concentrated. The e was purified by silica gel column chromatography eluting with 30 : 1 PE/EA to get the title compound (100 mg, 20%) as colorless oil. MS (ESI): m/Z = 495.3[M + H. 2-(1-(tert-butoxycarbonyl)pyrrolidiny])(4-phenoxyphenyl)thiazole—S-carboxylic acid (6). A solution of ethyl 2-(1-(tert-butoxycarbonyl)pyrrolidin-3 -yl)(4-phenoxyphenyl)thiazole- - carboxylate 5 (100 mg, 0.2 mmol ) in THF-HZO (1/ 1, 20 mL) and added LiOH (84 mg, 2 mmol) was stirred at rt for 13 h. The e was evaporated and diluted with water (5 mL), and the solution was acidified with 2 N hydrochloric acid to pH = 4. The residue was extracted with EA (3 X 30 mL). Dried and evaporated to get crude compound (95 mg, 100%) as red oil. MS (ESI): m/Z = 411.0 [M + Hr. tert-butyl 3-(5-carbamoyl-4—(4-phenoxyphenyl)thiazol-Z-yl)pyrrolidine—l-carboxylate (7).
The mixture of 2-(1-(tert-butoxycarbonyl)pyrrolidinyl)(4-phenoxyphenyl)thiazole carboxylic acid 6 (950 mg, 0.2 mmol), HATU (116 mg, 0.3 mmol), DIPEA (103 mg, 0.8 mmol) and dry DMF (10 mL) was bubbled with NH3 for 20 min, and the ing solution was stirred for 3 h at ambient ature. The mixture was diluted with ethyl acetate (30 mL), and washed with water (2 X 20 mL) and brine (2 X 20 mL). The organic layer was dried over anhydrous sodium sulfate, d and concentrated. The residue was purified by Prep-TLC with 2 : l PE/EA to get the title compound (70 mg, 75%) as colorless oil. MS (ESI): m/z = 466.1 [M + H]+. tert-butyl 3-(5-carbamoyl-4—(4-phenoxyphenyl)thiazol-Z-yl)pyrrolidine-l-carboxylate (8).
To a solution of tert-butyl 3-(5-carbamoyl(4-phenoxyphenyl)thiazolyl)pyrrolidine carboxylate 7 (70 mg, 0.15 mmol) in DCM (5 mL) was added TFA (2.5 mL) at ambient temperature. The mixture was stirred for 3 h. The mixture was diluted with water (2 X 150 mL) and extracted with ethyl acetate (2 X 20 mL) and washed with brine (2 X 150 mL). The organic layer was dried over ous sodium sulfate, filtered and concentrated to give the title nd (65 mg, 100%) as brown oil. MS (ESI): m/z = 366.1 [M + H]+.
Example 41 2-(1-acryloylpyrrolidiny])(4-phenoxyphenyl)thiazolecarboxamide f CONH2 O "in To a tert-butyl 3-(5-carbamoyl(4-phenoxyphenyl)thiazol—2-y1)pyrrolidine—1-carboxylate 8 (65 mg, 0.15 mmol) in dry dichloromethane (10 mL) were added TBA (50 mg, 0.45 mmol) and acryloyl chloride 9 (20.4 mg, 0.225 mmol), and the resulting solution was stirred at It for 1 h.
Water (10 mL) was added to quench the reaction. The e was diluted with ethyl acetate (30 mL), washed with brine (2 X 20 mL). The organic layer was dried over Na2S04, filtered and concentrated to get the residue which was d by Prep-TLC with 1 : 1 PE/EA to get the title compound (22 mg, 35%) as a white solid. 1H NMR (400 MHz, DMSO) 8 7.76 (d, J = 8.0 Hz, 2H), 7.76 (brs, 1H),7.70 (brs, 1H), 7.44 (t, J: 8.0 Hz, 2H), 7.19 (t, J: 7.4 Hz, 1H), 7.07 (t, J: 8.6 Hz, 4H), 6.65—6.59 (m, 1H), 6.19—6.15 (m, 1H), 5.72—5.68 (m, 1H), 4.11—4.07 (m, 0.5H), 3.99—3.95 (m, 0.5H), 3.91—3.78 (m, 2H), 3.70—3.62 (m, 1.5H), .47 (m, 0.5H), 2.44—2.36 (m, 1H), 2.28—2.25 (m, 0.5H), 2.18—2.13 (m, 0.5H). MS (ESI, method A): m/z = 419.8 [M + H]+, tR=1.429 min. HPLC: 97.2% (214 nm), 97.5% (254 nm).
Scheme 32 AJ°L J 0 0 0EtBr2, dioxane o°c~n 2h—>©\o NaH, toluene. reflux, 40 min 0 DIPEA, CH3CN rt o Q EtO AcONH4, AcOH, reflulx ° NaOH. MeOH, H20 Boc20, Nazco3 0 —> —> / —> Eto / Eto O N ° ° 0 /\g’/ 0 HATU, NH3, DMF HCI/EtOH HO / —>H2N —> / HZN / H2N / o / o /N DIPEA,DCM o /N o ’N "‘30:: N~Boc NH N 8 9 Example 42 ethyl 3-0x0(4-phenoxyphenyl)propanoate (2). To a mixture of diethyl carbonate (14 g, 120 mmol) and NaH (4.8 g, 120 mmol) in toluene (100 mL) was added 1-(4- phenoxyphenyl)ethanone 1 (10 g, 47 mmol) dropwise for 20 min. The resulting mixture was refluxed for 40 min. When it cooled to rt, which was quenched with AcOH/HZO (6 mL/30 mL), then diluted with EA (100 mL). The organic layer was separated, washed with brine, dried over sodium sulfate, filtered and trated. The residue was applied onto silica gel column g with 20:1 PE/EA to get the title compound (7.5 g, 56%) as yellow oil. MS (ESI): m/z = 285.1 [M + H]+. ethyl 2-br0m00x0(4-phen0xyphenyl)pr0panoate (3). To a mixture of ethyl 3-oxo(4- phenoxyphenyl)propanoate 2 (6.55 g, 23.1 mmol) in e (100 mL) was added Brz (3.69 g, 23.1 mmol) dropwise at 0 °C under N2. The resulting mixture was stirred at rt for 3 h. The volatile phase was removed under reduced re. This ed in crude title compound (9.5 g, overweight) as yellow oil. MS (ESI): m/Z = 3630/3650 [M + Hr. 1-tert—buty] 3-(l-ethoxy-1,3-dioxo(4-phenoxyphenyl)propanyl) piperidine-1,3- dicarboxylate (4). To a mixture of ethyl 2-bromo-3—oxo(4-phenoxyphenyl)propanoate 3 (1.0 g, 2.75 mmol) in CH3CN (20 mL) was added DIEA (0.39 g, 3.0 mmol) se. The resulting mixture was stirred at rt overnight. The volatile phase was removed under reduced pressure. The residue was applied onto silica gel column eluting with 3 :1 PE/EA to get the title nd (1.15 g, 82%) as yellow oil. MS (ESI): m/Z = 412.1 [M + H — Boer. ethyl 4-(4-phen0xyphenyl)(piperidinyl)oxazole-S-carboxylate (5). A mixture of 1-tert- butyl 3—(1-ethoxy-1,3—dioxo-3—(4-phenoxyphenyl)propanyl) piperidine-l ,3-dicarboxylate 4 (1.15 g, 2.25 mmol) and AcONH4 (0.86 g, 11.23 mmol) in AcOH (20 mL) was stirred at 120 CC for 2 h. The volatile phase was removed under reduced pressure. The residue was dissolved in EA (50 mL), which was washed with sat. NaHCOg, brine, dried over sodium sulfate, filtered and concentrated. This resulted in crude title compound (0.85 g, crude) as yellow oil. MS (ESI): m/z = 393.1 [M + H.
Ethyl(1-(tert-butoxycarbonyl)piperidinyl)—4—(4-phenoxyphenyl)oxazole-S-carboxylate (6). The title compound was obtained using a procedure analogous to the ure described in ethyl 2-(4-(tert-butoxycarbonyl)piperazin(4-phenoxyphenyl)thiazole-5 -carboxylate (see Scheme 37) as pale yellow oil (0.35 g, 33%, two steps). MS (ESI): m/z = 437.0 [M + H - 56]+. 2-(1-(tert—butoxycarb0nyl)piperidinyl)(4-phen0xyphenyl)0xazole-5—carboxylic acid (7). The title compound was obtained using a procedure analogous to the procedure described in -(1-(tert-butoxycarbony1)piperidin-4—y1)-4'-phenoxybiphenylcarboxylic acid (see Scheme 45) as yellow oil (350 mg, overweight). MS (ESI): m/z = 465.1 [M + H]+. tert-butyl 3-(5-carbamoyl(4-phenoxyphenyl)0xazolyl)piperidine-l-carboxylate (8).
The title compound was obtained using a procedure analogous to the procedure described in tert- butyl-3 -(4-carbamoyl—3-(4-phenoxyphenyl)—lH-pyrazolyl)pyrrolidine—1—carboxylate (see Scheme 23) as pale yellow solid (250 mg, overweight). MS (ESI): m/z = 408.0 [M + H - 56]+. 4-(4-phenoxyphenyl)(piperidinyl)0xazole-S-carboxamide hydrochloride (9). The title compound was obtained using a procedure analogous to the procedure bed in 1-(4- phenoxyphenyl)(piperidinyl)-1H-pyrazolecarboxamide hydrochloride (see Scheme 46) as white solid (150 mg, overweight). MS (ESI): m/z = 364.1 [M + H]+.
Example 42 2-(1-acryloylpiperidinyl)(4-phenoxyphenyDoxazole—S-carboxamide The title compound was obtained using a ure analogous to the procedure described below in Example 43 as white solid (60 mg, 45%, four steps). 1H NMR (300 MHz, DMSO) 8 8.26 (d, J: 9.0 Hz, 2H), 7.92 (s, 1H), 7.67 (s, 1H), 7.53—7.29 (m, 2H), 7.25—7.13 (m, 1H), .99 (m, 4H), 6.85 (dd, J: 16.7, 10.5 Hz, 1H), 6.11 (dd, J: 16.7, 2.4 Hz, 1H), 5.68 (dd, J: 10.4, 2.4 Hz, 1H), 4.39—4.31 (m, 1H), 4.12—4.04 (m, 1H),3.33—3.14(m,2H),3.02—2.89(m, 1H), .06 (m, 2H), 1.90—1.65 (m, 2H). MS (ESI, method A): m/z = 418.1 [M + H]+, tR=1.488 min. HPLC: 97% (214nm), 97% (254nm).
Scheme 33 OQ o@ o@ O/Q HO N.Bon: 0 O 0 02—0 510 AcONH4,AcOH,reflulx Etc, / 3092010132903 5,0 / e0H,Hzo —> 0 —> ' ’ O N N 0 ° / THFIH o / 0 2 0 DIPEA, CH3CN, rt NH N\ N Boc 1 3 4 0 0 0 Cl / / HO / HATU. NHa. DMF HCIIEtOH HzN / q: H2" N HZN / N N —> —> —> ’ O / o I N ° o / DIPEA,DCM z) N N E NH HCI ‘Boc N‘ A Bee 0 6 7 Example 43 1-tert—butyl 3-(1-eth0xy-1,3-di0X0(4-phenoxyphenyl)propanyl) pyrrolidine-1,3- dicarboxylate (2). The title compound was obtained using a procedure analogous to the procedure described in 1-tert—buty1 3—( 1 -ethoxy- 1 ,3 (4-phenoxypheny1)propanyl) piperidine-l,3-dicarboxy1ate (see Scheme 32) as pale yellow oil (1.1 g, 80%). MS (ESI): m/z = 441.8 [M + H - 561+. ethyl 4-(4-phenoxyphenyl)(pyrrolidinyl)oxazole-S-carboxylate (3). The title compound was obtained using a procedure analogous to the procedure described in ethyl 4-(4- yphenyl)(piperidin—3-y1)oxazole-5—carboxy1ate (see Scheme 32) as yellow oil (0.80 g, crude). MS (ESI): m/Z = 420.1 [M + H + 411*. ethyl 2-(1-(tert-butoxycarbonyl)pyrrolidinyl)(4-phenoxyphenyl)oxazole—S-carboxylate (4). The title compound was obtained using a procedure analogous to the procedure described in ethyl 2—(4-(tert—butoxycarbonyl)piperazinyl)(4—phenoxyphenyl)thiazole—5-carboxy1ate (see Scheme 37) as pale yellow oil (0.35 g, 33%, two steps). MS (ESI): m/z = 423.1 [M + H - 56]+. 2-(1-(tert-butoxycarbonyl)pyrrolidinyl)(4-phenoxyphenyl)oxazole-S-carboxylic acid (5). The title compound was obtained using a procedure analogous to the procedure described in -(1-(tert-butoxycarbony1)piperidinyl)-4'-phenoxybiphenylcarboxylic acid (see Scheme 45) as yellow oil (350 mg, ight). MS (ESI): m/z = 395.0 [M + H — 56]+. tert-butyl 3-(5-carbam0yl—4—(4-phenoxyphenyl)oxazol-Z-yl)pyrrolidine-l-carboxylate (6).
The title nd was obtained using a procedure analogous to the procedure described in tert- butyl-3 —(4-carbamoyl—3-(4-phenoxyphenyl)-lH-pyrazolyl)pyrrolidine-1 -carboxylate (see Scheme 23) as pale yellow solid (250 mg, overweight). MS (ESI): m/z = 394.1 [M + H - 56]+. 4-(4-phenoxyphenyl)—2-(pyrrolidinyl)oxazole-S-carboxamide hydrochloride (7). The title compound was obtained using a procedure analogous to the procedure described in 1-(4- phenoxyphenyl)(piperidinyl)—lH-pyrazole-3—carboxamide hydrochloride (see Scheme 46) as white solid (150 mg, overweight). MS (ESI): m/z = 350.1 [M + H]+.
Example 43 2-(1-acryloylpyrrolidinyl)—4-(4—phenoxyphenyDoxazole-S-carboxamide The title compound was ed using a procedure ous to the procedure described in e 15 as white solid (45 mg, 34%, four steps). 1H NMR (400 MHZ, DMSO) 5 8.27 (d, J = 8.8 Hz, 2H), 7.94 (d, J: 8.0 Hz, 1H), 7.70 (d, J: 8.0 Hz, 1H), 7.43 (t, J: 7.9 Hz, 2H), 7.19 (t, J = 7.9 Hz, 1H), 7.11—7.02 (m, 4H), 6.69—6.55 (m, 1H), 6.19 (d, J: 18.0 Hz, 1H), 5.70 (d, J: .4 Hz, 1H), 4.08—3.96 (m, 1H), 3.90—3.65 (m, 3H), 3.64—3.55 (m, 0.5H), 3.53—3.45 (m, 0.5H), 2.45—2.37 (m, 1H), 2.36—2.27 (m, 1H). MS (ESI, method A): m/z = 404.1 [M + H]+, tR=1.542 min. HPLC: 98% (214nm), 98% (254nm).
Scheme 34 O O NBoc O 0 . OEt 1, oxalyl chloride Iawesson s reagent, OEt—>pho HN o S —> \ 2, TEA, DCM \ NH THF 2 HC' COOEt NBoc PhD 1 2 3 NBoc 8PNBOC LiOH H20 NH3, HATU \\N —> 3.9 THF/MeOH/HZO DIPEA! DMF COOH PhO o NH2 \ TEA,DCM HCI ’ HCI/EtOH N \ s PhD 0 NHz PhD 0 NH2 Example44 tert-butyl 3-(1-eth0xy—1,3-di0x0(4-phenoxyphenyl)propan-Z-ylcarbamoyl)pyrrolidine carboxylate (2). The title compound was obtained using a procedure analogous to the ure described in tert-butyl 3-(1-ethoxy-l,3-dioxo(4-phenoxyphenyl)propan ylcarbamoyl)piperidine-l-carboxylate (see Scheme 35) as yellow oil (0.35 g, 30%). MS (ESI): m/Z = 440.7 [M — 551+. ethyl tert-butoxycarbonyl)pyrrolidinyl)(4-phenoxyphenyl)thiazole—4—carb0xylate (3). The title compound was obtained using a procedure analogous to the ure described in ethyl 2-(1 -(tert-butoxycarbonyl)piperidin-3 -yl)—5 -(4-phenoxyphenyl)thiazolecarboxylate (see Scheme 35) as yellow oil (0.12 g, 61%). MS (ESI): m/z = 494.7 [M + H]+. 2-(1-(tert—butoxycarb0nyl)pyrrolidinyl)(4-phenoxyphenyl)thiazolecarboxylic acid (4). The title compound was obtained using a procedure analogous to the procedure bed in -(l -(tert-butoxycarbonyl)piperidinyl)- l -(4-phenoxyphenyl)- l H-pyrazole-3 -carboxylic acid (see Scheme 46) as colorless oil (110 mg, 97%). MS (ESI): m/z = 488.7 [M + Na]+. tert-butyl 3-(4-carbamoyl-S—(4-phenoxyphenyl)thiazol-Z-yl)pyrrolidine-l-carb0xylate (5).
The title compound was obtained using a procedure analogous to the ure described in tert- butyl4-carbamoylpiperidinecarboxylate (see Scheme 42) as colorless oil (95 mg, 87%). MS (ESI): m/Z = 487.7 [M + Na]+. -(4-phenoxyphenyl)(pyrrolidinyl)thiazole-4—carboxamide hydrochloride (6). The title compound was obtained using a procedure analogous to the procedure described in 1-(4- phenoxyphenyl)—5-(piperidinyl)-1H—pyrazolecarboxamide hydrochloride (see Scheme 46) as colorless oil (90 mg, 100%). MS (ESI): m/z = 365.8 [M + H]+.
Example 44 2-(1-acryloylpyrrolidinyl)—5-(4-phenoxyphenyl)thiazole—4-carboxamide N .0 The title compound was obtained using a procedure ous to the procedure described in Example 3 as a White solid (30 mg, 30%). 1H NMR (300 MHZ, CD30D) 5 7.52 (d, J = 9.0 Hz, 2H), 7.37 (d, J = 9.0 Hz, 2H), 7.15 (t, J = 7.4 Hz, 1H), .02 (m, 2H), 6.99—6.94 (m, 2H), 6.64 (ddd, J = 16.9, 10.4, 7.2 Hz, 1H), 6.29 (dt, J =16.8, 1.9 Hz, 1H), 5.76 (dt, J = 10.4, 1.7 Hz, 1H), 4.19—4.05 (m, 0.5H), 4.03—3.82 (m, 3H), 3.83—3.71 (m, 1H), 3.65—3.55 (m, 0.5H), 2.61— 2.23 (m, 2H). MS (ESI, method F): m/z = 419.7 [M + H]+, tR=1.487 min. HPLC: 99.3% (214nm), 98.7% (254nm).
Scheme 35 NaNOQ, ACOH Pd/C HCl/EtOH OEt H—O> 0 O O 0 1, oxalyl chloride GE 00 OEt —> Iawesson's reagent H" O 2, TEA, DCM —> S NH2 HCl Pho \ PhO THF mN COOEt NBoc PhO 4 5 NBoc NBoc HCl/EtOH LiOH H20 NH3, HATU S 8 , —> \N —> \ N THF THF/MeOH/HZO m DIPEA, DMF COOH PhO O NH2 6 7 NH N‘<— S TEA, DCM \ HCl S PhD 0 NH2 PhD 0 NH2 3 Example 45 hyl 2-(hydr0xyimin0)—3-0x0(4-phen0xyphenyl)pr0panoate (2). To a solution of ethyl 3-oxo(4-phenoxyphenyl)propanoate 1 (1 g, 3.52 mmol) in AcOH (15 mL) was added a solution ofNaNOz (0.364 g, 5.28 mmol) in water (10 mL) at 0 oC. The mixture was d at ambient temperature for 15 h. After finished, the mixture was extracted with ethyl acetate (2 X 20 mL). The organic layers were washed with water (2 X 10 mL) and brine (2 X 10 mL). The c layer was dried over NaZSO4, d and concentrated to give the title compound (1.1 g, 100%) as a yellow solid. MS (ESI): m/z = 313.8 [M + H]+. ethyl 2-amin00x0(4-phen0xyphenyl)pr0pan0ate hydrochloride (3). To the solution of (E)-ethyl 2-(hydroxyimino)—3—oxo(4—phenoxyphenyl)propanoate 2 (6 g, 19.15 mmol) in MeOH (50 mL) was added Pd/C (10%, 500 mg) and HCl/EtOH (33%, 20 mL) under hydrogen atmosphere, and the resulting solution was stirred for 24 h at ambient temperature, then filtered and the filtrate was trated. The crude product was purified by Prep-HPLC eluting with CH3CN/H20 (containing 0.5% TFA) from 10:90 to 60:40 to get the title compound (3.5 g, 61%) as yellow oil. MS (ESI): m/Z = 299.9 [M + Hr. tert-butyl 3-(1-eth0xy-1,3-di0xo(4-phenoxyphenyl)pr0panylcarbamoyl)piperidine—1- carboxylate (4). To the solution of l-(tert-butoxycarbonyl)piperidinecarboxylic acid (0.5 g, 2.18 mmol) in DCM (10 mL) was added oxalyl chloride (0.415 g, 3.27 mmol) and 5 drops of DMF. The mixture was stirred at rt for 2 h, concentrated to give the crude e. To the solution of ethyl ooxo-3—(4-phenoxyphenyl)propanoate hydrochloride 3 (0.73 g, 2.18 mmol) in DCM (20 mL) was added TEA (0.66 g, 6.54 mmol) and a solution of above mixture in DCM (10 mL). The resulting solution was d at rt for 2 h. The reaction mixture was washed with brine (2 X 10 mL), dried over NaZSO4, filtered and concentrated to get a e which was purified by silica gel column chromatography eluting with 1:1 PE/EA to get the title compound (0.16 g, 14%) as a yellow oil. MS (ESI): m/z = 454.7 [M — 55]+. ethyl 2-(1-(tert—butoxycarbonyl)piperidinyl)(4-phenoxyphenyl)thiazole—4-carboxylate (5). To a solution of tert-butyl 3-(1-ethoxy-1,3-dioxo(4-phenoxyphenyl)propan ylcarbamoyl)piperidine-l-carboxylate 4 (0.16 g, 0.31 mmol) in THF (20 mL) was added lawesson’s reagent (0.127 g, 0.31 mmol). The mixture was degassed with N; for 3 times, then heated to reflux and stirred for 2 h. When finished, the mixture was extracted with ethyl e (2 X 20 mL). The organic layers were washed with sat. NaHC03 (2 X 20 mL) and brine (2 X 20 mL). The c layer was dried over Na2S04, filtered and concentrated to get a residue which was purified by silica gel column chromatography eluting with 2:1 PE/EA to get the title compound (90 mg, 57%) as a yellow oil. MS (ESI): m/z = 508.8 [M + H]+. 2-(1-(tert-but0xycarb0nyl)piperidinyl)(4-phenoxyphenyl)thiazolecarboxylic acid (6). The title compound was obtained using a procedure analogous to the procedure described in -(l -(tert-butoxycarbonyl)piperidinyl)- l enoxyphenyl)— l H-pyrazole-3 -carboxylic acid (see Scheme 46) as a white solid (80 mg, 94%). MS (ESI): m/z = 480.8 [M + H]+. tert-butyl 3-(4-carbamoyl(4-phenoxyphenyl)thiazolyl)piperidine—l-carboxylate (7).
The title compound was obtained using a procedure analogous to the procedure described in tert- butyl 4-carbamoylpiperidine-l-carboxylate (see Scheme 42) as colorless oil as colorless oil (40 mg, 50%). MS (ESI): m/Z = 479.7[M + Hr. henoxyphenyl)—2-(piperidinyl)thiazolecarboxamide hydrochloride (8). The title compound was obtained using a procedure analogous to the procedure described in 1-(4- phenoxyphenyl)—5-(piperidinyl)-1H—pyrazolecarboxamide hydrochloride (see Scheme 46) as yellow oil (35 mg, 100%). MS (ESI): m/z = 379.8[M + H]+.
Example 45 2-(1-acryloylpiperidinyl)—5-(4-phenoxyphenyl)thiazolecarboxamide (fifioQ The title compound was obtained using a procedure ous to the procedure described in Example 3 as a white solid (10 mg, 27%). 1H NMR (300 MHz, CD30D) 5 7.56—7.48 (m, 2H), 7.44—7.32 (m, 2H), 7.15 (t, J: 7.4 Hz, 1H), 7.03 (d, J: 0.9 Hz, 2H), 6.99—6.94 (m, 2H), 6.84 (ddd,J= 23.2, 16.7, 10.6 Hz, 1H), 6.21 (dd,J= 16.8, 1.9 Hz, 1H), 5.75 (d,J= 10.7 Hz, 1H), 4.62 (d, J: 11.6 Hz, 0.5H), 4.27 (d, J: 13.2 Hz, 0.5H), 4.15 (d, J: 12.8 Hz, 0.5H), 4.00 (d, J: 13.6 Hz, 0.5H), 3.72 (dd, J= 13.5, 8.9 Hz, 0.5H), .33 (m, 1H), 3.29—3.15 (m, 15H), 2.35— 2.23 (m, 1H), 2.08—1.85 (m, 2H), 1.75—1.55 (m, 1H). MS (ESI, method F): m/z = 433.8 [M + H]: tR=1.557 min. HPLC: 96.7% (214nm), 98.0% (254nm).
Scheme 36 QC? 0@ 0 g o AcONH4,AcOH,reflulx EtO / Boc2O,Na2603 OC 0 —> —> N ° ) Etc O / THFIHZO DIPEA, CchN, rt 0 N N Boc H 1 2 3 o@ o@ °Q 0 0 EtO / NaOH, MEOH, H20 HATU, NHg, DMF H2N / / HCl/EtOH IN —> HO —> 03> /N —> O IN 0 Bee N Eoc o Wm / o o H2N —> o / "'2N / DIPEA,DCM Bee \ Example 46 l-tert-butyl 4-(l-ethoxy-1,3-di0X0(4-phenoxyphenyl)pr0panyl) piperidine—1,4- dicarboxylate (2). The title compound was ed using a procedure analogous to the procedure bed in l -tert—butyl 3-( l -ethoxy- l ,3 -dioxo(4-phenoxyphenyl)propanyl) piperidine-l,3-dicarboxylate (see Scheme 32) as pale yellow oil (0.85 g, 60%). MS (ESI): m/z = 456.1 [M + H — 561+. ethyl 4-(4-phenoxyphenyl)(piperidinyl)oxazole—S-carboxylate (3). The title compound was obtained using a procedure analogous to the procedure described in ethyl 4-(4- phenoxyphenyl)(piperidinyl)oxazolecarboxylate (see Scheme 32) as yellow oil (0.80 g, crude). MS (ESI): m/Z = 393.2 [M + H.
Ethyl(1-(tert-butoxycarbonyl)piperidinyl)—4—(4-phenoxyphenyl)oxazole-S-carboxylate (4). The title nd was obtained using a procedure analogous to the procedure described in ethyl 2—(4-(tert—butoxycarbonyl)piperazinyl)(4—phenoxyphenyl)thiazole—5 -carboxylate (see Scheme 37) as pale yellow oil (0.85 g, 68%, two steps). MS (ESI): m/z = 437.2 [M + H - 56]+. 2-(1-(tert—butoxycarbonyl)piperidinyl)(4-phenoxyphenyl)0xazole-5—carboxylic acid (5). The title compound was ed using a procedure analogous to the procedure described in -(1—(tert-butoxycarbonyl)piperidin—4-yl)-4'-phenoxybipheny1—2-carboxylic acid (see Scheme 45) as yellow oil (0.8 g, 99%). MS (ESI): m/Z = 409.1 [M + H — 561+. tert-butyl 4-(5-carbamoyl-4—(4-phenoxyphenyl)0xazolyl)piperidine-l-carboxylate (6).
The title compound was obtained using a procedure analogous to the procedure bed in tert- butyl-3 -(4-carbamoyl(4-phenoxyphenyl)—1H-pyrazolyl)pyrrolidine-1—carboxylate (see Scheme 23) as pale yellow solid (390 mg, overweight). MS (ESI): m/z = 408.0 [M + H - 56]+. henoxyphenyl)(piperidinyl)oxazole-S-carboxamide hydrochloride (7). The title compound was obtained using a procedure analogous to the ure described in 1—(4- phenoxyphenyl)(piperidinyl)-1H-pyrazolecarboxamide hydrochloride (see Scheme 46) as white solid (400 mg, overweight). MS (ESI): m/z = 364.1 [M + H]+. e 46 2-(1-acryloylpiperidinyl)(4-phenoxyphenyl)0xazolecarboxamide The title compound was obtained using a procedure analogous to the procedure described in Example 15 as white solid (45 mg, 34%, three steps). 1H NMR (300 MHz, DMSO) 8 8.26 (d, J = 9.0 Hz, 2H), 7.92 (s, 1H), 7.674 (s, 1H), 7.53—7.29 (m, 2H), 7.25—7.13 (m, 1H), 7.11—6.99 (m, 4H), 6.85 (dd, J: 16.7, 10.5 Hz, 1H), 6.11 (dd, J: 16.7, 2.4 Hz, 1H), 5.68 (dd, J: 10.4, 2.4 Hz, 1H), 4.39—4.31 (m, 1H), 4.12—4.04 (m, 1H), 3.33—3.14(m, 2H), 3.02—2.89 (m, 1H), 2.14—2.06 (m, 2H), 1.90—1.65 (m, 2H). MS (ESI, method A): m/z = 418.1 [M + H]+, tR=1.489 min. HPLC: 97% (214nm), 97% (254nm).
Scheme 37 GNi"D J 0"" (N’ Y""2 ODMO 0 J(Boc)20 STNJ [N)1. 2, THF 55°C, 1h o N 2N;3H20 ET] 0 N r..,t 3d /0 Egg/H reflux 2h TEA, THF, Boc o r.t., 2h,73% 1 3 00 00 6 OH \NH o S /—\ L'OH. |/>_N N_BOC HATU,CH3NH2 o s /—‘\ —’ N—Boc N \__/ —> | />—N THF/HZO/MeoH Q TEA, DCM, r.t., 3h,90% N 60°C, 4h, 97% 0 7 ©\0 8 1;:thr..t 1h ©\OO film—N Iii/39w TEA THF 0°C 10min Example 47 tert-butyl amothioylpiperazine—1-carb0xylate (3). To a solution of di(lH-imidazol-l- yl)methanethione 2 (2.14 g, 12 mmol) in anhydrous THF (30 mL) was added tert-butyl piperazine-l-carboxylate 1 (1.86 g, 10 mmol) at ambient temperature. The mixture was allowed to stir at ambient temperature for 2 h, then the mixture was heated at 55 °C for l h. The mixture was concentrated under vacuum to about half the volume. To the ing reaction mixture was added 2 M solution of ammonia in methanol (20 mL) and allowed to stir at ambient temperature for 3 days. The solvent was removed and the residue was purified by chromatography eluting with 50:1 DCM/MeOH to afford the title compound (1.7 g, 69%) as white solid. MS (ESI): m/z = 246.1 [M + H]+. ethyl 4-(4-phen0xyphenyl)—2-(piperazinyl)thiazolecarboxylate (5). To a solution of ethyl ooxo(4-phenoxyphenyl)propanoate 4 (362 mg, 1 mmol) in ethanol (10 mL)was added tert-butyl amothioylpiperazine—l-carboxylate 3 (245 mg, 1 mmol) at ambient ature. The e was then heated to reflux and stirred for 2 h. After cooling to ambient temperature, the solvent was removed and the residue was purified by silica gel column chromatography eluting with 40:1 to 20:1 DCM/MeOH to afford the title compound (214 mg, 52%) as brown solid. MS (ESI): m/Z = 410.1 [M + H. ethyl 2-(4-(tert-but0xycarb0nyl)piperazinyl)—4—(4-phenoxyphenyl)thiazole—5-carboxylate (6). To the compound of ethyl 4-(4-phenoxyphenyl)—2-(piperazin-1—yl)thiazolecarboxylate 5 (214 mg, 0.51 mmol) were added di-tert-butyl dicarbonate (134 mg, 0.6 mmol) and TEA (0.2 mL, 1.5 mmol) at t temperature. The mixture was then stirred at ambient temperature for 2 h. The solvent was removed and the e was purified by silica gel column chromatography eluting with 50:1 DCM/MeOH to afford the title nd (190 mg, 73%) as brown solid. MS (ESI): m/Z = 510.1 [M + Hr. 2-(4-(tert-but0xycarbonyl)piperazinyl)(4-phenoxyphenyl)thiazole—5-carboxylic acid (7). To a solution of ethyl 2-(4-(tert—butoxycarbonyl)piperazinyl)(4- yphenyl)thiazolecarboxy1ate 6 (190 mg, 0.37 mmol) in THF (50 mL)/H20 (1 mL)/MeOH (3 mL) was added lithium hydroxide (30 mg, 0.74 mmol) at ambient temperature.
The mixture was then heated to 60 °C and stirred for 2 h. After cooling to ambient temperature, the solvent was d and the residue was purified by chromatography eluting with 10:1 DCM/MeOH to afford the title compound (173 mg, 97%) as white solid. MS (ESI): m/z = 482.0 [M + Hr. tert-butyl 4-(5-(methylcarbamoyl)(4—phenoxyphenyl)thiazolyl)piperazine—1- carboxylate (8). To a solution of 2-(4-(tert-butoxycarbonyl)piperaziny1)—4-(4- phenoxyphenyl)thiazole carboxylic acid 7 (124 mg, 0.26 mmol) in DCM (10 mL) was added HATU (117 mg, 0.3 mmol) and methanamine (0.26 ml, 0.26 mmol) at ambient temperature. The mixture was stirred at ambient temperature for 3 h. The solvent was removed and the residue was d by silica gel column chromatography eluting with 1:5 EA/PE to afford the title compound (115 mg, 90%) as colorless oi1. MS (ESI): m/z = 495.2 [M + H]+.
N-methyl(4-phenoxyphenyl)(piperazinyl)thiazolecarb0xamide (9). To a solution of tert—butyl 4-(5 -(methylcarbamoy1)—4-(4-phenoxypheny1)thiazo1-2—y1)piperazineCarboxy1ate 8 (115 mg, 0.23 mmol) in DCM (5 mL) was added TFA (1 mL) at t temperature. The mixture was stirred for 1 h at ambient temperature. The solvent was removed and the residue was purified by silica gel column chromatography eluting with 10:1 OH to afford the title compound (117 mg, 100%) as colorless oil.
Example 47 2-(4-acryloylpiperazin-l-y])—N-methyl—4-(4—phenoxyphenyl)thiazole-S-carboxamide AWOSEQD../ To a solution of N—methyl(4-phenoxyphenyl)(piperazinyl)thiazole—5-carboxamide 9 (117 mg, 0.23 mmol) in DCM (5 mL) were added TEA (0.1 mL, 0.7 mmol) and acryloyl chloride 10 (0.21 mg, 0.23 mol) at 0 CC. The mixture was stirred at 0 CC for 10 minutes. The solvent was removed and the e was purified by Prep-TLC eluting with 50:1 to 20:1 DCM/MeOH to afford the title nd (50 mg, 49%) as white solid. 1H NMR (400 MHz, CDCl3) 5 7.57 (d, J: 8.6 Hz, 2H), 7.40 (t, J: 7.9 Hz, 2H), 7.19 (t, J: 7.4 Hz, 1H), 7.09 (d, J: 8.4 Hz, 4H), 6.60 (dd, J: 16.8, 10.5 Hz, 1H), 6.37 (d, J: 16.7 Hz, 1H), 5.79 (d, J: 11.8 Hz, 1H), 5.59 (d, J: 4.1 Hz, 1H), 3.78 (d, J: 48.5 Hz, 4H), 3.62 (s, 4H), 2.80 (d, J: 4.8 Hz, 3H), MS (ESI, method A): m/z = 449.1 [M + H]+, 28 min. HPLC: 96.9% (214nm), 96.9% (254nm).
Scheme 38 O O NBoc NBoc O O 1, oxalyl chloride. 12, Pth LIOH H20 OEt—>Ph0 "N o —> O O \ —> \ \ N \ N NH 2, TEA, DCM TEA, DCM THF/MeOH/HZO 2 HCI coca COOH NBOC PhO PhD 1 2 3 4 NBoc NH NH3: HATU HCI/E OHt O O \N TEA,DCM \N HCI O DIPEA‘ DMF m THF m \ N PhD 0 NH2 PhD 0 NH2 PhD 0 6 Example 48 tert-butyl(1-eth0xy—1,3-di0x0(4-phenoxyphenyl)pr0panylcarbamoyl)pyrrolidine carboxylate (2). The title compound was obtained using a procedure analogous to the procedures described in the General Scheme and e 15 as yellow oil (0.35 g, 30%). MS (ESI): m/Z = 440.7 [M — 551+.
Ethyl-2—(1-(tert-butoxycarbonyl)pyrrolidinyl)(4-phenoxyphenyl)0xazole carboxylate (3). To a solution of Pth (159 mg, 0.604 mmol) in DCM (20 mL) was added 12 (153 mg, 0.604 mmol). The resulting mixture was degassed with N2 3 times and stirred at ambient temperature for 2 h. TEA (122 mg, 1.208 mmol) was added and stirred for 10 min, then a solution of tert-butyl 3-(1-ethoxy-1,3-dioxo—3-(4-phenoxyphenyl)propan-2— ylcarbamoy1)pyrrolidinecarboxy1ate 2 (150 mg, 0.302 mmol) was added and d for 15 h.
The mixture was diluted with ethyl acetate (50 mL), and washed with sat. Na2S203 (20 mL), brine (3 X 20 mL). The organic layer was dried over NazSO4, filtered and concentrated to get a residue which was purified by silica gel column chromatography eluting with 1:1 PE/EA to get the title compound (0.11 g, 76%) as a ess oil. MS (ESI): m/z = 422.8 [M — 55]+. tert—butoxycarbonyl)pyrrolidinyl)(4-phenoxyphenyl)oxazole—4-carboxylic acid (4). The title compound was obtained using a procedure analogous to the ure described in -(1 -(tert-butoxycarbonyl)piperidinyl)(4-phenoxyphenyl)— 1 zole-3 -carboxylic acid (see Scheme 46) as yellow oil (110 mg, 100%). MS (ESI): m/z = 394.8 [M — 55]+ tert-butyl arbam0yl-5—(4-phenoxyphenyl)oxazol-Z-yl)pyrrolidine-l-carboxylate (5).
The title compound was obtained using a procedure ous to the procedure described in tert- butyl 4-carbamoylpiperidinecarboxylate (see Scheme 42) as colorless oil (95 mg, 92%). MS (ESI): m/z = 393.8 [M — 551+. -(4-phenoxyphenyl)(pyrrolidinyl)0xazole—4—carb0xamide hydrochloride (6). The title compound was obtained using a procedure analogous to the procedure described in 1-(4- phenoxyphenyl)—5-(piperidinyl)-1H-pyrazolecarboxamide hydrochloride (see Scheme 46) as a white solid (75 mg, 92%). MS (ESI): m/z = 349.9 [M + H]+.
Example 48 2-(1-acryloylpyrrolidinyl)(4—phenoxyphenyl)0xazolecarboxamide The title compound was obtained using a procedure analogous to the procedure described in Example 1 as an off white solid (50 mg, 64%). 1H NMR (400 MHz, DMSO) 5 8.27—8.22 (m, 2H), 7.61 (s, 1H), 7.58 (s, 1H), 7.45 (t, J: 7.9 Hz, 2H), 7.21 (t, J: 7.3 Hz, 1H), 7.14—7.06 (m, 4H), 6.67—6.58 (m, 1H), 6.16 (d, J: 16.7 Hz, 1H), 5.70 (d, J: 10.4 Hz, 1H), 4.05—4.01 (m, 0.5H), 3.97—3.92 (m, 0.5H), 3.90—3.59 (m, 3.5H), 3.53—3.45 (m, 0.5H), 2.45—2.21 (m, 2H). MS (ESI, method A): m/z = 404.1 [M + H]+, tR=1.484 min. HPLC: 99.5% (214nm), 99.3% (254nm) Scheme 39 O O NBoc NBoc 1 oxalyl chloride HN O on's rea ent LiOH H 0 08—»Pho —g> —2> S \ NHz HCI 2, TEA DCM PhO Et OHiHZOmNCOOH N PhO 1 2 NBoc NH3. HATU HCI/EtOH TEA DCM S —> \ —> sp\ HCI '—>Pho DIPEA, DMF m" THF MHZ PhD 0 NH2 NH PhD 0 6 Example 49 tert-butyl—4-(1-ethoxy—1,3-di0X0(4-phenoxyphenyl)propanylcarbamoyl)piperidine carboxylate (2). The title compound was obtained using a procedure analogous to the procedures described in the General Scheme and Example 15 as colorless oil (0.18 g, 16%). MS (ESI): m/Z = 454.8[M — 55]+ ethyl 2-(1-(tert—butoxycarb0nyl)piperidinyl)—5-(4-phenoxyphenyl)thiazolecarboxylate (3). The title compound was obtained using a ure analogous to the procedure described in tert-butyl 2-carbamothioylpiperidinecarboxylate (see Scheme 30) as colorless oil (0.12 g, 67%). MS (EST): m/Z = 508.8 [M + H]+. 2-(1-(tert—butoxycarb0nyl)piperidinyl)(4-phenoxyphenyl)thiazolecarboxylic acid (4). The title compound was obtained using a procedure analogous to the procedure described in -(1 -(tert-butoxycarbonyl)piperidin-4—yl)(4-phenoxyphenyl)— 1 H-pyrazole-3 -carboxylic acid (see Scheme 46) as yellow oil (120 mg, 100%). MS (ESI): m/z = 480.8 [M + H]+. tert-butyl 4-(4-carbam0yl-5—(4-phenoxyphenyl)thiazolyl)piperidine—l-carboxylate (5).
The title compound was obtained using a procedure analogous to the procedure described in tert- butyl arbamoyl—4—(4-phenoxyphenyl)thiazol-2—yl)piperidine-1—carboxylate (see Scheme ) as colorless oil (100 mg, 88%). MS (ESI): m/z = 479.8[M + H]+. -(4-phenoxyphenyl)(piperidinyl)thiazole—4-carboxamide hydrochloride (6). The title compound was obtained using a procedure analogous to the procedure described in 1-(4- yphenyl)—5-(piperidinyl)—1H-pyrazolecarboxamide hydrochloride (see Scheme 46) as a white solid (80 mg, 92%). MS (ESI): m/z = 379.8[M + H]+.
Example 49 2-(1-acryloylpiperidinyl)—5-(4-phenoxyphenyl)thiazole—4-carboxamide PhD SQ O \ / The title compound was obtained using a procedure ous to the procedure described in Example 51 as an off white solid (20 mg, 24%). 1H NMR (400 MHz, DMSO) 8 7.68 (s, 1H), 7.56 (d, J: 8.7 Hz, 2H), 7.50 (s, 1H), 7.47—7.42 (m, 2H), 7.21 (t, J: 7.4 Hz, 1H), 7.10 (d, J: 7.7 Hz, 2H), 7.00 (d, J= 8.7 Hz, 2H), 6.85 (dd, J= 16.7, 10.5 Hz, 1H), 6.12 (dd, J= 16.7, 2.4 Hz, 1H), .69 (dd, J: 10.5, 2.4 Hz, 1H), 4.49 (d, J: 12.8 Hz, 1H), 4.15 (d, J: 12.8 Hz, 1H), 3.33—3.19 (m, 2H), 2.88 (d, J: 11.5 Hz, 1H), 2.12 (d, J: 12.8 Hz, 2H), 1.73—1.55 (m, 2H). MS (ESI, method A): m/z = 434.0 [M + H]+, tR=1.606 min. HPLC: 95.0% (214nm), 96.6% (254nm) Scheme 40 OO o O "Gk/IN O O ‘N,.CNH N / ~N,CN/ Scheme 41 C D 0 0 J NH ~ ~ . SW (1 .r 0/‘0 m mB..
O SYN N \ [ 1 ' 2 THF 55°C 1h N IN (300120 ’ ‘ ’ E 4 0 o \SYN{I N 2. NH H O, r.t., 3d EtOH, reflux, 2h, face 69%3 2 '1 TEAvTHE 3°C at, 2h, 73% 1 3 00 5 QOG LiOH />_N/—\—NBoc HATU NH3 THFiHZO/MeOH TEA DCM, rt 3h 100% |:\/:/\,>—NN-Boc 60°C 4h 97% l:/—\/>—N >~N Ego/M rt 1h goo TEA THF 0°C 10mim Example 51 tert-butyl 4-carbamothioylpiperazine-l-carb0xylate (3). To a solution of di(1H—irnidazol yl)methanethione 2 (2.14 g, 12 mmol) in anhydrous THF (30 mL) was added tert-butyl zine-l—carboxylate 1 (1.86 g, 10 mmol) at t temperature. The e was allowed to stir at ambient temperature for 2 h, and then the mixture was heated to 55 °C for 1 h. The mixture was concentrated in vacuum to about half the volume. To the remaining reaction mixture was added a 2 M ammonia in methanol (20 mL) and was d to stir at ambient temperature for 3 days. The t was removed and the residue was purified by silica gel column chromatography eluting with 50:1 DCM/MeOH to afford the title compound (1.7 g, 69%) as white solid. MS (ESI): m/Z = 246.1 [M + H]+. ethyl 4-(4-phen0xyphenyl)(piperazinyl)thiazolecarboxylate (5). To a solution of ethyl 2-bromooxo(4-phenoxyphenyl)propanoate 4 (362 mg, 1 mmol) in ethanol (10 l 1 1 mL)was added tert-butyl 4-carbamothioylpiperazine—1-carboxy1ate 3 (245 mg, 1 mmol) at ambient ature. The mixture was then heated to reflux and stirred for 2 h. After cooling to ambient temperature, the solvent was removed and the residue was d by silica gel column chromatography eluting with 40:1 to 20:1 DCM/MeOH to afford the title nd (214 mg, 52%) as brown solid. MS (ESI): m/z = 410.1 [M + H]+.
Ethyl(4-(tert-butoxycarbonyl)piperazinyl)-4—(4-phenoxyphenyl)thiazole-S-carboxylate (6). To the compound of ethyl 4-(4-phenoxyphenyl)(piperazin-1—yl)thiazolecarboxylate 5 (214 mg, 0.51 mmol) was added di-tert-butyl dicarbonate (134 mg, 0.6 mmol) and TEA (0.2 mL, 1.5 mmol) at ambient temperature. The mixture was then stirred at ambient temperature for 2 h.
The solvent was removed and the residue was purified by silica gel column chromatography eluting with 50:1 DCM/MeOH to afford the title compound (190 mg, 73%) as brown solid. MS (ESI): m/Z = 510.1 [M + Hr. 2-(4-(tert-but0xycarb0nyl)piperazinyl)(4-phenoxyphenyl)thiazole—5-carb0xylic acid (7). To a solution of ethyl 2-(4-(tert-butoxycarbonyl)piperazinyl)(4- phenoxyphenyl)thiazolecarboxylate 6 (190 mg, 0.37 mmol) in THF (50 mL)/H20(1mL)/MeOH(3 mL) was added lithium hydroxide (30 mg, 0.74 mmol) at ambient temperature. The mixture was then heated to 60 CC and stirred for 2 h. After cooling to ambient temperature, the solvent was removed and the residue was purified by silica gel column chromatography eluting with 10:1 DCM/MeOH to afford the title compound (173 mg, 97%) as white solid. MS (ESI): m/Z = 482.0 [M + H]+. tert-butyl 4-(5-carbamoyl-4—(4-phenoxyphenyl)thiazol-Z-yl)piperazine—l-carboxylate (8).
To a solution of 2-(4-(tert-butoxycarbonyl)piperazinyl)(4-phenoxyphenyl)thiazole carboxylic acid 7 (173 mg, 4.6 mmol) in DCM (10 mL) was added HATU (164 mg, 0.43 mmol) at ambient temperature. The mixture was degassed three times with ammonia gas and stirred at ambient temperature under a here for 6 h. The solvent was d and the residue was purified by silica gel column chromatography eluting with 30:1 DCM/MeOH to afford the title compound (170 mg, 100%) as white solid. MS (ESI): m/z = 481.1 [M + H]+. 4-(4-phen0xypheny])—2-(piperazinyl)thiazole-S-carboxamide (9). A solution of tert-butyl arbamoyl(4-phenoxyphenyl)thiazolyl)piperazinecarboxylate 8 (170 mg, 0.35 mmol) in DCM (5 mL) and TFA (1 mL) at ambient temperature was d for 1 h. The solvent was removed and the residue was purified by silica gel column chromatography g with :1 to 10:1 DCM/MeOH to afford the title compound (110 mg, 58%) as white solid.
Example 51 cryloylpiperazinyl)(4-phenoxyphenyl)thiazole—5-carboxamide 0 S /—\ 0 lN/>_N\__/NJ<= To a solution of 4-(4-phenoxyphenyl)—2-(piperazin-l—yl)thiazolecarboxamide 9 (110 mg, 0.22 mmol) in DCM (5 mL) was added TEA (0.1 mL, 0.66 mmol) and acryloyl chloride 10 (0.20 mg, 0.22 mmol) at 0 OC. The mixture was stirred at 0 °C for 10 minutes. The solvent was removed and the residue was purified by Prep-TLC g with 25 :1 DCM/MeOH to afford the title compound (70 mg, 73%) as white solid. 1H NMR (400 MHz, MeOD) 8 7.66—7.61 (m, 2H), 7.37— 7.43 (m, 2H), 7.18 (t, J: 7.4 Hz, 1H), 7.10—7.04 (m, 4H), 6.83 (dd, J: 16.8, 10.6 Hz, 1H), 6.27 (dd,J=16.8, 1.8 Hz, 1H), 5.81 (dd,J= 10.6, 1.9 Hz, 1H), 3.87—3.78 (m, 4H), 3.69—3.61 (m, 4H). MS (ESI, method A): m/z = 435.0 [M + H]+, tR=1.539 min., HPLC: 95.5% (214nm), 96.4% (254nm).
Scheme 42 HO s 60 Q mBr 4 HATU NH3 DMF 150 Lawessons reagent 0 O OEt toluene, reflux, 2h EtOH, reflux 2 3 o@ o@ o@ o 0 "0 / NHS’HATU'DMF EtO / EC / Boc20,NaZCO3 NaOH,MeOH,H20 N —’ —> 3% N —> s THF/H20 3% E/ N N Boc H Boc e 7 o o H2N / / N HCI/EtOH HZN "I H2N S / 3 / i S /N E DIPEA,DCM N N Example 52 tert-butyl 4-carbamoylpiperidine-l-carboxylate (2). To a mixture of l-(tert- butoxycarbonyl)piperidinecarboxylic acid 1 (2.29 g, 10 mmol), DIEA (3.87 g, 30 mmol) and HATU (4.18 g, 11 mmol) in DMF (50 mL) was added NH3 by bubbling for 20 min. The resulting mixture was d at rt overnight. The e was diluted with water (200 mL) and ted with EA (2 X 50 mL). The organic layers were combined, washed with brine, dried over sodium sulfate, filtered and concentrated. The residue was applied onto silica gel column g with EA to get the title compound (1.3 g, 56%) as white solid. MS (ESI): m/Z = 173.2 [M + H — 561+. tert-butyl 4-carbamothioylpiperidinecarb0xylate (3). The title compound was obtained using a procedure analogous to the procedure described in cyclopentanecarbothioamide (see Scheme 30) as pale yellow solid (0.35 g, 29%). MS (ESI): m/z = 245.2 [M + H]+. ethyl 4-(4-phenoxyphenyl)—2-(piperidinyl)thiazolecarb0xylate (5). The crude of the title compound was obtained using a procedure analogous to the procedure described in ethyl 2- cyclopentyl-4—(4-phenoxyphenyl)thiazolecarboxylate (see Scheme A-2) as yellow oil (0.90 g, overweight). MS (ESI): m/Z = 408.8 [M + H]+. ethyl 4-(4-phenoxyphenyl)—2-(piperidinyl)thiazolecarboxylate (6). The title compound was obtained using a procedure analogous to the procedure described in ethyl 2-(4-(tert- butoxycarbony1)piperazinyl)-4—(4-phenoxyphenyl)thiazolecarboxylate (see Scheme 37) as yellow solid (0.30 g, 30%, two . MS (ESI): m/Z = 509.1 [M + H]+. 2-(1-(tert-but0xycarb0nyl)piperidinyl)(4-phenoxyphenyl)thiazolecarboxylic acid (7). The title compound was obtained using a procedure analogous to the procedure bed in -(1-(tert-butoxycarbonyl)piperidiny1)-4'-phenoxybiphenylcarboxylic acid (see Scheme 45) as yellow oil (250 mg, overweight). MS (ESI): m/z = 481.0 [M + H]+. tert-butyl 4-(5-carbamoyl(4-phenoxyphenyl)thiazolyl)piperidine—l-carboxylate (8).
The title nd was obtained using a procedure analogous to the procedure described in tert- butyl-3 -(4-carbamoyl(4-phenoxyphenyl)-1H-pyrazoly1)pyrrolidinecarboxylate (see Scheme 23) as pale yellow solid (250 mg, overweight). MS (ESI): m/Z = 480.1 [M + H]+. 4-(4-phenoxyphenyl)(piperidinyl)thiazole—5-carb0xamide (9). The title compound was obtained using a procedure ous to the procedure described in 1-(4-phenoxyphenyl) (piperidinyl)—1H-pyrazolecarboxamide hloride (see Scheme 46) as white solid (300 mg, overweight). MS (ESI): m/z = 380.1 [M + H]+.
Example 52 2-(1-acryloylpiperidinyl)(4-phen0xyphenyl)thiazolecarb0xamide WNO"i \ o O o The title compound was obtained using a procedure analogous to the procedure described in Example 15 as white solid (50 mg, 23%, four steps). 1H NMR (300 MHz, DMSO) 8 .69 (m, 4H), 7.42 (t, J= 7.4 Hz, 2H), 7.19 (t, J= 7.4 Hz, 1H), 7.09—7.00 (m, 4H), 6.84 (dd, J= 16.7, .4 Hz, 1H), 6.10 (dd, J: 16.7, 2.4 Hz, 1H), 5.68 (dd, J: 10.4, 2.4 Hz, 1H), 4.52—4.41 (m, 1H), 4.19—4.08 (m, 1H), 3.32—3.15 (m, 2H), 2.90—2.78 (m, 1H), 2.14—2.06 (m, 1.73—1.46 , 2H), (m, 2H). MS (ESI, method A): m/Z = 434.0 [M + H]+, tR=1.540 min. HPLC: 96% (214nm), 96% Scheme 43 w (9 o .
EtOH,70°C / Example 50 Example 53 e 53 (E)(1-(2-cyan0cyclopropylacryloyl)azetidinyl)—3-(4-phenoxyphenyl)—1H-pyrazole carboxamide OO O / ‘N/CN o / To a solution of 1-(1—(2-cyanoacetyl)azetidinyl)—3-(4-phenoxyphenyl) -1H-pyrazole carboxamide (100 mg, 0.25 mmol) and piperidine (2 drops) in EtOH (10 mL) was added cyclopropanecarbaldehyde (70 mg, 1.0 mmol). Then the solution was stirred at 70°C for 1 h.
After the reaction was completed, the solution was concentrated and purified by Prep—TLC with :1 DCM/MeOH to give the crude product (70 mg) and then purified by PLC (ACN/H20 = 42%, ) to afford the title compound (15 mg, 13%) as a white solid. 1H NMR (400 MHZ, CDClg) 8 8.16 (s, 1H), 7.64—7.57 (m, 2H), 7.45—7.37 (m, 2H), 7.22—7.16 (m, 1H), 7.15—7.03 (m, 5H), 5.60 (s, 2H), 5.23—5.13 (m, 1H), 5.11—4.95 (m, 2H), 4.68—4.54 (m, 2H), 2.16—2.05 (m, 1H), 1.33—1.29 (m, 2H), 1.02—0.95 (m, 2H). MS (ESI, Method A): m/z = 454.1 [M + H]+, tR = 1.485 min. HPLC: 100% (214nm), 100% (254nm).
Scheme 44 O O NBOC NBOC O O 1 ,oxayc one[ | hl 'd M03 HN o A|,PhP LiOHHO (mt—who o\ —2, o\ NHz HC] 2, TEA, DCM TEA, DCM mN THF/MeOH/HZO @N NBoc COOEt COOH PhO PhO 1 2 3 4 N_<— 0QNBOC NH3, HATU HCl/EIOH 0 TEA, DCM —, \ —> QNH\ HQ] —> \ DIPEA, DMF m" THF O/jl" PhD ml 0 NHz PhO o NHz PhO o NH2 6 Example 54 tert-butyl—3-(1-eth0xy—1,3-di0x0(4-phenoxyphenyl)propanylcarbamoyl)piperidine carboxylate (2). The title compound was obtained using a procedure analogous to the procedures described in the General Scheme and Example 15 as yellow oil (0.4 g, 36%). MS (ESI): m/z = 454.8 [M —55]+.
Ethyl(1-(tert-butoxycarbonyl)piperidinyl)—5—(4-phenoxyphenyl)0xazole-4—carboxylate (3). The title compound was obtained using a ure ous to the ure described in ethyl 2-(1-(tert-butoxycarbonyl)pyrrolidinyl)(4—phenoxyphenyl)oxazolecarboxylate (see Scheme 44) as yellow oil (0.25 g, 65%). MS (ESI): m/z = 492.8 [M + H]+. 2-(1-(tert—butoxycarbonyl)piperidinyl)(4-phenoxyphenyl)0xazolecarboxylic acid (4). The title compound was ed using a procedure analogous to the procedure described in -(1 -(tert-butoxycarbonyl)piperidin-4—yl)(4—phenoxyphenyl)— 1 H-pyrazole—3 -carboxylic acid (see Scheme 46) as yellow oil (0.25 g, 100%). MS (ESI): m/z = 464.8 [M + H]+. tert-butyl 3-(4-carbamoyl-5—(4-phenoxyphenyl)0xazolyl)piperidine-l-carboxylate (5).
The title compound was obtained using a procedure analogous to the procedure described in tert- butyl 3-(5-carbamoyl—4-(4—phenoxyphenyl)thiazol—2—yl)piperidinecarboxylate (see Scheme ) as yellow oil (0.2 g, 84%). MS (ESI): m/z = 407.8 [M — 55]+. -(4-phenoxyphenyl)(piperidinyl)oxazolecarboxamide hydrochloride (6). The title compound was obtained using a ure analogous to the procedure described in 1-(4- phenoxyphenyl)(piperidinyl)—1H-pyrazolecarboxamide hydrochloride (see Scheme 46) as brown oil (180 mg, 100%). MS (ESI): m/Z = 363.8[M + H]+.
Example 54 2-(1-acryloylpiperidinyl)—5-(4—phenoxyphenyl)0xazolecarboxamide The title compound was obtained using a procedure analogous to the procedure described in Example 1 as a yellow solid (70 mg, 37%). 1H NMR (400 MHz, DMSO) 8 8.24 (d, J= 7.2 Hz, 2H), 7.57 (s, 1.5H), 7.50 (s, 0.5H), 7.45 (t, J: 7.9 Hz, 2H), 7.21 (t, J: 7.4 Hz, 1H), 7.11 (d, J: 3.1 Hz, 2H), 7.08 (d,J= 4.2 Hz, 2H), 6.96—6.78 (m, 1H), 6.13 (t, J= 18 Hz, 1H), 5.75—5.57 (m, 1H), 4.51 (d, J: 11.6 Hz, 0.5H), 4.08 (d, J: 12 Hz, 0.5H), 3.93 (d, J: 13.2 Hz, 0.5H), 3.85— 3.73 (m, 0.8H), 3.34—3.20 (m, 2H), .97 (m, 0.7H), 2.27—2.09 (m, 1H), 2.07—1.64 (m, 2H), 1.60—1.43 (m, 1H). MS (ESI, method F): m/z = 418.1 [M + H]+, tR=1.679 (min). HPLC: 100% (214nm), 100% (254nm).
Scheme 45 C')H COOH COOEt Boc-N::>—Blo Cl HO‘B Cl / EtOH st04 Cl ‘o / 000 EtOOC N-Boc reflux gh' Pd(dppf)ClZ, chog, Pd2(dba)3, K3PO4, dioxane H20, 80°C dioxane H20,110°C COOEt COOEt COOH O/RPd/CH2 MeOHmO/Oi‘:NaOH, MeOH THF H20 CONHz CONH2 NH3 HATU DMF HCI/THF DIEA DCM Example 55 ethyl 4-br0mochlor0benzoate (2). To a mixture of 4-bromochlorobenzoic acid 1 (1.9 g, 8.1 mmol) in EtOH (50 mL) was added H2S04 (5 mL) dropwise carefully at 0 CC. The resulting mixture was refluxed overnight. The le phase d under reduced pressure. The residue was diluted with EA (100 mL), which was washed with water (2 X 50 mL) and brine, dried over sodium sulfate, filtered and concentrated. This resulted in the title compound (2.0 g, 95%) as brown oil. MS (ESI): m/Z = 263.0/2650 [M + H]+. tert-butyl 4-(3-chlor0(ethoxycarb0nyl)phenyl)-5,6-dihydr0pyridine-l(2H)—carb0xylate (3). A mixture of ethyl ochlorobenzoate 2 (0.53 g, 2.0 mmol), tert-butyl 4-(4,4,5,5- tetramethyl-1,3,2-dioxaborolanyl)—5,6-dihydropyridine-1(2H)-carboxylate (0.74 g, 2.4 mmol), potassium carbonate (0.83 g, 6.0 mmol) and f)Cl2 (0.15 g, 0.2 mmol) in dioxane/H2O (20 mL/5 mL) was stirred at 80 °C for 4h under N2 atmosphere. The volatile phase was removed under reduced pressure. The residue was d onto silica gel column eluting with 6:1 PE/EA to get the title compound (0.7 g, 96%) as yellow oil. MS (ESI): m/z = 310.1 [M + H — 56]+. tert-butyl 4-(6-(eth0xycarb0nyl)—4'-phenoxybiphenylyl)-5,6-dihydr0pyridine—1(2H)- carboxylate (4). A e of tert-butyl 4-(3—chloro—4—(ethoxycarbonyl)phenyl)-5,6— dihydropyridine- 1(2H)-carboxylate 3 (200 mg, 0.66 mmol), 4-phenoxyphenylboronic acid (172 mg, 0.80 mmol), K3PO4 (414 mg, 2.0 mmol), tricyclohexylphosphine (40 mg, 0.14 mmol) and Pd2(dba)3 (64 mg, 0.07 mmol) in dioxane/H2O (15 mL/3 mL) was stirred at 110 CC overnight under N2 here. The volatile phase was removed under reduced pressure. The residue was applied onto silica gel column eluting with 6:1 PE/EA to get the title compound (200 mg, 61%) as yellow oil. MS (ESI): m/z = 500.0 [M + H]+. tert-butyl 4-(6-(eth0xycarb0nyl)—4'-phen0xybiphenylyl)piperidine—l-carboxylate (5). A mixture of 4-(6-(ethoxycarbonyl)-4'-phenoxybiphenylyl)—5,6-dihydropyridine-1(2H)- carboxylate 4 (180 mg, 0.36 mmol) and Pd/C (wet 10%, 18 mg) in MeOH (10 mL) was stirred at rt under H2 atmosphere for 5h. The solid was filtered off and the filtrate was concentrated under reduced pressure. This resulted in the title compound (180 mg, 99%) as colorless oil, which was used directly for the next step. MS (ESI): m/z = 524.0 [M + Na]+. -(1-(tert—butoxycarbonyl)piperidinyl)—4'-phenoxybiphenyl—Z-carboxylic acid (6). A mixture of tert-butyl 4-(6-(ethoxycarbonyl)-4'-phenoxybiphenylyl)piperidinecarboxylate 5 (180 mg, 0.36 mmol) and NaOH (72 mg, 1.8 mmol) in THF/MeOH/H2O (5 mL/5 mL/5 mL) was stirred at rt overnight. The le phase was removed under d pressure. The PH of which was adjusted to 3 by HCl (1 N), which was extracted with EA (2 X 30 mL). The organic layers were combined, washed with brine, dried over sodium e, filtered and concentrated. This resulted in the title compound (180 mg, overweight) in colorless oil, which was used directly for the next step. MS (ESI): m/Z = 374.1 [M + H - Boc]+. tert-butyl 4-(6-carbamoyl-4'-phenoxybiphenylyl)piperidine—l-carboxylate (7). The title compound was ed using a procedure analogous to the procedure bed in tert-butyl (4-carbamoyl(4-phenoxyphenyl)—1H-pyrazol-l-yl)pyrrolidine—1-carboxylate (see Scheme 23) as pale yellow solid (200 mg, overweight). MS (ESI): m/z = 416.8 [M + H - 56]+. tert-butyl 4-(6-carbam0yl-4'-phenoxybiphenylyl)piperidine—l-carboxylate (8). The title compound was obtained using a procedure analogous to the procedure described in 1-(4- phenoxypheny1)(piperidiny1)—1H-pyrazolecarboxamide hydrochloride (see Scheme 46) as white solid (200 mg, ight). MS (ESI): m/z = 373.1 [M + H]+.
Example 55 -(1-acryloylpiperidiny])—4'-phenoxybiphenyl-Z-carboxamide 4009 The title compound was obtained using a procedure analogous to the procedure described in Example 61 as white solid (70 mg, 20%). 1H NMR (300 MHZ, CDClg) 5 7.75 (d, J: 7.9 Hz, 1H), 7.44—7.32 (m, 4H), 7.23—7.28 (m, 1H), 7.20—7.12 (m, 2H), 7.11—6.99 (m, 4H), 6.62 (dd, J: 16.5 Hz, 10.5 Hz, 1H), 6.31 (dd, J: 16.5 Hz, 1.8 Hz, 1H), 5.73 (brs, 1H), 5.71 (dd,J= 10.5 Hz, 1.8 Hz, 1H), 5.35 (brs, 1H), 4.99—4.74 (m, 1H), 4.24—4.03 (m, 1H), 3.30—3.05 (m, 1H), 2.97— 2.58 (m, 2H), 2.04—1.88 (m, 2H), 1.83—1.58 (m, 2H). MS (ESI, method A): m/z = 427.1 [M + H]+, 63 min. HPLC: 99% (214nm), 99% (254nm).
Scheme 46 H N o 0 N _, N\ / \. 0%N w N 0 0v \ I H \ o 0 0H 8 O 9 0 o G o NH4C| HCI-EtOH —> —> Q AvofN _> :1 ‘IN m 37" HCI HN O NH2 0 ""2 MWN‘N I 2 0 1 1 12 Example 56 (4-phenoxyphenyl)hydrazine (2). To a solution of 4—phenoxybenzenamine 1 (1.0 g, 5.4 mmol) in HCl (100 mL) was added NaNOz (700 mg, 10.1 mmol) at 0°C. Then the mixture was stirred at 0°C for 1 h. A solution of SnClz (5.0 g, 22.1 mmol) in HCl (100 mL) was added to the mixture, and the resulting mixture was stirred at rt for 3 h. Aqueous NaOH (3N) was added to adjust pH to 10, and the mixture was extracted with EA (3 X 50 mL), the combined organic phase was washed with brine (20 mL), dried over NaZSO4. The solvent was d under reduced pressure to give a crude title compound (567 mg, 56%) as a yellow solid, which was used to next step without further purification. MS (ESI): m/z = 201.0 [M+H]+. ethyl 5-hydr0xy—1-(4-phen0xyphenyl)—1H-pyrazolecarb0xylate (4). To the solution of diethyl fumarate 3 (260mg, 1.5 mmol) in EtOH (25 mL) was added (4-phenoxyphenyl)hydrazine 2 (254 mg, 1.3 mmol), and the resulting solution was stirred overnight at 80°C. The solvent was evaporated under vacuum and the crude residue was diluted with water (30 mL). The solution was extracted with ethyl acetate (3 X 30 mL). The organic layers were ed, dried over ous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography eluting with 20:1 DCM/MeOH to afford the title nd (174 mg, 42%) as a yellow solid. MS (ESI): m/Z = 325.1 [M+H]+. ethyl 1-(4-phenoxyphenyl)—5—(trifluoromethylsulfonyloxy)—1H-pyrazole—3-carb0xylate (6).
To a solution of ethyl 5-hydroxy-l-(4-phenoxyphenyl)-1H-pyrazole—3-carboxylate 4 (170 mg, 0.5 mmol) in DCM (20 mL) was added trifluoromethanesulfonic anhydride 5 (295 mg, 1.0 mmol) and stirred for 1 h at -30°C under N2 atmosphere. The mixture was poured into water (60 mL), and the solution was ted with ethyl acetate (3 X 30 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography eluting with 5:1 PE/EA to afford the title compound (210 mg, 92%) as a yellow solid. MS (ESI): m/z = 457.0 [M+H]+. tert-butyl(3-(eth0xycarb0nyl)—1-(4-phen0xyphenyl)—1H—pyrazol-S-yl)—5,6- dihydropyridine— 1(2H)—carb0xylate (8). To a solution of ethyl 1-(4-phenoxyphenyl) (trifluoromethylsulfonyloxy)-1H-pyrazolecarboxylate 6 (210 mg, 0.5 mmol), K2C03 (552 mg, 4.0 mmol) and tert-butyl 4-(4,4,5,5-tetramethyl— l ,3,2—dioxaborolan-2—yl)-5,6—dihydropyridine— 1(2H)—carboxylate 7 (201 mg, 0.6 mmol) in dioxane/H2O (10:1, 20 mL) was added Pd(dppf)Cl2 (327 mg, 0.2 mmol) under en atmosphere, and the e was degassed with nitrogen 6 times, then heated to 90°C and stirred overnight under nitrogen atmosphere. After cooling to room temperature, the solvent was evaporated and the crude product was purified by silica gel column chromatography eluting with 20:1 DCM/MeOH to afford the title compound (95 mg, 42%) as a yellow solid. MS (ESI): m/Z = 490.2[M+H]+. tert-butyl(3-(eth0xycarb0nyl)—1-(4-phen0xyphenyl)—1H—pyrazolyl)piperidine carboxylate (9). The mixture of tert—butyl 4—(3-(ethoxycarbonyl)—l—(4-phenoxyphenyl)-1H- pyrazol—5-yl)—5,6- dihydropyridine-l(2H)-carboxylate 8 (95 mg, 0.2 mmol), Pd/C (10% palladium on carbon, 56.5% water, 48 mg) and MeOH (20 mL) was degassed with H2 6 times and then d under H2 at rt for l h. Then the mixture was filtered and the filtrate was trated in vacuo to give the title compound (56 mg, 58%) as colorless oil. MS (ESI): m/z = 492.2 [M + Hr. -(1-(tert-but0xycarbonyl)piperidinyl)—1-(4-phen0xyphenyl)—lH-pyrazolecarb0xylic acid (10). To the solution of tert-butyl 4-(3-(ethoxycarbonyl)(4-phenoxyphenyl)—lH-pyrazol- -yl)piperidine-l-carboxylate 9 (166mg, 0.3 mmol) in THF/MeOH/H2O (20 : 20 : 10 mL) was added LiOH (60mg, 1.4 mmol), and the resulting solution was stirred for 15 h at ambient temperature. The e was concentrated, the residue was d with water (10 mL), and the solution was acidified with citric acid to pH = 4, ted with ethyl acetate (3 X 20 mL), washed with brine (20 mL), dried over , filtered and concentrated to get the title compound (120 mg, 76%) as a brown solid. MS (ESI): m/z = 464.2 [M + H]+ utyl(3-carbam0y](4-phenoxyphenyl)—1H—pyrazol-S-yl)piperidine—l-carboxylate (11). To a solution of 5-(1-(tert-butoxycarbonyl)piperidinyl)-l-(4-phenoxyphenyl)-1H- pyrazole ylic acid 10 (250 mg, 0.59 mmol) and HATU (147 mg, 0.38 mmol) in dry N,N—dimethyl formamide (25 mL) was added DIPEA (67 mg, 0.51 mmol), and the resulting solution was stirred for 20 min at ambient temperature, then NH4C1 (28 mg, 0.51 mmol) was added and stirred overnight. The mixture was diluted with ethyl acetate (50 mL), and washed with water (2 X 20 mL) and brine (2 X 20 mL). The organic layer was dried over Na2SO4, filtered and concentrated to get a residue which was purified by silica gel column chromatography eluting with 20:1 DCM/MeOH to afford the title compound (100 mg, 84%) as a yellow solid.
MS (ESI): m/Z = 463.2 [M+H]+. 1-(4-phenoxyphenyl)—5-(piperidinyl)—1H-pyrazole—3-carb0xamide hydrochloride (12). To a solution of tert-butyl 4-(3 -carbamoyl(4-phenoxyphenyl)-1H-pyrazol-5 -yl)piperidine carboxylate 11 (100mg, 0.21 mmol) in EtOH (20 mL) was added HCl/EtOH (33%, 2 mL) at ambient temperature. The mixture was stirred for 12 h at room ature. The mixture concentrated to give the title compound (70 mg, 89%) as yellow oil. MS (ESI): m/z =363.1 [M + Example 56 -(1-acryloylpiperidinyl)—1-(4-phen0xyphenyl)-lH-pyrazolecarboxamide _ <3; 7w \.~ To the solution of l-(4—phenoxyphenyl)—5-(piperidin—4-yl)-lH-pyrazolecarboxamide hloride 12 (110 mg, 0.3 mmol), DIPEA (117 mg, 0.9 mmol) and CH2C12 (10 mL) was added acryloyl chloride (28 mg, 0.3 mmol) dropwise and then the reaction mixture was stirred at 0°C for 1 h. The mixture was diluted with CHzClz (20 mL) and washed with saturated aqueous NaHC03 on (20 mL). The aqueous phase was reextracted with EtOAc (20 mL). The ed organic phase was dried over Na2S04, trated in vacuo and purified by Prep- TLC developing with 20:1 CH2C12/1V1eOH to give the title compound (66 mg, 52%) as yellow oil. 1H NMR (300 MHz, CD30D) 5 7.52—7.37 (m, 4H), 7.24—7.06 (m, 5H), 6.84—6.68 (m, 2H), 6.21 (d, J= 2.0 Hz, 0.5H), 6.15 (d, J= 2.0 Hz, 0.5H), 5.73 (dd, J= 10.6, 2.0 Hz, 1H), 4.61 (d, J = 12.8 Hz, 1H), 4.15 (d, J: 14.0 Hz, 1H), 3.04 (tt, .1: 8.0, 7.5 Hz, 2H), 2.77—2.59 (m, 1H), 2.03—1.81 (m, 2H), 1.72—1.46 (m, 2H). MS (ESI, method A): m/z = 417.1 [M + H]+, tR=1.547 min. HPLC: 98.2% (214nm), 98.8% (254nm).
Scheme 47 0 Br 0 Br 0 Br 0 Br r"\ 3°C N\_,NH3_ SOCI2 HO NH3, HATU H2N HQ —>o —> —> MeOH K2003 DMF N/fi DIPEA,DMF N F F K/N. Boo 5km.Bee 1 2 4 ch03 Pd(dppf)C|2 HCUEtOH dioxane/HZO 6DK/NBoc OK/NH TEA/DOM 7 ONO? Example 57 methyl 2-brom0flu0r0benz0ate (2). To a mixture of ofluorobenzoic acid 1 (2.19 g, mmol) in MeOH (20 mL) was added SOC12 (0.5 mL) dropwise at rt. The resulting mixture was stirred at 60°C for 10 h. The mixture was concentrated to give the title compound (2 g, 86%) as brown oil. MS (ESI): m/Z = 232.8 [M + H]+. 2-brom0(4—(tert—butoxycarbonyl)piperazinyl)benzoic acid (4). To a solution of methyl 2-bromofluorobenzoate 2 (1.8 g, 7.72 mmol) in DMSO (30 mL) was added tert-butyl piperazine-l-carboxylate 3 (1.726 g, 9.27 mmol) and K2C03 (4.26 g, 30.9 mmol). The e was stirred at 120°C for 5 h. When finished, the mixture was extracted with ethyl acetate (2 X 50 mL), and washed with water (50 mL) and brine (2 X 50 mL). The organic layer was dried over Na2S04, filtered and concentrated to get a residue which was purified by silica gel column chromatography eluting with 10:1 PE/EA to get the title compound (1.1 g, 36%) as a yellow oil.
MS (ESI): m/Z = 328.7 [M — 551+. tert-butyl 4-(3-br0m0carbamoylphenyl)piperazine-l-carboxylate (5). The title compound was obtained using a procedure ous to the procedure described in tert—butyl 3-(5- carbamoyl(4-phenoxyphenyl)thiazoly1)pyrrolidinecarboxylate (see Scheme 31) as a yellow solid (0.8 g, 73%). MS (ESI): m/Z = 327.7 [M — 551+. tert-butyl 4-(6-carbamoyl-4'-phenoxybiphenylyl)piperazine—l-carboxylate (6). To a mixture of tert-butyl 4-(3-bromocarbamoylphenyl)piperazinecarboxylate 5 (192 mg, 0.5 mmol), 4-phenoxyphenylboronic acid (102 mg, 0.5 mmol) and K2C03 (207 mg, 1.5 mmol) in dioxane/water (20/4 mL) were added Pd(dppf)2C12 (36.55 mg, 0.05 mmol). The e was degassed with N2 3 times, then heated to 100 CC and stirred for 16 h. After g to room ature, the mixture was added to ethyl acetate (30 mL), washed with water (2 X 20 mL) and brine (2 X 20 mL). The organic layer was dried over NazSO4, filtered and concentrated to get a residue which was purified by silica gel column chromatography eluting with 30:1 DCM/MeOH to get the title compound (50 mg, 21%) as a yellow solid. MS (ESI): m/z = 473.8 [M + H]+ 4'-phenoxy-5—(piperazinyl)biphenylcarboxamide hydrochloride (7). The title compound was obtained using a procedure analogous to the procedure described in 1-(4- yphenyl)(piperidinyl)-1H-pyrazolecarboxamide hydrochloride (see Scheme 46) as a yellow solid (40 mg, 92%). MS (ESI): m/Z = 374.1[M + H.
Example 57 -(4-acryloylpiperazinyl)—4'-phenoxybiphenyl-Z-carboxamide The title compound was obtained using a procedure analogous to the procedure described in Example 1 as an off white solid (15 mg, 36%). 1H NMR (400 MHZ, DMSO) 5 7.52—7.30 (m, 6H), 7.25—6.93 (m, 7H), .82 (m, 2H), 6.15 (d,J= 16.7 Hz, 1H), 5.73 (d, J: 9.9 Hz, 1H), 3.70 (d, J: 12.0 Hz, 4H), 3.27 (s, 4H). MS (ESI, method A): m/z =428.1 [M + H]+, tR=1.525 min. HPLC: 96.4% (214nm), 99.3% (254nm) Scheme 48 NH2 \ Pd(dppf)C12,KZCO3 0 | \ Pd(dppf)Clz,K2CO3 \ O + I —>CI N/ —> CI N/ CI dioxane-Hzo (6/1 V) O O '3 dioxane—HZO (6/1 V) 90°C, 12 h 300 90 00, 12h 2 o 3 [foo O Pd/C H2 MeOH n Boo/N {5 040—,DCMCF3COOHrt \ O ' | / N/ N DCM 0°C 1h HN O O —>/\|OrN Example 58 2-(4-benz0ylphenyl)—6-chloronicotinamide (2). To a solution of 4-phenoxyphenylboronic acid (650 mg, 2.88 mmol), K2C03 (1.08 g, 7.86 mmol) and 2,6—dichloronicotinamide (500 mg, 2.62 mmol) in 1,4-dioxane (25 mL) and water (4 mL) was added Pd(dppf)Clg (192 mg, 0.262 mmol) under nitrogen atmosphere, and the mixture was degassed with nitrogen 6 times, then heated to 60 CC and stirred for 12 h under nitrogen atmosphere. After cooling to room ature, the solution was poured into water (50 mL), and then extracted with ethyl acetate (2 X 50 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated.
The crude t was purified by column tography, g with 80 : 1 dichloromethane/methanol to afford the title compound as a brown oil (868 mg, 98%). MS (ESI): m/Z = 336.9 [M + H]+. tert-butyl 4-(6-(4-benzoylphenyl)carbamoylpyridin-Z-yl)—5,6-dihydropyridine—1(2H)— carboxylate (4). To a solution of tert—butyl 4—(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)— 5,6- dihydropyridine-1(2H)—carboxylate (1.2 g, 3.87 mmol), K2C03 (1.07 g, 7.74 mmol) and 2-(4- benzoylphenyl)—6-chloronicotinamide 2 (868 mg, 2.58 mmol) in 1,4—dioxane (24 mL) and water (3 mL) was added f)C12 (188 mg, 0.258 mmol) under nitrogen atmosphere, and the mixture was degassed with nitrogen 6 times, then heated to 90 CC and stirred for 12 h under nitrogen atmosphere. After cooling to room temperature, the solution was poured into water (50 mL), and then extracted with ethyl acetate (3 X 40 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and trated. The crude product was purified by column chromatography, eluting with 80 : l dichloromethane/methanol to afford the title compound as a brown oil (800 mg, 64%). MS (ESI): m/z = 484.0 [M + H]+. tert-butyl(5-carbamoyl—6—(4-(hydr0xy(phenyl)methyl)phenyl)pyridinyl)piperidine—1- ylate (5). To a solution of tert—butyl 4-(6-(4-benzoylphenyl)—5-carbamoylpyridinyl) - hydropyridine-1(2H)- carboxylate 4 (800 mg, 1.65 mmol) in MeOH (15 mL) was added Pd/C (150 mg) under en atmosphere, and the mixture was ed with hydrogen 6 times, then d for 16 h at ambient temperature under hydrogen atmosphere. The solution was filtered and the filtrate was evaporated to provide crude t as a white solid (500 mg, 62%).
MS (ESI): m/Z = 488.1 [M+H]+. 2-(4-(hydroxy(phenyl)methyl)phenyl)(piperidinyl)nicotinamide (6). To a solution of tert—butyl 4-(5-carbamoyl(4-(hydroxy(phenyl)methyl)phenyl)pyridinyl)piperidine- l - carboxylate 5 (500 mg, 1.03 mmol) in dry dichloromethane (5 mL) was added TFA (2 mL), and the resulting mixture was stirred for 3 h at ambient temperature. The solvent was removed and the residue was ioned between saturated aqueous sodium bicarbonate (30 mL) and ethyl acetate (20 mL). The organic phase was separated, dried over anhydrous sodium sulfate, filtered and concentrated to afford the title compound as a white solid (350 mg, 88%). MS (ESI): m/z = 388.1 [M+H]+.
Example 58 6-(1-acryloylpiperidinyl)—2-(4-(hydroxy(phenyl)methyl)phenyl)nicotinamide \ O N O 0 0 OH To a solution of 2—(4-(hydroxy(phenyl)methyl)phenyl)-6—(piperidinyl) nicotinamide 6 (350 mg, 0.90 mmol) in DCM (10 mL) was added TEA (182 mg, 1.8 mmol) and acryloyl chloride (90 mg, 0.99 mmol) at 0 OC. The mixture was stirred at 0 °C for 10 min. The solvent was removed and the residue was purified by Prep-HPLC to afford the title compound (150 mg, 38%) as white solid. 1H NMR (300 MHz, CDClg) 8 8.03 (d, J: 7.9 Hz, 1H), 7.65 (d, J = 7.1 Hz, 2H), 7.56— 7.15 (m, 9H), 6.67—6.49 (m, 1H), 6.27 (d, J = 16.6 Hz, 1H), 5.88 (s, 1H), 5.68 (d, J: 10.1 Hz, 1H), 5.52 (d, .1: 27.1 Hz, 2H), 4.79—4.72 (m, 1H), 4.11—4.06 (m, 1H), 3.18—3.10 (m, 2H), 2.80— 2.74(m, 1H), 2.08—1.98(m, 2H), 1.78 (d, J: 10.5 Hz, 2H). MS (ESI, method F): m/Z = 441.8 [M + Hr, tR=1.268 min., HPLC: 100.0% (214nm), 100.0% (254nm).
Scheme 49 O0 O/\ O 0 O N N / ‘N'CN’KZN— / ‘N’CN :N \ \ o AcOH,45°C (>00 / NH2 NH2 Example 50 Example 59 Example 59 (1-(2-cyanobutenoyl)azetidinyl)—3-(4-phen0xyphenyl)—lH-pyrazole carboxamide : : N / \N’CN To a solution of 1-(1-(2-cyanoacetyl)azetidinyl)—3-(4-phenoxyphenyl)-1H-pyrazole amide (150 mg, 0.37 mmol) and dine (3 drops) in AcOH (10 mL) was added acetaldehyde (99 mg, 0.74 mmol), then stirred at 45°C overnight. After the reaction was completed, sat. NaOH was added to the solution to pH = 6—7. Then the solution was extracted with DCM (2 X 20 mL). The organic layer was combined and concentrated under vacuum to dryness. The residue was purified by Prep-HPLC (MeOH-HzO = 60-70, 0.1%FA) to afford the title compound (40 mg, 26%) as a white solid. 1H NMR (300 MHz, CDC13) 5 8.15 (S, 1H), 7.79— 7.68 (m, 1H), 7.62—7.54 (m, 2H), 7.43—7.34 (m, 2H), 7.21—7.13 (m, 1H), 7.13—7.04 (m, 4H), .62 (s, 2H), 5.26—5.10(m, 1H), 5.08—4.79 (m, 2H), 4.71—451 (m,2H),3.51—3.36(m,1H), 2.26—2.16 (m, 2H). MS (ESI, Method A): m/z= 428 1 [M + H], tR= 1 4.38 min HPLC: 98.4% (214nm), 98.4% (254nm).
Scheme 50 OH Cul 1 10--phenanthroline HCI (1 N) Br\©\ Q CSzCOg toluene 120°C 000OBTHF OOQ/OB + 0 o £0 1 2 3 4 DAST Pd(dppf)C|2 KOAc _>F?©/O Pd2(dba)3, 052003 DCM, rt 5Br—>\©\1,-4dioxane 100°C F70 08/0 dioxane/H20,1ZO°C 33F?#3" | 0 e ‘55 ’11* (‘N N C] O O HNQ \ NH2 \ I | NH2 FN , / N H2C|2,O°C FN N HNd O —C]> / Nd O /\n/ O (I? o E j F F F F ExampleGO 8-(4-br0m0phen0xy)—1,4-di0xaspir0[4.5]decane (3). The title compound was obtained using a ure ous to the procedure described in l-bromo(cyclohexyloxy)benzene (see Scheme 17) as colorless oil (0.272 g, 87%). 4-(4-bromophenoxy)cyclohexanone (4). A solution of 8-(4-bromophenoxy)— 1,4- dioxaspiro[4.5]decane 3 (0.272 g, 0.87 mmol) in THF (5 mL) was d with HCl (1 N, 5 mL) at 50 0C for l h. Then the mixture was neutralized with NaHCOg and extracted with EtOAc (5 mL X 3). The combined organic phase was dried over Na2S04, filtered and concentrated. The residue was purified by silica gel column chromatography eluting with 5:1 petroleum EtOAc to give the title compound (147 mg, 63%) as white solid. 1H NMR (400 MHz, CDC13) 8 7.46—7.37 (m, 2H), 6.91—6.83 (m, 2H), 4.68 (s, 1H), 2.75—2.64 (m, 2H), 2.43—2.25 (m, 4H), 2.15—2.08 (s, 2H). 1-brom0((4,4-diflu0r0cyclohexyl)0xy)benzene (5). To the solution of 4-(4- bromophenoxy)cyclohexanone 4 (0.538 g, 2.0 mmol) in dry DCM (5 mL) was added a solution ofDAST (0.654 g, 4.0 mmol) in dry DCM (5 mL) at 0 CC and the resulting mixture was stirred at rt for 4 h. The reaction was quenched by ice water (5 mL), basified with saturated NaHC03 to pH = 8 and extracted with EtOAc (10 mL X 3). The combined organic phase was dried over Na2S04, filtered and concentrated. The residue was purified by silica gel column chromatography eluting with 10:1 petroleum ether/EtOAc to afford the title compound (0.547 g, 94%) as yellow oil. 2-(4-((4,4-difluorocyclohexyl)oxy)phenyl)-4,4,5,5-tetramethyl—1,3,2-di0xabor0]ane (6). The mixture of 1-bromo((4,4-difluorocyclohexyl)oxy)benzene 5 (0.328 g, 1.13 mmol), bis(pinacolato)diboron (0.429 g, 1.69 mmol), Pd(dppf)C12 (0.168 g, 0.23 mmol), KOAc (0.323 g, 3.29 mmol) and dry dioxane (3 mL) was stirred at 100 CC for 3 h. After cooled to rt, the mixture was poured into water (10 mL) and extracted with EtOAc (15 mL X 3). The combined c phase was dried over Na2S04, filtered and concentrated. The residue was purified by silica gel column chromatography eluting with PE to afford the title compound (0.258 g, 68%) as a white solid. (4,4-diflu0r0cyclohexyl)0xy)phenyl)(piperazinyl)nic0tinamide (8). The title compound was obtained using a procedure analogous to the ure described in 6—(3- nitrophenyl)—2-(4-phenoxyphenyl)nicotinamide (see Scheme 1) as white solid (0.10 g, 31%). MS (ESI): m/Z = 417.1 [M + Hr.
Example 60 6-(4-acryloylpiperazinyl)(4-((4,4-difluorocyclohexyl)0xy)phenyl)nic0tinamide @115\ NH2 l F The title compound was obtained using a procedure analogous to the procedure described in e 1 as white solid (6 mg, 11%). 1H NMR (400 MHz, DMSO—d6) 5 7.88 (d, J: 8.7 Hz, 2H), 7.73 (d, J: 8.6 Hz, 2H), 7.68 (d, J: 8.7 Hz, 1H), 7.59 (s, 1H), 7.26 (s, 1H), 7.21—7.14 (m, 4H), 6.86 (dd, J: 17.8, 9.3 Hz, 2H), 6.16 (dd, J: 16.7, 2.2 Hz, 1H), 5.73 (dd, J: 10.4, 2.2 Hz, 1H), 3.66—3.67 (m, 8H). MS (ESI, method A): m/z = 471.2 [M + H]+, tR=1.753 (min). HPLC: 99.2% (214nm), 99.2% (254nm).
Scheme 51 cN NH2 \ conc)/H20 NNWZZES | —> —3> Cl N Cl 9000 m 73/ C, N/ [iiB-CN-Boo Cl Pd(dppf)Cl2 0520030 Pd(dppf)C|2 eszco3 DME/H20 90°C overnight O,DMEIH2090°C overnightB O—NHZ Pd/C/ H2/MeOH OLiOHfr—>HF/H2O ONHZQ rt. 4 days OH—>HATUDIEADMF BocN 5000 4 h BocN | NH2 TFA!DCM N/ HN NH M o HfN Example 61 2,6-dichloronicotinamide (2). The title compound was synthesized using a procedure analogous to the procedure described in 2,6-dichloronicotinamide (see Scheme 51) (9.5 g, 81%) as a brown solid. MS (ESI): m/z = 191.0 [M + Hr. methyl arbam0ylchloropyridin-Z-yl)benz0ate (4). To a solution of 2,6- dichloronicotinamide 2 (1.91 g, 10.0 mmol), 4-(methoxycarbonyl)phenylboronic acid 3 (1.8 g, .0 mmol) and Pd(dppf)Cl2 (816 mg, 1.0 mmol) in DME/H2O (20 mL/2mL) was added CS2C03 (6.5 g, 20.0 mmol). The resulting solution was degassed with N2 6 times and stirred ght at 90 0C under N2 tion. After the reaction was completed, the solution was concentrated, diluted with ethyl acetate (30 mL) and washed with water (2 X 20 mL) and brine (2 X 20 mL).
The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column diluted with 100:1 to 60:1 DCM/MeOH to afford the title compound (1 .95g, 67%) as a white solid. MS (ESI): m/z = 291.1 [M + H]+. tert-butyl(5-carbam0y]-6—(4-(methoxycarbonyl)phenyl)pyridinyl)-5,6- dihydropyridine— 1(2H)-carboxylate (6). To a solution of methyl 4-(3-carbamoyl chloropyridin—2-yl)benzoate 4 (170 mg, 0.59 mmol), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2— dioxaborolan—2-y1)-5,6-dihydropyridine-1(2H)- carboxylate 5 (200 mg, 0.65 mmol) and f)Cl2 (50 mg, 0.06 mmol) in DME/H2O (20 mL/2mL) was added Cs2C03 (390 mg, 1.2 mmol), the resulting solution was degassed with N2 6 times and stirred overnight at 90 0C under N2. After the reaction was completed, the on was concentrated, diluted with ethyl acetate (30 mL) and washed with water (2 X 20 mL) and brine (2 X 20 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and trated. The residue was purified by silica gel column diluted with 50:1 to 10:1 DCM/MeOH to afford the title compound (145 mg, 56%) as brown oil. MS (ESI): m/Z = 438.2 [M + Hr. utyl(5-carbam0yl—6—(4-(methoxycarbonyl)phenyl)pyridinyl)piperidine carboxylate (7). To a solution of tert-butyl 4-(5-carbamoy1(4- (methoxycarbonyl)phenyl)pyridinyl)-5,6- dihydropyridine-1(2H)—carboxylate 6 (145 mg, 0.33 mmol) in MeOH (10 mL) was added Pd/C (15 mg) and degassed with H2 6 times and stirred overnight at rt under H2. After the on was completed, the solution was filtered and the filtrate was concentrated to afford the title compound (100 mg, 69%) as brown oil. MS (ESI): m/Z = 440.2 [M + H]+. 4-(6-(1-(tert-but0xycarb0nyl)piperidinyl)—3-carbamoylpyridin-Z-yl)benzoic acid (8) To a solution of tert—butyl 4—(5-carbamoyl—6—(4-(methoxycarbonyl)phenyl)pyridin—2-yl)piperidine— 1- ylate 7 (460 mg, 1.05 mmol) in THF/HZO (20 mL/2 mL) was added LiOH (84 mg, 2.1 mmol), the resulting solution was stirred overnight at rt. After the reaction was complete, the solution was trated, added water (10 mL) and acidified with HCl (00110., 1 mL) to pH = 5- 6, diluted with ethyl acetate (30 mL) and washed with water (2 X 20 mL) and brine (2 X 20 mL).
The c layer was dried over anhydrous sodium sulfate, d and concentrated to afford the title nd (390 mg, 87%) as a yellow solid. MS (ESI): m/z = 426.2 [M + H]+. tert-butyl(5-carbamoyl(4-(phenylcarbamoyl)phenyl)pyridinyl)piperidine—1- carboxylate (9). To a solution of 4-(6-(1-(tert-butoxycarbonyl)piperidinyl)—3- carbamoylpyridin-Z-yl)benzoic acid 8 (390 mg, 0.917 mmol), aniline (102 mg, 1.101 mmol) and HATU (418 mg, 1.101 mmol) in dry DMF (10 mL) was added DIEA (355 mg, 2.751 mmol), the resulting solution was stirred overnight at rt. The mixture was diluted with ethyl acetate (30 mL), and washed with water (2 X 20 mL) and brine (2 X 20 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by Prep-TLC with :1 DCM/MeOH to get the title compound (120 mg, 27%) as a yellow solid. MS (ESI): m/z = 501.2 [M + Hr. 2-(4-(phenylcarbamoyl)phenyl)—6-(piperidinyl)nic0tinamide (10) To a solution of tert— butyl 4-(5 -carbamoyl(4-(phenylcarbamoyl)phenyl)pyridinyl)piperidinecarboxylate 9 (120 mg, 0.24 mmol) in dry DCM (10 mL) was added TFA (3 mL), the resulting solution was stirred overnight at rt. The mixture was washed with NaHC03/H20 (3 X 20 mL) and brine (3 X mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated.
The residue was concentrated to get the title compound (100 mg, 99%) as a yellow solid. MS (ESI): m/Z = 401.2 [M + Hr.
Example 61 6-(1-acryloylpiperidinyl)—2-(4-(phenylcarbamoyl)phenyl)nicotinamide 0 HNO To a solution of 2-(4-(phenylcarbamoyl)phenyl)(piperidinyl)nicotinamide 10 (100 mg, 0.24 mmol) in dry DCM (15 mL) was added DIEA (95 mg, 0.72 mmol) and acryloyl de (35 mg, 0.36 mmol) at 0 CC, and the resulting solution was stirred at 0 CC for 10 min. Water (10 mL) was added to quench the reaction. The e was diluted with DCM (20 mL), and washed with water (2 X 20 mL) and brine (2 X 20 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by Prep-HPLC (ACN—HzO = 30-90, 0.1%FA) to afford the title compound (31 mg, 29%) as a white solid. 1H NMR (300 MHz, CDC13) 8 8.59 (s, 1H), 8.04—7.58 (m, 3H), 7.75—7.54 (m, 4H), 7.37—7.27 (m, 2H), .08 (m, 2H), 6.65—6.49 (m, 1H), .10 (m, 3H), .63 (m, 1H), 4.79—4.63 (m, 1H), 4.17—3.99 (m, 1H), 3.27—2.96 (m, 2H), 2.83—2.66 (m, 1H), 2.07—1.88 (m, 2H), 1.83—1.60 (m, 2H). MS (ESI): m/z = 455.2 [M + H]+, tR= 1.316 min. HPLC: 95.3% (214nm), 93.0% (254nm).
Scheme 52 o o | NH2 0 Et3N \ NH2 + \\ /CI | ‘/\N N/ C|/\/3\\ / HN\/l 0 CHZCIZJt, 1 h 0" NJ 0 VS\\ 0 1 2 0 Example 62 Example 62 2-(4-phenoxypheny])—6-(4-(vinylsu]f0nyl)piperazinyl)nic0tinamide ' NH2 a O 0 \A’ o To a solution of 2-(4-phenoxyphenyl)(piperazinyl)nicotinamide 1 (200 mg, 0.53 mmol) in DCM (8 mL) was added TEA (161 mg, 1.59 mmol) and 2-chloroethanesulfonyl chloride (131 mg, 0.80 mmol) at rt. The mixture was stirred at rt for 1 h. The solution was poured into water (50 mL), and then extracted with CHzClz (2 X 50 mL). The combined organic layers were dried over anhydrous sodium sulfate, d and concentrated, and the residue was purified by Prep- TLC eluting with 100 : 1 OH to afford the title compound (17 mg, 6.9%) as a white solid. 1H NMR (300 MHz, CDC13)8 8.01 (d, J: 8.8 Hz, 1H), 7.59 (d, J: 8.6 Hz, 2H), 7.43— 7.30 (m, 2H), 7.15 (t, J: 7.4 Hz, 1H), 7.09—7.01(m, 4H), 6.64 (d, J: 8.8 Hz, 1H), 6.42 (dd, J: 16.6, 9.7 Hz, 1H), 6.26 (d, J= 16.5 Hz, 1H), 6.06 (d, J: 9.7 Hz, 1H), 5.46 (br, 1H), 5.28 (br, 1H), 3.87—3.75 (m, 4H), 3.32—3.18 (m, 4H). MS (ESI, method F): m/z = 465.1.0 [M + H]+, tR=1.546 min., HPLC: 99.5% (214nm), 98.3% (254nm).
Scheme 53 I NH2 \ W200 CIA/SO / | Q, Cl Et3N N / o \NCHZCIZ rt1 h O 1 Example 63 Example 63 2-(4-phen0xyphenyl)(1-(vinylsu]f0nyl)piperidinyl)nic0tinamide | NH2 V8" 0 To a solution of 2-(4-phenoxyphenyl)—6-(piperidin-4—yl)nicotinamide 1 (200 mg, 0.54 mmol) in DCM (8 mL) was added TEA (164 mg, 1.62 mmol) and 2-chloroethanesulfonyl chloride (131 mg, 0.80 mmol) at It. The mixture was stirred at rt for 1 h. The solution was poured into water (50 mL), and then extracted with ethyl acetate (2 X 50 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was purified by Prep-HPLC to afford the title nd (40 mg, 16%) as a white solid. 1H NMR (300 MHz, CDC13) 5 8.03 (d, J= 8.0 Hz, 1H), 7.71—7.61 (m, 2H), 7.43—7.31 (m, 2H), 7.17 (dd, J= 15.6, 7.8 Hz, 2H), 7.10—7.01(m, 4H), 6.46 (dd, J: 16.6, 9.8 Hz, 1H), 6.26 (d, J: 16.6 Hz, 1H), 6.04 (d, J = 9.9 Hz, 1H), 5.60 (b, 1H), 5.41 (b, 1H), 3.94—3.82(m, 2H), 2.97—2.86(m, 1H), 2.80—2.71(m, 2H), 2.11—1.92(m, 4H). MS (ESI, method F): m/Z = 464.0 [M + H]+, tR=1.566 min, HPLC: 99.3% (214nm), 100.0% (254nm).
The following examples can be synthesized ing to methods nced below and utilizing ordinary skill in the art. These examples are believed to be useful as inhibitors of BTK based on the biological activities of the nds described above.
Example 64 1-(1-acryloylpiperidinyl)—3-(4-(phenylcarbamoyl)phenyl)—1H-pyrazolecarb0xamide The title compound may be obtained using a procedure ous to the procedures described in the General Scheme and Example 15.
Example 65 1-(1-acryloylpiperidinyl)—3-(4-((4-(triflu0r0methyl)pyridinyl)carbamoyl)phenyl)—1H- pyrazolecarb0xamide The title compound may be obtained using a procedure analogous to the procedures described in the General Scheme and Example 15.
Example 66 6-(4-acrylamidophenyl)—2-(4-(phenylcarbamoyl)phenyl) nicotinamide The title compound may be ed using a procedure analogous to the procedures described in the General Scheme and Example 16. e 67 6-(4-acrylamid0phenyl)—2-(4-((4-(triflu0r0methyl)pyridinyl)carbamoyl)phenyl) nicotinamide The title compound may be obtained using a procedure analogous to the procedures described in the l Scheme and Example 16.
Example 68 1-(1-acryloylpiperidinyl)(4-(hydroxy(phenyl)methyl)phenyl)—1H-pyrazole—4- amide The title compound may be obtained using a procedure analogous to the procedures described in the General Scheme and Examples 15 and 58.
Example 69 1-(1-acryloylpiperidinyl)(4-(methyl(phenyl)amino)phenyl)—1H—pyrazole-4— carboxamide The title compound may be obtained using a procedure analogous to the procedures bed in the General Scheme and Example 15.
Example 70 6-(4-acrylamidophenyl)—2-(4-(1-hydr0xyphenylethyl)phenyl)nic0tinamide \. .' The title compound may be obtained using a procedure analogous to the procedures described in the General Scheme and Examples 16 and 58. e 71 6-(4-acrylamidophenyl)—2-(4-(difluor0(phenyl)methyl)phenyl)nicotinamide . 1‘ 1’? l The title compound may be obtained using a procedure analogous to the procedures described in the General Scheme and e 16.
Example 72 1-(1-acryloylpiperidinyl)(4-(phenylsulf0nyl)phenyl)—1H-pyrazolecarboxamide \\ // G o I The title compound may be ed using a procedure analogous to the procedures described in the General Scheme and Example 15.
Example 73 6-(4-acrylamidophenyl)—2-(4-(phenylsulfonyl)phenyl) nicotinamide The title compound may be obtained using a procedure analogous to the procedures described in the General Scheme and Example 16.
Scheme A-l o o HN’N PhO N/ EtOH COOEt C52C03, DMF ' COOEt 1 2 '-'OH H20 N»N NH3, HATU H2N ' / —> THF/MeOH/HZO / DIPEA DMF EN ’ N COOH (5 Analog 1 ethyl 5-(4-phen0xyphenyl)-1H-pyrazolecarb0xylate (2). The title compound was ed using a ure analogous to the procedure described in ethyl 3-(4-phenoxyphenyl)-lH- lecarboxylate (see Scheme 23) as yellow oil (0.3 g, 97%). MS (ESI): m/z = 308.8 [M + ethyl l-cyclopentyl—3-(4-phenoxyphenyl)-lH—pyrazolecarb0xylate (4). To a solution of ethyl 5—(4-phenoxyphenyl)-lH-pyrazolecarboxylate 2 (150 mg, 0.486 mmol) in DMF (10 mL) was added bromocyclopentane 3 (87 mg, 0.584 mmol) and C82C03 (475.5 mg, 1.46 mmol). The mixture was stirred at 100 °C for 3 h. After finished, the mixture was extracted with ethyl acetate (2 X 30 mL), and washed with water (2 X 10 mL) and brine (3 X 10 mL). The organic layer was dried over NaZSO4, d and concentrated to give the title compound (0.13 g, 71%) as yellow oil. MS (ESI): m/Z = 376.9 [M + H]+ 1-cyclopentyl(4-phenoxyphenyl)—1H-pyrazole-4—carboxylic acid (5). The title compound was obtained using a procedure analogous to the procedure described in 5-(1-(tert- butoxycarbonyl)piperidinyl)(4-phenoxyphenyl)—lH-pyrazole—3-carboxylic acid (see Scheme 46) as yellow oil (0.12 g, 100%). MS (ESI): m/z = 348.8 [M + H]+.
Analog 1 1-cyclopentyl(4-phen0xyphenyl)—1H-pyrazole—4—carboxamide The title nd was ed using a procedure analogous to the procedure described in tert- butyl 3-(5 -carbamoyl—4-(4-phenoxyphenyl)thiazo1-2—yl)pyrrolidine— l -carboxylate (see Scheme 31) as an offwhite solid (70 mg, 59%). 1H NMR (300 MHz, DMSO) 5 8.23 (s, 1H), 7.79 (d, J: 8.5 Hz, 2H), 7.41 (t, J: 7.0 Hz, 3H), 7.15 (t, J: 7.1 Hz, 1H), 7.05 (d, J: 7.6 Hz, 2H), 7.00 (s, 2H), 6.98 (d, J: 1.4 Hz, 1H), 4.78—4.62 (m, 1H), 2.19—1.55 (m, 8H). MS (ESI, method F): m/z = 347.9 [M + H]+, tR=1.589 (min). HPLC: 97.6% (214nm), 98.0% (254nm).
Scheme A—Z HO H N 0 5O 0 HZN S JL 1) (00002 Lawesson’s reagent QC : :Br 0 0E! —> —> 2) NH4OH toluene, reflux, 2h EtOH, reflux 1 2 3 CG OQ oJO o O NaOH, MeOH, H20 / NH3, HATU, DMF EtO —’ / N H0 / ’ HZN N 4 5 Analog 2 cyclopentanecarboxamide (2). To a e of cyclopentanecarboxylic acid 1 (2.85 g, 25 mmol) and DMF (3 drops) in DCM (60 mL) was added (COCl)2 (3.2 g, 25 mmol) dropwise carefully at 0 °C under N2. The resulting mixture was stirred at rt for 2h, then NH4OH (5 mL) was added se to this mixture at 0 0C. After the addition, the mixture was stirred at rt for another 1h, which was diluted with DCM (50 mL). It was washed with water (50 mL), brine, dried over sodium sulfate, ed and concentrated. This resulted in the title compound (1.8 g, 64%) as white solid. MS (ESI): m/Z = 114.8 [M + H]+. cyclopentanecarbothioamide (3). A mixture of cyclopentanecarboxamide 2 (1.8 g, 15.9 mmol) and lawesson’s reagent (3.2 g, 8.0 mmol) in toluene (40 mL) was stirred at 80 0C for 2h under N2 atmosphere. It was quenched with sat. NaHC03 (50 mL). which was extracted with EA (2 X 40 mL). The c layers were combined, washed with brine, dried over sodium sulfate, filtered and trated. The residue was applied onto silica gel column eluting with 3:1 PE/EA to get the title compound (0.25 g, 12%) as yellow solid. MS (ESI): m/z = 130.1 [M + H - 56]+. ethyl 2-cyclopentyl(4-phen0xyphenyl)thiazole—5-carboxylate (4). A mixture of cyclopentanecarbothioamide 3 (150 mg, 1.16 mmol) and ethyl 2-bromooxo(4— phenoxyphenyl)propanoate (422 mg, 1.16 mmol) in EtOH (15 mL) was refluxed for 2 h. The volatile phase was removed under reduced pressure. The residue was ved in EA (50 mL), which was washed with sat. NaHC03 (30 mL), brine, dried over sodium sulfate, filtered and concentrated. The residue was applied onto silica gel column eluting with 4:1 PE/EA to get the title compound (200 mg, 43%) as pale yellow oil. MS (ESI): m/z = 394.1 [M + H]+. 2-cyclopentyl(4-phenoxyphenyl)thiazole-S-carboxylic acid (5). The title compound was obtained using a procedure analogous to the procedure described in 5-(1-(tert- butoxycarbonyl)piperidinyl)-4'-phenoxybipheny1carboxy1ic acid (see Scheme 45) as pale yellow solid (190 mg, 99%). MS (ESI): m/Z = 366.1 [M + H.
Analog 2 2-cyclopentyl—4-(4-phenoxyphenyl)thiazole—5-carboxamide CW 0&3 The title compound was obtained using a procedure analogous to the procedure described in tert- butyl 4-(6-carbamoyl-4'-phenoxybiphenylyl)piperidinecarboxylate (see Scheme 45) as white solid (70 mg, 38%). 1H NMR (300 MHz, CDC13) 8 7.66—7.56 (m, 2H), 7.43—7.33 (m, 2H), 7.17 (t, J: 7.4 Hz, 1H), .00 (m, 4H), 5.73 (brs, 2H), 3.52—3.35 (m, 1H), 2.32—2.16 (m, 2H), 1.90—1.77 (m, 4H), 1.76—1.66 (m, 2H). MS (ESI, method A): m/z = 365.1 [M + H]+, tR=1.780 min. HPLC: 97% (214nm), 96% ).
Analflical conditions Unless otherwise noted, all ts, chemicals, and reagents were obtained commercially and used without purification. The lH-NMR spectra were obtained in CDClg, DMSO-d6, CD301), or acetone-d6 at 25°C at 300 MHz or 400 MHz on an OXFORD (Varian) with chemical shift (5, ppm) reported relative to TMS as an internal standard. HPLC-MS chromatograms and spectra were obtained with an Agilent 1200-6110 . Prep-HPLC instruments were Gilson GX—281 (Gilson) and P230 Preparative Gradient System ent: 95% water, 5% acetonitrile, 30-50 min gradient to 25% water, 75% acetonitrile). The microwave instrument was a CEM Discover Biological ties: IC50 ination OfBTK Inhibitors In ADP-Glo Kinase Biochemical Assay The activity of the Examples and Analogs described herein, as inhibitors of BTK are demonstrated and confirmed by pharmacological in vitro assays. Activity possessed by the compounds may be demonstrated in vivo. Those skilled in the art will appreciate that a variety of assay formats may be used to ine the activity of the compounds described herein.
Materials: ADP-GloTM Kinase Assay (cat. V9102, 10000 tests), components: 0 1><50ml oTM Reagent, o 1><100ml Kinase Detection Buffer, o 1><5ml Ultra Pure ATP, 10mM o 1><5ml ADP, 10mM Reagents and Plate: Tris.Hcl (Sigma cat. 154563), MgClz (Sigma cat.M1028), MnClz (Sigma, M3634), BSA (Sigma cat.05470), BTK Substrate (Signalchem, P61-58), DTT (Sigma, D0632), DMSO (Sigma, S5879), BTK . (1 .5mg/ml, purity 75%, 90ng/ul, made in house). 384 well assay plate (cat. 3674).
Assay conditions: 0 Enzyme concentration: l. 0 ATP concentration: 50uM o Substrate (peptide) concentration: 0.2mg/ml. 0 on buffer composition: 40mM Tris-HCl pH7.5, lOmM MgClg, 2mM MnClz, 0.1mg/mL BSA, 0.05mM DTT. 0 Test compound concentration: DMSOSO.5%.
Methods: Compound Dosage Gradient Solution Preparation: A 3-fold serial dilution of test compound was made for 10 gradient points (100, 33.33, 11.11, 3.70, 1.23, 0.41, 0.14, 0.046, 0.015, 0.005uM) in 100% DMSO. The intermediate dilution was done by adding 2ul of diluted compound into 78ul of assay buffer (containing 40mM Tris.Hcl, pH 7.5 10mM MgClz, 2mM MnCl 0.05mM DTT), making the final , 0.1mg/mL BSA, compound concentration (1000, 333.33, 111.11, 37.04, 12.35, 4.12, 1.37, 0.46, 0.15, 0.05nM) and DMSO concentration 0.5% percentage.
ADP-Glo Kinase Assay Protocol For BTK Inhibitors Testing: 1x and 2x assay buffer were made at first. BTK kinase was diluted with 1x assay buffer but substrate was diluted with 2x assay buffer. 1ul of diluted compound was transferred into 384- well assay plate, and then 2.0ul of enzyme solution was added, and spun at 2000rpm for 1min.
This mixture was incubated at 24°C for . 2ul of peptide ate/ATP mixture was added into the assay plate to start the on. The mixture was mixed thoroughly and then the 384- well plate was spun and ted at 24°C for 60mins. 5.0ul of ADP—Glo Reagent was added to stop the kinase activity and deplete the ATP unconsumed, and the plate was mixed thoroughly and incubated at 24°C for 40min. Then, 10.0ul of Kinase Detection reagent was added, and the plate was centrifuged and then kept at 24°C for 30min. The luminescence signal was read on Envision.
Data Analysis: % tion of compounds at each different concentration is calculated from Equation (1): % inhibition = 100-100*(Signal-low control)/(High control—low control). . .. Equation(1) IC50 values of compounds were calculated from a 4-parameter fit using Equation (2): Y=Bottom + (TOP-Bottom)/(1+((C/X)Ahillslope)) .............. Equation (2) In Equation 2, Y represents % inhibition, X is the log value of the test compound concentration. IC50 was the concentration of compound where half of maximal tion was achieved.
All data was analyzed with IDBS XLfit5 re (ID Business Solutions Ltd., UK). The IC50 data is ized in Table 1.
Table 1: IC50 BTK Activity Values For Examples 1-63 2, 4, 14, 27, 30, 33, 50, 53, 56 9, 24, 31 1, 3, 5, 6, 7, 8,10,11,12,13,15,16,17,18,19, 20, 21, 22, 23, 25, 26, 28, 29, 32, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 51, 52, 54, 55, 57, 58, 59, 60, 61, 62, 63 Table 2 provides a comparison of Examples 3 and 5 to Analogs 1 and 2 in terms of in Vitro BTK potency. Examples 3 and 5 demonstrate about a 100x improvement in potency over Analogs 1 and 2 when compared in head-to-head assays.
Table 2: Comparison of Examples 3 and 5 to Analogs 1 and 2 Example 3 Example 5 Analog 1 Analog 2 347.4 364.5 Examples 3 and 5 also demonstrate from 10x — 100x differences in potency between BTK and Src and are thus ive for BTK over Src.
Furthermore, selectivity of Examples 3 and 5 was determined. Table 3 provides in Vitro mical data demonstrating that Examples 3 and 5 are selective for BTK over Src.
Table 3: Selectivity Data for Examples 3 and 5 Target Example 3 Example 5 % Inhibition @ % Inhibition @ 1000 nM 1000 nM BT 99.35 99.7 SRC 23 33 Fold >100x >100x Difference To obtain the data provided in Table 3, -tagged T7 phage strains were grown in parallel in 24—well blocks in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and infected with T7 phage from a frozen stock (multiplicity of infection = 0.4) and incubated with shaking at 32°C until lysis (90-150 minutes). The lysates were fuged (6,000 x g) and filtered (0.2um) to remove cell debris. The remaining kinases were produced in HEK- 293 cells and subsequently tagged with DNA for qPCR detection. Streptavidin-coated magnetic beads were treated with biotinylated small molecule ligands for 30 minutes at room temperature to generate affinity resins for kinase . The liganded beads were blocked with excess biotin and washed with blocking buffer (SeaBlock (Pierce), 1 % BSA, 0.05 % Tween 20, 1 mM DTT) to remove unbound ligand and to reduce nonspecific phage binding. Binding reactions were assembled by combining kinases, liganded affinity beads, and test compounds in 1x g buffer (20 % SeaBlock, 0.17x PBS, 0.05 % Tween 20, 6 mM DTT).
Example compounds were prepared as 40x stocks in 100% DMSO and directly d into the assay. All ons were performed in polypropylene 384-well plates in a final volume of 0.04 ml. The assay plates were incubated at room temperature with shaking for 1 hour and the affinity beads were washed with wash buffer (1x PBS, 0.05 % Tween 20). The beads were then re-suspended in n buffer (lx PBS, 0.05 % Tween 20, 0.5 uM non-biotinylated affinity ligand) and incubated at room temperature with shaking for 30 minutes. The kinase concentration in the eluates was measured by qPCR.
The nd(s) were screened at 1000 nM, and results for y screen binding interactions are provided in Table 3 as "% Ctrl", where lower numbers indicate stronger hits. The % Ctrl is calculated according to Equation (1), below: Where: test compound = Example negative control = DMSO (100 % Ctrl) positive control = control compound ( 0% Ctrl) Additional ical selectivity data for Examples 3 and 5 against each member of the SRC family of protein kinases as well as EGFR are provided in Table 4, below. The data in Table 4 was obtained using the same proecedure as described above with respect to the data in Table 3.
Table 4: ivity Data for Examples 3 and 5 Example 3 Example 5 - %Inhibition @ 1000 nM % Inhibition @ 1000 nM --——_ -__— -__— Compositions: The present invention includes pharmaceutical compositions comprising a compound or pharmaceutically acceptable salt thereof of the invention, which is formulated for a desired mode of administration with or t one or more pharmaceutically acceptable and useful carriers.
The compounds can also be included in ceutical compositions in combination with one or more other therapeutically active compounds.
The pharmaceutical compositions of the invention comprise a compound of the invention (or a pharmaceutically acceptable salt thereof) as an active ingredient, optional pharmaceutically acceptable carrier(s) and optionally other therapeutic ingredients or nts. The compositions include itions suitable for oral, rectal, topical, and parenteral ding subcutaneous, intramuscular, and enous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being stered. The pharmaceutical itions can be conveniently ted in unit dosage form and prepared by any of the methods well known in the art of pharmacy.
Compounds of the invention can be combined as the active ingredient in te admixture with a pharmaceutical carrier ing to conventional pharmaceutical compounding techniques. The carrier can take a wide y of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous). Thus, the pharmaceutical compositions of the invention can be presented as discrete units suitable for oral administration such as capsules, s or tablets each containing a predetermined amount of the active ingredient. r, the compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous , as an oil-in-water emulsion, or as a water-in-oil liquid emulsion. In addition to the common dosage forms set out above, the compound represented by Formula I, or a ceutically acceptable salt thereof, can also be administered by controlled release means and/or delivery s. The compositions can be prepared by any of the methods of pharmacy. In general, such methods include a step of ng into association the active ingredient with the carrier that constitutes one or more ary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both. The product can then be conveniently shaped into the desired presentation.
The pharmaceutical carrier employed can be, for example, a solid, liquid, or gas.
Examples of solid rs include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. Examples of liquid carriers are sugar syrup, peanut oil, olive oil, and water. es of gaseous carriers include carbon dioxide and nitrogen.
A tablet containing the composition of this invention can be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants. ssed tablets can be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets can be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent. Each tablet preferably ns from about 0.05 mg to about 5 g of the active ingredient and each cachet or capsule preferably containing from about 0.05 mg to about 5 g of the active ingredient.
A formulation intended for the oral administration to humans may contain from about 0.5 mg to about 5 g of active agent, compounded with an riate and convenient amount of carrier material which may vary from about 5 to about 95 t of the total composition. Unit dosage forms will generally contain between from about 1 mg to about 2 g of the active ingredient, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, or 1000 mg.
Compounds of the invention can be provided for formulation at high purity, for example at least about 90%, 95%, or 98% pure by weight.
Pharmaceutical compositions of the invention suitable for parenteral administration may be prepared as solutions or suspensions of the active compounds in water. A suitable surfactant can be included such as, for example, hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid hylene glycols, and mixtures thereof in oils. r, a preservative can be included to prevent the detrimental growth of microorganisms.
Pharmaceutical itions of the invention suitable for injectable use include sterile aqueous solutions or dispersions. Furthermore, the compositions can be in the form of sterile powders for the extemporaneous ation of such sterile injectable solutions or dispersions. In all cases, the final injectable form must be sterile and must be effectively fluid for easy syringability. The pharmaceutical compositions must be stable under the conditions of cture and storage; thus, preferably should be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), ble oils, and suitable mixtures thereof. ceutical compositions of the invention can be in a form suitable for topical use such as, for example, an l, cream, ointment, lotion, dusting powder, or the like. Further, the itions can be in a form suitable for use in transdermal s. These formulations may be prepared, utilizing a compound represented by Formula I of this invention, or a pharmaceutically acceptable salt thereof, via conventional processing methods. As an example, a cream or ointment is prepared by admixing hydrophilic material and water, together with about 5 wt % to about 10 wt % of the compound, to produce a cream or ointment having a desired consistency. ceutical compositions of this invention can be in a form suitable for rectal administration wherein the carrier is a solid. It is preferable that the mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. The suppositories may be conveniently formed by first admixing the composition with the softened or melted carrier(s) followed by chilling and shaping in molds.
In addition to the aforementioned carrier ients, the pharmaceutical formulations described above may include, as appropriate, one or more additional carrier ingredients such as ts, s, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including anti-oxidants) and the like. Furthermore, other adjuvants can be included to render the formulation isotonic with the blood of the intended ent.
Compositions containing a compound described by Formula I, or pharmaceutically acceptable salts f, may also be ed in powder or liquid concentrate form.
Compounds of the present ion inhibit the activity of BTK in animals, including humans, and are useful in the ent and/or prevention ous es and conditions such as cancer, inflammation, fibrotic diseases, and autoimmune disease which are caused, mediated and/or propagated by BTK. In particular, nds of the invention, and compositions thereof, are inhibitors of BTK, and are useful in treating conditions ted, at least in part, by BTK.
In some aspects, the invention includes a method of treating cancer comprising administering to a mammal in need thereof a therapeutically effective amount of a compound or salt of the invention.
In some aspects, the invention includes a method of treating a cancer mediated at least in part by BTK comprising administering to a mammal in need thereof a therapeutically effective amount of a compound or salt of Formula I.
In some aspects, the invention includes a method of treating or a method of manufacturing a medicament for treating a cancer, such as those described herein, which is mediated at least in part by BTK, comprising administering to a mammal in need thereof a therapeutically effective amount of a nd or salt of the invention.
In some aspects, the invention includes a method of treating lymphocyte homing and inflammation mediated at least in part by BTK comprising administering to a mammal in need thereof a therapeutically effective amount of a compound or salt of Formula I.
In some aspects, the invention includes a method of treating or a method of manufacturing a ment for treating lymphocyte homing and inflammation, such as those described herein, which is ed at least in part by BTK, comprising administering to a mammal in need thereof a therapeutically ive amount of a nd or salt of the invention.
In some aspects, the invention includes a method of treating neuropathic pain comprising administering to a mammal in need f a therapeutically effective amount of a compound or salt of the invention.
In some aspects, the invention includes a method of treating neuropathic pain mediated at least in part by BTK comprising administering to a mammal in need thereof a therapeutically effective amount of a compound or salt of Formula I.
In some aspects, the invention includes a method of treating or a method of manufacturing a medicament for ng athic pain, such as those described herein, which is ed at least in part by BTK, comprising administering to a mammal in need thereof a therapeutically effective amount of a nd or salt of the invention.
In some aspects, the invention includes a method of treating f1brotic diseases comprising administering to a mammal in need thereof a eutically effective amount of a compound or salt of the invention.
In some aspects, the invention includes a method of treating fibrotic es mediated at least in part by BTK comprising stering to a mammal in need thereof a therapeutically effective amount of a compound or salt of Formula I.
In some aspects, the invention includes a method of treating or a method of manufacturing a medicament for treating a fibrotic disease, such as those described herein, which is mediated at least in part by BTK, comprising stering to a mammal in need thereof a therapeutically effective amount of a compound or salt of the invention.
In some aspects, the invention includes a method of treating thrombosis comprising administering to a mammal in need thereof a therapeutically effective amount of a compound or salt of the invention.
In some aspects, the invention includes a method of treating thrombosis mediated at least in part by BTK comprising administering to a mammal in need thereof a therapeutically effective amount of a compound or salt of Formula I.
In some aspects, the invention includes a method of treating or a method of manufacturing a ment for treating thrombosis, such as those described herein, which is ed at least in part by BTK, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound or salt of the invention.
In some aspects, the ion includes a method of treating cholestatic pruritus comprising administering to a mammal in need thereof a therapeutically effective amount of a compound or salt of the invention.
In some aspects, the invention includes a method of treating cholestatic pruritus mediated at least in part by BTK comprising administering to a mammal in need f a therapeutically effective amount of a compound or salt of Formula I.
In some aspects, the invention es a method of treating or a method of manufacturing a medicament for cholestatic pruritus, such as those described herein, which is mediated at least in part by BTK, comprising stering to a mammal in need thereof a therapeutically effective amount of a compound or salt of the invention.
The compounds of Formula I of the invention are usefial in the treatment of a variety of cancers, including, but not limited to, solid tumors, sarcoma, fibrosarcoma, osteoma, melanoma, blastoma, myosarcoma, glioblastoma, neuroblastoma, teratocarcinoma, hematopoietic malignancy, and ant s. More specifically, the cancers include, but not limited to, lung cancer, bladder cancer, pancreatic cancer, kidney cancer, gastric cancer, breast cancer, colon cancer, prostate cancer (including bone metastases), hepatocellular carcinoma, ovarian cancer, esophageal squamous cell carcinoma, melanoma, an anaplastic large cell ma, an inflammatory myofibroblastic tumor, and a glioblastoma.
In some aspects, the above methods are used to treat one or more of bladder, colorectal, non-small cell lung, breast, or pancreatic cancer. In some aspects, the above methods are used to treat one or more of ovarian, gastric, head and neck, prostate, hepatocellular, renal, glioma, or a cancer.
In some aspects, the invention includes a , including the above methods, wherein the nd is used to inhibit cellular epithelial to mesenchymal transition (EMT).
In some aspects, the method further comprises administering at least on additional active agent. In some aspects, the invention includes a method of treating cancer comprising administering to a mammal in need thereof a therapeutically effective amount of a compound or salt of the invention, wherein at least one additional active anti-cancer agent is used as part of the method.
In some aspects, the invention includes a method of ng the disease described herein ed at least in part by BTK comprising administering to a mammal in need thereof a therapeutically effective regimen comprising a compound or salt of Formula I and at least one additional active agent. lly, dosage levels on the order of from about 0.01 mg/kg to about 150 mg/kg of body weight per day are useful in the treatment of the above-indicated conditions, or alternatively about 0.5 mg to about 7 g per patient per day. For example, inflammation, , psoriasis, allergy/asthma, e and conditions of the immune system, disease and conditions of the l Nervous System (CNS), may be effectively treated by the administration of from about 0.01 to 50 mg of the compound per kilogram of body weight per day, or alternatively about 0.5 mg to about 3.5 g per patient per day.
It is understood, however, that the specific dose level for any particular patient will depend upon a y of factors including the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.
General Definitions and Abbreviations: Except where otherwise indicated, the following general conventions and definitions apply. Unless ise indicated herein, ge and terms are to be given their broadest reasonable interpretation as understood by the skilled artisan. Any examples given are nonlimiting.
Any section headings or subheadings herein are for the reader's convenience and/or formal compliance and are miting.
A recitation of a compound herein is open to and embraces any material or composition containing the recited compound (e.g., a composition containing a racemic mixture, tautomers, epimers, isomers, impure mixtures, etc.). In that a salt, solvate, or hydrate, polymorph, or other complex of a compound es the compound itself, a recitation of a compound embraces materials containing such forms. Isotopically labeled compounds are also encompassed except where specifically excluded. For example, hydrogen is not limited to hydrogen containing zero neutrons. For example, deuterium is ed to herein as "D" and means a hydrogen atom having one n.
The term "active agent" means a compound of the invention in any salt, polymorph, crystal, solvate, or hydrated form.
The term "substituted" and substitutions contained in formulas herein refer to the replacement of one or more hydrogen radicals in a given ure with a specified radical, or, if not specified, to the replacement with any chemically feasible radical. When more than one position in a given structure can be substituted with more than one substituent selected from specified groups, the tuents can be either the same or different at every position (independently selected) unless otherwise indicated. In some cases, two positions in a given structure can be substituted with one shared substituent. It is tood that chemically impossible or highly unstable configurations are not desired or intended, as the skilled artisan would appreciate.
In descriptions and claims where subject matter (e.g., substitution at a given molecular position) is recited as being selected from a group of possibilities, the recitation is specifically intended to include any subset of the recited group. In the case of multiple variable positions or substituents, any combination of group or variable subsets is also contemplated.
Unless ted ise, a substituent, diradical or other group ed to herein can be bonded through any suitable position to a referenced subject molecule. For e, the term "indolyl" includes l-indolyl, 2-indolyl, 3-indolyl, etc.
The convention for describing the carbon content of certain moieties is "(Ca-b)" or "Ca- Cb" meaning that the moiety can contain any number of from "a" to "b" carbon atoms. Coalkyl means a single covalent chemical bond when it is a connecting moiety, and a hydrogen when it is a al moiety. Similarly, "x-y" can indicate a moiety containing from x to y atoms, e.g.,5_ 6heterocycloalkyl means a heterocycloalkyl having either five or six ring members. "CH" may be used to define number of carbons in a group. For example, "C0_1galkyl" means alkyl having 0- 12 carbons, wherein Coalkyl means a single nt chemical bond when a linking group and means hydrogen when a terminal group. C0_12alkyl includes s alternative embodiments, ing, but not 111111th to, C1_12alkyl, C2_12alkyl, C3_12alkyl, C4_12alkyl, C5_12alkyl, C6_12alkyl, C7_12alkyl, Cg_12alkyl, C9_12alkyl, C10_12alkyl, C11_12alkyl, C1_11alkyl, C1_10alkyl, C1_9alkyl, C1_ , C1_7alkyl, C1_6alkyl, kyl, C1_4alkyl, C1_3alkyl, C1_2alkyl, Clalkyl, and Coalkyl. C0_ lzalkyl further includes any combination of "a" and "b" and/or "x" and "y" number of carbon atoms including, but not d to, C2_12alkyl, C3_11alkyl, C4_10alkyl, C5_9alkyl, C6_galkyl and C7alky1.
The term "absent," as used herein to be a structural variable (e.g., "—R— is absent") means that diradical R has no atoms, and merely represents a bond between other adjoining atoms, unless ise indicated.
Unless ise indicated (such as by a connecting "-"), the connections of compound name moieties are at the rightmost recited . That is, the substituent name starts with a terminal moiety, continues with any bridging moieties, and ends with the ting moiety. For example, "heteroarylthioC1-4alkyl" is a heteroaryl group connected through a thio sulfur to a C1- 4alkyl, which alkyl connects to the chemical species bearing the substituent.
The term "aliphatic" means any hydrocarbon moiety, and can n linear, branched, and cyclic parts, and can be saturated or unsaturated.
The term " means any saturated hydrocarbon group that is straight-chain or branched. es of alkyl groups include methyl, ethyl, propyl, 2—propyl, n-butyl, iso-butyl, tert-butyl, pentyl, and the like.
The term "alkenyl" means any ethylenically unsaturated straight-chain or branched hydrocarbon group. Representative examples include, but are not limited to, ethenyl, l-propenyl, 2-propenyl, l—, 2-, or 3—butenyl, and the like.
The term "alkynyl" means any acetylenically unsaturated straight-chain or branched hydrocarbon group. Representative examples include, but are not limited to, ethynyl, l-propynyl, 2-propynyl, l—, 2-, or 3-butynyl, and the like.
The term "alkoxy" means —O-alkyl, —O-alkenyl, or ynyl. "Haloalkoxy" means an —O-(haloalkyl) group. Representative examples include, but are not limited to, trifluoromethoxy, momethoxy, and the like.
"Haloalkyl" means an alkyl, preferably lower alkyl, that is substituted with one or more same or different halo atoms.
"Hydroxyalkyl" means an alkyl, preferably lower alkyl, that is substituted with one, two, or three hydroxy groups; e.g., hydroxymethyl, l or 2-hydroxyethyl, 1,2-, 1,3-, or 2,3- dihydroxypropyl, and the like.
The term "alkanoyl" means alkyl, —C(O)-alkenyl, or —C(O)—alkynyl.
"Alkylthio" means an —S-(alkyl) or an —S-(unsubstituted cycloalkyl) group.
Representative examples include, but are not limited to, methylthio, ethylthio, propylthio, butylthio, cyclopropylthio, cyclobutylthio, cyclopentylthio, cyclohexylthio, and the like.
The term "cyclic" means any ring system with or t heteroatoms (N, O, or S(O)0_2), and which can be saturated, partially saturated, or unsaturated. Ring systems can be bridged and can include fused rings. The size of ring s may be described using terminology such as "X- ycyclic," which means a cyclic ring system that can have from x to y ring atoms. For example, the term "9.1ocarbocyclic" means a 5,6 or 6,6 fused bicyclic carbocyclic ring system which can be saturated, unsaturated or aromatic. It also means a phenyl fused to one 5 or 6 membered saturated or unsaturated carbocyclic group. Nonlimiting examples of such groups include yl, l,2,3,4 tetrahydronaphthyl, indenyl, indanyl, and the like.
The term "carbocyclic" means a cyclic ring moiety containing only carbon atoms in the ring(s) without regard to aromaticity. A 3-10 membered carbocyclic means chemically feasible monocyclic and filSGd bicyclic carbocyclics having from 3 to 10 ring atoms. Similarly, a 4-6 membered carbocyclic means monocyclic yclic ring es having 4 to 6 ring s, and a 9-10 membered carbocyclic means fused bicyclic carbocyclic ring moieties having 9 to 10 ring carbons.
The term "cycloalkyl" means a non-aromatic 3-12 carbon yclic, ic, or polycyclic aliphatic ring moiety. Cycloalkyl can be bicycloalkyl, polycycloalkyl, bridged, or spiroalkyl. One or more of the rings may contain one or more double bonds but none of the rings has a completely ated pi-electron system. Examples, without limitation, of cycloalkyl groups are cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, exadiene, adamantane, cycloheptane, eptatriene, and the like.
The term "unsaturated carbocyclic" means any cycloalkyl containing at least one double or triple bond. The term "cycloalkenyl" means a cycloalkyl having at least one double bond in the ring moiety.
The terms "bicycloalkyl" and "polycycloalkyl" mean a structure consisting of two or more cycloalkyl moieties that have two or more atoms in common. If the cycloalkyl moieties have exactly two atoms in common they are said to be "fused". Examples include, but are not limited to, bicyclo[3.l .0]hexyl, perhydronaphthyl, and the like. If the cycloalkyl es have more than two atoms in common they are said to be ed". es include, but are not limited to, bicyclo[2.2. l]heptyl ("norbornyl"), bicyclo[2.2.2]octyl, and the like.
The term "spiroalkyl" means a ure consisting of two cycloalkyl moieties that have exactly one atom in common. Examples include, but are not limited to, spiro[4.5]decyl, spiro[2.3]hexyl, and the like.
The term "aromatic" means a planar ring es containing 4n+2 pi electrons, wherein n is an integer.
The term "aryl" means aromatic es containing only carbon atoms in its ring system.
Non-limiting examples include phenyl, naphthyl, and anthracenyl. The terms "aryl-alkyl" or "arylalkyl" or "aralkyl" refer to any alkyl that forms a bridging portion with a terminal aryl.
"Aralkyl" means alkyl that is tuted with an aryl group as defined above; e. g., — CH2 phenyl, —(CH2)2phenyl, —(CH2)3 phenyl, CH3CH(CH3)CH2phenyl, and the like and derivatives thereof.
The term "heterocyclic" means a cyclic ring moiety containing at least one heteroatom (N, O, or S(O)0_2), ing heteroaryl, heterocycloalkyl, including unsaturated heterocyclic rings.
The term "heterocycloalkyl" means a non-aromatic clic, bicyclic, or polycyclic heterocyclic ring moiety of 3 to 12 ring atoms ning at least one ring having one or more heteroatoms. The rings may also have one or more double bonds. However, the rings do not have a completely conjugated pi-electron system. Examples, without limitation, of heterocycloalkyl rings include azetidine, oxetane, tetrahydrofiiran, tetrahydropyran, oxepane, oxocane, thietane, thiazolidine, oxazolidine, oxazetidine, pyrazolidine, olidine, isothiazolidine, tetrahydrothiophene, tetrahydrothiopyran, thiepane, thiocane, azetidine, pyrrolidine, dine, N—methylpiperidine, azepane, azapane, azocane, ioxane, oxazolidine, piperazine, homopiperazine, morpholine, thiomorpholine, l,2,3,6-tetrahydropyridine and the like. Other examples of heterocycloalkyl rings include the oxidized forms of the sulfur—containing rings.
Thus, tetrahydrothiophene- l -oxide, tetrahydrothiophene-l , l-dioxide, thiomorpholine- l -oxide, thiomorpholine- l , 1 -dioxide, tetrahydrothiopyranoxide, ydrothiopyran-l , 1 -dioxide, thiazolidine-l-oxide, and lidine- l , l -dioxide are also considered to be heterocycloalkyl rings. The term "heterocycloalkyl" also es fused ring systems and can include a carbocyclic ring that is partially or fully unsaturated, such as a benzene ring, to form used heterocycloalkyl rings. For e, 3,4-dihydro-1,4-benzodioxine, tetrahydroquinoline, tetrahydroisoquinoline and the like. The term "heterocycloalkyl" also includes heterobicycloalkyl, polycycloalkyl, or heterospiroalkyl, which are bicycloalkyl, polycycloalkyl, or spiroalkyl, in which one or more carbon atom(s) are replaced by one or more heteroatoms selected from O, N, and S. For example, spiro[3.3]heptane, 2,7-diaza- spiro[4.5]decane, 6-oxa-2—thia—spiro[3.4]octane, octahydropyrrolo[l,2-a]pyrazine, 7—azabicyclo [2.2. l]heptane, 2-oxa-bicyclo[2.2.2]octane, and the like, are such heterocycloalkyls.
Examples of saturated heterocyclic groups e, but are not limited to oxiranyl, thiaranyl, aziridinyl, oxetanyl, thiatanyl, azetidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, 1,4-dioxanyl, 1,4-oxathianyl, linyl, l,4-dithianyl, piperazinyl, 1,4-azathianyl, oxepanyl, thiepanyl, azepanyl, 1,4- dioxepanyl, 1,4-oxathiepanyl, 1,4-oxaazepanyl, 1,4—dithiepanyl, 1,4-thieazepanyl, 1,4-diazepanyl Non-aryl heterocyclic groups include saturated and unsaturated systems and can include groups having only 4 atoms in their ring system. The heterocyclic groups include benzo-fused ring systems and ring systems substituted with one or more oxo moieties. Recitation of ring sulfur is tood to include the , sulfoxide or sulfone where feasible. The heterocyclic groups also include partially rated or fully saturated 4—10 membered ring systems, e.g., single rings of 4 to 8 atoms in size and bicyclic ring systems, including aromatic 6-membered aryl or heteroaryl rings fused to a non-aromatic ring. Also included are 4-6 membered ring systems ("4-6 membered heterocyclic"), which e 5-6 membered heteroaryls, and include groups such as inyl and piperidinyl. Heterocyclics can be heteroatom—attached where such is possible. For instance, a group derived from pyrrole can be pyrrol—l-yl (N-attached) or pyrrol- 3-yl (C-attached). Other heterocyclics include imidazo(4,5—b)pyridinyl and benzoimidazol-l- Examples of heterocyclic groups include pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, nyl, piperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, l,2,3,6-tetrahydropyridinyl, 2- pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, oxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, lidinyl, imidazolinyl, imidazolidinyl, 3-azabicyclo[3.1.0]hexanyl, 3- yclo[4.1.0]heptanyl, 3H—indolyl, izinyl, and the like.
The term "unsaturated heterocyclic" means a heterocycloalkyl containing at least one unsaturated bond. The term "heterobicycloalkyl" means a bicycloalkyl structure in which at least one carbon atom is replaced with a heteroatom. The term "heterospiroalkyl" means a spiroalkyl structure in which at least one carbon atom is replaced with a heteroatom. es of partially unsaturated heteroalicyclic groups include, but are not limited to: 3,4-dihydro-2H-pyranyl, 5,6-dihydro-2H-pyranyl, ZH-pyranyl, l,2,3,4-tetrahydropyridinyl, and l ,2,5 rahydropyridinyl.
The terms "heteroaryl" or "hetaryl" mean a clic, ic, or polycyclic aromatic heterocyclic ring moiety containing 5-12 atoms. Examples of such heteroaryl rings e, but are not limited to, fiiryl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl. The terms "heteroaryl" also include heteroaryl rings with fused carbocyclic ring systems that are lly or fiJlly unsaturated, such as a e ring, to form a benzofused heteroaryl. For example, benzimidazole, benzoxazole, benzothiazole, benzofuran, quinoline, isoquinoline, quinoxaline, indazole, imidazo[l,2-a]pyridine, 3-methyloxo-2,3- dihydrobenzo[d]oxazol—5-yl, 2—methyl—2H-indazol-5—yl, 3-methylimidazo[l,5—a]pyridine, 2— methyl- 1 o [d]imidazole, lH-pyrrolo [2,3 -b]pyridine, 3,4-Dihydro-2H- benzo[b][1,4]oxazine, 2-oxo-2,3-dihydrobenzo[d]oxazole, 3-oxo-3,4-dihydro-2H- benzo[b] [l ,4]oxazine, 2,3-Dihydrobenzo [b] [l ,4]dioxine, 2-methyl-[l riazolo[ l ,5-a]pyridine, and the like. Furthermore, the terms "heteroaryl" include filSCd 5-6, 5-5, 6-6 ring systems, ally possessing one nitrogen atom at a ring junction. Examples of such hetaryl rings include, but are not limited to, pyrrolopyrimidinyl, imidazo[l,2-a]pyridinyl, imidazo[2,l- b]thiazolyl, imidazo[4,5-b]pyridine, pyrrolo[2,l-f][l,2,4]triazinyl, and the like. Heteroaryl groups may be attached to other groups through their carbon atoms or the heteroatom(s), if applicable. For example, pyrrole may be connected at the nitrogen atom or at any of the carbon atoms.
Heteroaryls include, e.g., 5 and 6 membered monocyclics such as pyrazinyl and pyridinyl, and 9 and 10 membered fused bicyclic ring moieties, such as quinolinyl. Other examples of heteroaryl e quinolinyl, oxy-quinolin-4—yl, pyridinyl, pyridin—3- yl, and pyridinyl. Other examples of heteroaryl include pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furanyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, fiarazanyl, benzofiarazanyl, hiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, furopyridinyl, and the like. Examples of 5-6 membered heteroaryls e, thiophenyl, olyl, triazolyl, oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-triazolyl, 1,3,4-oxadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-oxadiazolyl, 1,2,5- thiadiazolyl, pyridyl, zinyl, pyrimidinyl, pyrazinyl, 1,2,4 oxadiazolyl, 1,2,5-triazinyl, 1,3,5-triazinyl, 6-oxo-l,6-dihydropyridine, and the like.
"Heteroaralkyl" group means alkyl, preferably lower alkyl, that is substituted with a aryl group; e.g., —CH2 pyridinyl, —(CH2)2pyrimidinyl, —(CH2)3imidazolyl, and the like, and derivatives thereof.
A pharmaceutically acceptable heteroaryl is one that is sufficiently stable to be attached to a compound of the invention, formulated into a pharmaceutical ition and subsequently administered to a patient in need thereof Examples of monocyclic heteroaryl groups include, but are not limited to: pyrrolyl, l, enyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isothiazolyl, thiazolyl, 1,2,3— triazolyl, 1,3,4-triazolyl, l-oxa-2,3-diazolyl, 2,4-diazolyl, l-oxa-2,5-diazolyl, l-oxa-3,4- diazolyl, l-thia-2,3-diazolyl, 1-thia-2,4-diazolyl, 1-thia-2,5-diazolyl, l-thia-3,4-diazolyl tetrazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl.
Examples of fused ring heteroaryl groups include, but are not limited to: benzoduranyl, hiophenyl, indolyl, idazolyl, indazolyl, benzotriazolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3-c]pyridinyl, pyrrolo[3,2-c]pyridinyl, pyrrolo[3,2-b]pyridinyl, imidazo[4,5- b]pyridinyl, imidazo[4,5-c]pyridinyl, pyrazolo[4,3-d]pyridinyl, pyrazolo[4,3—c]pyridinyl, pyrazolo[3,4-c]pyridinyl, pyrazolo[3,4-b]pyridinyl, isoindolyl, indazolyl, purinyl, indolinyl, imidazo[l,2-a]pyridinyl, imidazo[l,5—a]pyridinyl, pyrazolo[l ,5-a]pyridinyl, pyrrolo[l ,2- b]pyridazinyl, o[l,2-c]pyrimidinyl, quinolinyl, isoquinolinyl, cinnolinyl, azaquinazoline, quinoxalinyl, phthalazinyl, 1,6—naphthyridinyl, phthyridinyl, 1,8-naphthyridinyl, 1,5- naphthyridinyl, 2,6-naphthyridinyl, 2,7-naphthyridinyl, pyrido[3,2-d]pyrimidinyl, pyrido[4,3- d]pyrimidinyl, [3,4-d]pyrimidinyl, pyrido[2,3—d]pyrimidinyl, pyrido[2,3—b]pyrazinyl, pyrido[3,4-b]pyrazinyl, pyrimido[5,4-d]pyrimidinyl, pyrimido[2,3-b]pyrazinyl, pyrimido[4,5- d]pyrirnidinyl.
"Arylthio" means an —S-ary1 or an —S-heteroaryl group, as defined herein.
Representative examples include, but are not limited to, phenylthio, pyridinylthio, furanylthio, thienylthio, pyrimidinylthio, and the like and derivatives thereof.
The term "9-10 membered heterocyclic" means a fused 5,6 or 6,6 bicyclic heterocyclic ring moiety, which can be saturadated, unsaturated or aromatic. The term "9—10 membered fused bicyclic heterocyclic" also means a phenyl fused to one 5 or 6 membered cyclic group. es include benzofuranyl, benzothiophenyl, indolyl, benzoxazolyl, 3H—imidazo[4,5- c]pyridin-yl, dihydrophthazinyl, dazo[4,5-c]pyridinyl, imidazo[4,5-b]pyridyl, 1,3 benzo[1,3]dioxolyl, 2H-chromanyl, isochromanyl, 5-oxo-2,3 dihydro-SH—[l,3]thiazolo[3,2- a]pyrimidyl, 1,3-benzothiazolyl, 1,4,5,6 tetrahydropyridazyl, 1,2,3,4,7,8hexahydropteridinyl, 2- thioxo-2,3,6,9-tetrahydro-1H—purinyl, hydro-1H—purinyl, 3,4-dihydropyrimidin-l-yl, 2,3-dihydro-1,4-benzodioxinyl, 1,3]dioxolyl, omenyl, chromanyl, 3,4— dihydrophthalazinyl, 2,3-ihydro-1H—indolyl, 1,3-dihydro-2H-isoindolyl, 2,4,7-trioxo- 1 ,2,3 ,4,7,8-hexahydropteridin—yl, thieno[3 ,2-d]pyrimidinyl, 4—oxo-4,7-dihydro-3H-pyrrolo[2,3- d]pyrimidin-yl, 1,3-dimethyloxothioxo-2,3,6,9-tetrahydro-1H-purinyl, 1,2- dihydroisoquinolinyl, 2—oxo- 1 ,3-benzoxazolyl, hydro-5H-1,3-thiazolo—[3,2-a]pyrimidinyl, ,6,7,8-tetrahydro-quinazolinyl, 4-oxochromanyl, 1,3-benzothiazolyl, idazolyl, benzotriazolyl, purinyl, fiarylpyridyl, enylpyrimidyl, thiophenylpyridyl, pyrrolylpiridyl, oxazolylpyridyl, thiazolylpiridyl, 3,4—dihydropyrimidinyl imidazolylpyridyl, quinoliyl, isoquinolinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, pyrazolyl[3,4]pyridine, 1,2- dihydroisoquinolinyl, cinnolinyl, 2,3—dihydro-benzo[1,4]dioxin4-yl, 4,5,6,7—tetrahydro-benzo[b]— thiophenyl-Z-yl, 1,8-naphthyridinyl, 1,5-napthyridinyl, 1,6-naphthyridinyl, 1,7-napthyridinyl, 3 ,4-dihydro-2H- 1 ,4-benzothiazine, 4,8-dihydroxy-quinolinyl, 1-oxo— 1 ,2-dihydro-isoquinolinyl, 4-phenyl-[1,2,3]thiadiazolyl, and the like.
The term "aryloxy" means an —O-aryl or an —O-heteroaryl group, as defined herein.
Representative es include, but are not limited to, y, nyloxy, furanyloxy, thienyloxy, pyrimidinyloxy, pyrazinyloxy, and the like, and derivatives thereof.
The term "oxo" means a compound containing a carbonyl group. One in the art understands that an "oxo" requires a second bond from the atom to which the oxo is attached.
The term "halo" or "halogen" means fluoro, chloro, bromo, or iodo.
"Acyl" means a —C(O)R group, where R can be selected from the nonlimiting group of hydrogen or optionally substituted lower alkyl, trihalomethyl, unsubstituted cycloalkyl, aryl, or other suitable substituent.
"Thioacyl" or "thiocarbonyl" means a—C(S)R" group, with R as defined above.
The term "protecting group" means a suitable chemical group that can be attached to a functional group and removed at a later stage to reveal the intact functional group. Examples of suitable protecting groups for various onal groups are described in T. W. Greene and P. G.
M. Wuts, tive Groups in Organic Synthesis, 2d Ed, John Wiley and Sons (1991 and later editions); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed. Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995). The term "hydroxy protecting group", as used herein, unless ise indicated, includes Ac, CBZ, and various hydroxy ting groups familiar to those d in the art including the groups referred to in Greene.
The term "linear ure" means a moiety having substituents that do not cyclize to form a ring system. A representative example includes, but is not limited to, a compound including —NRXRY where any atoms of " X" and any atoms of "RY" do not connect to form a ring.
As used herein, the term "pharmaceutically acceptable salt" means those salts which retain the biological effectiveness and properties of the parent compound and do not present safety or toxicity issues. The term aceutically acceptable salt(s)" is known in the art and includes salts of acidic or basic groups which can be present in the compounds and ed or resulting from pharmaceutically acceptable bases or acids.
The term "pharmaceutical composition" means an active compound in any form suitable for effective administration to a subject, e.g., a mixture of the compound and at least one pharmaceutically acceptable carrier.
As used herein, a "physiologically/pharmaceutically acceptable carrier" means a carrier or diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound.
A "pharmaceutically acceptable excipient" means an inert substance added to a pharmaceutical composition to further facilitate administration of a compound. Examples, without limitation, of excipients include calcium ate, calcium ate, various sugars and types of starch, cellulose derivatives, n, vegetable oils and polyethylene s.
The terms "treat,3, CEtreatment," and "treating" means reversing, alleviating, inhibiting the progress of, or partially or completely preventing the disorder or condition to which such term applies, or one or more symptoms of such er or condition. "Preventing" means treating before an infection occurs.
"Therapeutically effective " means that amount of the compound being administered which will relieve to some extent one or more of the ms of the disorder being treated, or result in inhibition of the progress or at least partial reversal of the ion.
NMR Nuclear magnetic resonance MDP(S) Mass-directed HPLC purification (system) LC/MS Liquid tography mass spectrometry LDA Lithium diisopropylamide tert-BuOH tert-Butanol AcOH Acetic acid CDI 1,1 ’-Carbonyldiimidazole DCE 1,1-Dichloroethane DCM Dichloromethane DMF Dimethylformamide THF Tetrahydrofuran MeOH Methanol EtOH Ethanol EtOAc Ethyl acetate MeCN Acetonitrile DMSO Dimethylsulfoxide Boc utyloxycarbonyl DME 1,2-Dimethoxyethane DMF N,N—Dimethylformamide DIPEA/DIEA ropylethylamine PS—DIEA Polymer—supported diisopropylethylamine PS—PPhg-Pd Polymer-supported Pd(PPh3)4 LAH Lithium aluminum hydride EDC 1-(3-Dimethylaminopropyl)ethylcarbodiimide HATU: l- [bis(dimethylamino)methylene] - l H— l ,2,3—triazolo[4,5 -b]pyridinium—3 -oxide hexafluorophosphate HOBt l-Hydroxybenzotnazole DMAP 4-Dimethylaminopyridine SEM-Cl 2-(Trimethylsilyl)ethoxymethyl chloride TBTU O-(Benzotriazolyl)-N,N,N',N’-tetramethyluronium tetrafluoroborate TEMPO 2,2,6,6-Tetramethylpiperidine- l -oxyl TFA (A) Trifluoroacetic acid (anhydride) TLC Thin layer chromatography TMSCN Trimethylsilyl cyanide Min Minute(s) NMO N—Methylmorpholine N—oxide h Hour(s) d Day(s) RT, R.T., r.t., r.t or rt Room temperature tR Retention time Conc. Concentrated
Claims (10)
1. A compound selected from the group ting of: 6-(3-acrylamidophenyl)(4-phenoxyphenyl)nicotinamide; 6-(1-acryloylpiperidinyl)(4-phenoxyphenyl)nicotinamide; 6-(4-acryloylpiperazinyl)(4-phenoxyphenyl)nicotinamide; N N 6-(1-acryloylpyrrolidinyl)(4-phenoxyphenyl)nicotinamide; N N 6-(4-acrylamidophenyl)(4-phenoxyphenyl)nicotinamide; O N N O 6-(1-acryloylpiperidinyl)(4-phenoxyphenyl)nicotinamide; O NH2 N N 6-(4-acrylamidopiperidinyl)(4-phenoxyphenyl)nicotinamide; O N N N O crylamidopyrrolidinyl)(4-phenoxyphenyl)nicotinamide; HN N N 1-(1-acryloylpyrrolidinyl)(4-phenoxyphenyl)-1H-pyrazolecarboxamide; O N N O 1-(1-acryloylazetidinyl)(4-phenoxyphenyl)-1H-pyrazolecarboxamide; N O crylamidophenyl)(4-phenoxyphenyl)-1H-pyrazolecarboxamide; N O 1-(3-acrylamidophenyl)(4-phenoxyphenyl)-1H-pyrazolecarboxamide; N N N O (S)(1-acryloylpyrrolidinyl)(4-phenoxyphenyl)-1H-pyrazolecarboxamide; O N N N O (R)(1-acryloylpyrrolidinyl)(4-phenoxyphenyl)-1H-pyrazolecarboxamide; O N O N N 2-(1-acryloylpyrrolidinyl)(4-phenoxyphenyl)pyrimidinecarboxamide; N NH2 N N (E)(4-(4-(dimethylamino)butenoyl)piperazinyl)(4- phenoxyphenyl)nicotinamide; N N N O cryloylpiperazinyl)(4-(cyclohexyloxy)phenyl)nicotinamide; N N 6-(4-acryloylpiperazinyl)(3-methoxymethylphenyl)nicotinamide; N N 6-(4-acryloylpiperazinyl)-6'-phenoxy-2,3'-bipyridinecarboxamide; N N N O cryloylpiperazinyl)(4-(pyridinyloxy)phenyl)nicotinamide; N N O N 1-(1-(4-(dimethylamino)butenoyl)pyrrolidinyl)(4-phenoxyphenyl)-1H-pyrazole- 4-carboxamide; O N N O 6-(4-acryloylpiperazinyl)(4-(3-fluorophenoxy)phenyl)nicotinamide; N N O F 6-(4-acryloylpiperazinyl)(3-fluorophenoxyphenyl)nicotinamide; N N 6-(4-acryloylpiperazinyl)(4-(4-fluorophenoxy)phenyl)nicotinamide; N N 6-(4-acryloylpiperazinyl)(4-(2-fluorophenoxy)phenyl)nicotinamide; N N 6-(4-acryloylpiperazinyl)(2-fluorophenoxyphenyl)nicotinamide; N N F O cryloylpiperidinyl)(4-phenoxyphenyl)thiazolecarboxamide; O S N N 2-(1-acryloylpyrrolidinyl)(4-phenoxyphenyl)thiazolecarboxamide; N N 2-(1-acryloylpiperidinyl)(4-phenoxyphenyl)oxazolecarboxamide; O O N N O 2-(1-acryloylpyrrolidinyl)(4-phenoxyphenyl)oxazolecarboxamide; N N 2-(1-acryloylpyrrolidinyl)(4-phenoxyphenyl)thiazolecarboxamide; S O 2-(1-acryloylpiperidinyl)(4-phenoxyphenyl)thiazolecarboxamide; O N N S O cryloylpiperidinyl)(4-phenoxyphenyl)oxazolecarboxamide; N O 2-(1-acryloylpyrrolidinyl)(4-phenoxyphenyl)oxazolecarboxamide; N O O 2-(1-acryloylpiperidinyl)(4-phenoxyphenyl)thiazolecarboxamide; S O cryloylpiperidinyl)(4-phenoxyphenyl)thiazolecarboxamide; N O 2-(1-acryloylpiperidinyl)(4-phenoxyphenyl)oxazolecarboxamide; O N N O 5-(1-acryloylpiperidinyl)-4'-phenoxybiphenylcarboxamide; 5-(4-acryloylpiperazinyl)-4'-phenoxybiphenylcarboxamide; cryloylpiperidinyl)(4-(hydroxy(phenyl)methyl)phenyl)nicotinamide; O OH (E)(1-(2-cyanobutenoyl)azetidinyl)(4-phenoxyphenyl)-1H-pyrazole carboxamide; N O 6-(4-acryloylpiperazinyl)(4-((4,4-difluorocyclohexyl)oxy)phenyl)nicotinamide; N N F 6-(1-acryloylpiperidinyl)(4-(phenylcarbamoyl)phenyl)nicotinamide; N N O O 2-(4-phenoxyphenyl)(4-(vinylsulfonyl)piperazinyl)nicotinamide; N N S O 2-(4-phenoxyphenyl)(1-(vinylsulfonyl)piperidinyl)nicotinamide; S O or a pharmaceutically able salt thereof.
2. The compound according to Claim 1, wherein the compound is: 6-(3-acrylamidophenyl)(4-phenoxyphenyl)nicotinamide; 6-(1-acryloylpiperidinyl)(4-phenoxyphenyl)nicotinamide; 6-(4-acryloylpiperazinyl)(4-phenoxyphenyl)nicotinamide; N N 6-(1-acryloylpyrrolidinyl)(4-phenoxyphenyl)nicotinamide; N N 6-(4-acrylamidophenyl)(4-phenoxyphenyl)nicotinamide; O N N O cryloylpiperidinyl)(4-phenoxyphenyl)nicotinamide; O NH2 N N 6-(4-acrylamidopiperidinyl)(4-phenoxyphenyl)nicotinamide; O N N N O 6-(3-acrylamidopyrrolidinyl)(4-phenoxyphenyl)nicotinamide; HN N N (4-(4-(dimethylamino)butenoyl)piperazinyl)(4- phenoxyphenyl)nicotinamide; N N N O 6-(4-acryloylpiperazinyl)(4-(cyclohexyloxy)phenyl)nicotinamide; N N 6-(4-acryloylpiperazinyl)(3-methoxymethylphenyl)nicotinamide; N N 6-(4-acryloylpiperazinyl)-6'-phenoxy-2,3'-bipyridinecarboxamide; N N N O 6-(4-acryloylpiperazinyl)(4-(pyridinyloxy)phenyl)nicotinamide; N N O N 6-(4-acryloylpiperazinyl)(4-(3-fluorophenoxy)phenyl)nicotinamide; N N O F cryloylpiperazinyl)(3-fluorophenoxyphenyl)nicotinamide; N N 6-(4-acryloylpiperazinyl)(4-(4-fluorophenoxy)phenyl)nicotinamide; N N 6-(4-acryloylpiperazinyl)(4-(2-fluorophenoxy)phenyl)nicotinamide; N N 6-(4-acryloylpiperazinyl)(2-fluorophenoxyphenyl)nicotinamide; N N F O cryloylpiperidinyl)-4'-phenoxybiphenylcarboxamide; 5-(4-acryloylpiperazinyl)-4'-phenoxybiphenylcarboxamide; 6-(1-acryloylpiperidinyl)(4-(hydroxy(phenyl)methyl)phenyl)nicotinamide; O OH 6-(4-acryloylpiperazinyl)(4-((4,4-difluorocyclohexyl)oxy)phenyl)nicotinamide; N N F 6-(1-acryloylpiperidinyl)(4-(phenylcarbamoyl)phenyl)nicotinamide; N N O O 2-(4-phenoxyphenyl)(4-(vinylsulfonyl)piperazinyl)nicotinamide; N N S O 2-(4-phenoxyphenyl)(1-(vinylsulfonyl)piperidinyl)nicotinamide; S O or a pharmaceutically acceptable salt thereof.
3. The nd according to Claim 2, wherein the compound is N N O .
4. A nd selected from the group consisting of: 2-(4-phenoxyphenyl)(piperidinyl)nicotinamide; 2-(4-phenoxyphenyl)(piperazinyl)nicotinamide; N N 1-(azetidinyl)(4-phenoxyphenyl)-1H-pyrazolecarboxamide; N O 1-(3-aminophenyl)(4-phenoxyphenyl)-1H-pyrazolecarboxamide; H2N N O 6-(1-acryloylpiperidinyl)(4-phenoxyphenyl)pyridinecarbonitrile; 6-(4-acryloylpiperazinyl)(4-phenoxyphenyl)pyridinecarboxylic acid; N N 2-(4-acryloylpiperazinyl)-N-methyl(4-phenoxyphenyl)thiazolecarboxamide; N N O .
5. A compound having a Formula IId, or a pharmaceutically acceptable salt or e thereof: R3 X Z R2 O O Formula IId wherein X is N , N , N , or ; Z is C or N; G1, G2, and G3 are selected from the group consisting of one or more H, D (deuterium), C1-12 alkyl, halogen, and CF3; R2 and R3 are each independently selected from the group ting of H, D, C1-12 alkyl, halogen, CN, and CF3, wherein C1-12 alkyl is optionally substituted with NR11R12; R4 is selected from the group consisting of H, D, C1-12 alkyl, halogen, CN, and CF3; and R11 and R12 are independently H or C1-6 alkyl.
6. The compound according to Claim 5, wherein X is N or N .
7. The compound according to Claim 5, wherein G1, G2, and G3 are one or more H, or halogen.
8. The nd according to Claim 5, wherein R2 and R3 are H or C1-12 alkyl, wherein C1- 11R12, and R11 and R12 are H or CH 12 alkyl is optionally substituted with NR 3.
9. A pharmaceutical composition for treating a disease mediated by Bruton’s tyrosine Kinase (BTK), comprising the compound of any one of Claims 1-3 and 5-8, and a ceutically acceptable salt thereof.
10. Use of the compound or the pharmaceutically able salt thereof of any one of Claims 1-3 and 5-8, in the cture of a medicament for treating of at least one of cancer, chronic inflammation, and autoimmune disease mediated at least in part by BTK. Guangzhou Innocare Pharma Tech Co., Ltd. By the Attorneys for the Applicant SPRUSON & FERGUSON
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361884958P | 2013-09-30 | 2013-09-30 | |
US61/884,958 | 2013-09-30 | ||
CN201310485048.1 | 2013-10-16 | ||
CN201310485048 | 2013-10-16 | ||
PCT/US2014/058084 WO2015048662A2 (en) | 2013-09-30 | 2014-09-29 | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ718073A NZ718073A (en) | 2021-04-30 |
NZ718073B2 true NZ718073B2 (en) | 2021-08-03 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11840513B2 (en) | Substituted nicotinimide inhibitors of BTK for treating cancer | |
JP7418395B2 (en) | SHP2 phosphatase inhibitors and methods of using them | |
JP6571215B2 (en) | Heteroarylpyridone and azapyridone compounds as inhibitors of BTK activity | |
JP2022528562A (en) | METTL3 inhibitor compound | |
DK2545045T3 (en) | PIPERIDINE-4-YL-azetidine derivatives AS JAK1 INHIBITORS | |
ES2612503T3 (en) | 9H-purine compounds as PI3K-delta inhibitors and methods for their preparation | |
JP2018150358A (en) | Tank-binding kinase inhibitor compounds | |
CA2857302C (en) | Use of inhibitors of the activity or function of pi3k | |
CN116444515A (en) | Di-ring derivative-containing inhibitor, preparation method and application thereof | |
KR20130002991A (en) | 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds | |
KR20130094710A (en) | 5,7-substituted-imidazo[1,2-c]pyrimidines as inhibitors of jak kinases | |
AU2021309876B2 (en) | Rock inhibitor, and preparation method therefor and use thereof | |
JPWO2014109414A1 (en) | Nitrogen-containing heterocyclic compound or salt thereof | |
NZ718073B2 (en) | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | |
NZ718073A (en) | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | |
WO2023185073A1 (en) | Parp7 inhibitor and use thereof |